Page last updated: 2024-11-04

mesalamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Mesalamine, also known as 5-aminosalicylic acid (5-ASA), is an anti-inflammatory drug primarily used to treat inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn\\'s disease. It is a derivative of salicylic acid and works by reducing inflammation in the digestive tract. Mesalamine is typically administered orally or rectally, depending on the location and severity of the inflammation. While its exact mechanism of action is not fully understood, it is believed to work by reducing the production of pro-inflammatory cytokines, inhibiting the activity of certain enzymes involved in inflammation, and protecting the intestinal lining from damage. Mesalamine is a mainstay treatment for IBD due to its relatively good tolerability and effectiveness in reducing symptoms. It is often used in combination with other medications, such as corticosteroids or biologics, depending on the individual\\'s needs and the severity of their disease. Research on mesalamine continues to explore its potential benefits in other inflammatory conditions, such as rheumatoid arthritis and osteoarthritis, and to develop novel delivery methods to improve its effectiveness and reduce side effects.'

Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID4075
CHEMBL ID704
CHEBI ID6775
SCHEMBL ID31297
SCHEMBL ID18038934
MeSH IDM0029386

Synonyms (213)

Synonym
BIDD:GT0811
HMS3393M21
AB00374979-09
mesalamine (usan)
gtpl2700
nsc38877
mesalamine
5-aminosalicylic acid ,
benzoic acid, 5-amino-2-hydroxy-
m-aminosalicylic acid
salicylic acid, 5-amino-
nsc-38877
wln: zr dq cvq
spd-480
mezavant
sfrowasa
z-206
2-hydroxy-5-aminobenzoic acid
mezavant xl
ajg-501
mesavance
max-002
apriso
mesavancol
3-carboxy-4-hydroxyaniline
asacol hd
spd-476
mesalazine mmx
salofalk granu-stix
md-0901
p-aminosalicylsaeure [german]
mesalamine [usan]
5-asa
canasa
claversal
mesalazinum [latin]
nsc 38877
mesasal
lialda
pentasa
salofalk
mesalazina [spanish]
ai3-15564
asacol
ccris 7334
rowasa
meta-aminosalicylic acid
einecs 201-919-1
brn 2090421
PRESTWICK3_001069
CMAP_000045
NCGC00016344-01
cas-89-57-6
PRESTWICK2_001069
5-amino-2-hydroxy-benzoic acid
BSPBIO_001058
OPREA1_847633
5-amino-2-hydroxybenzoic acid
inchi=1/c7h7no3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9h,8h2,(h,10,11
NCGC00090934-01
AB00374979
MLS001424012 ,
STK301678
89-57-6
C07138
mesalazine
5-aminosalicylic acid, >=99%
5-aminosalicylic acid, 95%
5-aminosalicylic acid, tablet
MLS000758287
smr000145728
DB00244
canasa (tn)
pentasa (tn)
asacol (tn)
mesalamine (usp)
mesalamine (tn)
apriso (tn)
lialda (tn)
mesalazine (jp17/inn)
sfrowasa (tn)
rowasa (tn)
D00377
delzicol (tn)
BPBIO1_001164
NCGC00090934-02
KBIO2_004993
KBIO2_007561
KBIOGR_002425
KBIO2_002425
KBIOSS_002431
KBIO3_002904
PRESTWICK0_001069
SPBIO_002969
PRESTWICK1_001069
5 aminosalicylic acid
meta aminosalicylic acid
m aminosalicylic acid
asacolitin
fisalamine
mesalazina
mesalazinum
lixacol
iialda
p-aminosalicylsaeure
CHEBI:6775 ,
HMS2090I09
HMS2051M21
AC-2764
A0317
CHEMBL704
HMS1571E20
NCGC00016344-03
AKOS000118959
HMS2098E20
5-amino salicylic acid
ec 201-919-1
4q81i59gxc ,
pentacol
4-14-00-02058 (beilstein handbook reference)
delzicol
spd 476
unii-4q81i59gxc
mesalamine [usan:usp]
mesalazine [inn]
hsdb 7512
dtxsid5024506 ,
NCGC00257142-01
dtxcid804506
tox21_303125
NCGC00259159-01
tox21_201610
BBL013046
pharmakon1600-01505993
nsc-759301
nsc759301
BCP9000175
tox21_110384
5-as
F1918-0003
CCG-100829
NCGC00016344-02
NCGC00016344-05
NCGC00016344-04
BP-13074
FT-0619950
AM20060091
mesalazine [mart.]
mesalamine [hsdb]
mesalazine [jan]
mesalamine [usp-rs]
mesalazine [ep monograph]
mesalamine [mi]
mesalazine [who-dd]
mesalamine [vandf]
mesalamine [usp monograph]
mesalazine [ep impurity]
mesalamine [orange book]
S1681
HY-15027
NC00079
SCHEMBL31297
NCGC00016344-07
tox21_110384_1
HS-0100
AB00374979-10
SCHEMBL18038934
5-amino-salicylic acid
5-aminosalicyclic acid
3-amino-6-hydroxybenzoic acid
3amino-6-hydroxybenzoic acid
Q-201355
bdbm60918
cid_4075
HMS3649K15
AB00374979_12
AB00374979_11
mfcd00007877
SR-01000763486-3
sr-01000763486
SR-01000763486-4
5-?aminosalicylic acid (mesalazine)
Z57127471
mesalamine, united states pharmacopeia (usp) reference standard
5-aminosalicylic acid, analytical standard
HMS3651M15
mesalazine, european pharmacopoeia (ep) reference standard
mesalazine for system suitability, european pharmacopoeia (ep) reference standard
mesalamine, pharmaceutical secondary standard; certified reference material
HMS3715E20
SY002854
SW197303-4
BCP05326
Q412479
5-aminosalicylic_acid
5-amino-2-hydroxobenzoic acid monohydrate
mesalamine (lialda)
SR-01000763486-9
AC8101
EN300-18389
mesalamine-d3
mesalazine (ep monograph)
mesalamine rectal
mesalamine (usan:usp)
mesalazine (ep impurity)
mesalazine (mart.)
zaldyon
5-amino-2-hydroxybenzene-1-carboxylic acid
a07ec02
mesalamine (usp-rs)
mesalazinum (latin)
sfrowasasulfite-free formulation
mesalamine (usp monograph)

Research Excerpts

Overview

Oral mesalamine is an effective and safe treatment of mild-to-moderate or quiescent ulcerative colitis regardless of the chosen formulation. Mesalamine can be rarely associated with myocarditis through a mechanism of drug hypersensitivity.

ExcerptReferenceRelevance
"Mesalamine is a first-line drug in the treatment of inflammatory bowel diseases, while its intolerance occasionally occurs in clinical practice. "( The culprit of mesalamine intolerance: case series and literature review.
Fu, Y; Hong, F; Quan, R; Xie, C; Yan, W; Zou, K, 2019
)
2.31
"Oral mesalamine is an effective and safe treatment of mild-to-moderate or quiescent ulcerative colitis regardless of the chosen formulation."( Are there any differences in the efficacy and safety of different formulations of Oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? evidence from cochrane reviews.
Chande, N; Feagan, BG; MacDonald, JK, 2013
)
0.84
"Mesalamine is a common treatment for Crohn's disease, and can be rarely associated with myocarditis through a mechanism of drug hypersensitivity. "( Mesalamine-induced myocarditis following diagnosis of Crohn's disease: a case report.
Arantes, C; Correia, A; Galvão Braga, C; Magalhães, S; Martins, J; Ramos, V; Salgado, A; Vieira, C, 2013
)
3.28
"Mesalamine is a first-line treatment for induction and maintenance of UC remission."( Once-daily Mesalamine Formulation for Maintenance of Remission in Ulcerative Colitis: A Randomized, Placebo-controlled Clinical Trial.
Barrett, AC; Bortey, E; Forbes, WP; Gordon, GL; Lichtenstein, GR; Murthy, U; Paterson, C; Pruitt, R; Sedghi, S; Zakko, S, 2016
)
2.27
"Mesalamine is a locally acting antiinflammatory agent that is widely used both to maintain and induce remission in inflammatory bowel disease."( Encapsulated mesalamine granules (Apriso) for ulcerative colitis.
, 2009
)
1.44
"Mesalamine is a mainstay therapeutic agent in chronic ulcerative colitis (CUC) in which condition it reverses crypt architectural changes and reduces colitis-associated cancer (CAC). "( Mesalamine inhibits epithelial beta-catenin activation in chronic ulcerative colitis.
Barrett, TA; Blatner, NR; Brown, JB; Cheresh, P; Dirisina, R; Goretsky, T; Grimm, GR; Khazaie, K; Lee, G; Li, L; Managlia, E; Yang, GY, 2010
)
3.25
"Mesalamine is an anti-inflammatory drug used to treat Crohn's disease and ulcerative colitis."( Transportation of drug-(polystyrene bead) conjugate by actomyosin motor system.
Bharadwaj, LM; Kaur, H; Kaur, I; Kukkar, D; Kumar, S; Singh, K, 2010
)
1.08
"Mesalamine (mesalazine) is a 5-aminosalicylic acid compound that is the first-line treatment for patients with mild-to-moderate UC."( Mesalamine in the treatment and maintenance of remission of ulcerative colitis.
Ham, M; Moss, AC, 2012
)
2.54
"Mesalamine is an anti-inflammatory agent, effective in the treatment of inflammatory bowel disease."( Double-blind placebo-controlled study of mesalamine in post-infective irritable bowel syndrome--a pilot study.
Al-Suqi, M; Fang, JC; Hale, DC; Stoddard, GJ; Tuteja, AK, 2012
)
1.37
"Mesalamine is a topically active agent with anti-inflammatory properties."( Multi-Matrix System (MMX®) mesalamine for the treatment of mild-to-moderate ulcerative colitis.
Horst, SN; Kane, S, 2012
)
1.4
"Mesalamine is a first-line drug in the treatment of inflammatory bowel disease. "( The safety of mesalamine in human pregnancy: a prospective controlled cohort study.
Bologa, M; Diav-Citrin, O; Koren, G; Park, YH; Pastuszak, A; Polachek, H; Veerasuntharam, G, 1998
)
2.1
"Mesalamine is a drug used to treat inflammatory bowel disease."( Clinical efficacy of mesalamine in the treatment of the spondyloarthropathies.
Ducharme, JS; Thomson, BR; Thomson, GT; Thomson, KS, 2000
)
1.35

Effects

Mesalamine has a well-established role in the management of ulcerative colitis. Treatment has an effect on epithelial miRNAs.

Mesalamine has shown efficacy in preventing relapse in inflammatory bowel disease, and there is preliminary evidence that it might be effective for diverticular disease. Mesalamine treatment has an effect on epithelial miRNAs.

ExcerptReferenceRelevance
"Mesalamine treatment has an effect on epithelial miRNAs. "( miR-206 as a Biomarker for Response to Mesalamine Treatment in Ulcerative Colitis.
Amenta, PS; Bajpai, M; Brant, SR; Das, KM; Geng, X; Minacapelli, CD; Poplin, E; Van Gurp, J, 2019
)
2.23
"Mesalamine has a well-established role in the management of ulcerative colitis. "( The case for using 5-aminosalicyclates in Crohn's disease: pro.
Hanauer, SB, 2005
)
1.77
"Mesalamine has a well-established role in the management of ulcerative colitis. "( Debate: should mesalamine be used in Crohn's disease?: comments and conclusions.
Kamm, MA, 2005
)
2.12
"Mesalamine treatment has an effect on epithelial miRNAs. "( miR-206 as a Biomarker for Response to Mesalamine Treatment in Ulcerative Colitis.
Amenta, PS; Bajpai, M; Brant, SR; Das, KM; Geng, X; Minacapelli, CD; Poplin, E; Van Gurp, J, 2019
)
2.23
"Mesalamine has been proposed as a treatment option for collagenous colitis, although its efficacy has never been investigated in placebo-controlled trials."( Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis.
Böhm, G; Bonderup, OK; Fernández-Bañares, F; Greinwald, R; Kupcinskas, L; Madisch, A; Marks, HJ; Miehlke, S; Mohrbacher, R; Nathan, T; Neumeyer, M; Petrauskas, D; Vieth, M, 2014
)
1.4
"Mesalamine suppositories have been used widely for the treatment of distal ulcerative colitis and considered to be safer than systemic administration for its limited systemic absorption. "( Ulcerative colitis flair induced by mesalamine suppositories hypersensitivity.
Ding, H; Hu, J; Hu, XY; Liu, XC; Mei, Q; Xu, JM, 2014
)
2.12
"Mesalamine has shown efficacy in preventing relapse in inflammatory bowel disease, and there is preliminary evidence that it might be effective for diverticular disease."( Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials.
Barrett, K; Jamal, MM; Kamm, MA; Márquez, J; Melzer, E; Raskin, JB; Schoen, RE; Streck, P; Szalóki, T, 2014
)
2.57
"Mesalamine has been reported to protect against inflammatory bowel disease-related colorectal cancer (CRC), but several drug-related issues have limited its use in chemopreventive programs. "( Inhibition of colon carcinogenesis by 2-methoxy-5-amino-N-hydroxybenzamide, a novel derivative of mesalamine.
Caruso, R; Fantini, MC; Fina, D; Macdonald, TT; Monteleone, G; Pallone, F; Palmieri, G; Pellegrini, R; Sarra, M; Stolfi, C, 2010
)
2.02
"Mesalamine has been used as the first-line medication for the treatment of ulcerative colitis (UC). "( Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: a double-blind, randomized study.
Aida, Y; Hibi, T; Iida, M; Ito, H; Matsumoto, T; Suzuki, Y; Takano, Y; Yoshida, T, 2010
)
2.08
"Mesalamine has been demonstrated in randomized controlled trials to induce both clinical response and remission, and maintain clinical remission, in these patients."( Mesalamine in the treatment and maintenance of remission of ulcerative colitis.
Ham, M; Moss, AC, 2012
)
2.54
"Mesalamine has no clear benefit over placebo in treating active Crohn's disease."( Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithm.
Feagan, BG; Sandborn, WJ, 2003
)
1.04
"Mesalamine has a well-established role in the management of ulcerative colitis. "( The case for using 5-aminosalicyclates in Crohn's disease: pro.
Hanauer, SB, 2005
)
1.77
"Mesalamine has a well-established role in the management of ulcerative colitis. "( Debate: should mesalamine be used in Crohn's disease?: comments and conclusions.
Kamm, MA, 2005
)
2.12
"Mesalamine has demonstrated clinical effectiveness as a therapeutic agent in the treatment of active ulcerative colitis and inactive Crohn's disease. "( The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease.
Bonapace, CR; Mays, DA,
)
1.93
"Mesalamine has many effects and is commonly used for the treatment of inflammatory bowel diseases. "( Effects of mesalamine on the hsp72 stress response in rat IEC-18 intestinal epithelial cells.
Burress, GC; Chang, EB; Jurivich, DA; Musch, MW; Welk, J, 1997
)
2.13
"Mesalamine has been studied extensively as a therapeutic option in patients with Crohn's disease. "( Mesalamine for prophylaxis of small bowel Crohn's disease recurrence.
Bauer, WM; Brzezinski, A; Lashner, BA, 1999
)
3.19

Actions

Mesalamine was found to inhibit IL-1-stimulated RelA phosphorylation. It may cause hypersensitivity pneumonitis in patients with Crohn's disease.

ExcerptReferenceRelevance
"Mesalamine may cause hypersensitivity pneumonitis in patients with Crohn's disease."( Mesalamine-induced hypersensitivity pneumonitis. A case report and review of the literature.
Ben-Chetrit, E; Gafanovich, I; Kramer, MR; Sviri, S; Tsvang, E, 1997
)
2.46
"Mesalamine was found to inhibit IL-1-stimulated RelA phosphorylation."( Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity.
Bell, MP; Egan, LJ; Huntoon, CJ; Lipsky, JJ; Mays, DC; McKean, DJ; Pike, MG; Sandborn, WJ, 1999
)
1.25

Treatment

Mesalamine is a common treatment for Crohn's disease, and can be rarely associated with myocarditis through a mechanism of drug hypersensitivity. Mesalamine granules treatment resulted in a significantly longer remission duration versus placebo (P=0.02)

ExcerptReferenceRelevance
"Mesalamine is the core treatment of mild‑to‑moderate ulcerative colitis (UC) and corticosteroids are crucial for the induction of remission of moderate‑to‑severe flares in both UC and Crohn's disease (CD)."( Inflammatory Bowel Disease - Non-biological treatment.
Cordeiro, G; Dias, AM; Estevinho, MM; Magro, F, 2020
)
1.28
"Mesalamine treatment has an effect on epithelial miRNAs. "( miR-206 as a Biomarker for Response to Mesalamine Treatment in Ulcerative Colitis.
Amenta, PS; Bajpai, M; Brant, SR; Das, KM; Geng, X; Minacapelli, CD; Poplin, E; Van Gurp, J, 2019
)
2.23
"Mesalamine is a common treatment for Crohn's disease, and can be rarely associated with myocarditis through a mechanism of drug hypersensitivity. "( Mesalamine-induced myocarditis following diagnosis of Crohn's disease: a case report.
Arantes, C; Correia, A; Galvão Braga, C; Magalhães, S; Martins, J; Ramos, V; Salgado, A; Vieira, C, 2013
)
3.28
"Mesalamine granules treatment resulted in a significantly longer remission duration versus placebo (P=0.02) and decreased patients' risk of relapse by 43% (hazard ratio=0.57; 95% confidence interval, 0.35-0.93; P=0.02)."( Once-daily Mesalamine Formulation for Maintenance of Remission in Ulcerative Colitis: A Randomized, Placebo-controlled Clinical Trial.
Barrett, AC; Bortey, E; Forbes, WP; Gordon, GL; Lichtenstein, GR; Murthy, U; Paterson, C; Pruitt, R; Sedghi, S; Zakko, S, 2016
)
1.55
"Mesalamine treatment reduced relapse compared with placebo treatment, although conventional statistical significance was not achieved."( A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group.
Bailey, RJ; Dallaire, C; Fedorak, RN; Lariviere, L; Martin, F; Poleski, M; Rossman, R; Saibil, F; Sutherland, LR, 1997
)
1.99
"Treatment with mesalamine to maintain endoscopic remission (mucosal healing) of ulcerative colitis (UC) has been shown to reduce the risk of relapse and is the recommended first-line maintenance therapy. "( Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis.
Barrett, K; D'Haens, G; Hodgson, I; Sandborn, WJ; Streck, P, 2012
)
1.07
"Treatment with mesalamine enemas allowed patients to decrease or discontinue glucocorticoid treatment."( Long-term use of mesalamine enemas to induce remission in ulcerative colitis.
Biddle, WL; Miner, PB, 1990
)
0.96

Toxicity

Mesalamine 500-mg BID and 1-g QHS suppositories are safe and effective for patients with UP. Adverse events requiring the withdrawal of therapy seem to occur less frequently with balsalazide, mesalamine, and olsalazine compared with sulfasalazine.

ExcerptReferenceRelevance
"There is a growing body of experimental and clinical evidence to suggest that oral or rectal administration of 5-ASA or 5-ASA conjugates is associated with significant adverse side effects including pancreatitis, hepatitis, and renal toxicity."( Prooxidant properties of 5-aminosalicylic acid. Possible mechanism for its adverse side effects.
Grisham, MB; Marshall, S; Sandhu, IS; Ware, K; Yamada, T, 1992
)
0.28
" Forty-seven (14%) of 331 patients receiving mesalazine reported adverse events, whereas 33 (23%) of 144 patients receiving sulphasalazine and 23 (19%) of 123 patients receiving placebo reported adverse effects."( Mesalazine: a global safety evaluation.
Brimblecombe, R, 1990
)
0.28
" This suggests that, at least in some patients, the adverse effects of sulfasalazine are due to 5-aminosalicylic acid rather than sulfapyridine."( Adverse effects with oral 5-aminosalicyclic acid.
Fardy, JM; Lloyd, DA; Reynolds, RP, 1988
)
0.27
" Treatment-related adverse events were rare."( Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group.
Arora, S; Hanauer, S; Miner, P; Robinson, M; Schwartz, J, 1995
)
0.56
"We investigated the adverse effects of sulfasalazine in the treatment of inflammatory bowel disease in Japan."( Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine.
Munakata, A; Nakajima, H; Yoshida, Y, 1995
)
0.29
" No dose-related adverse events were found."( Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group.
Blok, P; Dekker, W; Ferwerda, J; Fockens, P; Gasthuis, K; Meuwissen, SG; Mulder, CJ; Tuynman, HA; Tytgat, GN; van Hees, PA, 1995
)
0.29
" These higher doses are not associated with a higher incidence of adverse reactions."( Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group.
Blok, P; Dekker, W; Ferwerda, J; Fockens, P; Gasthuis, K; Meuwissen, SG; Mulder, CJ; Tuynman, HA; Tytgat, GN; van Hees, PA, 1995
)
0.29
"Pentasa-related adverse events were recorded from 1 January 1993 to 31 December 1994."( Adverse events in patients treated with 5-aminosalicyclic acid: 1993-1994 pharmacovigilance report for Pentasa in France.
Devaux, C; Le Lu, M; Marteau, P; Nelet, F, 1996
)
0.29
"Pentasa seldom has adverse effects."( Adverse events in patients treated with 5-aminosalicyclic acid: 1993-1994 pharmacovigilance report for Pentasa in France.
Devaux, C; Le Lu, M; Marteau, P; Nelet, F, 1996
)
0.29
" The free acid compounds were less toxic than their corresponding salts."( Comparative cytotoxicity of 5-aminosalicylic acid (mesalazine) and related compounds in different cell lines.
Dierickx, PJ; Janssen, L; Noble, E, 1997
)
0.3
"Mesalazine is an aminosalicillic derivative considered as a safe alternative to the relative frequency (5-55%) of adverse effects observed with sulfasalazine."( [Non-immunoallergic hepatotoxicity due to mesalazine].
Barroso, N; Gavilán, F; Guil, A; Larrauri, J; Leo, E; Reina, FR; Tirado, C; Zafra, C, 1999
)
0.3
"5-aminosalicylates are extensively prescribed for the treatment of ulcerative colitis but have a wide range of described adverse effects."( Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines.
Langman, MJ; Ransford, RA, 2002
)
0.31
"To determine whether serious adverse effect profiles differ for sulphasalazine and mesalazine."( Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines.
Langman, MJ; Ransford, RA, 2002
)
0.31
"Analysis of suspected serious adverse reactions reported to the Committee on Safety of Medicines of the UK in 1991-1998."( Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines.
Langman, MJ; Ransford, RA, 2002
)
0.31
"3 weeks (range 2-22), 8 of the 20 patients prematurely stopped the medication because of adverse effects, mainly gastrointestinal complaints."( Efficacy and safety of mesalazine (Salofalk) in an open study of 20 patients with ankylosing spondylitis.
Bezemer, PD; Dijkmans, BA; van Denderen, JC; van der Horst-Bruinsma, I, 2003
)
0.32
"To determine whether there is a difference in short-term adverse events in patients with ulcerative colitis treated with mesalazine, olsalazine or balsalazide."( Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis.
Bjorkman, D; Kane, SV; Loftus, EV, 2004
)
0.32
" Outcomes of interest were the frequencies of patients experiencing adverse events and those withdrawn due to adverse events."( Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis.
Bjorkman, D; Kane, SV; Loftus, EV, 2004
)
0.32
" sulfasalazine for active colitis showed significantly fewer patients with adverse events with mesalazine."( Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis.
Bjorkman, D; Kane, SV; Loftus, EV, 2004
)
0.32
"All three 5-aminosalicylic acid agents are safe in the short term."( Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis.
Bjorkman, D; Kane, SV; Loftus, EV, 2004
)
0.32
" Adverse events requiring the withdrawal of therapy seem to occur less frequently with balsalazide, mesalamine, and olsalazine compared with sulfasalazine."( The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis.
Baker, DE; Kane, S, 2004
)
0.54
" There was no significant difference between treatments in adverse events, and both groups had an overall drug compliance of greater than 95%."( Efficacy and safety of mesalamine 1 g HS versus 500 mg BID suppositories in mild to moderate ulcerative proctitis: a multicenter randomized study.
Dallaire, C; de Montigny, D; Grace, M; Lamet, M; Ptak, T; Shah, U; Spenard, J, 2005
)
0.64
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
"001; chi-square test) with no differences in frequency of adverse events."( Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis.
Bátovský, M; Fixa, B; Florin, TH; Gabalec, L; Gibson, PR; Greinwald, R; Pekárková, B; Radford-Smith, G; Tibitanzl, J, 2006
)
0.33
" Recently, a high-volume 5-aminosalicylic acid foam has been shown to be as effective and safe as standard 5-aminosalicylic acid enema."( Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis.
Adamonis, K; Bar-Meir, S; Chermesh, I; Eliakim, R; Greinwald, R; Gross, V; Kupcinskas, L; Lavy, A; Mueller, R; Pokrotnieks, J; Tulassay, Z, 2007
)
0.34
"Low-volume 5-aminosalicylic acid foam is as effective and safe as a high-volume 5-aminosalicylic acid foam in the treatment of active distal ulcerative colitis, but offers compliance advantages compared to the high-volume preparation."( Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis.
Adamonis, K; Bar-Meir, S; Chermesh, I; Eliakim, R; Greinwald, R; Gross, V; Kupcinskas, L; Lavy, A; Mueller, R; Pokrotnieks, J; Tulassay, Z, 2007
)
0.34
"To investigate the occurrence of adverse events and efficacy of azathioprine with or without mesalazine."( Should azathioprine and 5-aminosalicylates be coprescribed in inflammatory bowel disease?: an audit of adverse events and outcome.
Edwards, CM; Probert, CS; Shah, JA, 2008
)
0.35
" Data were recorded on adverse events, azathioprine dose and thiopurine methyl transferase (TPMT) level."( Should azathioprine and 5-aminosalicylates be coprescribed in inflammatory bowel disease?: an audit of adverse events and outcome.
Edwards, CM; Probert, CS; Shah, JA, 2008
)
0.35
" No relationship between TPMT activity and adverse events was observed."( Should azathioprine and 5-aminosalicylates be coprescribed in inflammatory bowel disease?: an audit of adverse events and outcome.
Edwards, CM; Probert, CS; Shah, JA, 2008
)
0.35
" Adverse events are unrelated to dose of azathioprine."( Should azathioprine and 5-aminosalicylates be coprescribed in inflammatory bowel disease?: an audit of adverse events and outcome.
Edwards, CM; Probert, CS; Shah, JA, 2008
)
0.35
" The most common adverse events reported were worsening of UC and headache; both were reported more often in the placebo group."( Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.
Forbes, WP; Gordon, GL; Huang, S; Lamet, M; Mareya, S; Pruitt, R; Scherl, EJ; Shaw, A, 2009
)
0.35
" Adverse events and laboratory changes were monitored throughout the study."( Safety, efficacy, and pharmacokinetics of balsalazide in pediatric patients with mild-to-moderate active ulcerative colitis: results of a randomized, double-blind study.
Attard, TM; Bortey, E; Forbes, WP; Heyman, MB; Pieniaszek, HJ; Pohl, JF; Quiros, JA; Walker, K, 2009
)
0.35
" Adverse events were similar between the treatment groups, the most common being headache and abdominal pain."( Safety, efficacy, and pharmacokinetics of balsalazide in pediatric patients with mild-to-moderate active ulcerative colitis: results of a randomized, double-blind study.
Attard, TM; Bortey, E; Forbes, WP; Heyman, MB; Pieniaszek, HJ; Pohl, JF; Quiros, JA; Walker, K, 2009
)
0.35
"All adverse events were "not serious."( Pharmacokinetics and safety of single and multiple doses of Asacol tablets in Japanese healthy volunteers.
Furuta, S; Hibi, T; Ito, H; Sasaki, H; Takano, Y; Yoshida, T, 2009
)
0.35
"Asacol was safe and well tolerated in this Japanese population, and the non-Japanese clinical data could be extrapolated to the Japanese population."( Pharmacokinetics and safety of single and multiple doses of Asacol tablets in Japanese healthy volunteers.
Furuta, S; Hibi, T; Ito, H; Sasaki, H; Takano, Y; Yoshida, T, 2009
)
0.35
"Mesalamine 500-mg BID and 1-g QHS suppositories are safe and effective for patients with UP."( A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg Twice daily in patients with active mild-to-moderate ulcerative proctitis.
Lamet, M, 2011
)
2.05
" Forty-one patients experienced at least one adverse event, most of which were deemed mild and unrelated to study therapy."( Efficacy and safety of mesalamine suppositories for treatment of ulcerative proctitis in children and adolescents.
Giguere, M; Heyman, MB; Kierkus, J; Shbaklo, H; Spénard, J, 2010
)
0.67
"This study showed that a daily bedtime dose of a 500 mg mesalamine suppository is safe and efficacious in children with ulcerative proctitis."( Efficacy and safety of mesalamine suppositories for treatment of ulcerative proctitis in children and adolescents.
Giguere, M; Heyman, MB; Kierkus, J; Shbaklo, H; Spénard, J, 2010
)
0.92
" Some animal studies indicate that such nanomaterials may have some toxicity, but their synergistic actions on the adverse effects of drugs are not well understood."( Effect of 70-nm silica particles on the toxicity of acetaminophen, tetracycline, trazodone, and 5-aminosalicylic acid in mice.
Hasezaki, T; Isoda, K; Kondoh, M; Li, X; Tsutsumi, Y; Watari, A; Yagi, K, 2011
)
0.37
"Compared with HD, a mesalamine enteric-coated tablet, FCC is similarly effective and safe in the treatment of active UC with TCM pattern of damp-heat accumulation interior pattern."( Efficacy and safety of Fufangkushen colon-coated capsule in the treatment of ulcerative colitis compared with mesalazine: a double-blinded and randomized study.
Gong, Y; Jiang, M; Li, L; Lin, Y; Liu, L; Liu, Y; Lu, A; Yang, B; Zha, Q, 2012
)
0.7
" We investigated the toxic effects of MnCl2 in an immortalized rat brain endothelial cell line (RBE4) and the protective effects of the radical scavenging aminosalicylic acids, 5-aminosalicylic acid (5-ASA) and 4-aminosalicylic acid (4-PAS)."( Comparison between 5-aminosalicylic acid (5-ASA) and para-aminosalicylic acid (4-PAS) as potential protectors against Mn-induced neurotoxicity.
Aschner, M; Batoreu, MC; Marreilha dos Santos, AP; Santos, D, 2013
)
0.39
" No significant difference was demonstrated in rates of adverse events or withdrawal due to adverse events."( Are there any differences in the efficacy and safety of different formulations of Oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? evidence from cochrane reviews.
Chande, N; Feagan, BG; MacDonald, JK, 2013
)
0.39
" Oral mesalamine is an effective and safe treatment of mild-to-moderate or quiescent ulcerative colitis regardless of the chosen formulation."( Are there any differences in the efficacy and safety of different formulations of Oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? evidence from cochrane reviews.
Chande, N; Feagan, BG; MacDonald, JK, 2013
)
0.87
" The older patient with IBD is more susceptible to disease-related complications and also to adverse events with therapy, particularly immunosuppression."( Medical management of inflammatory bowel disease in the elderly: balancing safety and efficacy.
Ha, CY, 2014
)
0.4
" However, its use is associated with a high rate of adverse effects (AEs) which can be cutaneous, hematological, renal, hepatic, gastrointestinal or neurological."( [Adverse effects of sulfasalazine: discussion of mechanism and role of sulfonamide structure].
Affes, H; Atheymen, R; Hammami, S; Ksouda, K; Mnif, L; Sahnoun, Z; Tahri, N; Zeghal, KM,
)
0.13
" The overall safety profile was good; no serious adverse events were recorded."( Safety and efficacy of sodium hyaluronate (IBD98E) in the induction of clinical and endoscopic remission in subjects with distal ulcerative colitis.
Danese, S; Fiorino, G; Gilardi, D; Naccarato, P; Sociale, OR, 2014
)
0.4
"IBD98E seems to be safe and effective for the induction of clinical and endoscopic remission."( Safety and efficacy of sodium hyaluronate (IBD98E) in the induction of clinical and endoscopic remission in subjects with distal ulcerative colitis.
Danese, S; Fiorino, G; Gilardi, D; Naccarato, P; Sociale, OR, 2014
)
0.4
" These adverse events appear to be caused by a hypersensitivity reaction and resolve after cessation of 5-ASA drugs."( Febrile pleuropericarditis, a potentially life-threatening adverse event of balsalazide--case report and literature review of the side effects of 5-aminosalicylates.
Coman, RM; Gjymishka, A; Glover, SC, 2014
)
0.4
" Safety assessments included monitoring of adverse events (AEs) and clinical laboratory tests."( Long-term safety and tolerability of once-daily mesalamine granules in the maintenance of remission of ulcerative colitis.
Barrett, AC; Bortey, E; Forbes, WP; Lichtenstein, GR; Paterson, C, 2014
)
0.66
" Adverse events at least possibly related to treatment were observed in 23%, 12."( Safety and activity of dersalazine sodium in patients with mild-to-moderate active colitis: double-blind randomized proof of concept study.
Panés, J; Pontes, C; Torres, F; Vives, R, 2014
)
0.4
" Weekly measurements of liver function tests may be necessary for early detection of adverse events."( Safety and activity of dersalazine sodium in patients with mild-to-moderate active colitis: double-blind randomized proof of concept study.
Panés, J; Pontes, C; Torres, F; Vives, R, 2014
)
0.4
" The toxic chemicals tested were acetaminophen (APAP), 5-aminosalicylic acid (5-ASA), tetracycline (TC), and sodium valproate (VPA)."( Toxicity of 50-nm polystyrene particles co-administered to mice with acetaminophen, 5-aminosalicylic acid or tetracycline.
Ishida, I; Isoda, K; Nozawa, T; Tezuka, M, 2014
)
0.4
" The occurrence of withdrawals due to adverse events was not shown different between budesonide, mesalazine and placebo, in both the induction and maintenance phases."( Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease.
Bonovas, S; Danese, S; Del Giovane, C; Fiorino, G; Moja, L, 2015
)
0.63
" Physicians who prescribe 5-aminosalicylate to patients with inflammatory bowel disease should be aware of this adverse event."( Chronic tubulointerstitial nephritis induced by 5-aminosalicylate in an ulcerative colitis patient: a rare but serious adverse event.
Chagas, C; Magalhães-Costa, P; Matos, L, 2015
)
0.42
" No serious adverse event, including progressive multifocal leukoencephalopathy, was observed, although more investigations are needed to confirm the safety profile of this drug."( Safety and Efficacy of AJM300, an Oral Antagonist of α4 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis.
Hibi, T; Iwakiri, R; Matsuoka, K; Motoya, S; Tominaga, K; Watanabe, K; Watanabe, M; Yoshimura, N, 2015
)
0.42
" Relapse was defined as revised Sutherland Disease Activity Index (SDAI) rectal bleeding score ≥1 and mucosal appearance score ≥2, UC flare, or UC-related adverse event (AE)."( Once-daily mesalamine granules for maintaining remission of ulcerative colitis: pooled analysis of efficacy, safety, and prognostic factors.
Barrett, AC; Bortey, E; Forbes, WP; Gordon, GL; Lichtenstein, GR; Murthy, U; Paterson, C; Pruitt, R; Sedghi, S; Zakko, SF, 2016
)
0.82
" Treatment-emergent adverse events were reported by ten subjects."( Randomized clinical trial: pharmacokinetics and safety of multimatrix mesalamine for treatment of pediatric ulcerative colitis.
Cuffari, C; Edwards, AY; Fyderek, K; Hossack, S; Korczowski, B; Martin, P; Pierce, D; Van Heusen, H; Wan, H, 2016
)
0.67
" The frequency of adverse events was comparable between groups, regardless of baseline 5-ASA use."( Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies.
Bosworth, BP; Harper, JR; Rubin, DT; Sandborn, WJ, 2016
)
0.43
"Budesonide foam was efficacious and safe for induction of remission of mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis in patients receiving oral 5-ASA at baseline and those who were not (Clinicaltrials."( Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies.
Bosworth, BP; Harper, JR; Rubin, DT; Sandborn, WJ, 2016
)
0.43
" Adverse events [AEs] in pre-specified categories and serious AEs were recorded at least every 6 months of the 5-year observation period."( Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn's Disease Treated With Infliximab [Remicade®] or Conventional Therapy.
Boice, J; Colombel, JF; Cornillie, F; D'Haens, G; Ghosh, S; Hommes, DW; Huang, Z; Huyck, S; Lindgren, S; Panes, J; Prantera, C; Reinisch, W, 2017
)
0.46
" The occurrence of adverse events was not significantly different between each treatments and placebo."( Efficacy and safety of rectal 5-aminosalicylic acid versus corticosteroids in active distal ulcerative colitis: a systematic review and network meta-analysis.
Ma, H; Ma, J; Sun, M; Wang, P; Zhang, H; Zhang, Y; Zhao, X; Zhou, C; Zhu, Y, 2017
)
0.46
"To summarise adverse drug events to mesalazine and recommend techniques for management."( Systematic review: safety of mesalazine in ulcerative colitis.
Aboubakr, A; Colombel, JF; Narula, N; Sehgal, P, 2018
)
0.48
" Data obtained from randomised controlled trials was used to estimate incidence rates of each adverse event."( Systematic review: safety of mesalazine in ulcerative colitis.
Aboubakr, A; Colombel, JF; Narula, N; Sehgal, P, 2018
)
0.48
" Adverse events attributed to mesalazine included inflammatory reactions, pancreatitis, cardiotoxicity, hepatotoxicity, musculoskeletal complaints, respiratory symptoms, nephropathies and sexual dysfunction."( Systematic review: safety of mesalazine in ulcerative colitis.
Aboubakr, A; Colombel, JF; Narula, N; Sehgal, P, 2018
)
0.48
" High-dose mesalazine appears to have similar safety profile as low dose, and is not associated with greater risk of adverse events."( Systematic review: safety of mesalazine in ulcerative colitis.
Aboubakr, A; Colombel, JF; Narula, N; Sehgal, P, 2018
)
0.48
"Despite NUDT15 variants showing significant association with thiopurine-induced adverse events (AEs) in Asians, it remains unclear which variants of NUDT15 or whether additional genetic variants should be tested to predict AEs."( NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study.
Andoh, A; Araki, H; Endo, K; Hanai, H; Hiraoka, S; Hisamatsu, T; Hokari, R; Ikeya, K; Ishiguro, Y; Kakuta, Y; Kawai, Y; Kinouchi, Y; Kobayashi, T; Masamune, A; Matsumoto, T; Miura, M; Mizuno, S; Moroi, R; Motoya, S; Naganuma, M; Nagasaki, M; Naito, T; Nakagawa, S; Nakagawa, T; Nakamura, S; Nakase, H; Nishida, A; Okamoto, D; Onodera, K; Sakuraba, H; Sasaki, M; Shiga, H; Shimosegawa, T; Shinozaki, M; Suzuki, Y; Takagawa, T; Takahara, M; Toyonaga, T; Yanai, S, 2018
)
0.48
" The rates of adverse events (AE), serious AEs, and steroid-related side-effects are similar to placebo and mesalamine and slightly inferior to traditional corticosteroids."( The safety of beclomethasone dipropionate in the treatment of ulcerative colitis.
Calabrese, C; Calafiore, A; Campieri, M; Gionchetti, P; Mazza, M; Rizzello, F; Salice, M, 2018
)
0.69
" The incidence of adverse events was 47."( Efficacy and Safety of Budesonide, vs Mesalazine or Placebo, as Induction Therapy for Lymphocytic Colitis.
Armerding, P; Aust, D; Böhm, G; Bonderup, O; Fernández-Bañares, F; Greinwald, R; Kupcinskas, J; Miehlke, S; Mihaly, E; Münch, A; Munck, LK; Nacak, T; Rehbehn, KU, 2018
)
0.48
"In a randomized multicenter study, we found oral budesonide 9 mg once daily to be effective and safe for induction of clinical and histologic remission in patients with lymphocytic colitis, compared with placebo."( Efficacy and Safety of Budesonide, vs Mesalazine or Placebo, as Induction Therapy for Lymphocytic Colitis.
Armerding, P; Aust, D; Böhm, G; Bonderup, O; Fernández-Bañares, F; Greinwald, R; Kupcinskas, J; Miehlke, S; Mihaly, E; Münch, A; Munck, LK; Nacak, T; Rehbehn, KU, 2018
)
0.48
" Also, no obvious difference was found between OD and BD regime dosing of mesalazine regardless of total adverse events, treatment-related adverse events or serious adverse events."( Efficacy and safety of once daily versus twice daily mesalazine for mild-to-moderate ulcerative colitis: A meta-analysis of randomized controlled trials.
Li, J; Qiu, C; Wang, B; Wang, X; Zhang, Q; Zhang, Z; Zheng, X, 2019
)
0.51
"OD is as effective and safe as BD regime dosing of mesalazine for active UC."( Efficacy and safety of once daily versus twice daily mesalazine for mild-to-moderate ulcerative colitis: A meta-analysis of randomized controlled trials.
Li, J; Qiu, C; Wang, B; Wang, X; Zhang, Q; Zhang, Z; Zheng, X, 2019
)
0.51
" The authors found that the treatment showed slightly adverse events in FAP patients."( Utility of Mesalazine in Familial Adenomatous Polyposis: Clinical Report of Reduction of Polyp Size in Patients with Ulcerative Colitis, and Safety Examination in Familial Adenomatous Polyposis Patients.
Abe, T; Doyama, H; Ezoe, Y; Ishikawa, H; Mutoh, M; Nakajima, T; Sakai, T; Takeuchi, Y; Wakabayashi, K, 2019
)
0.51
" Adverse events were reported in 58 (62%) of 93 patients in the upadacitinib group versus 52 (55%) of 94 in the placebo group."( Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial.
Chu, AD; Deodhar, A; Everding, A; Kim, TH; Kishimoto, M; Maksymowych, WP; Pangan, AL; Sieper, J; Song, IH; Sui, Y; van den Bosch, F; van der Heijde, D; Wang, X, 2019
)
0.51
" Treatment-emergent adverse events and morning cortisol levels were assessed throughout the treatment and follow-up phases."( Efficacy and safety of prolonged release budesonide granules in mesalazine-refractory ulcerative colitis: A multi-centre Phase IIa study (TOPICAL-1).
Derova, J; Fellermann, K; Greinwald, R; Jonaitis, L; Nacak, T; Rácz, I; Schiefke, I; Wehrum, S, 2020
)
0.56
" Adverse event rates were similar (QCHS granules 38."( Randomised clinical trial: Efficacy and safety of Qing-Chang-Hua-Shi granules in a multicenter, randomized, and double-blind clinical trial of patients with moderately active ulcerative colitis.
Chen, S; Chen, Y; Cheng, J; Gu, P; Gu, Q; Hu, J; Ke, X; Liu, Y; Ren, S; Shen, H; Shen, Z; Tang, Z; Xie, J; Zhang, L; Zhang, S; Zhao, W; Zheng, K; Zhu, L; Zou, J, 2021
)
0.62
" This case reinforces the possibility of a causal relationship between mesalazine therapy and toxic hepatic injury without systemic hypersensitivity."( "Hepatotoxicity in inflammatory bowel disease: mesalazine, the forgotten drug".
Garrido, I; Lopes, J; Lopes, S; Macedo, G; Santos, AL, 2021
)
0.62
"Paternal and maternal use of 5-ASA was safe across offspring outcomes; none of the findings reached statistical significance."( The safety of paternal and maternal use of 5-aminosalicylic acid during conception and pregnancy: a nationwide cohort study.
Friedman, S; Kjeldsen, J; Nielsen, J; Nørgård, BM, 2022
)
0.72
" Four (8%) developed nonserious adverse reactions and switched to 5-aminosalicylates (5-ASA) by 1 year."( Efficacy and Safety of Sulfasalazine Suspension in Children With Ulcerative Colitis.
Bousvaros, A; Chan, C; Liu, E; Mansuri, I; Rufo, PA; Wang, S, 2023
)
0.91
"SZ suspension is a safe and effective treatment for UC in children with difficulty swallowing a pill."( Efficacy and Safety of Sulfasalazine Suspension in Children With Ulcerative Colitis.
Bousvaros, A; Chan, C; Liu, E; Mansuri, I; Rufo, PA; Wang, S, 2023
)
0.91

Pharmacokinetics

Existing pharmacokinetic data are insufficient to determine whether a delayed-release formulation of mesalamine (Asacol) results in greater systemic exposure to 5-aminosalicylic acid and its major metabolite. Sulfamethoxazole exposure increased by a statistically significant amount when coadministered with MMX mesalamines.

ExcerptReferenceRelevance
" Following intravenous administration, the drug was rapidly eliminated with a plasma half-life of about 40 min, mainly due to rapid metabolism."( Pharmacokinetics of 5-aminosalicylic acid in man following administration of intravenous bolus and per os slow-release formulation.
Bondesen, S; Hansen, CP; Hansen, SH; Hegnhøj, J; Larsen, F; Rasmussen, SN, 1991
)
0.28
"The pharmacokinetic profile of a new 4-g 5-aminosalicyclic acid (5-ASA) retention enema, Mesasal, was investigated."( Steady-state pharmacokinetics of a new 4-gram 5-aminosalicylic acid retention enema in patients with ulcerative colitis in remission.
Almer, S; Norlander, B; Osterwald, H; Ström, M, 1991
)
0.28
" The purpose of this study was to compare the pharmacokinetic profile of this drug between two patient groups, with either inflamed small or large bowel and with volunteers."( Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet in patients with Crohn's disease or ulcerative colitis and in healthy volunteers.
Gotthard, R; Norlander, B; Ström, M, 1990
)
0.28
" The purpose of this study was to compare the pharmacokinetic profile of this product to sulphasalazine (SASP; Salazopyrin) and to assess the pharmacokinetics of a suppository 5-ASA dosage form."( Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet and suppository dosage form.
Gotthard, R; Norlander, B; Ström, M, 1989
)
0.28
" Sulphasalazine itself is poorly absorbed (3 to 12%) and its elimination half-life of about 5 to 10 hours is probably affected by the absorption process."( Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.
Klotz, U,
)
0.13
" The knowledge of the pharmacokinetic properties of 5-ASA from different drug formulations might contribute to a better understanding of its mode of action in IBD."( Pharmacology and pharmacokinetics of 5-aminosalicylic acid.
Klotz, U; Maier, KE, 1987
)
0.27
"5-Aminosalicylic acid-O-sulfate (5-ASA sulfate), a new agent for the treatment of ulcerative colitis and Crohn's disease of the large intestine, was investigated for its pharmacokinetic and toxicological properties, following local and systemic application."( Experimental studies on the pharmacokinetics and toxicity of 5-aminosalicylic acid-O-sulfate following local and systemic application.
Herzog, R; Leuschner, J, 1995
)
0.29
"The pharmacokinetic properties of benzalazine ((2-hydroxy-5-[(4-carboxyphenyl)azo]benzoic acid, CAS 64896-26-0), a new agent for the treatment of ulcerative colitis and Crohn's disease of the large intestine, were investigated."( Pharmacokinetic studies of benzalazine.
Herzog, R; Leuschner, J, 1994
)
0.29
" Although the time for the first appearance of 5-ASA into the systemic circulation was almost the same value between SASP capsule and PCC containing 5-ASA, longer Tmax was observed from SASP capsule than from PCC."( Application of a colon delivery capsule to 5-aminosalicylic acid and evaluation of the pharmacokinetic profile after oral administration to beagle dogs.
Funaoka, A; Matsuda, K; Sawada, K; Suzuki, H; Takada, K; Takaya, T, 1997
)
0.3
" This concept of drug targeting could be accomplished by both special galenic formulations and by utilizing the pharmacokinetic properties of the agents especially their high intestinal and hepatic presystemic elimination."( [Pharmacokinetic data for different 5-aminosalicylic acid and budesonide preparations].
Klotz, U, 1999
)
0.3
"A pharmacokinetic model of colon-specific drug delivery developed in a previous study has been validated by use of 5-aminosalicylic acid (5-ASA) as a model anti-inflammatory drug."( Validation of a pharmacokinetic model of colon-specific drug delivery and the therapeutic effects of chitosan capsules containing 5-aminosalicylic acid on 2,4,6-trinitrobenzenesulphonic acid-induced colitis in rats.
Fujita, T; Muranishi, S; Odoriba, T; Okabe, S; Terabe, A; Tozaki, H; Yamamoto, A, 1999
)
0.3
"The release of 5-ASA from various preparations depends on the presence of bacterial azoreductases (sulphasalazine, olsalazine, balsalazide) or the pharmacokinetic properties of the mesalazine-containing pharmaceutical preparations."( Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties.
Griga, T; May, B; Tromm, A,
)
0.13
" Since the factors that determine tissue drug concentrations are unknown we have studied the relationships between the oral dose of delayed-release mesalazine, rectal tissue drug concentrations and standard pharmacokinetic parameters."( Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters.
Ajjan, RA; Hussain, FN; Riley, SA, 2000
)
0.31
" Although significant differences are found between the various aminosalicylates in release patterns and the resulting pharmacokinetic parameters, no differences in therapeutic effects have been found in comparative studies."( Clinical pharmacokinetics of slow release mesalazine.
De Vos, M, 2000
)
0.31
": To quantify through systematic review the pharmacokinetic profiles of the oral delayed release and sustained release mesalazine (5-aminosalicylate, 5ASA) formulations (Asacol, Salofalk, Mesasal, Claversal, Pentasa) and pro-drugs (sulfasalazine, olsalazine, balsalazide) used in the management of ulcerative colitis."( Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis.
Hanauer, SB; Sandborn, WJ, 2003
)
0.32
": Selected articles had: (1) adult healthy volunteers or patients with ulcerative colitis and (2) quantification of pharmacokinetic data to include, at a minimum, urinary excretion of total 5ASA [5ASA plus N-Acetyl-5ASA (N-Ac-5ASA)]."( Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis.
Hanauer, SB; Sandborn, WJ, 2003
)
0.32
": Pharmacokinetic data (Tmax, Cmax, AUC, urinary excretion, faecal excretion) of 5ASA, its major metabolite N-Acetyl-5ASA, total 5ASA, and the parent pro-drug compounds was extracted."( Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis.
Hanauer, SB; Sandborn, WJ, 2003
)
0.32
"Existing pharmacokinetic data are insufficient to determine whether a delayed-release formulation of mesalamine (Asacol) results in greater systemic exposure to 5-aminosalicylic acid and its major metabolite N-acetyl-5-aminosalicylic acid than a prodrug (balsalazide)."( Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers.
Buch, A; Hanauer, SB; Sandborn, WJ, 2004
)
0.76
"To determine the pharmacokinetic parameters of 5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid from equimolar doses of 5-aminosalicylic acid administered as Asacol and balsalazide."( Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers.
Buch, A; Hanauer, SB; Sandborn, WJ, 2004
)
0.54
" Pharmacokinetic parameters assessed for 5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid included: percentage of dose excreted in urine (A(e)%), area under the plasma concentration-time curve (AUCt(last)); and maximum plasma concentration (C(max))."( Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers.
Buch, A; Hanauer, SB; Sandborn, WJ, 2004
)
0.54
"The systemic absorption of 5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid from Asacol and balsalazide are comparable based upon plasma pharmacokinetic parameters and urinary excretion values."( Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers.
Buch, A; Hanauer, SB; Sandborn, WJ, 2004
)
0.54
" In children, pharmacokinetic data are scarce, and dosage recommendations are largely extrapolated from studies in adults."( Pharmacokinetics of mesalazine pellets in children with inflammatory bowel disease.
Benninga, MA; Dilger, K; Escher, JC; Taminiau, J; Trenk, D; van Boxtel, CJ; Wiersma, H, 2004
)
0.32
"To examine the in vivo pharmacokinetic interaction between mesalazine and mercaptopurine."( The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients.
Bierau, J; Bos, LP; Derijks, LJ; Engels, LG; Gilissen, LP; Hooymans, PM; Stockbrügger, RW; van Gennip, A, 2005
)
0.33
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" Statistics provided no evidence for a true difference in mesalazine pharmacokinetics between slow and rapid acetylators, and no significant correlation between NAT2 activity and any mesalazine pharmacokinetic parameter was found."( Mesalazine pharmacokinetics and NAT2 phenotype.
Fuhr, U; Jetter, A; Kinzig, M; Lück, H; Sörgel, F, 2009
)
0.35
" Pharmacokinetic parameters for balsalazide, 5-aminosalicylic acid, and N-acetyl-5-aminosalicylic acid were determined at 2 weeks."( Safety, efficacy, and pharmacokinetics of balsalazide in pediatric patients with mild-to-moderate active ulcerative colitis: results of a randomized, double-blind study.
Attard, TM; Bortey, E; Forbes, WP; Heyman, MB; Pieniaszek, HJ; Pohl, JF; Quiros, JA; Walker, K, 2009
)
0.35
"To evaluate the potential for pharmacokinetic interactions between MMX mesalamine and amoxicillin, ciprofloxacin extended release (XR), metronidazole, or sulfamethoxazole in four open-label, randomized, placebo-controlled, two-period crossover studies."( Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials.
Barrett, K; Corcoran, M; Inglis, S; Martin, P; Pierce, D; Preston, P; Thompson, TN; Willsie, SK, 2014
)
0.99
" Sulfamethoxazole exposure increased by a statistically significant amount when coadministered with MMX mesalamine; however, increased exposure (by 12% in Cmax at steady state; by 15% in AUC at steady state) was not considered clinically significant, as the 90% CIs for each point estimate fell entirely within the predefined equivalence range."( Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials.
Barrett, K; Corcoran, M; Inglis, S; Martin, P; Pierce, D; Preston, P; Thompson, TN; Willsie, SK, 2014
)
0.97
"To evaluate pharmacokinetic and safety profiles of 5-ASA and metabolite acetyl-5-ASA (Ac-5-ASA) after once-daily, oral administration of multimatrix mesalamine to children and adolescents with UC."( Randomized clinical trial: pharmacokinetics and safety of multimatrix mesalamine for treatment of pediatric ulcerative colitis.
Cuffari, C; Edwards, AY; Fyderek, K; Hossack, S; Korczowski, B; Martin, P; Pierce, D; Van Heusen, H; Wan, H, 2016
)
0.87
" 5-ASA and Ac-5-ASA plasma and urine concentrations were analyzed by non-compartmental methods and used to develop a population pharmacokinetic model."( Randomized clinical trial: pharmacokinetics and safety of multimatrix mesalamine for treatment of pediatric ulcerative colitis.
Cuffari, C; Edwards, AY; Fyderek, K; Hossack, S; Korczowski, B; Martin, P; Pierce, D; Van Heusen, H; Wan, H, 2016
)
0.67
"Children and adolescents with UC receiving multimatrix mesalamine demonstrated 5-ASA and Ac-5-ASA pharmacokinetic profiles similar to historical adult data."( Randomized clinical trial: pharmacokinetics and safety of multimatrix mesalamine for treatment of pediatric ulcerative colitis.
Cuffari, C; Edwards, AY; Fyderek, K; Hossack, S; Korczowski, B; Martin, P; Pierce, D; Van Heusen, H; Wan, H, 2016
)
0.92
" This study aimed to obtain the pharmacokinetic profiles, tissue distribution and plasma protein binding of C2 in Wistar Rats."( Pharmacokinetics in Wistar Rats of 5-[(4-Carboxybutanoyl)Amino]-2-Hydroxybenzoic Acid: A Novel Synthetic Derivative of 5-Aminosalicylic Acid (5-ASA) with Possible Anti-Inflammatory Activity.
Correa-Basurto, J; Gutiérrez-Sánchez, M; Mendieta-Wejebe, JE; Padilla Martínez, II; Romero-Castro, A; Rosales Hernández, MC, 2016
)
0.43
" The pharmacokinetic parameters were determined by noncompartmental methods and analyzed with a linear mixed-effect model."( Effects of Differential Food Patterns on the Pharmacokinetics of Enteric-Coated Mesalazine Tablets in the Same Cohort of Healthy Chinese Volunteers.
Cai, HL; Chen, Y; Guo, L; Huang, XM; Li, Y; Wei, SS; Wu, XX; Zhang, BK; Zhang, SH, 2020
)
0.56
"In this study, a new, fast and sensitive HPLC method with fluorometric detection was developed for the determination of mesalazine in human plasma and applied to a pharmacokinetic study."( Development of An HPLC Method for the Determination of Mesalazine in Human Plasma by Fluorimetric Derivatization and Application to A Prototype Pharmacokinetic Study.
Ceylan, B; Önal, C; Tekkeli, EK, 2022
)
0.72
" Through population pharmacokinetic (PK) analysis and in-vitro in-vivo correlation (IVIVC) modeling on the dissolution and BE data of a generic enteric-coated product (EM) and its reference Salofalk® 250 mg tablet (SM), we for the first time revealed the underlying mechanism of the high inter-subject variability for such delayed-release formulation."( Population pharmacokinetics and IVIVC for mesalazine enteric-coated tablets.
Gao, F; Leng, W; Wo, SK; Yan, X; Zhang, Y; Zuo, Z, 2022
)
0.72
" Mechanisms of combination therapy have been widely discussed from a pharmacodynamic perspective."( Pharmacokinetic and gut microbiota analyses revealed the effect of Lactobacillus acidophilus on the metabolism of Olsalazine in ulcerative colitis rats.
Feng, Y; Li, Z; Liu, L; Ma, S; Mei, Q; Wang, J; Wang, S; Wang, X; Wang, Y; Xu, Z; Yan, R; Yang, P, 2022
)
0.72

Compound-Compound Interactions

Bifidobacterium quadruple viable bacteria combined with mesalamine has a satisfactory effect in the treatment of UC in China. The clinical improvement correlates with a decrease of chemokines such as MCP-1 and IL-8.

ExcerptReferenceRelevance
"Beclomethasone dipropionate enemas combined with oral 5-aminosalicylic acid may be a safe and useful therapeutic approach in the treatment of ulcerative colitis not responsive to oral 5-aminosalicylic acid alone."( Beclomethasone dipropionate (3 mg) enemas combined with oral 5-ASA (2.4 g) in the treatment of ulcerative colitis not responsive to oral 5-ASA alone.
Bennato, R; Castiglione, GN; D'Arienzo, A; Manguso, F; Mazzacca, G; Sanges, M; Scaglione, G; Vicinanza, G, 1998
)
0.3
"To investigate the effects of 5-aminosalicylic acid (5-ASA) in combination with nimesulide on the proliferation of HT-29 colon carcinoma cells and its potential mechanisms."( 5-aminosalicylic acid in combination with nimesulide inhibits proliferation of colon carcinoma cells in vitro.
Fang, HM; Ma, WJ; Mei, Q; Xu, JM, 2007
)
0.34
" 5-ASA in combination with nimesulide suppressed the proliferation of HT-29 colon carcinoma cells more than either of these agents in a dose-dependent and time-dependent manner (t=5."( 5-aminosalicylic acid in combination with nimesulide inhibits proliferation of colon carcinoma cells in vitro.
Fang, HM; Ma, WJ; Mei, Q; Xu, JM, 2007
)
0.34
"In group A (oral NAC combined with mesalamine) contrarily to group B (mesalamine alone), the clinical improvement correlates with a decrease of chemokines such as MCP-1 and IL-8."( N-acetyl-L-cysteine combined with mesalamine in the treatment of ulcerative colitis: randomized, placebo-controlled pilot study.
Arriaza, E; Castillejo, MS; Delgado, M; Gisbert, JP; Gonzalez Lara, V; Guijarro, LG; Marin-Jimenez, I; Mate, J; Olleros, T; Pena, AS; Perez-Calle, JL; Prieto-Merino, D, 2008
)
0.9
"To investigate the effect of herb-partitioned moxibustion combined with acupuncture on the expression of intestinal epithelial tight junction (TJ) proteins."( Moxibustion combined with acupuncture increases tight junction protein expression in Crohn's disease patients.
Bao, CH; Chen, WF; Ji, R; Shang, HX; Shi, Y; Wang, AQ; Wu, HG; Wu, LY; Zhao, JM, 2015
)
0.42
"Sixty patients diagnosed with mild to moderate Crohn's disease (CD) were allocated into the herb-partitioned moxibustion combined with acupuncture (HMA) group (n = 30) or the mesalazine (MESA) group (n = 30) using a parallel control method."( Moxibustion combined with acupuncture increases tight junction protein expression in Crohn's disease patients.
Bao, CH; Chen, WF; Ji, R; Shang, HX; Shi, Y; Wang, AQ; Wu, HG; Wu, LY; Zhao, JM, 2015
)
0.42
"After the treatment, both herb-partitioned moxibustion combined with acupuncture and mesalazine improved intestinal morphology and ultrastructure of CD patients; the patients treated with HMA showed better improvement."( Moxibustion combined with acupuncture increases tight junction protein expression in Crohn's disease patients.
Bao, CH; Chen, WF; Ji, R; Shang, HX; Shi, Y; Wang, AQ; Wu, HG; Wu, LY; Zhao, JM, 2015
)
0.42
"Present investigation is conducted to investigate the clinical efficacy of mesalazine in combination with the Bifid Triple Viable Capsules on the ulcerative colitis (UC) and the resultant effect on the inflammatory factors (TNF-α, IL-8 and IL-10) of UC patients."( Efficacy of mesalazine in combination with bifid triple viable capsules on ulcerative colitis and the resultant effect on the inflammatory factors.
Chen, J; Chen, Z; Huang, M; Lang, C; Xue, L; Yang, B; Zhang, Y, 2018
)
0.48
" Its combination with bifid triple viable could mitigate adverse effects."( Effects of mesalazine combined with bifid triple viable on intestinal flora, immunoglobulin and levels of cal, MMP-9, and MPO in feces of patients with ulcerative colitis.
Jiang, XE; Yang, SM; Zhang, Y; Zhou, XJ, 2020
)
0.56
"5 g/d) combined with bifid triple viable (1."( Effects of mesalazine combined with bifid triple viable on intestinal flora, immunoglobulin and levels of cal, MMP-9, and MPO in feces of patients with ulcerative colitis.
Jiang, XE; Yang, SM; Zhang, Y; Zhou, XJ, 2020
)
0.56
"Mesalazine combined with bifid triple viable is able to enhance the curative effect for UC, improve the composition of intestinal flora, weaken the immune response, and reduce levels of Cal and MMP-9 in the intestinal tract."( Effects of mesalazine combined with bifid triple viable on intestinal flora, immunoglobulin and levels of cal, MMP-9, and MPO in feces of patients with ulcerative colitis.
Jiang, XE; Yang, SM; Zhang, Y; Zhou, XJ, 2020
)
0.56
" We, therefore, conduct a randomized and controlled trial to evaluate the efficacy and safety of mesalazine enteric-coated tablets combined with Kangfuxin Liquid (KFX) enema for the child-bearing period female with active UC."( Effect of Kangfuxin Liquid enema combined with mesalazine on gestational outcomes and quality of life in child-bearing female with active ulcerative colitis: A protocol for randomized, double-blind, controlled trial.
Li, F; Lu, H; Wang, T; Zhang, Q, 2021
)
0.62
" The control group will be taken mesalazine enteric-coated tablets combined with placebo enema and the experimental group will be taken mesalazine enteric-coated tablets combined with KFX enema."( Effect of Kangfuxin Liquid enema combined with mesalazine on gestational outcomes and quality of life in child-bearing female with active ulcerative colitis: A protocol for randomized, double-blind, controlled trial.
Li, F; Lu, H; Wang, T; Zhang, Q, 2021
)
0.62
"To systematically assess effectiveness and safety of Bifidobacterium quadruple viable bacteria combined with mesalamine against ulcerative colitis (UC) in the Asian population."( Efficacy and Safety of Bifidobacterium Quadruple Viable Bacteria Combined with Mesalamine against UC Management: A Systematic Review and Meta-Analysis.
Chen, Y; Fan, Y; Li, S; Li, W; Lv, Q; Sun, X; Xie, F; Yang, X, 2022
)
1.16
"An electronic search was conducted in PubMed, Embase, Cochrane Library, CNKI, VIP, and Wanfang databases for a random collection of controlled trials of Bifidobacterium quadruple viable bacteria combined with mesalamine against UC."( Efficacy and Safety of Bifidobacterium Quadruple Viable Bacteria Combined with Mesalamine against UC Management: A Systematic Review and Meta-Analysis.
Chen, Y; Fan, Y; Li, S; Li, W; Lv, Q; Sun, X; Xie, F; Yang, X, 2022
)
1.14
"In conclusion, the current meta-analysis shows that Bifidobacterium quadruple viable bacterium combined with mesalamine has a satisfactory effect in the treatment of UC in China, and its safety is better than that of mesalamine or Bifidobacterium quadruple viable bacteria alone."( Efficacy and Safety of Bifidobacterium Quadruple Viable Bacteria Combined with Mesalamine against UC Management: A Systematic Review and Meta-Analysis.
Chen, Y; Fan, Y; Li, S; Li, W; Lv, Q; Sun, X; Xie, F; Yang, X, 2022
)
1.16

Bioavailability

ExcerptReferenceRelevance
"The local and systemic bioavailability of a mesalazine enema (Pentasa, Ferring A/S, Denmark) and a mesalazine suppository (Pentasa, Ferring) was assessed during steady-state conditions."( Availability of mesalazine (5-aminosalicylic acid) from enemas and suppositories during steady-state conditions.
Abildgaard, K; Christensen, LA; Fallingborg, J; Hansen, SH; Jacobsen, BA; Rasmussen, HH; Rasmussen, SN, 1991
)
0.28
"The aim of this investigation was to compare two formulations of the prodrug olsalazine (OLZ) with regard to local bioavailability of 5-aminosalicylic acid (5-ASA) in the colon."( Relative bioavailability of olsalazine from tablets and capsules: a drug targeted for local effect in the colon.
Huitfeldt, B; Pettersson, R; Ryde, M, 1991
)
0.28
"The bioavailability of three pure 5-aminosalicylic (5-ASA) preparations (Asacol, Claversal, and Pentasa) was studied in 8 ileostomy patients and 12 normal subjects after 6 days of treatment with 2000 mg 5-ASA."( Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man.
Abildgaard, K; Bondesen, S; Christensen, LA; Fallingborg, J; Hansen, SH; Hvidberg, EF; Jacobsen, BA; Rasmussen, SN; Sanchez, G, 1990
)
0.28
" Variations in gastric pH have negligible effect on the bioavailability of mesalazine in vivo."( Absorption of oral mesalazine-containing preparations and the influence of famotidine on the absorption.
Mulder, CJ; Rietbroek, R; Stolk, LM; Tytgat, GN; Verbeek, C; Wiltink, EH, 1990
)
0.28
" Food coadministration reduced 5-ASA and acetyl 5-ASA systemic relative bioavailability to 44% and 76%, respectively, compared with the fasting treatment."( Effect of food coadministration on 5-aminosalicylic acid oral suspension bioavailability.
Eichmeier, LS; Elvin, AT; Giesing, DH; Lanman, MB; Lanman, RC; Morrill, B; Yu, DK, 1990
)
0.28
" Sulphasalazine itself is poorly absorbed (3 to 12%) and its elimination half-life of about 5 to 10 hours is probably affected by the absorption process."( Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.
Klotz, U,
)
0.13
" The mean plasma levels and AUC values confirmed that the active substance is poorly absorbed by rectal route."( 5-Aminosalicylic acid in patients with ulcerative colitis in remission: plasma levels after administration of a new rectal enema.
Barbara, L; Belluzzi, A; Brignola, C; Campieri, M; Gionchetti, P; Miglioli, M; Tabanelli, GM; Torresan, F, 1988
)
0.27
"Knowledge of the bioavailability of 5-aminosalicylic acid (5-ASA, mesalazine) from the different 5-ASA-containing drugs is important for rational therapy of inflammatory bowel diseases."( Comparative bioavailability of 5-aminosalicylic acid from a controlled release preparation and an azo-bond preparation.
Abildgaard, K; Christensen, LA; Fallingborg, J; Hansen, SH; Jacobsen, BA; Rasmussen, HH; Rasmussen, SN, 1994
)
0.29
"The local and systemic bioavailability of 5-ASA from a controlled release 5-ASA preparation (Pentasa--2, 4 or 6 g/day) was investigated and compared with the azo-bond 5-ASA preparation olsalazine (Dipentum--2 g/day) in 13 healthy volunteers during steady state conditions."( Comparative bioavailability of 5-aminosalicylic acid from a controlled release preparation and an azo-bond preparation.
Abildgaard, K; Christensen, LA; Fallingborg, J; Hansen, SH; Jacobsen, BA; Rasmussen, HH; Rasmussen, SN, 1994
)
0.29
"The bioavailability of a controlled release 5-aminosalicyclic acid preparation (Pentasa) was investigated in nine healthy children after a medication period of six days (1000 mg/day) and compared with sulfasalazine (Salazopyrin) (2000 mg/day)."( Bioavailability of 5-aminosalicyclic acid from slow release 5-aminosalicyclic acid drug and sulfasalazine in normal children.
Abildgaard, K; Christensen, LA; Fallingborg, J; Hansen, SH; Jacobsen, BA; Rasmussen, HH; Rasmussen, SN, 1993
)
0.29
" In none of the pharmacokinetic parameters of 5-ASA characterizing bioavailability (e."( Steady state disposition of 5-aminosalicyclic acid following oral dosing.
Klotz, U; Stracciari, GL, 1993
)
0.29
" Colonic delivery of azathioprine may reduce its systemic bioavailability and limit toxicity."( Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration.
Lipsky, JJ; Mahoney, DW; Mays, DC; Sandborn, WJ; Tremaine, WJ; Van Os, EC; Zins, BJ; Zinsmeister, AR, 1996
)
0.29
"To determine the bioavailability of 6-mercaptopurine after administration of azathioprine via three colonic delivery formulations."( Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration.
Lipsky, JJ; Mahoney, DW; Mays, DC; Sandborn, WJ; Tremaine, WJ; Van Os, EC; Zins, BJ; Zinsmeister, AR, 1996
)
0.29
"The bioavailabilities of 6-mercaptopurine after colonic azathioprine administration via delayed release oral, hydrophobic rectal foam, and hydrophilic rectal foam (7%, 5%, 1%; respectively) were significantly lower than the bioavailability of 6-mercaptopurine after oral azathioprine administration (47%) by Wilcoxon rank sum pairwise comparison."( Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration.
Lipsky, JJ; Mahoney, DW; Mays, DC; Sandborn, WJ; Tremaine, WJ; Van Os, EC; Zins, BJ; Zinsmeister, AR, 1996
)
0.29
" The bioavailability of these drugs depends on their coating."( Gastrointestinal pH profiles in patients with inflammatory bowel disease.
Ewe, K; Fuchs, B; Fuchs, M; Hauptmann, IA; Hauptmann, L; Press, AG; Ramadori, G, 1998
)
0.3
" It is conceivable that reduced intracolonic pH in active ulcerative colitis impairs bioavailability of 5-aminosalicylic acid from pH dependent release formulations (Asacol, Salofalk) and those requiring cleavage by bacterial azo reductase (sulphasalazine, olsalazine, balsalazide), but further pharmacokinetic studies are needed to confirm this possibility."( Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs.
Evans, DF; Kumar, D; Nugent, SG; Rampton, DS, 2001
)
0.31
") transit time of small intestine and the bioavailability (AUC(0-->t*)) of the drug was found to be 85."( An in vitro and in vivo investigation into the suitability of bacterially triggered delivery system for colon targeting.
Jenita, JA; Muthulingam, C; Raghavan, CV; Ravi, TK, 2002
)
0.31
" It is widely accepted that for medicinal products not intended to be delivered into the systemic circulation, pharmacokinetic bioavailability cannot be used."( Bioequivalence testing for locally acting gastrointestinal products: what role for gamma scintigraphy?
Wilding, I, 2002
)
0.31
"Mesalazine is released in the rectum of patients, with a bioavailability of about 40%."( Rectal tissue, plasma and urine concentrations of mesalazine after single and multiple administrations of 500 mg suppositories to healthy volunteers and ulcerative proctitis patients.
Aumais, G; Bitton, A; Giard, A; Lefebvre, M; Madi, M; Martin, F; Spénard, J; Tremblay, C, 2003
)
0.32
" median relative bioavailability of 60 mL rectal foam: 36%)."( A clinical trial on absorption and N-acetylation of oral and rectal mesalazine.
Cap, M; Cascorbi, I; Dilger, K; Kreisel, W; Novacek, G; Remmler, C; Rössle, M; Trenk, D; Wacheck, V; Zähringer, A, 2007
)
0.34
"The purpose of this study was to develop a physiologically based simulation tool that is able to predict local as well as systemic bioavailability of 5-aminosalicylic acid (5-ASA)-targeted delivery formulations using the existing understanding of the transport and metabolism mechanisms of 5-ASA."( SIMDOT-AbMe: microphysiologically based simulation tool for quantitative prediction of systemic and local bioavailability of targeted oral delivery formulations.
Farhadi, A; Haddish-Berhane, N; Haghighi, K; Keshavarzian, A; Nyquist, C, 2009
)
0.35
" These "in combo" PAMPA data were used to predict the human absolute bioavailability of the ampholytes."( The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
Avdeef, A; Sun, N; Tam, KY; Tsinman, O, 2010
)
0.36
" Our results demonstrate that DSMs can be considered as a non-cytotoxic biomaterial with high potential to improve the mesalamine and prednisone bioavailability by sustaining the drug release and enhancing drug permeability."( Diatom silica microparticles for sustained release and permeation enhancement following oral delivery of prednisone and mesalamine.
da Silva, TH; Hirvonen, JT; Mäkilä, EM; Reis, RL; Salonen, JJ; Santos, HA; Shahbazi, MA; Zhang, H, 2013
)
0.81
"The purpose was to propose two-stage single-compartment models for evaluating dissolution characteristics in distal ileum and ascending colon, under conditions simulating the bioavailability and bioequivalence studies in fasted and fed state by using the mini-paddle and the compendial flow-through apparatus (closed-loop mode)."( Two-Stage Single-Compartment Models to Evaluate Dissolution in the Lower Intestine.
Kesisoglou, F; Markopoulos, C; Reppas, C; Symillides, M; Vertzoni, M, 2015
)
0.42
"5 g/mL and an AUCtot value of 157 μg min-1/mL; the oral bioavailability was approximately 13%."( Pharmacokinetics in Wistar Rats of 5-[(4-Carboxybutanoyl)Amino]-2-Hydroxybenzoic Acid: A Novel Synthetic Derivative of 5-Aminosalicylic Acid (5-ASA) with Possible Anti-Inflammatory Activity.
Correa-Basurto, J; Gutiérrez-Sánchez, M; Mendieta-Wejebe, JE; Padilla Martínez, II; Romero-Castro, A; Rosales Hernández, MC, 2016
)
0.43
"Absorption windows in particular segments of the small intestine can contribute to the development of orally administered drug formulations and can limit the bioavailability of released compounds."( The Importance of Wireless Capsule Endoscopy for Research into the Intestin al Absorption Window of 5-Aminosalicylic Acid in Experimental Pigs.
Bures, J; Kopacova, M; Kunes, M; Kvetina, J; Nobilis, M; Tacheci, I, 2017
)
0.46
" The delayed release and the lower bioavailability of 5-ASA from xylan-5-ASA conjugate administration compared to free 5-ASA administration confirmed the successful local colon delivery of 5-ASA using xylan-5-ASA conjugate."( Xylan from Pineapple Stem Waste: a Potential Biopolymer for Colonic Targeting of Anti-inflammatory Agent Mesalamine.
Anindya, AL; Damayanti, S; Kurniati, NF; Oktaviani, RD; Praevina, BR; Rachmawati, H; Riani, C, 2019
)
0.73
"This study aimed to simultaneously determine mesalazine (5-ASA) and its major metabolite N-Ac-5-ASA in the plasma and to evaluate the impact of different food patterns on the relative bioavailability and pharmacokinetics of a single oral dose of 5-ASA in healthy subjects."( Effects of Differential Food Patterns on the Pharmacokinetics of Enteric-Coated Mesalazine Tablets in the Same Cohort of Healthy Chinese Volunteers.
Cai, HL; Chen, Y; Guo, L; Huang, XM; Li, Y; Wei, SS; Wu, XX; Zhang, BK; Zhang, SH, 2020
)
0.56
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Because 5-ASA is well absorbed in the small intestine, very high dose of 5-ASA is required to deliver it to the large intestine which is a target site."( Transport characteristics of 5-aminosalicylic acid into colonic epithelium: Involvement of sodium-coupled monocarboxylate transporter SMCT1-mediated transport system.
Fujita, T; Kono, Y; Yuri, T, 2020
)
0.56
" Because 5-ASA is well absorbed from the small intestine when orally administered, several 5-ASA formulations for selective delivery to the colon have been developed and used in clinical practice."( Transport Characteristics of 5-Aminosalicylic Acid Derivatives Conjugated with Amino Acids via Human H
Fujita, T; Kono, Y; Miyauchi, S; Okada, T; Terada, T; Yuri, T, 2020
)
0.56
"The use of PAMAM macromolecule as a carrier for mesalazine increases the bioavailability of the drug, ensuring enhanced cellular uptake and bypassing the need to utilize mesalazine-specific membrane transporters."( Mesalazine-PAMAM Nanoparticles for Transporter-Independent Intracellular Drug Delivery: Cellular Uptake and Anti-Inflammatory Activity.
Gorzkiewicz, M; Karwaciak, I; Klajnert-Maculewicz, B; Marcinkowska, M; Pulaski, L; Studzian, M, 2023
)
0.91

Dosage Studied

Once-daily dosing with mesalamine is as effective as conventional dosing schedules for the prevention of relapse of quiescent UC. Relapse rates were not significantly different between once-daily and conventional doses schedules.

ExcerptRelevanceReference
" This dosage form provides the possibility to deliver drug to the lower intestinal tract with minimal early release, followed by sustained release in the colon."( Calcium alginate beads as core carriers of 5-aminosalicylic acid.
Ayres, JW; Lin, SY, 1992
)
0.28
" Incubation with higher concentrations of the drugs revealed a dose-response effect on binding with complete inhibition by 100 mM 4ASA and 10 mM olsalazine, and lesser degrees of inhibition by 100 mM 5ASA, N-acetyl-5ASA, and N-acetyl-4ASA."( Inhibition of binding of interferon-gamma to its receptor by salicylates used in inflammatory bowel disease.
Aronson, JK; Crotty, B; Jewell, DP; Rosenberg, WM, 1992
)
0.28
"The history, pharmacology, pharmacokinetics, clinical uses and efficacy, adverse effects, drug interactions, and dosage and administration of rectal mesalamine and oral olsalazine in the treatment of inflammatory bowel disease (IBD) are reviewed."( Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease.
Gales, BJ; Segars, LW, 1992
)
1.93
" This may be of interest in the design of controlled-release formulations and dosage regimes for the treatment of diseases of the small-bowel, where 5-ASA is easily absorbed."( Pharmacokinetics of 5-aminosalicylic acid in man following administration of intravenous bolus and per os slow-release formulation.
Bondesen, S; Hansen, CP; Hansen, SH; Hegnhøj, J; Larsen, F; Rasmussen, SN, 1991
)
0.28
" This study suggests that 1 g 5-ASA (in a 100 ml enema) is a sufficient dosage for patients with a mild to moderate attack of ulcerative colitis."( Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis.
Barbara, L; Belluzzi, A; Brignola, C; Campieri, M; Gionchetti, P; Iannone, P; Miglioli, M; Tampieri, M, 1991
)
0.28
" Our data suggest that both the route of drug administration and dosing regimen employed affect the antiinflammatory potency and/or efficacy of compounds on colitis induced by acetic acid in the rat."( Antiinflammatory effects of various drugs on acetic acid induced colitis in the rat.
Bostwick, JS; Decktor, DL; Fitzpatrick, LR; Pendleton, RG; Renzetti, M, 1990
)
0.28
" To avoid the side effects associated with sulfapyridine, researchers have developed dosage forms that deliver mesalazine to the site of inflammation."( Pharmaceutic development: mesalazine.
Osterwald, HP, 1990
)
0.28
" For subjects in a fasting state, plasma 5-ASA and acetyl 5-ASA concentrations peaked rapidly 1 hour after dosing to 14."( Effect of food coadministration on 5-aminosalicylic acid oral suspension bioavailability.
Eichmeier, LS; Elvin, AT; Giesing, DH; Lanman, MB; Lanman, RC; Morrill, B; Yu, DK, 1990
)
0.28
" The purpose of this study was to compare the pharmacokinetic profile of this product to sulphasalazine (SASP; Salazopyrin) and to assess the pharmacokinetics of a suppository 5-ASA dosage form."( Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet and suppository dosage form.
Gotthard, R; Norlander, B; Ström, M, 1989
)
0.28
" There are no data to suggest that patients unresponsive to oral sulfasalazine will respond to 5-ASA in any form, although it is possible that better toleration of the 5-ASA formulations will allow more effective dosage levels to be delivered."( New oral salicylates in the therapy of chronic idiopathic inflammatory bowel disease.
Robinson, MG, 1989
)
0.28
" Metronidazole and azathioprin are considered to be reserve drugs and can be used in the treatment of fistulae or in order to cut down the dosage of prednisolone during remission."( [Drug therapy of chronic inflammatory intestinal diseases--current status of 5-aminosalicylic acid].
Gerok, W; Schölmerich, J, 1986
)
0.27
" In an apparently all-or-none manner, both caused a sinistral shift in dose-response curves for the phasic component of the contractile response to histamine at H1 receptors on the ileum."( Metronidazole and 5-aminosalicylic acid enhance the contractile activity of histaminergic agonists on the guinea-pig isolated ileum.
Barker, LA; Winbery, SL, 1986
)
0.27
" Specific procedures of preparation and dosage remain to be established."( New enema treatments for inflammatory bowel disease.
Karp, LC; Targan, SR, 1988
)
0.27
" The present results indicate that 5-ASA, at least in the dosage used, is not superior to placebo."( 5-Aminosalicylic acid in the treatment of Crohn's disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa.
Binder, V; Bytzer, P; Jacobsen, O; Ladefoged, K; Lauritsen, K; Nielsen, OH; Rask-Madsen, J; Rasmussen, SN; Tage-Jensen, U; Vilien, M, 1987
)
0.27
"A controlled trial has been carried out in order to compare the efficacy of enemas containing a high dosage of 5-ASA (4 g) versus enemas containing hydrocortisone 100 mg."( Efficacy of 5-aminosalicylic acid enemas versus hydrocortisone enemas in ulcerative colitis.
Barbara, L; Bazzocchi, G; Belluzzi, A; Brignola, C; Campieri, M; Gionchetti, P; Migaldi, M; Miglioli, M; Tabanelli, GM, 1987
)
0.27
" In conclusion, the present data would suggest that the new oral dosage form delivers sufficient amounts of therapeutically active 5-AS for local and systemic action in patients with inflammatory bowel disease."( A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics.
Bauer, KH; Fischer, C; Klotz, U; Maier, KE, 1985
)
0.27
"Miniaturised methods have been used to construct dose-response curves for the effects of inhibitory drugs on prostaglandin synthesis using individual rectal biopsies obtained from patients with ulcerative colitis."( Inhibition of prostaglandin synthetase in human rectal mucosa.
Hawkey, CJ; Lo Casto, M, 1983
)
0.27
" A pharmacokinetic comparison of polymer and SASP showed similar deliveries of 5-ASA and metabolites to the lower bowel, blood, and urine of orally dosed rats."( A polymeric drug for treatment of inflammatory bowel disease.
Brown, JP; McGarraugh, GV; Onderdonk, AB; Parkinson, TM; Wingard, RE, 1983
)
0.27
" Plasma and urine concentrations of 5-AS and its acetylated major metabolite (AcAS) were monitored during one dosing interval."( Disposition of 5-aminosalicylic acid, the active metabolite of sulphasalazine, in man.
Fischer, C; Klotz, U; Maier, K; Stumpf, E; von Gaisberg, U, 1983
)
0.27
"5-Aminosalicylic acid (5-ASA) is the active component of Salazopyrin and induces a prompt and excellent improvement, when administered as high dosage enema, in patients suffering from active ulcerative colitis."( A double-blind clinical trial to compare the effects of 4-aminosalicylic acid to 5-aminosalicylic acid in topical treatment of ulcerative colitis.
Bazzocchi, G; Bertoni, F; Brignola, C; Campieri, M; Labò, G; Lanfranchi, GA; Minguzzi, MR, 1984
)
0.27
"To compare a low dosage (1 g/day) rectal preparation of 5-aminosalicylic acid in slightly acidic, buffered suspension (Pentasa) with a hydrocortisone 100 mg/day enema (Cortenema)."( Low Pentasa dosage versus hydrocortisone in the topical treatment of active ulcerative colitis: a randomized, double-blind study.
Ardizzone, S; Bianchi Porro, G; Fasoli, A; Imbesi, V; Molteni, P; Petrillo, M, 1995
)
0.29
"Our experience confirms that short term topical treatment with a low dosage 5-aminosalicylic acid is at least as effective as 100-mg hydrocortisone enemas in treating mild to moderate distal ulcerative colitis and is generally well tolerated."( Low Pentasa dosage versus hydrocortisone in the topical treatment of active ulcerative colitis: a randomized, double-blind study.
Ardizzone, S; Bianchi Porro, G; Fasoli, A; Imbesi, V; Molteni, P; Petrillo, M, 1995
)
0.29
" The tissue level of 5-ASA had a significant correlation to the dosage of 5-ASA."( [Localization of salazopyrin in colonic mucosa patients with ulcerative colitis].
Fukushima, R; Kashima, K; Kitano, A; Nakagawa, M; Nakamura, S; Obayashi, M; Okabe, H; Tabata, A; Tomobuchi, M; Yasuda, K, 1993
)
0.29
"Cyclosporine enemas administered in a dosage of 350 mg/day for 4 weeks are not efficacious in mildly to moderately active left-sided ulcerative colitis."( A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis.
Batts, KP; Harrison, JM; Lawson, GM; Sandborn, WJ; Schroeder, KW; Steiner, BL; Tremaine, WJ; Zinsmeister, AR, 1994
)
0.29
" In an open-labeled initial trial, timed-release 5-aminosalicylic acid (5-ASA), administered at a daily dosage of 30."( Slow-release 5-aminosalicylic acid therapy in children with small intestinal Crohn's disease.
Griffiths, A; Koletzko, S; Marcon, M; Sherman, P; Sylvester, F, 1993
)
0.29
" Available evidence indicates that 5-aminosalicylic acid is beneficial in this role, although high dosage is needed."( Maintenance strategies in Crohn's disease.
Sachar, DB, 1996
)
0.29
"To compare the systemic load of 5-aminosalicylic acid (5-ASA) as a basis for potential long-term toxicity during treatment in usual dosage with olsalazine (Dipentum) and one controlled-release mesalazine preparation (Salofalk) in patients with inactive ulcerative colitis."( Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine.
Karamanolis, DG; Papatheodoridis, GV; Xourgias, V, 1996
)
0.29
" These results suggest that this 5-ASA preparation would be an useful dosage form for the therapy of IBD from the point of avoiding the side effect of sulfapyridine, one of the metabolites of SASP."( Application of a colon delivery capsule to 5-aminosalicylic acid and evaluation of the pharmacokinetic profile after oral administration to beagle dogs.
Funaoka, A; Matsuda, K; Sawada, K; Suzuki, H; Takada, K; Takaya, T, 1997
)
0.3
" Other studies have not found a dose-response relationship with lower dosages of mesalamine."( The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease.
Bonapace, CR; Mays, DA,
)
0.72
" However, there is still only limited comparative information available on the dispersion of such dosage forms in human subjects."( Colonic spread of three rectally administered mesalazine (Pentasa) dosage forms in healthy volunteers as assessed by gamma scintigraphy.
Brown, J; Haines, S; Wilding, IR, 1997
)
0.3
" The optimal dosage of oral 5-ASA in the maintenance therapy of ulcerative colitis in remission is not clear."( Guidelines for the treatment of ulcerative colitis in remission.
Ardizzone, S; Bianchi Porro, G; Bollani, S; Molteni, P, 1997
)
0.3
" Although there is controversy concerning dosage or duration of therapy, oral and topical mesalazine is effective in the treatment of mild to moderately active distal ulcerative colitis."( A practical guide to the management of distal ulcerative colitis.
Ardizzone, S; Bianchi Porro, G, 1998
)
0.3
" No dose-response relation was demonstrated."( Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The U.S. PENTASA Enema Study Group.
Hanauer, SB, 1998
)
0.61
" Little is known about the dose-response relationship and about possible dose related side effects."( Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease.
Mulder, CJ; van den Hazel, SJ, 1998
)
0.3
"Mesalamine in microgranular formulation seems to be equally as effective as a standard dosage of steroids in the treatment of the mild to moderate form of Crohn's ileitis."( Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial.
Annese, V; Bianchi Porro, G; Cerutti, R; Cottone, M; Franzè, A; Pallone, F; Prantera, C, 1999
)
3.19
" This study shows that at lumenal levels below 200 microg/ml (concentrations that are typically achieved by controlled release dosage forms), intestinal secretion of 5ASA accounts for more than 50% of the total elimination and can significantly affect tissue levels and, therefore, may be an important factor in determining the response to 5ASA therapy."( Intestinal metabolism and transport of 5-aminosalicylate.
Fleisher, D; Li, C; Pao, LH; Winward, B; Zhou, SY; Zimmermann, EM, 1999
)
0.3
" To directly evaluate the ability of 5-ASA to suppress intestinal tumors, we studied several formulations of 5-ASA (free acid, sulfasalazine, and Pentasa) at multiple oral dosage levels [500, 2400, 4800, and 9600 parts/million (ppm)] in the adenomatous polyposis coli (Apc) mouse model of multiple intestinal neoplasia (Min)."( Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse.
Gendler, SJ; Hirsch, RE; Leighton, JA; Morrow, JD; Ritland, SR; Weaver, AL, 1999
)
0.3
"To evaluate the disposition, dispersion and movements of Pentasa prolonged-release microgranules following single dosing of either tablets (2 x 500 mg) or a new 1 g sachet (unit dose, microgranules in a foil bag)."( Gastrointestinal spread of oral prolonged-release mesalazine microgranules (Pentasa) dosed as either tablets or sachet.
Hooper, G; Kenyon, CJ; Wilding, IR, 2000
)
0.31
" Both formulations were radiolabelled by neutron activation and dosed in the fasted state."( Gastrointestinal spread of oral prolonged-release mesalazine microgranules (Pentasa) dosed as either tablets or sachet.
Hooper, G; Kenyon, CJ; Wilding, IR, 2000
)
0.31
"Cells were dosed with each compound for 24 h in the presence or absence of PMA inducer and messenger RNA (mRNA) extracted and subjected to Northern blot analysis."( Effects of sulfasalazine and its metabolites on steady state messenger RNA concentrations for inflammatory cytokines, matrix metalloproteinases, and tissue inhibitors of metalloproteinase in rheumatoid synovial fibroblasts.
Blackburn, WD; Minghetti, PP, 2000
)
0.31
"8 g daily dosing whereas faecal N-acetyl 5ASA excretion was similar at all three doses."( Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters.
Ajjan, RA; Hussain, FN; Riley, SA, 2000
)
0.31
" Induction of clinical and endoscopic remission was achieved in more patients receiving a daily dosage of 4 g/day than in those receiving placebo."( Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.
Clemett, D; Markham, A, 2000
)
0.31
" Metronidazole and 6-mercaptopurine or azathioprine also seem to be of benefit in postoperative prophylaxis of disease recurrence, but additional controlled studies are required to define better the efficacy and dose-response of these agents."( Medical therapy to reduce postoperative Crohn's disease recurrence.
Achkar, JP; Hanauer, SB, 2000
)
0.31
" Mesalamine enema dosing intervals between QHS to Q3 days maintained efficacy."( A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis.
Cohen, RD; Hanauer, SB; Thisted, RA; Woseth, DM, 2000
)
1.22
" The dosage forms available for rectal delivery include suppositories, foams, and liquid enemas, and selection among these preparations should be guided by the proximal extent of disease and patient preference."( Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis.
Irvine, EJ; Marshall, JK, 2000
)
0.31
" However, it is well-recognized that dosing frequency has a significant impact on compliance and that once daily dosing is preferable."( Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters.
Ajjan, RA; Hussain, FN; Kapur, K; Moustafa, M; Riley, SA, 2001
)
0.31
" Peak serum concentrations were found at 06:00-09:00 following divided dosing and at 17:00-20:00 following once daily dosing."( Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters.
Ajjan, RA; Hussain, FN; Kapur, K; Moustafa, M; Riley, SA, 2001
)
0.31
" Clinical trials should examine the efficacy and toxicity of once daily dosing in patients with ulcerative colitis."( Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters.
Ajjan, RA; Hussain, FN; Kapur, K; Moustafa, M; Riley, SA, 2001
)
0.31
"The aim of the present study was to develop a multi-unit dosage form containing 5-aminosalicylic acid (5-ASA) for the treatment of ulcerative colitis (UC), optimised on the basis of recent studies indicating that UC patients have higher intestinal pH than was previously thought to be the case."( A new 5-aminosalicylic acid multi-unit dosage form for the therapy of ulcerative colitis.
Beckert, TE; Dressman, JB; Klein, S; Petereit, H; Rudolph, MW, 2001
)
0.31
"High doses of mesalazine usually result in an inconvenient dosage schedule and reduced compliance."( Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis.
Campieri, M; Farup, PG; Hébuterne, X; Hinterleitner, TA; Keller, R; Lukás, M; Meier, R; Oddsson, E; Rachmilewitz, D; Rathbone, B, 2001
)
0.31
" The aim of this study was to determine the dose-response of balsalazide for efficacy and safety in active, mild-to-moderate ulcerative colitis and to compare this profile with that of mesalamine, pH-dependent, delayed-release tablets."( A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
Bell, JK; Johnson, LK; Koval, G; Levine, DS; Pruitt, R; Riff, DS; Sales, D; Wruble, L, 2002
)
0.72
"6 g/day is recommended) and oral sulfasalazine 2 g/day (recommended dosage) in the prevention of relapse in ulcerative colitis in remission after 6 to 12 months of treatment; the balsalazide dosage was 3 g/day versus mesalazine and 2 g/day versus sulfasalazine."( Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis.
Goa, KL; Muijsers, RB, 2002
)
0.31
" Synovial tissue explants from RA patients secreted a decreased amount of the chemokines IL-8 and growth-related gene product alpha (GROalpha) when treated with SASP over a broad range of concentrations based on the typical clinical dosage of 2 g/day."( The effect of sulfasalazine on rheumatoid arthritic synovial tissue chemokine production.
Campbell, PL; Connors, MA; Koch, AE; Volin, MV; Woodruff, DC, 2002
)
0.31
" Mesalazine has been shown equivalent or superior to sulfasalazine, and superior to placebo, with a dose-response benefit, in inducing remission of acute disease."( Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications.
Schroeder, KW, 2002
)
0.31
" Thus, selection of a mesalazine therapy for the treatment of ulcerative colitis should be based on other factors such as efficacy, dose-response, toxicity of the parent compound and its metabolites, compliance issues related to dose forms and dosing schedules, and costs."( Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis.
Hanauer, SB; Sandborn, WJ, 2003
)
0.32
" No clear relationship, however, has been shown between dosage and response."( Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial.
Annese, V; Cammà, C; Caprilli, R; Castiglione, F; Corrao, G; Cottone, M; Latella, G; Papi, C; Sturniolo, G; Tonelli, F; Viscido, A, 2003
)
0.32
" Prednisone dosage was reduced from a mean of 19."( Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions.
France, R; Kinney, T; Kozarek, R; Patterson, D; Rawlins, M, 2003
)
0.32
" Three-times daily dosing and full-time employment are predictors of partial non-compliance, whilst depression is associated with complete non-compliance."( Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease.
Riley, SA; Shale, MJ, 2003
)
0.32
" A dose-response trend for 5-ASA was also observed."( Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
MacDonald, JK; Sutherland, L, 2003
)
0.32
"To assess the feasibility, safety and efficacy of patient-led dosing using balsalazide in the long-term treatment of ulcerative colitis."( Patient-led variable dosing with balsalazide as long-term therapy for maintenance in ulcerative colitis: a 3-year prospective observational study.
Gibson, JA; Green, JR; Kerr, GD; Swan, CH; Swarbrick, ET; Thornton, PC, 2004
)
0.32
"The scheduled oral + topical 5-ASA treatment, at the lowest cumulative topical dosage tested over the longest known observation period, is efficacious in improving clinical outcome and decreasing overall costs in UC patients."( Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitis.
Cermesoni, L; Cesana, BM; Piodi, LP; Ulivieri, FM, 2004
)
0.32
"This study was conducted to assess, in a small sample, the short-term outcomes of once-daily mesalamine versus conventional dosing in maintaining quiescent ulcerative colitis (UC) and to assess adherence rates with both regimens."( A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis.
Huo, D; Kane, S; Magnanti, K, 2003
)
0.77
" The need for site-specific dosage medications has led to the use of enteric coatings that allow the release of the active ingredients into the small intestine or in the colon."( Medications as a source of human exposure to phthalates.
Calafat, AM; Duty, S; Godfrey-Bailey, L; Hauser, R, 2004
)
0.32
" The detection of these drugs in commercial dosage formulations is reported."( Identification of 5-aminosalicylic acid, ciprofloxacin and azithromycin by abrasive stripping voltammetry.
Komorsky-Lovrić, S; Nigović, B, 2004
)
0.32
" In children, pharmacokinetic data are scarce, and dosage recommendations are largely extrapolated from studies in adults."( Pharmacokinetics of mesalazine pellets in children with inflammatory bowel disease.
Benninga, MA; Dilger, K; Escher, JC; Taminiau, J; Trenk, D; van Boxtel, CJ; Wiersma, H, 2004
)
0.32
" Current oral regimens require the use of large tablets and frequent dosing to reach the recommended treatment dose."( Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial.
Behrens, C; Bias, P; Raedler, A, 2004
)
0.32
"This phase 2, double-blind, active-controlled, parallel-group, multiple dose clinical trial randomized 362 patients to either mesalazine micropellets or tablets, at a dosage of 3 g/day."( Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial.
Behrens, C; Bias, P; Raedler, A, 2004
)
0.32
"The continuous use of topical mesalazine associated with a high oral dosage significantly improves the clinical course of ulcerative colitis patients at high risk of relapse."( Long-term oral plus topical mesalazine in frequently relapsing ulcerative colitis.
Caprilli, R; Chiaramonte, M; Corrao, G; Frieri, G; Galletti, B; Latella, G; Palumbo, G; Pimpo, M, 2005
)
0.33
" Mesalazine is as effective as rifaximin (higher dosage schedule) for diminishing some symptoms, but it appears to be better than rifaximin for improving the global score in those patients."( Efficacy of mesalazine in the treatment of symptomatic diverticular disease.
Aragona, G; Cavallaro, LG; Cavestro, GM; Comparato, G; Di Mario, F; Fanigliulo, L; Franzé, A; Gnocchi, A; Iori, V; Leandro, G; Maino, M; Mazzocchi, G; Moussa, AM, 2005
)
0.33
" However, the optimal dosage remains to be defined."( Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study.
Consolazio, A; Crispino, P; Iacopini, F; Marcheggiano, A; Paoluzi, OA; Paoluzi, P; Pica, R; Rivera, M, 2005
)
0.33
" The aim of this study was to develop a test system able to reflect the changing environment that a dosage form incorporating the anti-inflammatory agent is exposed to as it moves through the gastrointestinal tract."( Site-specific delivery of anti-inflammatory drugs in the gastrointestinal tract: an in-vitro release model.
Dressman, J; Klein, S; Stein, J, 2005
)
0.33
" This coating has traditionally been applied to multi-unit systems, in part because of the small size and divided nature of this type of dosage form, which provides a large surface area for enzymatic attack and drug release."( Exploiting gastrointestinal bacteria to target drugs to the colon: an in vitro study using amylose coated tablets.
Basit, AW; Wilson, PJ, 2005
)
0.33
" However, the minimal dosage to achieve this chemopreventive effect remains unclear."( Prevention of colorectal cancer in inflammatory bowel disease: value of screening and 5-aminosalicylates.
Esendal, B; Kornbluth, A; Loftus, EV; Mittmann, U; Munkholm, P; Reinacher-Schick, A, 2006
)
0.33
" This review examines the prevalence and impact of non-adherence to 5-aminosalicylic acid therapy among patients with ulcerative colitis, as well as drug delivery strategies that may enhance dosing regimens to improve patient acceptability, adherence and long-term clinical outcomes."( Systematic review: adherence issues in the treatment of ulcerative colitis.
Kane, SV, 2006
)
0.33
" Additionally, established therapies are attracting renewed interest with novel dosage regimens and new formulations offering improved efficacy whilst maintaining an excellent tolerance profile."( What's new: innovative concepts in inflammatory bowel disease.
Sandborn, WJ, 2006
)
0.33
" This review highlights how novel formulations and dosing regimens can ensure treatment success at a greater convenience for the patient with no increased risk of adverse effects."( New lessons: classic treatments, expanding options in ulcerative colitis.
Hanauer, SB, 2006
)
0.33
" A dose-response trend for 5-ASA was also observed."( Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Macdonald, JK; Sutherland, L, 2006
)
0.33
" Similarly, when 5-aminosalicylic acids are used to induce remission, continuing the induction dosage for an extra 4 weeks prolongs remission and reduces the frequency of relapse."( Review article: maintenance therapy in patients with ulcerative colitis.
Keshav, S; Orchard, T; Probert, CS, 2006
)
0.33
" Therapeutic success of mesalazine may be optimized by a combination of high dose and low frequency of dosage to improve compliance."( Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete?
Mulder, CJ; van Bodegraven, AA, 2006
)
0.33
" The commercially available 5-ASA containing oral dosage forms exhibit different release profiles, which suggests that the optimal product may differ per patient."( A novel dissolution method relevant to intestinal release behaviour and its application in the evaluation of modified release mesalazine products.
Frijlink, HW; Kosterink, JG; Schellekens, RC; Stuurman, FE; van der Weert, FH, 2007
)
0.34
"A randomized, 2-way, crossover study was conducted in 30 volunteers to compare the pharmacokinetic profile of a new once-daily dosing regimen of mesalazine (1 x 4 g/d) with the current twice-daily dosage (2 x 2 g/d) used in many European countries."( Is once-daily mesalazine equivalent to the currently used twice-daily regimen? A study performed in 30 healthy volunteers.
Gandia, P; Houin, G; Idier, I, 2007
)
0.34
" Multiple daily dosing or rectal administration of 5-aminosalicylate medications also can adversely affect adherence rates."( "Take your medicine": nonadherence issues in patients with ulcerative colitis.
Turnbough, L; Wilson, L,
)
0.13
"Delayed release dosage forms such as Asacol employ coatings that are engineered to breakdown and release the drug topically at the nominal pH of the lower intestinal tract."( Delayed release tablet dissolution related to coating thickness by terahertz pulsed image mapping.
Buhse, LF; Gao, Z; Husain, A; Moore, T; Newnham, DA; Portieri, A; Shen, Y; Spencer, JA; Taday, PF, 2008
)
0.35
" Nonadherence to therapy can be associated with several other factors, including forgetfulness, male sex, complicated dosing regimens, treatment delivery methods (oral vs."( Mild-to-moderate ulcerative colitis: your role in patient compliance and health care costs.
Boltri, JM; Tindall, WN; Wilhelm, SM, 2007
)
0.34
"8 g per day of the active 5-aminosalicylate moiety, rather than starting at a lower dosage and increasing if treatment fails."( Ulcerative colitis: responding to the challenges.
Achkar, JP, 2007
)
0.34
" Following our positive results with nIFN-beta in a previously published open-labeled study, the present study was designed as an extension with the hypothesis that administration of higher dosage of nIFN-beta (1."( Successful treatment of steroid refractory active ulcerative colitis with natural interferon-beta--an open long-term trial.
Andus, T; Chrissafidou, A; Malek, M; Musch, E; Schulz, M, 2007
)
0.34
" In so doing, oral dosage forms displaying enteric properties may be produced in a continuous, rapid process, providing significant advantages over traditional pharmaceutical coating technology."( The manufacture and characterisation of hot-melt extruded enteric tablets.
Andrews, GP; Diak, OA; Jones, DS; McCoy, CP; McGinity, JW; Watts, AB, 2008
)
0.35
" Current mesalamine formulations are not ideal for long-term treatment due to issues with patient adherence secondary to complex dosing regimens and high pill burden."( Multi-matrix system mesalamine: to use or not to use.
Kale-Pradhan, PB; Pradhan, RS; Wilhelm, SM, 2008
)
1.09
" It has the advantage of once-daily dosing regimens with lower pill burden than comparable products and, as an oral agent, may have better patient acceptability compared with topical mesalamine formulations."( Multi-matrix system mesalamine: to use or not to use.
Kale-Pradhan, PB; Pradhan, RS; Wilhelm, SM, 2008
)
0.86
" This study evaluated the safety and efficacy of MMX mesalazine dosed once or twice daily as maintenance therapy in patients with ulcerative colitis."( Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis.
Barrett, K; Joseph, R; Kamm, MA; Lees, K; Lichtenstein, GR; Sandborn, WJ; Schreiber, S, 2008
)
0.35
" Consequently, new guidelines for the management of distal colitis have focussed more on rectal delivery and on optimizing 5-ASA dosage than previously."( Management of distal ulcerative colitis: frequently asked questions analysis.
Gearry, RB; Gibson, PR; Irving, PM; James, SL, 2008
)
0.35
" With the advantage of low pill burden and easy dosing schedule, it may potentially improve patient compliance and treatment success."( MMX mesalamine: a novel high-dose, once-daily 5-aminosalicylate formulation for the treatment of ulcerative colitis.
Hu, MY; Peppercorn, MA, 2008
)
0.9
" For patients with severe ulcerative colitis (UC), steroid dosing has been clarified, and a mega-analysis of steroid outcomes and toxicities has been reported."( Optimizing drug therapy in inflammatory bowel disease.
Kornbluth, A; Swaminath, A, 2007
)
0.34
"Medication non-adherence is multifactorial involving factors other than dosing frequency."( Review article: medication non-adherence in ulcerative colitis--strategies to improve adherence with mesalazine and other maintenance therapies.
Ghosh, S; Hawthorne, AB; Rubin, G, 2008
)
0.35
" Such sharpened indications have reiterated attention to correct dosing: the results of controlled trials have shown mesalamine to be fully effective at twice the traditional daily dosage (4."( Mesalamine for inflammatory bowel disease: recent reappraisals.
Actis, GC; Pazienza, P; Rosina, F, 2008
)
2
" Nonadherence may be affected by such factors as complicated dosing regimens, forgetfulness, male sex, and treatment delivery methods."( Maximizing patient adherence and clinical outcomes with mesalamine in mildly-to-moderately active ulcerative colitis.
Lichtenstein, GR; Rubin, DT; Sabesin, SM; Velayos, FS; Vitat, P, 2008
)
0.59
"While assessment of 5-ASA release is important, limitations of individual measurement techniques mean that randomized clinical studies in UC patients remain the best guide for dosing and treatment regimen decisions."( Review article: 5-aminosalicylate formulations for the treatment of ulcerative colitis--methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa.
Kamm, MA; Lichtenstein, GR, 2008
)
0.35
" In study A, 1,000 mg mesalazine doses were given thrice daily for 5 days, and urine and blood samples were drawn during the last dosing interval."( Mesalazine pharmacokinetics and NAT2 phenotype.
Fuhr, U; Jetter, A; Kinzig, M; Lück, H; Sörgel, F, 2009
)
0.35
" In addition, the effectiveness of oral therapy relies on good compliance, which may be adversely affected by frequent daily dosing and a large number of tablets."( Once daily 5-aminosalicylic acid for the treatment of ulcerative colitis; are we there yet?
Lakatos, L; Lakatos, PL,
)
0.13
"To determine the therapeutic equivalence and safety of once daily (OD) versus three times daily (TID) dosing of a total daily dose of 3 g Salofalk (mesalazine) granules in patients with active ulcerative colitis."( Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial.
Batovsky, M; Boehm, S; Gorelov, IA; Greinwald, R; Horynski, M; Kiudelis, G; Kruis, W; Kykal, J; Mueller, R; Pokrotnieks, J; Rácz, I, 2009
)
0.35
"3%) in the TID group, indicating that the two dosing regimens were equally safe and well tolerated."( Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial.
Batovsky, M; Boehm, S; Gorelov, IA; Greinwald, R; Horynski, M; Kiudelis, G; Kruis, W; Kykal, J; Mueller, R; Pokrotnieks, J; Rácz, I, 2009
)
0.35
" With respect to the best possible adherence of patients to the treatment, OD dosing of mesalazine should be the preferred application mode in active ulcerative colitis."( Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial.
Batovsky, M; Boehm, S; Gorelov, IA; Greinwald, R; Horynski, M; Kiudelis, G; Kruis, W; Kykal, J; Mueller, R; Pokrotnieks, J; Rácz, I, 2009
)
0.35
" 5-ASA clinical pharmacokinetic profiles of a once-daily (one 4-g/day dose) and twice-daily (two 2-g/day doses) dosing regimen were used to partially calibrate and validate the model, respectively."( SIMDOT-AbMe: microphysiologically based simulation tool for quantitative prediction of systemic and local bioavailability of targeted oral delivery formulations.
Farhadi, A; Haddish-Berhane, N; Haghighi, K; Keshavarzian, A; Nyquist, C, 2009
)
0.35
" Once daily dosing may improve patient adherence."( A dynamic model of colonic concentrations of delayed-release 5-aminosalicylic acid (Asacol).
Ehrenpreis, ED; Hannon, B; Putt, KS; Thorpe, MP, 2009
)
0.35
" In addition, the effectiveness of oral therapy relies on good compliance, which may be adversely affected by frequent daily dosing and a large number of tablets."( [Effectiveness of new, once-daily 5-aminosalicylic acid in the treatment of ulcerative colitis].
Lakatos, L; Lakatos, PL, 2009
)
0.35
" However, poor adherence due to frequent daily dosing and a large number of tablets has been shown to be an important barrier to successful management of patients with UC."( Use of new once-daily 5-aminosalicylic acid preparations in the treatment of ulcerative colitis: Is there anything new under the sun?
Lakatos, PL, 2009
)
0.35
" We investigated the efficacy and safety of once daily administration of prolonged-release mesalamine granules in maintenance of remission in patients with quiescent ulcerative colitis, compared with the well established twice daily dosing regimen."( Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.
Adamek, H; Bhatt, A; Bokemeyer, B; Börner, N; Dietel, P; Dignass, AU; Klugmann, T; Mross, M; Pool, MO; Silvennoinen, J; Stijnen, T; Tan, G; Veerman, H; Vermeire, S; Vinter-Jensen, L, 2009
)
2.02
" Most of these agents require frequent dosing and have a high pill burden."( Encapsulated mesalamine granules (Apriso) for ulcerative colitis.
, 2009
)
0.72
"1 g tablet dosing regimen (6."( Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.
Forbes, WP; Gordon, GL; Huang, S; Lamet, M; Mareya, S; Pruitt, R; Scherl, EJ; Shaw, A, 2009
)
0.35
" This new formulation with a reduced pill and dosing burden offers the potential to improve convenience and compliance in patients with active UC."( Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.
Forbes, WP; Gordon, GL; Huang, S; Lamet, M; Mareya, S; Pruitt, R; Scherl, EJ; Shaw, A, 2009
)
0.35
" Patients often take only 40 to 80% of their prescribed dosage of medication."( [The problems of compliance and adherence, using the example of chronic inflammatory bowel disease].
Siegmund, SV; Singer, MV; Zimmerer, T, 2009
)
0.35
"Colon-specific delivery of drugs can be achieved with dosage forms coated with biopolymers that are metabolized selectively by the colonic microflora and yet resistant to enzymatic digestion in the small intestine."( Influence of the coating formulation on enzymatic digestibility and drug release from 5-aminosalicylic acid pellets coated with mixtures of high-amylose starch and Surelease intended for colon-specific drug delivery.
Freire, C; Podczeck, F; Sousa, J; Veiga, F, 2010
)
0.36
"2 g/tablet) is a 5-aminosalicylic acid formulation, designed for once-daily dosing in the treatment of ulcerative colitis."( Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol.
Ardia, A; Bellinvia, S; Campieri, M; Caprilli, R; Cottone, M; Kohn, A; Pallone, F; Prantera, C; Savarino, V; Sturniolo, GC; Vecchi, M, 2009
)
0.35
"Multi-unit dosage forms of mesalamine targeted to the colon were formulated by extrusion-spheronization, and then coated with Eudragit S (30%)."( Development and in vitro evaluation of mesalamine delayed release pellets and tableted reservoir-type pellets.
Ayres, JW; Bendas, ER; Christensen, JM, 2010
)
0.93
", an S-phase and G2/M phase arrest, dependent on 5-ASA dosage and concentration, together with an increased mitotic index."( 5-aminosalicylic acid interferes in the cell cycle of colorectal cancer cells and induces cell death modes.
Corver, WE; Hommes, DW; Koelink, PJ; Lamers, CB; Mieremet-Ooms, MA; Verspaget, HW; Wolanin, K, 2010
)
0.36
" Recently, attention has focused on optimizing dosing strategies for biologic agents; however, of equal importance are recent advances in the optimization of conventional IBD therapies."( Optimizing conventional therapies for inflammatory bowel disease.
Hanauer, SB; Irving, PM; Sparrow, MP, 2009
)
0.35
" An Asacol dosage of 800 mg, three times a day, was compared to 2400 mg given once a day."( A dynamic model of once-daily 5-aminosalicylic acid predicts clinical efficacy.
Ehrenpreis, ED; Hannon, B; Parakkal, D; Putt, KS; Thorpe, MP, 2010
)
0.36
" In the main dosing study, the mean RBC 6-TGN level in patients who remained in remission during the 1-year observation time (n = 151) was 322."( Thiopurine maintenance therapy for ulcerative colitis: the clinical significance of monitoring 6-thioguanine nucleotide.
Abe, J; Arai, O; Hanai, H; Hosoda, Y; Iida, T; Ikeya, K; Kageoka, M; Kubota, T; Maruyama, Y; Miwa, I; Oohata, A; Takeuchi, K; Watanabe, F; Yoshirou, S, 2010
)
0.36
"The practice of dosing mesalamines in divided doses for the treatment of ulcerative colitis (UC) began with sulfasalazine and was driven by sulfapyridine toxicity."( Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis.
Dunnmon, P; Friedenberg, KA; Kane, S; Korzenik, J; Lashner, B; Leighton, JA; Mahadevan, U; Marion, JF; Patel, RM; Ramsey, D; Safdi, M; Sandborn, WJ; Sninsky, CA, 2010
)
0.94
"5% of patients receiving once-daily dosing had maintained clinical remission, compared with 91."( Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis.
Dunnmon, P; Friedenberg, KA; Kane, S; Korzenik, J; Lashner, B; Leighton, JA; Mahadevan, U; Marion, JF; Patel, RM; Ramsey, D; Safdi, M; Sandborn, WJ; Sninsky, CA, 2010
)
0.62
" Participants had better adherence than the expected population rate, with a significant dose-response effect."( Telephone nurse counseling for medication adherence in ulcerative colitis: a preliminary study.
Cook, PF; El-Hajj, D; Emiliozzi, S; McCabe, MM, 2010
)
0.36
" The potential effect of dosing frequency on adherence and possible long-term effects of remission maintenance on colorectal cancer (CRC) rates were also investigated."( A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective.
Akehurst, R; Bodger, K; Brereton, N; Hodgkins, P; Kamm, MA; Yan, S, 2010
)
0.36
" New dosage regimens are likely to become standard practice in the near future."( Mesalazine in inflammatory bowel disease: a trendy topic once again?
de Silva, S; Ghosh, S; Iacucci, M, 2010
)
0.36
" The first-line therapy remains 5-aminosalicylic acid, which is available in several different formulations and dosing schedules."( Insight into the widespread problem of nonadherence to therapy in ulcerative colitis patients.
Bernick, SJ; Kane, S, 2010
)
0.36
" dosing led to lower patient satisfaction and overall adherence."( Does treatment schedule matter? Once daily versus divided doses of 5-ASAs.
Kane, S, 2010
)
0.36
" These patients frequently fail to receive the full benefit from this treatment, often as a result of nonadherence to complex dosing regimens."( Oral 5-aminosalicylic acid therapy for mild-to-moderate ulcerative colitis.
Olmstead, J, 2010
)
0.36
"An HPLC method for the quantitative analysis of mebeverine HCl, 5-aminosalicylic acid (5-ASA), sulphasalazine and dispersible aspirin has been developed and then applied to these specific medicines when stored, with other medications, in Venalink blister packs (monitored dosage system) for periods of up to 35 days."( Quantitative HPLC analysis of mebeverine, mesalazine, sulphasalazine and dispersible aspirin stored in a Venalink monitored dosage system with co-prescribed medicines.
Blagbrough, IS; Elmasry, MS; Kheir, AA; Rogers, PJ; Rowan, MG; Saleh, HM, 2011
)
0.37
" In addition, topical rectal steroids were considered as effective as topical mesalazine by 48% of the GGs vs 31% of the GSIBDs, indefinite treatment with 5-ASA was prescribed by only 26% of the GGs vs 41% of the GSIBDs, and the once daily dosing of 5-ASA was generally used by 46% of the GGs vs 51% of the GSIBDs."( Adherence of gastroenterologists to European Crohn's and Colitis Organisation consensus on ulcerative colitis: a real-life survey in Spain.
Gisbert, JP; Gomollón, F; Hinojosa, J; López San Román, A, 2010
)
0.36
" However, several randomized controlled trials (RCTs) have been published recently, and no previous meta-analysis has studied the effect of 5-ASA dosage used."( Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis.
Achkar, JP; Ford, AC; Kane, SV; Khan, KJ; Marshall, JK; Moayyedi, P; Talley, NJ, 2011
)
0.37
"This article is a review of recently published research dealing with new 5-ASA dosage forms."( Multiparticulate systems containing 5-aminosalicylic acid for the treatment of inflammatory bowel disease.
Bautzová, T; Lamprecht, A; Rabišková, M, 2011
)
0.37
" Traditionally these agents have required a large pill burden and multiple daily dosing regimens which may account for the low adherence rates, especially in patients in remission."( Maintaining remission in ulcerative colitis--role of once daily extended-release mesalamine.
Cohen, RD; Oliveira, L, 2011
)
0.6
" Some trials evaluated also the efficacy and safety of once-daily dosing of older 5-ASA formulations in maintenance of remission, finding a greater adherence to therapy in the group given the once daily regimen, compared with the classic twice daily groups."( Is 5-ASA still the treatment of choice for ulcerative colitis?
Cottone, M; Modesto, I; Orlando, A; Renna, S, 2011
)
0.37
" If adherence and its influence on the remission rates and the risk of developing colorectal cancer were included in the model, the results might have even been more favorable to Mezavant due to its once daily dosing regimen."( Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine.
Mittendorf, T; Prenzler, A; von der Schulenburg, JM; Yen, L, 2011
)
0.37
"Mesalazine was administered to 33 patients with CIU, starting at 500 mg/day with weekly incremental dosing to a total of 1 g/day."( Mesalazine as a new therapeutic option for chronic idiopathic urticaria.
Abdollahee, A; Dastgheib, L; Jowkar, F; Namazi, MR, 2012
)
0.38
" The tailored intervention included educational and motivational components, plus options including simplified dosing regimes and practical reminders such as pill dispensers."( Impact of a tailored patient preference intervention in adherence to 5-aminosalicylic acid medication in ulcerative colitis: results from an exploratory randomized controlled trial.
Baker, R; Bankart, J; Mayberry, JF; Moshkovska, T; Smith, RM; Stone, MA, 2011
)
0.37
" Once-daily dosing may improve adherence, but impact on the relapse of disease activity is unclear as no previous meta-analysis has studied this issue."( Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis.
Ford, AC; Kane, SV; Khan, KJ; Moayyedi, P; Sandborn, WJ, 2011
)
0.62
" Eligible randomized controlled trials (RCTs) recruited adults with quiescent UC, and compared once-daily dosing of 5-ASAs with a more frequent dosing schedule of an identical total daily dose of the same 5-ASA drug."( Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis.
Ford, AC; Kane, SV; Khan, KJ; Moayyedi, P; Sandborn, WJ, 2011
)
0.62
" Relapse rates were not significantly different between once-daily and conventional dosing schedules for mesalamine (RR of relapse=0."( Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis.
Ford, AC; Kane, SV; Khan, KJ; Moayyedi, P; Sandborn, WJ, 2011
)
0.83
"Once-daily dosing with mesalamine is as effective as conventional dosing schedules for the prevention of relapse of quiescent UC, although there is no definitive evidence that compliance with once-daily dosing is better."( Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis.
Ford, AC; Kane, SV; Khan, KJ; Moayyedi, P; Sandborn, WJ, 2011
)
0.93
" The drugs and their corresponding placebos were administrated at advised dosage for 8 weeks."( Efficacy and safety of Fufangkushen colon-coated capsule in the treatment of ulcerative colitis compared with mesalazine: a double-blinded and randomized study.
Gong, Y; Jiang, M; Li, L; Lin, Y; Liu, L; Liu, Y; Lu, A; Yang, B; Zha, Q, 2012
)
0.38
" dosing in left-sided colitis (CR 73% vs."( Mesalazine granules are superior to Eudragit-L-coated mesalazine tablets for induction of remission in distal ulcerative colitis - a pooled analysis.
Gibson, PR; Greinwald, R; Kruis, W; Leifeld, L; Marakhouski, Y; Morgenstern, J; Mueller, R; Pfützer, R, 2011
)
0.37
"The goal was to make available a delayed-release dosage form of mesalazine to be dispersed in water to facilitate swallowing in adults and children."( Layered lipid microcapsules for mesalazine delayed-release in children.
Balducci, AG; Buttini, F; Cavallari, C; Colombo, G; Colombo, P; Corace, G; Rodriguez, L; Rossi, A, 2011
)
0.37
" Multivariate analysis, however, showed OD dosing was associated with lower relapse risk independently of adherence."( One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis.
Dhar, A; Gillespie, D; Hawthorne, AB; Hood, K; Kapur, KC; Probert, CS; Stenson, R; Swarbrick, ET, 2012
)
0.38
"Pellets with high loading of 5-aminosalicylic acid (5-ASA, mesalamine) are desired to reduce the number of tablets required to deliver the daily dosing regimen."( Optimisation and scale-up of a highly-loaded 5-ASA multi-particulate dosage form using a factorial approach.
Di Pretoro, G; Gazzaniga, A; Palugan, L; Rough, SL; Wilson, DI; Zema, L, 2012
)
0.62
" The PODIUM study compared a once daily to a twice daily dosing regimen of a slow-release mesalazine (Pentasa®); here we assess the efficacy, in terms of maintenance of remission and mucosal healing, of both regimens in patients with left-sided disease."( Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing.
Bokemeyer, B; Broberg, P; Dignass, A; Gill, I; Hommes, D, 2012
)
0.38
" Slow-release mesalazine was well tolerated in both dosing regimens, with no difference in reported adverse events."( Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing.
Bokemeyer, B; Broberg, P; Dignass, A; Gill, I; Hommes, D, 2012
)
0.38
" By introducing a novel initiator, through which PEG-AIBN-PEG was synthesized, it was revealed that the PEG segments from PEG-AIBN-PEG with a dosage of initiator had a significant influence over the macro-state and stability of the nanogels."( Synthesis and characterization of novel dual-responsive nanogels and their application as drug delivery systems.
Fan, M; Li, H; Liao, J; Luo, F; Peng, J; Qi, T; Qian, Z, 2012
)
0.38
"We systematically reviewed and compared the efficacy and safety of once daily (OD) mesalamine to conventional dosing for induction and maintenance of remission in ulcerative colitis (UC)."( Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: a systematic review and meta-analysis.
Feagan, BG; MacDonald, JK, 2012
)
0.95
" Further pediatric studies will be needed to address whether increased adherence and/or higher dosing schedules will improve outcomes."( Outcome following aminosalicylate therapy in children newly diagnosed as having ulcerative colitis.
Ashai-Khan, F; Bousvaros, A; Carvalho, R; Evans, J; Faubion, W; Griffiths, A; Grossman, A; Hyams, J; Kappelman, M; Kay, M; Keljo, D; Leleiko, N; Lerer, T; Mack, D; Markowitz, J; Oliva-Hemker, M; Otley, A; Pfefferkorn, M; Rosh, J; Saeed, S; Sudel, B; Zeisler, B, 2013
)
0.39
"The optimal mesalazine dosing strategy for ulcerative colitis (UC) continues to evolve."( The effect of third-party reporting on adoption of evidence-based mesalazine regimens in ulcerative colitis: an observational study.
Ceplis-Kastner, S; Kruis, W; Leifeld, L; Morgenstern, J; Pfützer, R; Reimers, B, 2013
)
0.39
"In this analysis of mesalazine dosing in routine clinical practice, there was an improvement in adherence to European Crohn's and Colitis Organisation (ECCO) guidelines and in use of once-daily dosing, consistent with recent trial results, following documentation of dosing regimens."( The effect of third-party reporting on adoption of evidence-based mesalazine regimens in ulcerative colitis: an observational study.
Ceplis-Kastner, S; Kruis, W; Leifeld, L; Morgenstern, J; Pfützer, R; Reimers, B, 2013
)
0.39
" Intranasal administration of low dosage (<1."( Enhanced anti-influenza agents conjugated with anti-inflammatory activity.
Cheng, TJ; Cheng, YS; Fang, JM; Jan, JT; Liu, KC; Wang, SY; Wong, CH; Yang, ST, 2012
)
0.38
" A Multi-MatriX (MMX®) system formulation of mesalamine, MMX mesalamine (SPD476; Lialda®; Mesavancol®; Mezavant®), allows for high-dose, once-daily dosing for patients with mild-to-moderate UC."( Multi-Matrix System (MMX®) mesalamine for the treatment of mild-to-moderate ulcerative colitis.
Horst, SN; Kane, S, 2012
)
0.94
" The introduction of the first once-daily mesalamine has given practitioners and patients more flexibility in dosing administration, which will ultimately lead to higher satisfaction and improved clinical outcomes."( Multi-Matrix System (MMX®) mesalamine for the treatment of mild-to-moderate ulcerative colitis.
Horst, SN; Kane, S, 2012
)
0.94
" Given the high use of complementary alternative medicines in pediatric IBD, a prospective tolerability study of curcumin, an herbal therapy with known anti-inflammatory effects, was conducted to assess possible dosage in children with IBD."( Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study.
Burpee, T; Christie, D; Cohen, M; Suskind, DL; Wahbeh, G; Weber, W, 2013
)
0.39
" A secondary objective of this systematic review was to compare the efficacy and safety of once daily dosing of oral 5-ASA with conventional (two or three times daily) dosing regimens."( Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan, BG; Macdonald, JK, 2012
)
0.38
" Studies that compared once daily 5-ASA treatment with conventional dosing of 5-ASA (two or three times daily) and 5-ASA dose ranging studies were also considered for inclusion."( Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan, BG; Macdonald, JK, 2012
)
0.38
" Trials were separated into five comparison groups: 5-ASA versus placebo, 5-ASA versus sulfasalazine, once daily dosing versus conventional dosing, 5-ASA versus comparator 5-ASA, and 5-ASA dose-ranging."( Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan, BG; Macdonald, JK, 2012
)
0.38
" A dose-response trend for 5-ASA was also observed."( Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan, BG; Macdonald, JK, 2012
)
0.38
" 5-ASA dosed once daily appears to be as efficacious and safe as conventionally dosed 5-ASA."( Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan, BG; Macdonald, JK, 2012
)
0.38
" A secondary objective was to compare the efficacy and safety of once daily dosing of oral 5-ASA with conventional (two or three times daily) dosing regimens."( Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Feagan, BG; Macdonald, JK, 2012
)
0.38
" Studies that compared once daily 5-ASA treatment with conventional dosing of 5-ASA and 5-ASA dose ranging studies were also considered for inclusion."( Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Feagan, BG; Macdonald, JK, 2012
)
0.38
" Trials were separated into five comparison groups: 5-ASA versus placebo, 5-ASA versus sulfasalazine, once daily dosing versus conventional dosing, 5-ASA versus comparator 5-ASA formulation, and 5-ASA dose-ranging."( Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Feagan, BG; Macdonald, JK, 2012
)
0.38
" No statistically significant differences in efficacy or adherence were found between once daily and conventionally dosed 5-ASA."( Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Feagan, BG; Macdonald, JK, 2012
)
0.38
" Oral 5-ASA administered once daily is as effective and safe as conventional dosing for maintenance of remission in quiescent ulcerative colitis."( Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Feagan, BG; Macdonald, JK, 2012
)
0.38
" Well designed randomized trials are needed to establish the optimal dosing regimen for rectal 5-ASA, to compare rectal 5-ASA with rectal corticosteroids and to identify subgroups of patients who are more or less responsive to specific rectal 5-ASA regimens."( Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Anand, A; Irvine, EJ; Marshall, JK; Newman, JR; Steinhart, AH; Thabane, M, 2012
)
0.38
"Patients on once-daily dosed Multi-Matrix System mesalamine had the lowest risk of discontinuation and the highest adherence rate."( Medication use patterns and predictors of nonpersistence and nonadherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis.
Cohen, RD; Hodgkins, PL; Nichol, MB; Wu, J; Yen, L,
)
0.39
" To establish whether once daily (OD) mesalazine offers economic advantages over twice daily (BD) dosing in active UC, we evaluated the outcomes and costs of a recently published randomized study."( Cost and quality-adjusted life year differences in the treatment of active ulcerative colitis using once-daily 4 g or twice-daily 2g mesalazine dosing.
Connolly, MP; Kuyvenhoven, JP; Nielsen, SK; Postma, MJ, 2014
)
0.4
"Based on the results from a single randomized study, OD dosing resulted in a shorter time spent in active UC which resulted in lower healthcare costs."( Cost and quality-adjusted life year differences in the treatment of active ulcerative colitis using once-daily 4 g or twice-daily 2g mesalazine dosing.
Connolly, MP; Kuyvenhoven, JP; Nielsen, SK; Postma, MJ, 2014
)
0.4
" It is recommended that virtually all children with UC must be treated with some maintenance therapy and 5-ASA requirement and dosing are often higher in children."( Differences in the management of pediatric and adult onset ulcerative colitis--lessons from the joint ECCO and ESPGHAN consensus guidelines for the management of pediatric ulcerative colitis.
Ruemmele, FM; Turner, D, 2014
)
0.4
"A 1-year substudy was conducted alongside a trial that compared 2 different dosing regimens (once daily versus three times daily) of mesalazine for patients in remission with ulcerative colitis."( Electronic monitoring of medication adherence in a 1-year clinical study of 2 dosing regimens of mesalazine for adults in remission with ulcerative colitis.
Farewell, D; Gillespie, D; Hawthorne, AB; Hood, K; Probert, C; Stenson, R, 2014
)
0.4
"Simple dosing regimens are preferable to multiple daily dosing regimens."( Electronic monitoring of medication adherence in a 1-year clinical study of 2 dosing regimens of mesalazine for adults in remission with ulcerative colitis.
Farewell, D; Gillespie, D; Hawthorne, AB; Hood, K; Probert, C; Stenson, R, 2014
)
0.4
" From an economic standpoint, to analyze the impact of the adoption of this dosage in Brazil's public health system, considering patients' adherence to treatment."( Decision tree construction and cost-effectiveness analysis of treatment of ulcerative colitis with pentasa® mesalazine 2 g sachet.
Clark, O; Delfini, R; Kotze, PG; Nishikawa, AM; Paladini, L,
)
0.13
" The release studies indicated that the prepared matrices could control the drug release until the dosage form reaches the colon and the addition HPMC E15 LV showed the desirable changes in the dissolution profile by its hydrophilic nature since the colon is known for its less fluid content."( Effect of HPMC - E15 LV premium polymer on release profile and compression characteristics of chitosan/ pectin colon targeted mesalamine matrix tablets and in vitro study on effect of pH impact on the drug release profile.
Lakshmanan, P; Newton, AM, 2014
)
0.61
" The result from the present investigation indicates that STELLA® when coupled with biorelevant dissolution media can predict the in vivo performance of the drug product with prediction error less than 20% irrespective of the dosage form (immediate release versus modified release) and BCS Classification."( Prediction of in vivo drug performance using in vitro dissolution coupled with STELLA: a study with selected drug products.
Aggarwal, D; Chakraborty, S; Yadav, L, 2015
)
0.42
"For the treatment of inflammatory bowel disease, the development of pH responsive modified release dosage forms is one of the most common approaches to achieve targeted drug delivery."( Dissolution of mesalazine modified release tablets under standard and bio-relevant test conditions.
Garbacz, G; Koziolek, M; Rappen, GM; Weitschies, W, 2015
)
0.42
"The study demonstrates that besides the investigation of the pH dependency of drug release, the characterisation of the mechanical robustness of the dosage forms is an essential factor determining the dissolution characteristics of such pH-dependent targeted modified release tablets."( Dissolution of mesalazine modified release tablets under standard and bio-relevant test conditions.
Garbacz, G; Koziolek, M; Rappen, GM; Weitschies, W, 2015
)
0.42
"gov, through October 2014, was performed to identify randomised controlled trials (RCTs) that recruited adult patients with active or quiescent Crohn's disease, and compared budesonide or mesalazine with placebo, or against each other, or different dosing strategies of one drug."( Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease.
Bonovas, S; Danese, S; Del Giovane, C; Fiorino, G; Moja, L, 2015
)
0.63
" Immediate release products of two highly dosed active pharmaceutical ingredients (APIs), sulfasalazine and L-870,810, and one mesalamine colon targeting product were used for evaluating their usefulness."( Two-Stage Single-Compartment Models to Evaluate Dissolution in the Lower Intestine.
Kesisoglou, F; Markopoulos, C; Reppas, C; Symillides, M; Vertzoni, M, 2015
)
0.62
" Intestinal myeloperoxidase (MPO) determination could be used to estimate the average level of inflammation in colon as well as to determine the efficacy of drugs to be used in the treatment of inflammatory bowel diseases or study the specificity of dosage forms to be used for colonic targeting of anti-inflammatory drugs."( In Vivo Evaluation of 5-ASA Colon-Specific Tablets Using Experimental-Induced Colitis Rat Animal Model.
Bajaj, AN; Deshpande, SG; Nikam, VS; Sawarkar, SP, 2015
)
0.42
"Mesalazine is used as maintenance therapy in ulcerative colitis but the optimal dosage is still controversial."( A randomized trial comparing 4.8 vs. 2.4 g/day of oral mesalazine for maintenance of remission in ulcerative colitis.
Avallone, EV; Cassieri, C; Cocco, A; Crispino, P; De Nitto, D; Marcheggiano, A; Occhigrossi, G; Paoluzi, P; Pica, R; Zippi, M, 2015
)
0.42
"Postprandial administration of solid oral dosage forms greatly changes the dissolution environment compared to fasted state administration."( In vitro biorelevant models for evaluating modified release mesalamine products to forecast the effect of formulation and meal intake on drug release.
Andreas, CJ; Chen, YC; Dressman, J; Markopoulos, C; Reppas, C, 2015
)
0.66
" Preliminary studies with oral solid dosage forms based on MES-SUC complexes tested in vitro have shown a controlled MES release, opening the perspective of a new colon-targeted delivery system and a novel class of compounds with therapeutic application in inflammatory bowel diseases."( Novel self-assembled mesalamine-sucralfate complexes: preparation, characterization, and formulation aspects.
Dumoulin, Y; Friciu, MM; Ispas-Szabo, P; Mateescu, MA; Nguyen, P, 2016
)
0.75
"A capsule formulation of mesalamine granules (MG) was developed for once-daily dosing and better compliance."( Once-daily mesalamine granules for maintaining remission of ulcerative colitis: pooled analysis of efficacy, safety, and prognostic factors.
Barrett, AC; Bortey, E; Forbes, WP; Gordon, GL; Lichtenstein, GR; Murthy, U; Paterson, C; Pruitt, R; Sedghi, S; Zakko, SF, 2016
)
1.13
" This review summarizes data on pharmacokinetics and applications of oral and topical 5-ASA therapies in active and quiescent, extensive colitis and distal disease, both as monotherapies and in combination and reviews dosing and dosing intervals for oral 5-ASA in both active disease and to maintain remissions."( Oral or Topical 5-ASA in Ulcerative Colitis.
Hanauer, SB, 2016
)
0.43
" A secondary objective of this systematic review was to compare the efficacy and safety of once daily dosing of oral 5-ASA with conventional (two or three times daily) dosing regimens."( Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Bhanji, T; Feagan, BG; MacDonald, JK; Parker, CE; Wang, Y, 2016
)
0.43
" Studies that compared once daily 5-ASA treatment with conventional dosing of 5-ASA (two or three times daily) and 5-ASA dose ranging studies were also considered for inclusion."( Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Bhanji, T; Feagan, BG; MacDonald, JK; Parker, CE; Wang, Y, 2016
)
0.43
" Trials were separated into five comparison groups: 5-ASA versus placebo, 5-ASA versus sulfasalazine, once daily dosing versus conventional dosing, 5-ASA versus comparator 5-ASA, and 5-ASA dose-ranging."( Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Bhanji, T; Feagan, BG; MacDonald, JK; Parker, CE; Wang, Y, 2016
)
0.43
" A dose-response trend for 5-ASA was also observed."( Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Bhanji, T; Feagan, BG; MacDonald, JK; Parker, CE; Wang, Y, 2016
)
0.43
" 5-ASA dosed once daily appears to be as efficacious and safe as conventionally dosed 5-ASA."( Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Bhanji, T; Feagan, BG; MacDonald, JK; Parker, CE; Wang, Y, 2016
)
0.43
" A secondary objective was to compare the efficacy and safety of once daily dosing of oral 5-ASA with conventional (two or three times daily) dosing regimens."( Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Feagan, BG; MacDonald, JK; Parker, CE; Wang, Y, 2016
)
0.43
" Studies that compared once daily 5-ASA treatment with conventional dosing of 5-ASA and 5-ASA dose ranging studies were also considered for inclusion."( Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Feagan, BG; MacDonald, JK; Parker, CE; Wang, Y, 2016
)
0.43
" Trials were separated into five comparison groups: 5-ASA versus placebo, 5-ASA versus sulfasalazine, once daily dosing versus conventional dosing, 5-ASA versus comparator 5-ASA formulation, and 5-ASA dose-ranging."( Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Feagan, BG; MacDonald, JK; Parker, CE; Wang, Y, 2016
)
0.43
" No statistically significant differences in efficacy or adherence were found between once daily and conventionally dosed 5-ASA."( Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Feagan, BG; MacDonald, JK; Parker, CE; Wang, Y, 2016
)
0.43
" Oral 5-ASA administered once daily is as effective and safe as conventional dosing for maintenance of remission in quiescent ulcerative colitis."( Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Feagan, BG; MacDonald, JK; Parker, CE; Wang, Y, 2016
)
0.43
" Efficacy, safety and adherence to once daily (OD) and multiple daily (MD) dosing of mesalamine for the induction and maintenance of remission in mild to moderate UC were systematically reviewed and compared."( Once daily vs multiple daily mesalamine therapy for mild to moderate ulcerative colitis: a meta-analysis.
Jiang, XL; Li, W; Zhang, ZM, 2016
)
0.95
" No significant differences were noted in comparisons between OD and MD dosing for maintenance and induction of remission."( Once daily vs multiple daily mesalamine therapy for mild to moderate ulcerative colitis: a meta-analysis.
Jiang, XL; Li, W; Zhang, ZM, 2016
)
0.73
"Patients received budesonide foam 2 mg/25 mL twice daily for 2 weeks, then once daily for 4 weeks, or placebo, with or without continued stable dosing of baseline oral 5-ASAs, for remission induction at week 6 (primary endpoint) in 2 identically designed, randomized, double-blind, phase 3 studies."( Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies.
Bosworth, BP; Harper, JR; Rubin, DT; Sandborn, WJ, 2016
)
0.43
" By combining the advantages of thermally stable pharmaceutically approved polymers and fillers, this unique approach provides a low cost production method for on demand manufacturing of individualised dosage forms."( Adaptation of pharmaceutical excipients to FDM 3D printing for the fabrication of patient-tailored immediate release tablets.
Ahmed, W; Alhnan, MA; Arafat, B; Isreb, A; Kelarakis, A; Sadia, M; Sośnicka, A, 2016
)
0.43
" Dissolution studies of the prepared formulation conducted in simulated colonic fluid clearly demonstrated its superiority over the marketed, delayed release dosage forms of mesalamine."( Role of synbiotics in polysaccharide assisted colon targeted microspheres of mesalamine for the treatment of ulcerative colitis.
Gulati, M; Kaur, R; Singh, SK, 2017
)
0.88
"The study demonstrated the advantage of combination of wireless capsule enteroscopy and bioanalytical determination of pharmacokinetic parameters in an animal experiment to localise the disintegration site of solid dosage form and following kinetics of intestinal absorption of the released active agent."( The Importance of Wireless Capsule Endoscopy for Research into the Intestin al Absorption Window of 5-Aminosalicylic Acid in Experimental Pigs.
Bures, J; Kopacova, M; Kunes, M; Kvetina, J; Nobilis, M; Tacheci, I, 2017
)
0.46
" DAI and colonic histopathology scores in the normal dosage, high dosage and the 5‑ASA‑SiO2 NP groups demonstrated a significant improvement when compared with the model group."( 5-ASA-loaded SiO2 nanoparticles-a novel drug delivery system targeting therapy on ulcerative colitis in mice.
Mao, J; Tan, X; Tang, H; Wang, F; Wang, Y; Xiang, D, 2017
)
0.46
" The "good adherers" with false-negative urine tests were on a once daily dosing regimen and had collected a spot urine sample shortly before the next dosage."( Simple Urine Test to Evaluate Adherence to Oral 5-ASA in Teenagers With Ulcerative Colitis: Proof of Concept.
Dijkstra, A; Touw, DJ; van Rheenen, PF, 2017
)
0.46
" One comparing two different dosing regimens for the maintenance of remission in people with ulcerative colitis (CODA), and the other comparing an orally administered treatment to an intravenously administered treatment in preventing skeletal-related events in patients with bone metastases from breast cancer (ZICE)."( The use of randomisation-based efficacy estimators in non-inferiority trials.
Barrett-Lee, P; Casbard, A; Farewell, D; Gillespie, D; Hawthorne, AB; Hood, K; Hurt, C; Murray, N; Probert, C; Stenson, R, 2017
)
0.46
"QD dosing with Asacol is as effective and safe as TID for maintenance of remission in patients with ulcerative colitis."( 2.4 g Mesalamine (Asacol 400 mg tablet) Once Daily is as Effective as Three Times Daily in Maintenance of Remission in Ulcerative Colitis: A Randomized, Noninferiority, Multi-center Trial.
Arai, T; Hibi, T; Iida, M; Ito, H; Nishino, H; Ohmori, T; Okubo, T; Suzuki, Y; Yokoyama, T, 2017
)
0.94
"Efficacy of maintenance therapy in ulcerative colitis (UC) in the remission stage has been reported to depend on release profile or dosing regimen of oral 5-aminosalicylic acid (5-ASA) products used."( Real life results in using 5-ASA for maintaining mild to moderate UC patients in Japan, a multi-center study, OPTIMUM Study.
Hanai, H; Hibi, T; Kochi, S; Nagahori, M; Nakamura, S; Omuro, S; Watanabe, M; Yamamoto, T, 2017
)
0.46
" The remission maintenance rate at week 52 by dosage and frequency did not significantly differ between Pentasa® Tablets at 4000 mg/day in 2 divided doses (76."( Real life results in using 5-ASA for maintaining mild to moderate UC patients in Japan, a multi-center study, OPTIMUM Study.
Hanai, H; Hibi, T; Kochi, S; Nagahori, M; Nakamura, S; Omuro, S; Watanabe, M; Yamamoto, T, 2017
)
0.46
"Trials in adults suggested that, in ulcerative colitis [UC], once-daily [OD] dosing of 5-ASA [5-amino salicylic acid] may be as or more effective than twice-daily [BD] dosing."( Once- Versus Twice-daily Mesalazine to Induce Remission in Paediatric Ulcerative Colitis: A Randomised Controlled Trial.
Broide, E; Cohen, S; Kolho, KL; Kori, M; Ledder, O; Levine, A; Mozer-Glassberg, Y; On, A; Peleg, S; Shamaly, H; Shaoul, R; Shteyer, E; Turner, D; Yerushalmi, B, 2017
)
0.46
"Children, aged 4-18 years with a PUCAI [Paediatric Ulcerative Colitis Activity Index] of 10-55 points at inclusion, were randomised in blocks of six with blinded allocation to OD or BD mesalazine, using a weight-based dosing table."( Once- Versus Twice-daily Mesalazine to Induce Remission in Paediatric Ulcerative Colitis: A Randomised Controlled Trial.
Broide, E; Cohen, S; Kolho, KL; Kori, M; Ledder, O; Levine, A; Mozer-Glassberg, Y; On, A; Peleg, S; Shamaly, H; Shaoul, R; Shteyer, E; Turner, D; Yerushalmi, B, 2017
)
0.46
"In this first randomised controlled trial in children, no differences were found between OD and BD dosing for any clinical outcome."( Once- Versus Twice-daily Mesalazine to Induce Remission in Paediatric Ulcerative Colitis: A Randomised Controlled Trial.
Broide, E; Cohen, S; Kolho, KL; Kori, M; Ledder, O; Levine, A; Mozer-Glassberg, Y; On, A; Peleg, S; Shamaly, H; Shaoul, R; Shteyer, E; Turner, D; Yerushalmi, B, 2017
)
0.46
" We found large variation in spot (Nac-)5-ASA urinary excretion that was unrelated to brand, dosing schedule or dosage of 5-ASA."( Urinalysis of MMX-mesalazine as a tool to monitor 5-ASA adherence in daily IBD practice.
Burger, DM; Drenth, JPH; Hoentjen, F; Peters, W; Römkens, TEH; Te Morsche, R, 2018
)
0.48
" Results of the study indicate that dosage form performance can be significantly different in individual subjects and highlight the importance of addressing individual physiological parameters relevant to intraluminal drug release when the aim is to predict the in vivo performance of locally-acting mesalazine formulations in individual patients."( A Biopredictive In Vitro Comparison of Oral Locally Acting Mesalazine Formulations by a Novel Dissolution Model for Assessing Intraluminal Drug Release in Individual Subjects.
Karkossa, F; Klein, S, 2018
)
0.48
"4 g/day) vs low dosing (≤2."( Systematic review: safety of mesalazine in ulcerative colitis.
Aboubakr, A; Colombel, JF; Narula, N; Sehgal, P, 2018
)
0.48
" Only randomized clinical trials (RCTs) (irrespective of language, blinding, or publication status), which compared mesalazine, irrespective of the dosage assumption, with placebo in SUDD were evaluated."( Mesalazine to treat symptomatic uncomplicated diverticular disease and to prevent acute diverticulitis occurrence. A systematic review with meta-analysis of randomized, placebo-controlled trials.
Elisei, W; Picchio, M; Tursi, A, 2018
)
0.48
" This study was designed to determine transfer of mesalamine into human milk as a function of maternal dose and time, and dosage form."( Determination of Mesalamine levels in Human Milk as a Function of Dose.
Baker, T; Datta, P; Hale, TW; Kallem, RR; Rewers-Felkins, K, 2019
)
1.11
" Headaches initially improved but the dosage could not be decreased under 750 mg a day without recurrence of the symptoms."( Mesalazine treatment causing resolution of intracranial hypertension secondary to ulcerative colitis: A case report.
Hage, A; Hage, R; Khanna, RK; Polin, V; Sené, T; Vignal-Clermont, C, 2018
)
0.48
" In order to obtain the maximum efficacy of 5-ASA formulations when treating inflammatory bowel diseases, it is essential that the dosage and administration are appropriate."( 5-Aminosalicylic acid.
Iida, T; Nakase, H; Onodera, K, 2017
)
0.46
" With several medications (eg, sulfasalazine, diazo-bonded 5-aminosalicylates [ASA], mesalamines, and corticosteroids, including budesonide) and complex dosing formulations, regimens, and routes, to treat a disease with variable anatomic extent, there is considerable practice variability in the management of patients with mild-moderate UC."( AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis.
Binion, DG; Feuerstein, JD; Singh, S; Tremaine, WJ, 2019
)
0.74
"Site-specific colon drug delivery is a practical approach for the treatment of local diseases of the colon with several advantages such as rapid onset of action and reduction of the dosage of the drug as well as minimization of harmful side effects."( A review on 5-aminosalicylic acid colon-targeted oral drug delivery systems.
Afrasiabi Garekani, H; Akhgari, A; Bagheri, S; Sadeghi, F; Saremnejad, F; Shahdadi Sardo, H, 2019
)
0.51
" Within three years, all polyps had disappeared and the steroid therapy was finished while the dosage of mesalazine was reduced in a stepwise fashion."( Case report of patient with a Cronkhite-Canada syndrome: sustained remission after treatment with corticosteroids and mesalazine.
Drebber, U; Kaufmann, T; Kütting, F; Mertens, J; Nierhoff, D; Schulte, S; Steffen, HM; Töx, U, 2019
)
0.51
"We aimed to conduct a meta-analysis to evaluate the efficacy and safety between once daily (OD) and twice daily (BD) regime dosing of mesalazine for mild-to-moderate ulcerative colitis (UC)."( Efficacy and safety of once daily versus twice daily mesalazine for mild-to-moderate ulcerative colitis: A meta-analysis of randomized controlled trials.
Li, J; Qiu, C; Wang, B; Wang, X; Zhang, Q; Zhang, Z; Zheng, X, 2019
)
0.51
" We searched randomized controlled trials (RCTs) comparing OD with BD regime dosing of mesalazine for mild-to-moderate UC."( Efficacy and safety of once daily versus twice daily mesalazine for mild-to-moderate ulcerative colitis: A meta-analysis of randomized controlled trials.
Li, J; Qiu, C; Wang, B; Wang, X; Zhang, Q; Zhang, Z; Zheng, X, 2019
)
0.51
" Regardless of induction of remission or maintenance of remission of UC, OD regime dosing of mesalazine was as effective as BD regime dosing in clinical and endoscopic remission and clinical remission."( Efficacy and safety of once daily versus twice daily mesalazine for mild-to-moderate ulcerative colitis: A meta-analysis of randomized controlled trials.
Li, J; Qiu, C; Wang, B; Wang, X; Zhang, Q; Zhang, Z; Zheng, X, 2019
)
0.51
"OD is as effective and safe as BD regime dosing of mesalazine for active UC."( Efficacy and safety of once daily versus twice daily mesalazine for mild-to-moderate ulcerative colitis: A meta-analysis of randomized controlled trials.
Li, J; Qiu, C; Wang, B; Wang, X; Zhang, Q; Zhang, Z; Zheng, X, 2019
)
0.51
"We searched PubMed, Scopus, Embase, the Cochrane Library, clinical trial registries, regulatory agencies' websites and international conference proceedings, up to July 2018, to identify randomized controlled trials of adult patients with active, mild-to-moderate UC, comparing budesonide-MMX or mesalamine against placebo, or against each other, or different dosing strategies, for induction of remission."( Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis.
Bonovas, S; Danese, S; González-Lorenzo, M; Lytras, T; Nikolopoulos, GK; Pantavou, K; Peyrin-Biroulet, L; Piovani, D, 2019
)
0.95
" Time to symptom resolution was defined as the period between first drug dosage date and first 3 consecutive days of induction therapy when the patient achieved a score of 0 [normal] on a modified UC Disease Activity Index for stool frequency and/or rectal bleeding."( Time to Symptom Resolution in Ulcerative Colitis With Multimatrix Mesalazine Treatment: A Pooled Analysis.
Barrett, K; Hanauer, SB; Sandborn, WJ; Schreiber, S, 2020
)
0.56
" Mesalamine is commonly administered as divided dosing, although once-daily dosing may provide benefits for patients."( Similar pharmacokinetics of three dosing regimens comprising two oral delayed-release mesalamine formulations in healthy adult volunteers: Randomised, open-label, parallel-group study.
Jakate, A; McNamee, B; Sandborn, WJ; Vande Casteele, N, 2021
)
1.75
" (5) Optimization of 5-aminosalicylate dosage may be indicated even for quiescent patients with ulcerative colitis if mucosal healing is not obtained, and if patients have multiple risk factors for recurrence."( Solving the questions regarding 5-aminosalitylate formulation in the treatment of ulcerative colitis.
Naganuma, M, 2020
)
0.56
" A secondary objective was to compare the efficacy and safety of once-daily dosing of oral 5-ASA versus conventional dosing regimens (two or three times daily)."( Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan, BG; MacDonald, JK; Murray, A; Nguyen, TM; Parker, CE, 2020
)
0.56
" We also included studies that compared once-daily to conventional dosing as well as dose-ranging studies."( Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan, BG; MacDonald, JK; Murray, A; Nguyen, TM; Parker, CE, 2020
)
0.56
" We analyzed five comparisons: 5-ASA versus placebo, 5-ASA versus sulfasalazine, once-daily dosing versus conventional dosing, 5-ASA (e."( Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan, BG; MacDonald, JK; Murray, A; Nguyen, TM; Parker, CE, 2020
)
0.56
" We also observed a dose-response trend for 5-ASA."( Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan, BG; MacDonald, JK; Murray, A; Nguyen, TM; Parker, CE, 2020
)
0.56
" High-certainty evidence suggests 5-ASA dosed once daily appears to be as efficacious as conventionally-dosed 5-ASA."( Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan, BG; MacDonald, JK; Murray, A; Nguyen, TM; Parker, CE, 2020
)
0.56
" Mesalazine at 4,000 mg/day and prednisolone at 60 mg/day were started, and the prednisolone dosage was thereafter gradually reduced and switched to golimumab."( Multiple Cerebral Infarction Associated with Cerebral Vasculitis in a Patient with Ulcerative Colitis.
Dohi, O; Hasegawa, D; Hirose, R; Inoue, K; Ishikawa, T; Itoh, Y; Kamada, K; Konishi, H; Naito, Y; Takagi, T; Uchiyama, K; Yasuda, T; Yoshida, N, 2021
)
0.62
"To assess the efficacy, dose-responsiveness, and safety of oral 5-ASA compared to placebo, SASP, or 5-ASA comparators for maintenance of remission in quiescent UC and to compare the efficacy and safety of once-daily dosing of oral 5-ASA with conventional (two or three times daily) dosing regimens."( Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Feagan, BG; MacDonald, JK; Murray, A; Nguyen, TM; Parker, CE, 2020
)
0.56
" We also included studies that compared once-daily 5-ASA treatment with conventional dosing of 5-ASA and 5-ASA dose-ranging studies."( Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Feagan, BG; MacDonald, JK; Murray, A; Nguyen, TM; Parker, CE, 2020
)
0.56
" Trials were separated into five comparison groups: 5-ASA versus placebo, 5-ASA versus SASP, once-daily dosing versus conventional dosing, 5-ASA (balsalazide, Pentasa, and olsalazine) versus comparator 5-ASA formulation (Asacol and Salofalk), and 5-ASA dose-ranging."( Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Feagan, BG; MacDonald, JK; Murray, A; Nguyen, TM; Parker, CE, 2020
)
0.56
" There is little or no difference in clinical or endoscopic remission rates between once-daily and conventionally dosed 5-ASA."( Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Feagan, BG; MacDonald, JK; Murray, A; Nguyen, TM; Parker, CE, 2020
)
0.56
" Oral 5-ASA administered once daily has a similar benefit and harm profile as conventional dosing for maintenance of remission in quiescent UC."( Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Feagan, BG; MacDonald, JK; Murray, A; Nguyen, TM; Parker, CE, 2020
)
0.56
" Therefore, amino acids are safe potential co-formers, which are suitable for improving the physicochemical properties of API and prospective to be developed further in the dosage formula and solid-state syntheses."( Amino Acids as the Potential Co-Former for Co-Crystal Development: A Review.
Jessica, MA; Nugrahani, I, 2021
)
0.62
" For the last few decades, scientists have been endeavoring to invent and innovate technologies that can substitute the conventional dosage forms and enable targeted and prolonged drug release at a particular site."( Budding Multi-matrix Technology-a Retrospective Approach, Deep Insights, and Future Perspectives.
Atmakuri, S; Hoque, S; Khatri, D; Kumar, R; Madan, J; Mahajan, S; Maji, I; Modani, S; Singh, PK; Sriram, A; Srivastava, S; Tangirala, S, 2021
)
0.62
" UC patients on oral 5-ASA ≥ 2 g daily for ≥ 1 year with C-reactive protein (CRP) < 10 mg/dL and no 5-ASA dosage escalation, UC-related hospitalization or corticosteroid use in the past year were included."( No increased risk of flare in ulcerative colitis patients in corticosteroid-free remission after stopping 5-aminosalicylic acid: A territory-wide population-based study.
Chan, FKL; Cheng, CTY; Lam, BKH; Lam, RHM; Mak, JWY; Ng, SC; Wong, GLH; Yip, TCF; Yuen, NTK, 2022
)
0.72
"Although in-vivo bioequivalence (BE) study serves as a golden standard for establishing interchangeability of oral dosage forms, it remains challenging for products with high inter-subject variability such as mesalazine enteric-coated tablet to fulfil the BE criteria set by regulatory authorities."( Population pharmacokinetics and IVIVC for mesalazine enteric-coated tablets.
Gao, F; Leng, W; Wo, SK; Yan, X; Zhang, Y; Zuo, Z, 2022
)
0.72
" Together, the association of these systems with polymers will allow the release of 5-ASA through specific targeting mechanisms to the colon, as demonstrated in the mesalazine modified-release dosage form."( Polymeric Systems for Colon-specific Mesalazine Delivery in the Intestinal Bowel Diseases Management.
Chorilli, M; de Araújo, JTC; Di Filippo, LD; Duarte, JL; Junior, AGT; Silvestre, ALP, 2023
)
0.91
" This leads us to establish how rCDI and its resistance to different treatments make this a challenge for the health system, both for hospitals and for outpatients, as well as how time-consuming each treatment is from the first intake of the drug until its total efficacy or until patients reach a dose-response and time-response to the disease."( Recurrent Multidrug-Resistant
Castells, J; Ibrahimli, S; Jaramillo, AP; Siegel, S, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
non-steroidal anti-inflammatory drugAn anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
aromatic amineAn amino compound in which the amino group is linked directly to an aromatic system.
amino acidA carboxylic acid containing one or more amino groups.
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
monocarboxylic acidAn oxoacid containing a single carboxy group.
monohydroxybenzoic acidAny hydroxybenzoic acid having a single phenolic hydroxy substituent on the benzene ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (74)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency4.53740.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency4.91070.004023.8416100.0000AID485290
Chain A, Breast cancer type 1 susceptibility proteinHomo sapiens (human)Potency15.84891.258920.440939.8107AID892
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency3.53970.140911.194039.8107AID2451
Chain A, HADH2 proteinHomo sapiens (human)Potency16.86790.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency16.86790.025120.237639.8107AID886; AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency3.98110.177814.390939.8107AID2147
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency5.53030.125919.1169125.8920AID2549
LuciferasePhotinus pyralis (common eastern firefly)Potency39.68990.007215.758889.3584AID1224835; AID624030
15-lipoxygenase, partialHomo sapiens (human)Potency23.73590.012610.691788.5700AID887
phosphopantetheinyl transferaseBacillus subtilisPotency36.42610.141337.9142100.0000AID1490
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.18830.006038.004119,952.5996AID1159521
USP1 protein, partialHomo sapiens (human)Potency25.51540.031637.5844354.8130AID504865
GLS proteinHomo sapiens (human)Potency15.84890.35487.935539.8107AID624170
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency11.95070.011212.4002100.0000AID1030
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency10.00000.00137.762544.6684AID914; AID915
retinoid X nuclear receptor alphaHomo sapiens (human)Potency48.55910.000817.505159.3239AID1159527
pregnane X nuclear receptorHomo sapiens (human)Potency67.96230.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency45.14010.000229.305416,493.5996AID743069; AID743079
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency3.16230.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency68.58960.000723.06741,258.9301AID743085
thyroid stimulating hormone receptorHomo sapiens (human)Potency58.37420.001628.015177.1139AID1224843; AID1259385
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency23.91450.057821.109761.2679AID1159526
Histone H2A.xCricetulus griseus (Chinese hamster)Potency46.06130.039147.5451146.8240AID1224845; AID1224896
cytochrome P450 2C19 precursorHomo sapiens (human)Potency5.01190.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency12.58930.00636.904339.8107AID883
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency11.22020.001815.663839.8107AID894
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency44.66840.354828.065989.1251AID504847
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency70.00870.010039.53711,122.0200AID1469; AID1479
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency24.33650.000627.21521,122.0200AID743202; AID743219
DNA polymerase kappa isoform 1Homo sapiens (human)Potency3.51740.031622.3146100.0000AID588579
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency23.87700.031610.279239.8107AID884; AID885
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency7.94330.251215.843239.8107AID504327
caspase-1 isoform alpha precursorHomo sapiens (human)Potency9.44950.000311.448431.6228AID900
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency23.87701.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency23.87701.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency23.87701.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency23.87701.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency23.87701.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency23.87701.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency23.87701.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency23.87701.000012.224831.6228AID885
Platelet-activating factor receptorHomo sapiens (human)Potency15.848910.000025.781039.8107AID892
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency23.87701.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency23.87701.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency23.87701.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency12.58930.00638.235039.8107AID883
Caspase-7Homo sapiens (human)Potency16.53113.981118.585631.6228AID889
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency31.62280.009610.525035.4813AID1479145
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency23.87701.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency23.87701.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency23.87701.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency23.87701.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency23.87701.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
microphthalmia-associated transcription factor isoform 9Homo sapiens (human)IC50 (µMol)2.67270.00481.37104.9290AID1259371; AID1259373; AID1259375
Bile salt export pumpHomo sapiens (human)IC50 (µMol)381.00000.11007.190310.0000AID1449628
Tumor necrosis factorHomo sapiens (human)IC50 (µMol)10,310.00000.20000.67911.3000AID1413398; AID1498643
NeuraminidaseInfluenza A virus (A/Wilson-Smith/1933(H1N1))IC50 (µMol)100.00000.00040.13430.9930AID716614
Prostaglandin G/H synthase 1Ovis aries (sheep)IC50 (µMol)7.73000.00032.177410.0000AID1608176
60 kDa heat shock protein, mitochondrialHomo sapiens (human)IC50 (µMol)12.00000.17004.559010.0000AID1594139
Cystathionine gamma-lyaseHomo sapiens (human)IC50 (µMol)200.00000.57002.86098.0000AID1680654
Prostaglandin G/H synthase 2Homo sapiens (human)IC50 (µMol)7.53000.00010.995010.0000AID1608177
10 kDa heat shock protein, mitochondrialHomo sapiens (human)IC50 (µMol)12.00000.17004.559010.0000AID1594139
Thiosulfate sulfurtransferaseHomo sapiens (human)IC50 (µMol)0.28000.06003.96319.7000AID1594135
60 kDa chaperonin Escherichia coliIC50 (µMol)3.24500.03903.55529.8000AID1594140; AID1594141
10 kDa chaperonin Escherichia coliIC50 (µMol)3.24500.03903.55529.8000AID1594140; AID1594141
Protein-arginine deiminase type-4Homo sapiens (human)IC50 (µMol)10,000.00002.50004.20005.9000AID320706
Cystine/glutamate transporterHomo sapiens (human)IC50 (µMol)1,000.00000.14001.14005.0000AID622159
Hydroxyacid oxidase 1Mus musculus (house mouse)IC50 (µMol)7.80007.80007.80007.8000AID1397964
large T antigenBetapolyomavirus macacaeIC50 (µMol)19.10000.160024.9724100.0000AID1903
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier organic anion transporter family member 2B1 Homo sapiens (human)Km188.90000.70005.00608.0900AID1215361
Solute carrier organic anion transporter family member 1B3Homo sapiens (human)Km77.40000.03912.93886.4000AID1215362
Solute carrier organic anion transporter family member 1B1Homo sapiens (human)Km55.10000.00763.201810.0000AID1215363
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (382)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
monoatomic ion transportSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
organic anion transportSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
prostaglandin transportSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
heme catabolic processSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
transport across blood-brain barrierSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
bile acid and bile salt transportSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
positive regulation of gene expressionTumor necrosis factorHomo sapiens (human)
negative regulation of gene expressionTumor necrosis factorHomo sapiens (human)
positive regulation of MAP kinase activityTumor necrosis factorHomo sapiens (human)
positive regulation of MAPK cascadeTumor necrosis factorHomo sapiens (human)
positive regulation of interleukin-33 productionTumor necrosis factorHomo sapiens (human)
positive regulation of cytokine production involved in inflammatory responseTumor necrosis factorHomo sapiens (human)
negative regulation of miRNA transcriptionTumor necrosis factorHomo sapiens (human)
positive regulation of miRNA transcriptionTumor necrosis factorHomo sapiens (human)
negative regulation of signaling receptor activityTumor necrosis factorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IITumor necrosis factorHomo sapiens (human)
positive regulation of gene expressionTumor necrosis factorHomo sapiens (human)
negative regulation of gene expressionTumor necrosis factorHomo sapiens (human)
positive regulation of interleukin-8 productionTumor necrosis factorHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processTumor necrosis factorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IITumor necrosis factorHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityTumor necrosis factorHomo sapiens (human)
positive regulation of calcineurin-NFAT signaling cascadeTumor necrosis factorHomo sapiens (human)
positive regulation of cytokine production involved in inflammatory responseTumor necrosis factorHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionTumor necrosis factorHomo sapiens (human)
positive regulation of synoviocyte proliferationTumor necrosis factorHomo sapiens (human)
positive regulation of I-kappaB phosphorylationTumor necrosis factorHomo sapiens (human)
negative regulation of apoptotic signaling pathwayTumor necrosis factorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IITumor necrosis factorHomo sapiens (human)
response to hypoxiaTumor necrosis factorHomo sapiens (human)
microglial cell activationTumor necrosis factorHomo sapiens (human)
positive regulation of cytokine productionTumor necrosis factorHomo sapiens (human)
positive regulation of protein phosphorylationTumor necrosis factorHomo sapiens (human)
negative regulation of endothelial cell proliferationTumor necrosis factorHomo sapiens (human)
negative regulation of L-glutamate import across plasma membraneTumor necrosis factorHomo sapiens (human)
macrophage activation involved in immune responseTumor necrosis factorHomo sapiens (human)
chronic inflammatory response to antigenic stimulusTumor necrosis factorHomo sapiens (human)
leukocyte migration involved in inflammatory responseTumor necrosis factorHomo sapiens (human)
regulation of immunoglobulin productionTumor necrosis factorHomo sapiens (human)
negative regulation of cytokine production involved in immune responseTumor necrosis factorHomo sapiens (human)
positive regulation of chronic inflammatory response to antigenic stimulusTumor necrosis factorHomo sapiens (human)
positive regulation of humoral immune response mediated by circulating immunoglobulinTumor necrosis factorHomo sapiens (human)
skeletal muscle contractionTumor necrosis factorHomo sapiens (human)
negative regulation of systemic arterial blood pressureTumor necrosis factorHomo sapiens (human)
glucose metabolic processTumor necrosis factorHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processTumor necrosis factorHomo sapiens (human)
inflammatory responseTumor necrosis factorHomo sapiens (human)
humoral immune responseTumor necrosis factorHomo sapiens (human)
JNK cascadeTumor necrosis factorHomo sapiens (human)
circadian rhythmTumor necrosis factorHomo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptorsTumor necrosis factorHomo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageTumor necrosis factorHomo sapiens (human)
response to xenobiotic stimulusTumor necrosis factorHomo sapiens (human)
response to virusTumor necrosis factorHomo sapiens (human)
response to salt stressTumor necrosis factorHomo sapiens (human)
response to fructoseTumor necrosis factorHomo sapiens (human)
negative regulation of heart rateTumor necrosis factorHomo sapiens (human)
vascular endothelial growth factor productionTumor necrosis factorHomo sapiens (human)
positive regulation of gene expressionTumor necrosis factorHomo sapiens (human)
negative regulation of gene expressionTumor necrosis factorHomo sapiens (human)
negative regulation of lipid storageTumor necrosis factorHomo sapiens (human)
response to activityTumor necrosis factorHomo sapiens (human)
regulation of metabolic processTumor necrosis factorHomo sapiens (human)
calcium-mediated signalingTumor necrosis factorHomo sapiens (human)
extracellular matrix organizationTumor necrosis factorHomo sapiens (human)
osteoclast differentiationTumor necrosis factorHomo sapiens (human)
sequestering of triglycerideTumor necrosis factorHomo sapiens (human)
cortical actin cytoskeleton organizationTumor necrosis factorHomo sapiens (human)
positive regulation of protein-containing complex assemblyTumor necrosis factorHomo sapiens (human)
positive regulation of fever generationTumor necrosis factorHomo sapiens (human)
negative regulation of myelinationTumor necrosis factorHomo sapiens (human)
response to nutrient levelsTumor necrosis factorHomo sapiens (human)
negative regulation of interleukin-6 productionTumor necrosis factorHomo sapiens (human)
positive regulation of chemokine productionTumor necrosis factorHomo sapiens (human)
positive regulation of fractalkine productionTumor necrosis factorHomo sapiens (human)
positive regulation of type II interferon productionTumor necrosis factorHomo sapiens (human)
positive regulation of interleukin-1 beta productionTumor necrosis factorHomo sapiens (human)
positive regulation of interleukin-18 productionTumor necrosis factorHomo sapiens (human)
positive regulation of interleukin-6 productionTumor necrosis factorHomo sapiens (human)
positive regulation of interleukin-8 productionTumor necrosis factorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationTumor necrosis factorHomo sapiens (human)
tumor necrosis factor-mediated signaling pathwayTumor necrosis factorHomo sapiens (human)
positive regulation of heterotypic cell-cell adhesionTumor necrosis factorHomo sapiens (human)
toll-like receptor 3 signaling pathwayTumor necrosis factorHomo sapiens (human)
negative regulation of myosin-light-chain-phosphatase activityTumor necrosis factorHomo sapiens (human)
response to isolation stressTumor necrosis factorHomo sapiens (human)
response to macrophage colony-stimulating factorTumor necrosis factorHomo sapiens (human)
vasodilationTumor necrosis factorHomo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinTumor necrosis factorHomo sapiens (human)
positive regulation of apoptotic processTumor necrosis factorHomo sapiens (human)
positive regulation of programmed cell deathTumor necrosis factorHomo sapiens (human)
regulation of canonical NF-kappaB signal transductionTumor necrosis factorHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionTumor necrosis factorHomo sapiens (human)
negative regulation of protein-containing complex disassemblyTumor necrosis factorHomo sapiens (human)
positive regulation of protein-containing complex disassemblyTumor necrosis factorHomo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processTumor necrosis factorHomo sapiens (human)
positive regulation of MAP kinase activityTumor necrosis factorHomo sapiens (human)
positive regulation of MAPK cascadeTumor necrosis factorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionTumor necrosis factorHomo sapiens (human)
positive regulation of JUN kinase activityTumor necrosis factorHomo sapiens (human)
positive regulation of neuron apoptotic processTumor necrosis factorHomo sapiens (human)
negative regulation of blood vessel endothelial cell migrationTumor necrosis factorHomo sapiens (human)
negative regulation of viral genome replicationTumor necrosis factorHomo sapiens (human)
positive regulation of nitric oxide biosynthetic processTumor necrosis factorHomo sapiens (human)
response to ethanolTumor necrosis factorHomo sapiens (human)
regulation of fat cell differentiationTumor necrosis factorHomo sapiens (human)
negative regulation of fat cell differentiationTumor necrosis factorHomo sapiens (human)
negative regulation of myoblast differentiationTumor necrosis factorHomo sapiens (human)
negative regulation of osteoblast differentiationTumor necrosis factorHomo sapiens (human)
positive regulation of osteoclast differentiationTumor necrosis factorHomo sapiens (human)
positive regulation of protein catabolic processTumor necrosis factorHomo sapiens (human)
positive regulation of action potentialTumor necrosis factorHomo sapiens (human)
positive regulation of cell adhesionTumor necrosis factorHomo sapiens (human)
positive regulation of mitotic nuclear divisionTumor necrosis factorHomo sapiens (human)
negative regulation of DNA-templated transcriptionTumor necrosis factorHomo sapiens (human)
positive regulation of DNA-templated transcriptionTumor necrosis factorHomo sapiens (human)
negative regulation of mitotic cell cycleTumor necrosis factorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IITumor necrosis factorHomo sapiens (human)
positive regulation of translational initiation by ironTumor necrosis factorHomo sapiens (human)
negative regulation of glucose importTumor necrosis factorHomo sapiens (human)
positive regulation of JNK cascadeTumor necrosis factorHomo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATTumor necrosis factorHomo sapiens (human)
astrocyte activationTumor necrosis factorHomo sapiens (human)
embryonic digestive tract developmentTumor necrosis factorHomo sapiens (human)
positive regulation of smooth muscle cell proliferationTumor necrosis factorHomo sapiens (human)
positive regulation of inflammatory responseTumor necrosis factorHomo sapiens (human)
negative regulation of neurogenesisTumor necrosis factorHomo sapiens (human)
regulation of insulin secretionTumor necrosis factorHomo sapiens (human)
positive regulation of synaptic transmissionTumor necrosis factorHomo sapiens (human)
regulation of synapse organizationTumor necrosis factorHomo sapiens (human)
defense response to Gram-positive bacteriumTumor necrosis factorHomo sapiens (human)
cognitionTumor necrosis factorHomo sapiens (human)
leukocyte tethering or rollingTumor necrosis factorHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painTumor necrosis factorHomo sapiens (human)
negative regulation of lipid catabolic processTumor necrosis factorHomo sapiens (human)
positive regulation of membrane protein ectodomain proteolysisTumor necrosis factorHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityTumor necrosis factorHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityTumor necrosis factorHomo sapiens (human)
positive regulation of protein transportTumor necrosis factorHomo sapiens (human)
response to glucocorticoidTumor necrosis factorHomo sapiens (human)
positive regulation of hair follicle developmentTumor necrosis factorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionTumor necrosis factorHomo sapiens (human)
regulation of synaptic transmission, glutamatergicTumor necrosis factorHomo sapiens (human)
positive regulation of glial cell proliferationTumor necrosis factorHomo sapiens (human)
positive regulation of vitamin D biosynthetic processTumor necrosis factorHomo sapiens (human)
positive regulation of calcidiol 1-monooxygenase activityTumor necrosis factorHomo sapiens (human)
epithelial cell proliferation involved in salivary gland morphogenesisTumor necrosis factorHomo sapiens (human)
regulation of branching involved in salivary gland morphogenesisTumor necrosis factorHomo sapiens (human)
negative regulation of vascular wound healingTumor necrosis factorHomo sapiens (human)
negative regulation of branching involved in lung morphogenesisTumor necrosis factorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeTumor necrosis factorHomo sapiens (human)
cellular response to lipopolysaccharideTumor necrosis factorHomo sapiens (human)
cellular response to amino acid stimulusTumor necrosis factorHomo sapiens (human)
cellular response to retinoic acidTumor necrosis factorHomo sapiens (human)
cellular response to nicotineTumor necrosis factorHomo sapiens (human)
cellular response to type II interferonTumor necrosis factorHomo sapiens (human)
cellular response to ionizing radiationTumor necrosis factorHomo sapiens (human)
positive regulation of mononuclear cell migrationTumor necrosis factorHomo sapiens (human)
positive regulation of podosome assemblyTumor necrosis factorHomo sapiens (human)
endothelial cell apoptotic processTumor necrosis factorHomo sapiens (human)
protein localization to plasma membraneTumor necrosis factorHomo sapiens (human)
negative regulation of oxidative phosphorylationTumor necrosis factorHomo sapiens (human)
inflammatory response to woundingTumor necrosis factorHomo sapiens (human)
extrinsic apoptotic signaling pathwayTumor necrosis factorHomo sapiens (human)
cellular response to toxic substanceTumor necrosis factorHomo sapiens (human)
liver regenerationTumor necrosis factorHomo sapiens (human)
necroptotic signaling pathwayTumor necrosis factorHomo sapiens (human)
negative regulation of bile acid secretionTumor necrosis factorHomo sapiens (human)
antiviral innate immune responseTumor necrosis factorHomo sapiens (human)
response to Gram-negative bacteriumTumor necrosis factorHomo sapiens (human)
positive regulation of neuroinflammatory responseTumor necrosis factorHomo sapiens (human)
negative regulation of amyloid-beta clearanceTumor necrosis factorHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionTumor necrosis factorHomo sapiens (human)
positive regulation of amyloid-beta formationTumor necrosis factorHomo sapiens (human)
response to L-glutamateTumor necrosis factorHomo sapiens (human)
positive regulation of neutrophil activationTumor necrosis factorHomo sapiens (human)
positive regulation of protein localization to plasma membraneTumor necrosis factorHomo sapiens (human)
regulation of establishment of endothelial barrierTumor necrosis factorHomo sapiens (human)
negative regulation of bicellular tight junction assemblyTumor necrosis factorHomo sapiens (human)
cellular response to amyloid-betaTumor necrosis factorHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationTumor necrosis factorHomo sapiens (human)
positive regulation of leukocyte adhesion to vascular endothelial cellTumor necrosis factorHomo sapiens (human)
positive regulation of leukocyte adhesion to arterial endothelial cellTumor necrosis factorHomo sapiens (human)
regulation of membrane lipid metabolic processTumor necrosis factorHomo sapiens (human)
response to 3,3',5-triiodo-L-thyronineTumor necrosis factorHomo sapiens (human)
response to gold nanoparticleTumor necrosis factorHomo sapiens (human)
positive regulation of protein localization to cell surfaceTumor necrosis factorHomo sapiens (human)
positive regulation of blood microparticle formationTumor necrosis factorHomo sapiens (human)
positive regulation of chemokine (C-X-C motif) ligand 2 productionTumor necrosis factorHomo sapiens (human)
positive regulation of hepatocyte proliferationTumor necrosis factorHomo sapiens (human)
regulation of endothelial cell apoptotic processTumor necrosis factorHomo sapiens (human)
regulation of reactive oxygen species metabolic processTumor necrosis factorHomo sapiens (human)
positive regulation of DNA biosynthetic processTumor necrosis factorHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandTumor necrosis factorHomo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathwayTumor necrosis factorHomo sapiens (human)
protein folding60 kDa chaperoninEscherichia coli K-12
response to radiation60 kDa chaperoninEscherichia coli K-12
response to heat60 kDa chaperoninEscherichia coli K-12
virion assembly60 kDa chaperoninEscherichia coli K-12
chaperone cofactor-dependent protein refolding60 kDa chaperoninEscherichia coli K-12
protein refolding60 kDa chaperoninEscherichia coli K-12
chaperone cofactor-dependent protein refolding60 kDa chaperoninEscherichia coli K-12
response to heat60 kDa chaperoninEscherichia coli K-12
adhesion of symbiont to host60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of type II interferon production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
T cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
MyD88-dependent toll-like receptor signaling pathway60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of T cell mediated immune response to tumor cell60 kDa heat shock protein, mitochondrialHomo sapiens (human)
'de novo' protein folding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process60 kDa heat shock protein, mitochondrialHomo sapiens (human)
response to unfolded protein60 kDa heat shock protein, mitochondrialHomo sapiens (human)
response to cold60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interferon-alpha production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of type II interferon production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interleukin-10 production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interleukin-12 production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interleukin-6 production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein refolding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
B cell proliferation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
B cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of macrophage activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of apoptotic process60 kDa heat shock protein, mitochondrialHomo sapiens (human)
negative regulation of apoptotic process60 kDa heat shock protein, mitochondrialHomo sapiens (human)
isotype switching to IgG isotypes60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein stabilization60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of T cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
chaperone-mediated protein complex assembly60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein maturation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
biological process involved in interaction with symbiont60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cellular response to interleukin-760 kDa heat shock protein, mitochondrialHomo sapiens (human)
T cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein import into mitochondrial intermembrane space60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein folding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial unfolded protein response60 kDa heat shock protein, mitochondrialHomo sapiens (human)
apoptotic mitochondrial changes60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of cellular extravasationPlatelet-activating factor receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIPlatelet-activating factor receptorHomo sapiens (human)
chemotaxisPlatelet-activating factor receptorHomo sapiens (human)
inflammatory responsePlatelet-activating factor receptorHomo sapiens (human)
immune responsePlatelet-activating factor receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayPlatelet-activating factor receptorHomo sapiens (human)
parturitionPlatelet-activating factor receptorHomo sapiens (human)
response to symbiotic bacteriumPlatelet-activating factor receptorHomo sapiens (human)
lipopolysaccharide-mediated signaling pathwayPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of interleukin-6 productionPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of tumor necrosis factor productionPlatelet-activating factor receptorHomo sapiens (human)
inositol trisphosphate biosynthetic processPlatelet-activating factor receptorHomo sapiens (human)
G protein-coupled purinergic nucleotide receptor signaling pathwayPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of neutrophil degranulationPlatelet-activating factor receptorHomo sapiens (human)
transcytosisPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of translationPlatelet-activating factor receptorHomo sapiens (human)
negative regulation of blood pressurePlatelet-activating factor receptorHomo sapiens (human)
positive regulation of smooth muscle cell proliferationPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processPlatelet-activating factor receptorHomo sapiens (human)
cellular response to gravityPlatelet-activating factor receptorHomo sapiens (human)
cellular response to cAMPPlatelet-activating factor receptorHomo sapiens (human)
cellular response to fatty acidPlatelet-activating factor receptorHomo sapiens (human)
response to dexamethasonePlatelet-activating factor receptorHomo sapiens (human)
positive regulation of leukocyte tethering or rollingPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of transcytosisPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of maternal process involved in parturitionPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of gastro-intestinal system smooth muscle contractionPlatelet-activating factor receptorHomo sapiens (human)
cellular response to 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholinePlatelet-activating factor receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayPlatelet-activating factor receptorHomo sapiens (human)
cysteine metabolic processCystathionine gamma-lyaseHomo sapiens (human)
lipid metabolic processCystathionine gamma-lyaseHomo sapiens (human)
protein-pyridoxal-5-phosphate linkage via peptidyl-N6-pyridoxal phosphate-L-lysineCystathionine gamma-lyaseHomo sapiens (human)
cysteine biosynthetic process via cystathionineCystathionine gamma-lyaseHomo sapiens (human)
cysteine biosynthetic processCystathionine gamma-lyaseHomo sapiens (human)
transsulfurationCystathionine gamma-lyaseHomo sapiens (human)
endoplasmic reticulum unfolded protein responseCystathionine gamma-lyaseHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionCystathionine gamma-lyaseHomo sapiens (human)
protein sulfhydrationCystathionine gamma-lyaseHomo sapiens (human)
protein homotetramerizationCystathionine gamma-lyaseHomo sapiens (human)
hydrogen sulfide biosynthetic processCystathionine gamma-lyaseHomo sapiens (human)
positive regulation of aortic smooth muscle cell differentiationCystathionine gamma-lyaseHomo sapiens (human)
cellular response to leukemia inhibitory factorCystathionine gamma-lyaseHomo sapiens (human)
negative regulation of apoptotic signaling pathwayCystathionine gamma-lyaseHomo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 2Homo sapiens (human)
embryo implantationProstaglandin G/H synthase 2Homo sapiens (human)
learningProstaglandin G/H synthase 2Homo sapiens (human)
memoryProstaglandin G/H synthase 2Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell population proliferationProstaglandin G/H synthase 2Homo sapiens (human)
response to xenobiotic stimulusProstaglandin G/H synthase 2Homo sapiens (human)
response to nematodeProstaglandin G/H synthase 2Homo sapiens (human)
response to fructoseProstaglandin G/H synthase 2Homo sapiens (human)
response to manganese ionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 2Homo sapiens (human)
bone mineralizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fever generationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic plasticityProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergicProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin secretionProstaglandin G/H synthase 2Homo sapiens (human)
response to estradiolProstaglandin G/H synthase 2Homo sapiens (human)
response to lipopolysaccharideProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationProstaglandin G/H synthase 2Homo sapiens (human)
response to vitamin DProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to heatProstaglandin G/H synthase 2Homo sapiens (human)
response to tumor necrosis factorProstaglandin G/H synthase 2Homo sapiens (human)
maintenance of blood-brain barrierProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of protein import into nucleusProstaglandin G/H synthase 2Homo sapiens (human)
hair cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of apoptotic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vasoconstrictionProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
decidualizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle cell proliferationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of inflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
response to glucocorticoidProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of calcium ion transportProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicProstaglandin G/H synthase 2Homo sapiens (human)
response to fatty acidProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to mechanical stimulusProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to lead ionProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to ATPProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to hypoxiaProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to non-ionic osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to fluid shear stressProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of transforming growth factor beta productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fibroblast growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of platelet-derived growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of neuroinflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to homocysteineProstaglandin G/H synthase 2Homo sapiens (human)
response to angiotensinProstaglandin G/H synthase 2Homo sapiens (human)
proteolysisCaspase-7Homo sapiens (human)
apoptotic processCaspase-7Homo sapiens (human)
heart developmentCaspase-7Homo sapiens (human)
response to UVCaspase-7Homo sapiens (human)
protein processingCaspase-7Homo sapiens (human)
protein catabolic processCaspase-7Homo sapiens (human)
defense response to bacteriumCaspase-7Homo sapiens (human)
fibroblast apoptotic processCaspase-7Homo sapiens (human)
striated muscle cell differentiationCaspase-7Homo sapiens (human)
neuron apoptotic processCaspase-7Homo sapiens (human)
protein maturationCaspase-7Homo sapiens (human)
lymphocyte apoptotic processCaspase-7Homo sapiens (human)
cellular response to lipopolysaccharideCaspase-7Homo sapiens (human)
cellular response to staurosporineCaspase-7Homo sapiens (human)
execution phase of apoptosisCaspase-7Homo sapiens (human)
positive regulation of plasma membrane repairCaspase-7Homo sapiens (human)
positive regulation of neuron apoptotic processCaspase-7Homo sapiens (human)
osteoblast differentiation10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein folding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process10 kDa heat shock protein, mitochondrialHomo sapiens (human)
response to unfolded protein10 kDa heat shock protein, mitochondrialHomo sapiens (human)
chaperone cofactor-dependent protein refolding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
sulfur amino acid catabolic processThiosulfate sulfurtransferaseHomo sapiens (human)
cyanate catabolic processThiosulfate sulfurtransferaseHomo sapiens (human)
epithelial cell differentiationThiosulfate sulfurtransferaseHomo sapiens (human)
rRNA import into mitochondrionThiosulfate sulfurtransferaseHomo sapiens (human)
rRNA transportThiosulfate sulfurtransferaseHomo sapiens (human)
xenobiotic metabolic processSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
monoatomic ion transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
organic anion transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
bile acid and bile salt transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
heme catabolic processSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
chromatin organizationProtein-arginine deiminase type-4Homo sapiens (human)
nucleosome assemblyProtein-arginine deiminase type-4Homo sapiens (human)
chromatin remodelingProtein-arginine deiminase type-4Homo sapiens (human)
stem cell population maintenanceProtein-arginine deiminase type-4Homo sapiens (human)
protein modification processProtein-arginine deiminase type-4Homo sapiens (human)
post-translational protein modificationProtein-arginine deiminase type-4Homo sapiens (human)
innate immune responseProtein-arginine deiminase type-4Homo sapiens (human)
glutathione metabolic processCystine/glutamate transporterHomo sapiens (human)
visual learningCystine/glutamate transporterHomo sapiens (human)
response to toxic substanceCystine/glutamate transporterHomo sapiens (human)
response to organic cyclic compoundCystine/glutamate transporterHomo sapiens (human)
L-cystine transportCystine/glutamate transporterHomo sapiens (human)
L-glutamate transmembrane transportCystine/glutamate transporterHomo sapiens (human)
ventricular system developmentCystine/glutamate transporterHomo sapiens (human)
striatum developmentCystine/glutamate transporterHomo sapiens (human)
adult behaviorCystine/glutamate transporterHomo sapiens (human)
regulation of neutrophil apoptotic processCystine/glutamate transporterHomo sapiens (human)
cellular response to oxidative stressCystine/glutamate transporterHomo sapiens (human)
glutathione transmembrane transportCystine/glutamate transporterHomo sapiens (human)
response to nicotineCystine/glutamate transporterHomo sapiens (human)
regulation of cell population proliferationCystine/glutamate transporterHomo sapiens (human)
regulation of melanin biosynthetic processCystine/glutamate transporterHomo sapiens (human)
lung alveolus developmentCystine/glutamate transporterHomo sapiens (human)
modulation of chemical synaptic transmissionCystine/glutamate transporterHomo sapiens (human)
regulation of synapse organizationCystine/glutamate transporterHomo sapiens (human)
regulation of protein transportCystine/glutamate transporterHomo sapiens (human)
response to redox stateCystine/glutamate transporterHomo sapiens (human)
limb developmentCystine/glutamate transporterHomo sapiens (human)
lens fiber cell differentiationCystine/glutamate transporterHomo sapiens (human)
platelet aggregationCystine/glutamate transporterHomo sapiens (human)
intracellular glutamate homeostasisCystine/glutamate transporterHomo sapiens (human)
L-glutamate import across plasma membraneCystine/glutamate transporterHomo sapiens (human)
negative regulation of ferroptosisCystine/glutamate transporterHomo sapiens (human)
dipeptide import across plasma membraneCystine/glutamate transporterHomo sapiens (human)
L-kynurenine transmembrane transportCystine/glutamate transporterHomo sapiens (human)
regulation of cellular response to oxidative stressCystine/glutamate transporterHomo sapiens (human)
regulation of cysteine metabolic processCystine/glutamate transporterHomo sapiens (human)
regulation of glutathione biosynthetic processCystine/glutamate transporterHomo sapiens (human)
regulation of AMPA glutamate receptor clusteringCystine/glutamate transporterHomo sapiens (human)
regulation of glutamate metabolic processCystine/glutamate transporterHomo sapiens (human)
amino acid transmembrane transportCystine/glutamate transporterHomo sapiens (human)
xenobiotic metabolic processSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
monoatomic ion transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
organic anion transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
bile acid and bile salt transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
prostaglandin transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
heme catabolic processSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
thyroid hormone transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (75)

Processvia Protein(s)Taxonomy
organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
transmembrane transporter activitySolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
bile acid transmembrane transporter activitySolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
transcription cis-regulatory region bindingTumor necrosis factorHomo sapiens (human)
protease bindingTumor necrosis factorHomo sapiens (human)
cytokine activityTumor necrosis factorHomo sapiens (human)
tumor necrosis factor receptor bindingTumor necrosis factorHomo sapiens (human)
protein bindingTumor necrosis factorHomo sapiens (human)
death receptor agonist activityTumor necrosis factorHomo sapiens (human)
identical protein bindingTumor necrosis factorHomo sapiens (human)
magnesium ion binding60 kDa chaperoninEscherichia coli K-12
protein binding60 kDa chaperoninEscherichia coli K-12
ATP binding60 kDa chaperoninEscherichia coli K-12
isomerase activity60 kDa chaperoninEscherichia coli K-12
ATP hydrolysis activity60 kDa chaperoninEscherichia coli K-12
identical protein binding60 kDa chaperoninEscherichia coli K-12
unfolded protein binding60 kDa chaperoninEscherichia coli K-12
ATP-dependent protein folding chaperone60 kDa chaperoninEscherichia coli K-12
lipopolysaccharide binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
p53 binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
DNA replication origin binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
single-stranded DNA binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
RNA binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
double-stranded RNA binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
high-density lipoprotein particle binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
isomerase activity60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP hydrolysis activity60 kDa heat shock protein, mitochondrialHomo sapiens (human)
enzyme binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ubiquitin protein ligase binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
apolipoprotein binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
apolipoprotein A-I binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
unfolded protein binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein-folding chaperone binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP-dependent protein folding chaperone60 kDa heat shock protein, mitochondrialHomo sapiens (human)
lipopolysaccharide bindingPlatelet-activating factor receptorHomo sapiens (human)
lipopolysaccharide immune receptor activityPlatelet-activating factor receptorHomo sapiens (human)
G protein-coupled receptor activityPlatelet-activating factor receptorHomo sapiens (human)
platelet activating factor receptor activityPlatelet-activating factor receptorHomo sapiens (human)
protein bindingPlatelet-activating factor receptorHomo sapiens (human)
phospholipid bindingPlatelet-activating factor receptorHomo sapiens (human)
mitogen-activated protein kinase bindingPlatelet-activating factor receptorHomo sapiens (human)
G protein-coupled purinergic nucleotide receptor activityPlatelet-activating factor receptorHomo sapiens (human)
cystathionine gamma-lyase activityCystathionine gamma-lyaseHomo sapiens (human)
protein bindingCystathionine gamma-lyaseHomo sapiens (human)
calmodulin bindingCystathionine gamma-lyaseHomo sapiens (human)
pyridoxal phosphate bindingCystathionine gamma-lyaseHomo sapiens (human)
identical protein bindingCystathionine gamma-lyaseHomo sapiens (human)
L-cystine L-cysteine-lyase (deaminating)Cystathionine gamma-lyaseHomo sapiens (human)
homocysteine desulfhydrase activityCystathionine gamma-lyaseHomo sapiens (human)
L-cysteine desulfhydrase activityCystathionine gamma-lyaseHomo sapiens (human)
selenocystathionine gamma-lyase activityCystathionine gamma-lyaseHomo sapiens (human)
peroxidase activityProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 2Homo sapiens (human)
protein bindingProstaglandin G/H synthase 2Homo sapiens (human)
enzyme bindingProstaglandin G/H synthase 2Homo sapiens (human)
heme bindingProstaglandin G/H synthase 2Homo sapiens (human)
protein homodimerization activityProstaglandin G/H synthase 2Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 2Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 2Homo sapiens (human)
RNA bindingCaspase-7Homo sapiens (human)
aspartic-type endopeptidase activityCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-7Homo sapiens (human)
protein bindingCaspase-7Homo sapiens (human)
peptidase activityCaspase-7Homo sapiens (human)
cysteine-type peptidase activityCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic processCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activity involved in execution phase of apoptosisCaspase-7Homo sapiens (human)
RNA binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein folding chaperone10 kDa heat shock protein, mitochondrialHomo sapiens (human)
unfolded protein binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein-folding chaperone binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
metal ion binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
thiosulfate sulfurtransferase activityThiosulfate sulfurtransferaseHomo sapiens (human)
5S rRNA bindingThiosulfate sulfurtransferaseHomo sapiens (human)
3-mercaptopyruvate sulfurtransferase activityThiosulfate sulfurtransferaseHomo sapiens (human)
serine-type endopeptidase inhibitor activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
bile acid transmembrane transporter activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
protein-arginine deiminase activityProtein-arginine deiminase type-4Homo sapiens (human)
calcium ion bindingProtein-arginine deiminase type-4Homo sapiens (human)
protein bindingProtein-arginine deiminase type-4Homo sapiens (human)
identical protein bindingProtein-arginine deiminase type-4Homo sapiens (human)
histone arginine deiminase activityProtein-arginine deiminase type-4Homo sapiens (human)
histone H3R2 arginine deiminase activityProtein-arginine deiminase type-4Homo sapiens (human)
histone H3R8 arginine deiminase activityProtein-arginine deiminase type-4Homo sapiens (human)
histone H3R17 arginine deiminase activityProtein-arginine deiminase type-4Homo sapiens (human)
histone H3R26 arginine deiminase activityProtein-arginine deiminase type-4Homo sapiens (human)
protein bindingCystine/glutamate transporterHomo sapiens (human)
cystine:glutamate antiporter activityCystine/glutamate transporterHomo sapiens (human)
L-kynurenine transmembrane transporter activityCystine/glutamate transporterHomo sapiens (human)
L-amino acid transmembrane transporter activityCystine/glutamate transporterHomo sapiens (human)
organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
bile acid transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
thyroid hormone transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (50)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
apical plasma membraneSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
apical plasma membraneSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceTumor necrosis factorHomo sapiens (human)
phagocytic cupTumor necrosis factorHomo sapiens (human)
extracellular regionTumor necrosis factorHomo sapiens (human)
extracellular spaceTumor necrosis factorHomo sapiens (human)
plasma membraneTumor necrosis factorHomo sapiens (human)
external side of plasma membraneTumor necrosis factorHomo sapiens (human)
cell surfaceTumor necrosis factorHomo sapiens (human)
neuronal cell bodyTumor necrosis factorHomo sapiens (human)
membrane raftTumor necrosis factorHomo sapiens (human)
recycling endosomeTumor necrosis factorHomo sapiens (human)
cell surfaceTumor necrosis factorHomo sapiens (human)
cytoplasm60 kDa chaperoninEscherichia coli K-12
cytosol60 kDa chaperoninEscherichia coli K-12
membrane60 kDa chaperoninEscherichia coli K-12
GroEL-GroES complex60 kDa chaperoninEscherichia coli K-12
mitochondrial matrix60 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular space60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cytoplasm60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrion60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial inner membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial matrix60 kDa heat shock protein, mitochondrialHomo sapiens (human)
early endosome60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cytosol60 kDa heat shock protein, mitochondrialHomo sapiens (human)
plasma membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
clathrin-coated pit60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cell surface60 kDa heat shock protein, mitochondrialHomo sapiens (human)
membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
coated vesicle60 kDa heat shock protein, mitochondrialHomo sapiens (human)
secretory granule60 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular exosome60 kDa heat shock protein, mitochondrialHomo sapiens (human)
sperm midpiece60 kDa heat shock protein, mitochondrialHomo sapiens (human)
sperm plasma membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
migrasome60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein-containing complex60 kDa heat shock protein, mitochondrialHomo sapiens (human)
lipopolysaccharide receptor complex60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial inner membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membranePlatelet-activating factor receptorHomo sapiens (human)
membranePlatelet-activating factor receptorHomo sapiens (human)
secretory granule membranePlatelet-activating factor receptorHomo sapiens (human)
tertiary granule membranePlatelet-activating factor receptorHomo sapiens (human)
cytosolCystathionine gamma-lyaseHomo sapiens (human)
extracellular exosomeCystathionine gamma-lyaseHomo sapiens (human)
cytoplasmCystathionine gamma-lyaseHomo sapiens (human)
nuclear inner membraneProstaglandin G/H synthase 2Homo sapiens (human)
nuclear outer membraneProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulumProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum lumenProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 2Homo sapiens (human)
caveolaProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
protein-containing complexProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
extracellular spaceCaspase-7Homo sapiens (human)
nucleusCaspase-7Homo sapiens (human)
cytoplasmCaspase-7Homo sapiens (human)
cytosolCaspase-7Homo sapiens (human)
nucleusCaspase-7Homo sapiens (human)
nucleoplasmCaspase-7Homo sapiens (human)
cytosolCaspase-7Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
mitochondrion10 kDa heat shock protein, mitochondrialHomo sapiens (human)
membrane10 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular exosome10 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial matrix10 kDa heat shock protein, mitochondrialHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
extracellular spaceThiosulfate sulfurtransferaseHomo sapiens (human)
mitochondrionThiosulfate sulfurtransferaseHomo sapiens (human)
mitochondrial matrixThiosulfate sulfurtransferaseHomo sapiens (human)
mitochondrionThiosulfate sulfurtransferaseHomo sapiens (human)
plasma membraneSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
nucleusProtein-arginine deiminase type-4Homo sapiens (human)
nucleoplasmProtein-arginine deiminase type-4Homo sapiens (human)
cytosolProtein-arginine deiminase type-4Homo sapiens (human)
protein-containing complexProtein-arginine deiminase type-4Homo sapiens (human)
nucleusProtein-arginine deiminase type-4Homo sapiens (human)
cytoplasmProtein-arginine deiminase type-4Homo sapiens (human)
plasma membraneCystine/glutamate transporterHomo sapiens (human)
cell surfaceCystine/glutamate transporterHomo sapiens (human)
membraneCystine/glutamate transporterHomo sapiens (human)
brush border membraneCystine/glutamate transporterHomo sapiens (human)
microvillus membraneCystine/glutamate transporterHomo sapiens (human)
apical part of cellCystine/glutamate transporterHomo sapiens (human)
astrocyte projectionCystine/glutamate transporterHomo sapiens (human)
plasma membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (295)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1449696Chaperone activity at recombinant human C-terminal FLAG-tagged pendrin P123S mutant expressed in HEK293 cells assessed as increase in localization of protein mutant in plasma membrane at 1 to 30 mM after 12 hrs by DAPI staining based immunofluorescence mi2017Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9
Discovery of (2-aminophenyl)methanol as a new molecular chaperone that rescues the localization of P123S mutant pendrin stably expressed in HEK293 cells.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1764372Antiinflammatory activity in DSS-induced ulcerative colitis mouse model assessed as reduction in MPO activity at 200 mg/kg, po administered for 10 consecutive days2021Bioorganic & medicinal chemistry letters, 04-01, Volume: 37Synthesis of norisoboldine derivatives and bioactivity assay for inducing the generation of regulatory T cells.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1594144Inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured soluble pig heart MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID436237Antiarthritic activity against Freund's adjuvant-induced arthritis in Wistar rat assessed as reduction in paw volume administered 13 days after Freund's adjuvant challenge measured on day 212009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrugs of 5-aminosalicylic acid for colon-specific drug delivery in inflammatory bowel disease.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID190859Urinary recovery in non-colostomized rats at 2 hr intervals for 48 h1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Brush-border-enzyme-mediated intestine-specific drug delivery. Amino acid prodrugs of 5-aminosalicylic acid.
AID1215377Drug uptake in human OATP1B3 expressed HEK293 cells at 20 uM relative to control cells in presence of 100 uM cyclosporine2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1215352Inhibition of human OATP1A2 expressed HEK293 cells assessed as inhibition of [3H]sulfobromophthalein uptake by liquid scintillation counting2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1909003Anti-ulcerative colitis activity in DSS-induced C57BL/6 mouse ulcerative colitis model assessed as histopathological score recovery ratio at 50 mg/kg, IG via gavage measured after 7 days by H and E staining method relative to control
AID1594141Inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured soluble pig heart MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID299083Partition coefficient, log P at pH 7.42007Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7
Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrug of 5-aminosalicylic acid with D-phenylalanine for colon specific drug delivery in inflammatory bowel disease.
AID1413398Inhibition of TNFalpha (unknown origin)-induced adhesion of BCECF fluorescence-labeled human U937 cells to human HT-29 cells pretreated for 1 hr followed by BCECF fluorescence-labeled human U937 cell/TNFalpha addition and measured after 3 hrs by fluoresce2018MedChemComm, Aug-01, Volume: 9, Issue:8
Synthesis and evaluation of 6-heteroarylamino-2,4,5-trimethylpyridin-3-ols as inhibitors of TNF-α-induced cell adhesion and inflammatory bowel disease.
AID1215354Inhibition of human OATP2B1 expressed HEK293 cells assessed as inhibition of [3H]sulfobromophthalein uptake by liquid scintillation counting2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake.
AID1498641Inhibition of TNFalpha (unknown origin)-induced adhesion of BCECF fluorescence-labeled human U937 cells to human HT-29 cells at 20 mM measured at 3 hrs post TNFalpha stimulation relative to control2018Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14
Synthesis and biological evaluation of pyridine-linked indanone derivatives: Potential agents for inflammatory bowel disease.
AID1215368Drug uptake in human SCLO1B1*1a mutant expressed HEK293 cells assessed as net uptake measured per mg of protein2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake.
AID716602Antiinflammatory activity in LPS-activated mouse RAW264.7 cells assessed as inhibition of LPS induced IL6 production treated 30 mins prior to LPS challenge measured after 6 hrs by RT-PCR analysis2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Enhanced anti-influenza agents conjugated with anti-inflammatory activity.
AID179007Fecal recovery in colostomized rats at 2 hr intervals for 48 h1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Brush-border-enzyme-mediated intestine-specific drug delivery. Amino acid prodrugs of 5-aminosalicylic acid.
AID1606527Anti-inflammatory activity against DSS-induced ulcerative colitis C57BL/6J mouse model assessed as preservation of colon mucosal architecture at 3 and 30 mg/kg, po administered for 7 days and measured on day 7 by hoechst and eosin staining based microscop2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Small-Molecule Antagonist Targeting Exportin-1 via Rational Structure-Based Discovery.
AID1909011Antiinflammatory activity against DSS-induced C57BL/6 mouse model of acute ulcerative colitis assessed as inhibition ratio of IL-1beta protein expression at 50 mg/kg, IG via gavage measured after 7 days by ELISA relative to control
AID716614Inhibition of Influenza A virus A/WSN/1933(H1N1)) neuraminidase in the presence of 2'-(4-methyl-umbelliferyl)-alphaD-N-acetylneuraminic acid substrate after 10 mins by fluorometric assay2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Enhanced anti-influenza agents conjugated with anti-inflammatory activity.
AID1204231Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg indomethacin mol equivalent, ip administered 1 hr prior to carrageenan challenge measured at 3 hrs relative to indomethacin2015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
Synthesis and QSAR study of novel anti-inflammatory active mesalazine-metronidazole conjugates.
AID1215372Drug uptake in human OATP2B1 expressed HEK293 cells at 20 uM relative to control cells in presence of 100 uM pravastatin2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake.
AID1321635Antiinflammatory activity in human HT-29 cells assessed as inhibition of TNF-alpha induced BCECF-AM labeled human U937 cell adhesion at 1 uM preincubated for 1 hr followed by stimulation with TNF-alpha for 3 hrs followed by further co-incubation with BCEC2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
In vitro and in vivo inhibitory activity of 6-amino-2,4,5-trimethylpyridin-3-ols against inflammatory bowel disease.
AID1608176Inhibition of ovine COX1 using arachidonic acid as substrate pretreated for 5 mins followed by substrate addition and measured after 2 mins by fluorescence based enzyme immunoassay2019European journal of medicinal chemistry, Oct-15, Volume: 180Design of balanced COX inhibitors based on anti-inflammatory and/or COX-2 inhibitory ascidian metabolites.
AID417721Antiinflammatory activity against TNBS-induced Wistar rat colitis model assessed as decrease in severity of inflammation treated po 3 days after TNBS induction measured on day 72009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Colon-specific mutual amide prodrugs of 4-aminosalicylic acid for their mitigating effect on experimental colitis in rats.
AID1764378Antiinflammatory activity in DSS-induced ulcerative colitis mouse model assessed as protection against inflammation of colons at 200 mg/kg, po administered for 10 consecutive days by HE staining based histopathological analysis2021Bioorganic & medicinal chemistry letters, 04-01, Volume: 37Synthesis of norisoboldine derivatives and bioactivity assay for inducing the generation of regulatory T cells.
AID639970Antiinflammatory activity against trinitrobenzenesulfonic acid-induced colitis in rat assessed as decrease in CINC2 protein expression at 30 mM administered rectally QD for 6 days2012European journal of medicinal chemistry, Feb, Volume: 48Structure-activity relationship of salicylic acid derivatives on inhibition of TNF-α dependent NFκB activity: Implication on anti-inflammatory effect of N-(5-chlorosalicyloyl)phenethylamine against experimental colitis.
AID1594140Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding by measuring rhodanese enzyme activity 2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID78212Tested for mean score after quantitative histological evaluation result in guinea pig1983Journal of medicinal chemistry, Sep, Volume: 26, Issue:9
A polymeric drug for treatment of inflammatory bowel disease.
AID1498643Inhibition of TNFalpha (unknown origin)-induced adhesion of BCECF fluorescence-labeled human U937 cells to human HT-29 cells measured at 3 hrs post TNFalpha stimulation2018Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14
Synthesis and biological evaluation of pyridine-linked indanone derivatives: Potential agents for inflammatory bowel disease.
AID1759578Anti-ulcerative colitis activity in acetic acid-induced ulcerative colitis Wistar rat model assessed as mild deformation of mucosal layer with disruption of epithelium in colon at 400 mg/kg, po administrated for 14 days by microscopic analysis2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Design, synthesis and molecular modeling studies of novel mesalamine linked coumarin for treatment of inflammatory bowel disease.
AID1215366Drug uptake in human SCLO1B1*5 mutant expressed HEK293 cells assessed as net uptake2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1606529Anti-inflammatory activity against DSS-induced ulcerative colitis C57BL/6J mouse model assessed as reduction in colon inflammation at 3 and 30 mg/kg, po administered for 7 days and measured on day 7 by hoechst and eosin staining based microscopic analysis2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Small-Molecule Antagonist Targeting Exportin-1 via Rational Structure-Based Discovery.
AID1909061Antiinflammatory activity against IL-10-/- C57BL/6 mouse model of ulcerative colitis assessed as inhibition ratio of IL-6 protein expression at 50 mg/kg, IG via gavage and measured after 8 weeks by ELISA relative to control
AID1215361Drug uptake in human OATP2B1 expressed HEK293 cells assessed as net uptake2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake.
AID1909120Anti-ulcerative colitis activity in IL-10-/- C57BL/6 mouse ulcerative colitis model assessed as animal survival at 50 mg/kg, IG via gavage for 8 weeks
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1204224Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg indomethacin mol equivalent, ip administered 1 hr prior to carrageenan challenge measured at 2 hrs relative to control2015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
Synthesis and QSAR study of novel anti-inflammatory active mesalazine-metronidazole conjugates.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1909057Antiinflammatory activity against IL-10-/- C57BL/6 mouse model of ulcerative colitis assessed as inhibition ratio of IL-1beta protein expression at 50 mg/kg, IG via gavage and measured after 8 weeks by ELISA relative to control
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1759576Anti-ulcerative colitis activity in acetic acid-induced ulcerative colitis Wistar rat model assessed as reduction in damage of mucosa in colon at 400 mg/kg, po administrated for 14 days by microscopic analysis2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Design, synthesis and molecular modeling studies of novel mesalamine linked coumarin for treatment of inflammatory bowel disease.
AID1909037Antiinflammatory activity against DSS-induced C57BL/6 mouse model of acute ulcerative colitis assessed as inhibition ratio of IL-23 mRNA expression in colon tissue at 50 mg/kg, IG via gavage measured after 7 days by RT-qPCR analysis relative to control
AID1306038Antiinflammatory activity in DSS- induced C57BL/6 mouse colitis model assessed as body weight at 50 mg/kg, ig after 10 days (Rvb = 15.69 +/- 0.65 g)2016Bioorganic & medicinal chemistry, 07-15, Volume: 24, Issue:14
Development of hydroxy-based sphingosine kinase inhibitors and anti-inflammation in dextran sodium sulfate induced colitis in mice.
AID1764383Induction of Treg cell differentiation in DSS- induced ulcerative colitis mouse model assessed as number of Treg cells in colonic lamina proprias at 200 mg/kg, po administered for 10 consecutive days by flow cytometry analysis (Rvb= 7.97%)2021Bioorganic & medicinal chemistry letters, 04-01, Volume: 37Synthesis of norisoboldine derivatives and bioactivity assay for inducing the generation of regulatory T cells.
AID337238Inhibition of mouse EGFR by liquid scintillation counting
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1215359Drug uptake in human OATP1B1 expressed HEK293 cells assessed as net uptake measured per mg of protein2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake.
AID1759581Anti-ulcerative colitis activity in acetic acid-induced ulcerative colitis Wistar rat model assessed as reduction in blood content in feces with parrot green to green dotted colour at 400 mg/kg,po administrated for 14 days2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Design, synthesis and molecular modeling studies of novel mesalamine linked coumarin for treatment of inflammatory bowel disease.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID293915Ulcerogenic effect in Wistar rat at 2290 mg/kg, po by Rainsford's cold stress method relative to control2007European journal of medicinal chemistry, Jun, Volume: 42, Issue:6
Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrug of 5-aminosalicylic acid for colon-specific drug delivery in inflammatory bowel disease.
AID77143Tested for cecal ulceration with mortality at 60 umol concentration of compound1983Journal of medicinal chemistry, Sep, Volume: 26, Issue:9
A polymeric drug for treatment of inflammatory bowel disease.
AID1215379Drug uptake in human OATP2B1 expressed HEK293 cells at 20 uM relative to control cells in presence of 10 to 100 uM budesonide2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake.
AID1499307Inhibition of LPS-induced TNF-alpha expression in human HT-29 cells at 20 mM preincubated for 1 hr followed by TNF-alpha challenge measured after 3 hrs by Western blot method2017European journal of medicinal chemistry, Sep-08, Volume: 137Discovery and structure-activity relationship studies of 2-benzylidene-2,3-dihydro-1H-inden-1-one and benzofuran-3(2H)-one derivatives as a novel class of potential therapeutics for inflammatory bowel disease.
AID1909029Antiinflammatory activity against DSS-induced C57BL/6 mouse model of acute ulcerative colitis assessed as inhibition ratio of IL-1beta mRNA expression in colon tissue at 50 mg/kg, IG via gavage measured after 7 days by RT-qPCR analysis relative to control
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1596144Anti-inflammatory activity against DSS-induced ulcerative colitis C57BL/6 mouse model assessed as colon length at 100 mg/kg, ig administered for 7 consecutive days followed by 7 days treatment with drinking water followed by three additional DSS treatment2019European journal of medicinal chemistry, Jul-15, Volume: 174Development of M10, myricetin-3-O-β-d-lactose sodium salt, a derivative of myricetin as a potent agent of anti-chronic colonic inflammation.
AID1909007Antiinflammatory activity against DSS-induced C57BL/6 mouse model of acute ulcerative colitis assessed as inhibition ratio of TNF-alpha protein expression at 50 mg/kg, IG via gavage measured after 7 days by ELISA relative to control
AID1864294Antiinflammatory activity in DSS-induced acute enteritis C57BL mouse model assessed as suppression of DSS induced weight loss at 100 mg/kg, po administered daily and measured upto 11 days relative to control
AID1499294Inhibition of TNF-alpha-induced adhesion of BCECF-labeled human U937 cells to human HT-29 cells at 20 mM preincubated for 1 hr followed by TNF-alpha challenge measured after 3 hrs by fluorescence microscopic method relative to control2017European journal of medicinal chemistry, Sep-08, Volume: 137Discovery and structure-activity relationship studies of 2-benzylidene-2,3-dihydro-1H-inden-1-one and benzofuran-3(2H)-one derivatives as a novel class of potential therapeutics for inflammatory bowel disease.
AID1204230Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg indomethacin mol equivalent, ip administered 1 hr prior to carrageenan challenge measured at 24 hrs relative to control2015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
Synthesis and QSAR study of novel anti-inflammatory active mesalazine-metronidazole conjugates.
AID1864317Anti-inflammatory activity in TNBS induced IBD BALB/c mouse model assessed as reduction in stool softness by measuring disease activity index score at 100 mg/kg via oral gavage administered daily for 12 days
AID425632Antituberculosis activity against Mycobacterium paratuberculosis ATCC 19698 isolated from bovine assessed as minimum drug level resulting in no detectable growth at 10'6 CFU of inoculum after 56 days by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1215381Drug uptake in human OATP1B1 expressed HEK293 cells at 20 uM relative to control cells in presence of 10 to 100 uM budesonide2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake.
AID639952Inhibition of TNF-alpha-induced NF-kappaB activation in human HCT116 cells at 1 mM after 6 hrs by luciferase reporter gene assay2012European journal of medicinal chemistry, Feb, Volume: 48Structure-activity relationship of salicylic acid derivatives on inhibition of TNF-α dependent NFκB activity: Implication on anti-inflammatory effect of N-(5-chlorosalicyloyl)phenethylamine against experimental colitis.
AID1397965Inhibition of glycolate oxidase in C57BL/6 Agxt1-/- mouse hepatocytes using glycolate as substrate assessed as relative oxalate level at 10 uM after 24 hrs2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
Salicylic Acid Derivatives Inhibit Oxalate Production in Mouse Hepatocytes with Primary Hyperoxaluria Type 1.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1606530Anti-inflammatory activity against DSS-induced ulcerative colitis C57BL/6J mouse model assessed as reduction in colon ulceration at 3 and 30 mg/kg, po administered for 7 days and measured on day 7 by hoechst and eosin staining based microscopic analysis2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Small-Molecule Antagonist Targeting Exportin-1 via Rational Structure-Based Discovery.
AID1215356Drug uptake in human OATP1B3 expressed HEK293 cells at 20 uM relative to control cells2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake.
AID1449689Cytotoxicity against HEK293 cells harboring pendrin P123S mutant assessed as decrease in cell viability at 15 mM after 72 hrs by MTT assay2017Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9
Discovery of (2-aminophenyl)methanol as a new molecular chaperone that rescues the localization of P123S mutant pendrin stably expressed in HEK293 cells.
AID179008Fecal recovery in non-colostomized rats at 2 hr intervals for 48 h1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Brush-border-enzyme-mediated intestine-specific drug delivery. Amino acid prodrugs of 5-aminosalicylic acid.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID716597Antiinflammatory activity in LPS-activated mouse RAW264.7 cells assessed as inhibition of LPS induced TNFalpha production treated 30 mins prior to LPS challenge measured after 6 hrs by RT-PCR analysis2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Enhanced anti-influenza agents conjugated with anti-inflammatory activity.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1909081Antiinflammatory activity against IL-10-/- C57BL/6 mouse model of ulcerative colitis assessed as inhibition ratio of IL-23 mRNA expression in colon tissue at 50 mg/kg, IG via gavage and measured after 8 weeks by RT-qPCR analysis relative to control
AID1594137Inhibition of ATPase activity of Escherichia coli GroEL expressed in Escherichia coliDH5alpha incubated for 60 mins using ATP by spectrometric analysis2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID436412Partition coefficient, log P in n-octanol/phosphate buffer of pH 7.42009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrugs of 5-aminosalicylic acid for colon-specific drug delivery in inflammatory bowel disease.
AID1215364Drug uptake in human SCLO1B1*1a mutant expressed HEK293 cells assessed as net uptake2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1174762Antiinflammatory activity against carrageenan-induced ip dosed Wistar rat paw edema model assessed as inhibition of edema administered 30 mins prior to carrageenan challenge measured after 60 mins2015European journal of medicinal chemistry, Jan-07, Volume: 89Benzimidazole--ibuprofen/mesalamine conjugates: potential candidates for multifactorial diseases.
AID1215373Drug uptake in human OATP1B3 expressed HEK293 cells at 20 uM relative to control cells in presence of 100 uM pravastatin2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake.
AID417725Antiinflammatory activity against TNBS-induced po dosed Wistar rat colitis model assessed as inhibition of MPO activity in neutrophils per 100 mg of tissue2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Colon-specific mutual amide prodrugs of 4-aminosalicylic acid for their mitigating effect on experimental colitis in rats.
AID1215363Drug uptake in human OATP1B1 expressed HEK293 cells assessed as net uptake2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake.
AID1909073Antiinflammatory activity against IL-10-/- C57BL/6 mouse model of ulcerative colitis assessed as inhibition ratio of IL-1beta mRNA expression in colon tissue at 50 mg/kg, IG via gavage and measured after 8 weeks by RT-qPCR analysis relative to control
AID1864306Antiinflammatory activity in DSS-induced acute colitis C57BL/6 mouse model assessed as reduction in intestinal edema in colon by measuring histopathological score at 100 mg/kg, po by H and E staining based analysis
AID1759579Anti-ulcerative colitis activity in acetic acid-induced ulcerative colitis Wistar rat model assessed as reduction in diarrhea at 400 mg/kg, po administrated for 14 days and measured during initial 5 to 6 days of treatment2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Design, synthesis and molecular modeling studies of novel mesalamine linked coumarin for treatment of inflammatory bowel disease.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1215374Drug uptake in human OATP1B1 expressed HEK293 cells at 20 uM relative to control cells in presence of 100 uM pravastatin2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake.
AID1215370Drug uptake in human SCLO1B1*5 mutant expressed HEK293 cells assessed as net uptake measured per mg of protein2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake.
AID1763257Inhibition of TNF-alpha-induced cell adhesion in human U937 cells assessed as reduction in cell adhesion to HT-29 cells at 1000 uM relative to control2021Bioorganic & medicinal chemistry letters, 07-01, Volume: 43Synthesis and activity of N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)acetamide analogues as anticolitis agents via dual inhibition of TNF-α- and IL-6-induced cell adhesions.
AID1864312Anti-inflammatory activity in TNBS induced IBD BALB/c mouse model assessed as increase in survival probability at 100 mg/kg via oral gavage administered daily for 12 days
AID1594139Inhibition of human N-terminal octa-His-tagged HSP60 expressed in Escherichia coli Rosetta(DE3) pLysS/human HSP10 expressed in Escherichia coli Rosetta(DE3) assessed as reduction in HSP60/HSP10-mediated denatured MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1909065Antiinflammatory activity against IL-10-/- C57BL/6 mouse model of ulcerative colitis assessed as inhibition ratio of IL-23 protein expression at 50 mg/kg, IG via gavage and measured after 8 weeks by ELISA relative to control
AID1764388Induction of Treg cell differentiation in DSS- induced ulcerative colitis mouse model assessed as number of Treg cells in mesenteric lymph nodes at 200 mg/kg, po administered for 10 consecutive days by flow cytometry analysis (Rvb= 7.52%)2021Bioorganic & medicinal chemistry letters, 04-01, Volume: 37Synthesis of norisoboldine derivatives and bioactivity assay for inducing the generation of regulatory T cells.
AID1306046Antiinflammatory activity in DSS- induced C57BL/6 mouse colon colitis model assessed as mucosal/submucosal lesion at 50 mg/kg, ig after 24 hrs by hematoxylin/eosin staining based assay2016Bioorganic & medicinal chemistry, 07-15, Volume: 24, Issue:14
Development of hydroxy-based sphingosine kinase inhibitors and anti-inflammation in dextran sodium sulfate induced colitis in mice.
AID1909110Anti-ulcerative colitis activity against DSS-induced ulcerative colitis C57BL/6 mouse model assessed as reduction in DAI score at 50 mg/kg, IG via gavage administered for 7 days and measured everyday (Rvb = 4.0 No_unit)
AID1594134Inhibition of native soluble pig heart MDH assessed as reduction in MDH enzyme activity using sodium mesoxalate as substrate and NADH by malachite green dye based spectrometric analysis2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID106805Compound was tested for the inhibition of malate dehydrogenase (MDH) at 200 uM2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID625305Antiinflammatory activity against TNF-alpha-induced VCAM-1 protein expression in HAEC by ELISA2011European journal of medicinal chemistry, Nov, Volume: 46, Issue:11
Novel natural product-based cinnamates and their thio and thiono analogs as potent inhibitors of cell adhesion molecules on human endothelial cells.
AID293912Partition coefficient, log P in n-octanol/phosphate buffer at pH 7.42007European journal of medicinal chemistry, Jun, Volume: 42, Issue:6
Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrug of 5-aminosalicylic acid for colon-specific drug delivery in inflammatory bowel disease.
AID299837Ulcerogenic activity in Wistar rat at 2290 mg/kg, po by cold stress method relative to control2007Bioorganic & medicinal chemistry, Jul-15, Volume: 15, Issue:14
Colon-specific, mutual azo prodrug of 5-aminosalicylic acid with L-tryptophan: synthesis, kinetic studies and evaluation of its mitigating effect in trinitrobenzenesulfonic acid-induced colitis in rats.
AID293919Antiarthritic activity in Freund's adjuvant-induced arthritis Wistar rat model after 13 days2007European journal of medicinal chemistry, Jun, Volume: 42, Issue:6
Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrug of 5-aminosalicylic acid for colon-specific drug delivery in inflammatory bowel disease.
AID1864302Antiinflammatory activity in DSS-induced acute colitis C57BL/6 mouse model assessed as reduction in inflammatory cell infiltration in colon by measuring histopathological score at 100 mg/kg, po by H and E staining based analysis
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1215369Drug uptake in human SCLO1B1*1b mutant expressed HEK293 cells assessed as net uptake measured per mg of protein2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake.
AID1759577Anti-ulcerative colitis activity in acetic acid-induced ulcerative colitis Wistar rat model assessed as reduction in sub-mucosal edema in colon at 400 mg/kg, po administrated for 14 days by microscopic analysis2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Design, synthesis and molecular modeling studies of novel mesalamine linked coumarin for treatment of inflammatory bowel disease.
AID1764375Antiinflammatory activity in DSS-induced ulcerative colitis mouse model assessed as protection against colon destruction at 200 mg/kg, po administered for 10 consecutive days by HE staining based histopathological analysis2021Bioorganic & medicinal chemistry letters, 04-01, Volume: 37Synthesis of norisoboldine derivatives and bioactivity assay for inducing the generation of regulatory T cells.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID425631Antituberculosis activity against Mycobacterium paratuberculosis ATCC 19698 isolated from bovine assessed as lowest drug level producing inhibition at 10'6 CFU of inoculum by agar counting method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID1608177Inhibition of recombinant human COX2 using arachidonic acid as substrate pretreated for 5 mins followed by substrate addition and measured after 2 mins by fluorescence based enzyme immunoassay2019European journal of medicinal chemistry, Oct-15, Volume: 180Design of balanced COX inhibitors based on anti-inflammatory and/or COX-2 inhibitory ascidian metabolites.
AID299836Partition coefficient, log P in n-octanol/phosphate buffer at pH 7.42007Bioorganic & medicinal chemistry, Jul-15, Volume: 15, Issue:14
Colon-specific, mutual azo prodrug of 5-aminosalicylic acid with L-tryptophan: synthesis, kinetic studies and evaluation of its mitigating effect in trinitrobenzenesulfonic acid-induced colitis in rats.
AID1215360Drug uptake in human OATP1B3 expressed HEK293 cells assessed as net uptake measured per mg of protein2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1215353Inhibition of human OATP1B3 expressed HEK293 cells assessed as inhibition of [3H]sulfobromophthalein uptake by liquid scintillation counting2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake.
AID1204222Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg indomethacin mol equivalent, ip administered 1 hr prior to carrageenan challenge measured at 1 hr relative to control2015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
Synthesis and QSAR study of novel anti-inflammatory active mesalazine-metronidazole conjugates.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID77142Tested for cecal ulceration in necropsy at 60 umol concentration of compound1983Journal of medicinal chemistry, Sep, Volume: 26, Issue:9
A polymeric drug for treatment of inflammatory bowel disease.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1864318Anti-inflammatory activity in TNBS induced IBD BALB/c mouse model assessed as reduction in bloody stool by measuring disease activity index score at 100 mg/kg via oral gavage administered daily for 12 days
AID731789Antiinflammatory activity in DSS-induced C57Bl/6 mouse colitis model assessed as inhibition IL-1beta level in colonic homogenate at 400 mg/kg/day administered intragastrically for 7 days2013European journal of medicinal chemistry, Apr, Volume: 62Peroxisome proliferator-activated receptor-γ mediates the anti-inflammatory effect of 3-hydroxy-4-pyridinecarboxylic acid derivatives: synthesis and biological evaluation.
AID1321636Antiinflammatory activity in human HT-29 cells assessed as inhibition of TNF-alpha induced BCECF-AM labeled human U937 cell adhesion at 20 mM preincubated for 1 hr followed by stimulation with TNF-alpha for 3 hrs followed by further co-incubation with BCE2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
In vitro and in vivo inhibitory activity of 6-amino-2,4,5-trimethylpyridin-3-ols against inflammatory bowel disease.
AID1449688Cytotoxicity against HEK293 cells harboring pendrin P123S mutant after 72 hrs by MTT assay2017Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9
Discovery of (2-aminophenyl)methanol as a new molecular chaperone that rescues the localization of P123S mutant pendrin stably expressed in HEK293 cells.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1306039Antiinflammatory activity in DSS- induced C57BL/6 mouse colon colitis model assessed as cellular infiltration of mononuclear macrophages/neutrophils at 50 mg/kg, ig after 24 hrs by hematoxylin/eosin staining based assay2016Bioorganic & medicinal chemistry, 07-15, Volume: 24, Issue:14
Development of hydroxy-based sphingosine kinase inhibitors and anti-inflammation in dextran sodium sulfate induced colitis in mice.
AID1908999Anti-ulcerative colitis activity in DSS-induced C57BL/6 mouse ulcerative colitis model assessed as colon length recovery ratio at 50 mg/kg, IG via gavage measured after 7 days relative to control
AID1215355Drug uptake in human OATP2B1 expressed HEK293 cells at 20 uM relative to control cells2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake.
AID436230Gastrointestinal toxicity in Wistar rat assessed as ulcer index at 1154.3 mg/kg, po by Rainsford's cold stress method2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrugs of 5-aminosalicylic acid for colon-specific drug delivery in inflammatory bowel disease.
AID1909053Antiinflammatory activity against IL-10-/- C57BL/6 mouse model of ulcerative colitis assessed as inhibition ratio of TNF-alpha protein expression at 50 mg/kg, IG via gavage and measured after 8 weeks by ELISA relative to control
AID639968Antiinflammatory activity against trinitrobenzenesulfonic acid-induced colitis in rat assessed as healing of damaged colon at 30 mM administered rectally QD for 6 days2012European journal of medicinal chemistry, Feb, Volume: 48Structure-activity relationship of salicylic acid derivatives on inhibition of TNF-α dependent NFκB activity: Implication on anti-inflammatory effect of N-(5-chlorosalicyloyl)phenethylamine against experimental colitis.
AID1764366Antiinflammatory activity in DSS-induced ulcerative colitis mouse model assessed as reduction in DAI score at 200 mg/kg, po administered for 10 consecutive days2021Bioorganic & medicinal chemistry letters, 04-01, Volume: 37Synthesis of norisoboldine derivatives and bioactivity assay for inducing the generation of regulatory T cells.
AID1909118Antiinflammatory activity against DSS-induced C57BL/6 mouse model of acute ulcerative colitis assessed as inhibition of IL-23 mRNA expression in colon tissue administered intragastrically via gavage measured after 7 days by RT-qPCR analysis
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID716613Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) infected in MDCK cells assessed as inhibition of virus induced cytopathic effect2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Enhanced anti-influenza agents conjugated with anti-inflammatory activity.
AID1215375Drug uptake in human OATP1B1 expressed HEK293 cells at 20 uM relative to control cells in presence of 10 uM pravastatin2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID299084Ulcerogenic activity in Wistar rat assessed as ulcer index at 2290 mg/kg, po2007Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7
Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrug of 5-aminosalicylic acid with D-phenylalanine for colon specific drug delivery in inflammatory bowel disease.
AID1499295Inhibition of TNF-alpha-induced adhesion of BCECF-labeled human U937 cells to human HT-29 cells preincubated for 1 hr followed by TNF-alpha challenge measured after 3 hrs by fluorescence microscopic method2017European journal of medicinal chemistry, Sep-08, Volume: 137Discovery and structure-activity relationship studies of 2-benzylidene-2,3-dihydro-1H-inden-1-one and benzofuran-3(2H)-one derivatives as a novel class of potential therapeutics for inflammatory bowel disease.
AID716610Antiviral activity against Influenza A virus (A/California/07/2009(H1N1)) infected in BALB/c mouse assessed as protection from virus-induced death at 12 umol/kg/day, intranasally administered bid on days 1 to 4 and day 0 of infection measured over 14 days2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Enhanced anti-influenza agents conjugated with anti-inflammatory activity.
AID1909019Antiinflammatory activity against DSS-induced C57BL/6 mouse model of acute ulcerative colitis assessed as inhibition ratio of IL-23 protein expression at 50 mg/kg, IG via gavage measured after 7 days by ELISA relative to control
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1306050Antiinflammatory activity in DSS- induced C57BL/6 mouse colon colitis model assessed as inhibition of COX2 expression at 50 mg/kg, ig after 24 hrs by hematoxylin staining based assay2016Bioorganic & medicinal chemistry, 07-15, Volume: 24, Issue:14
Development of hydroxy-based sphingosine kinase inhibitors and anti-inflammation in dextran sodium sulfate induced colitis in mice.
AID425630Antituberculosis activity against Mycobacterium paratuberculosis ATCC 19698 isolated from bovine assessed as lowest drug level producing inhibition at 10'6 CFU of inoculum by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1594135Inhibition of native rhodanese (unknown origin) assessed as reduction in rhodanese enzyme activity after 45 mins by Fe(SCN)3 dye based spectrometric analysis2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1909045Anti-ulcerative colitis activity in IL-10-/- C57BL/6 mouse model of ulcerative colitis assessed as colon length recovery ratio at 50 mg/kg, IG via gavage for 8 weeks relative to control
AID731799Increase in PPAR-gamma mRNA transcript level in human macrophages at 30 mM by quantitative PCR analysis2013European journal of medicinal chemistry, Apr, Volume: 62Peroxisome proliferator-activated receptor-γ mediates the anti-inflammatory effect of 3-hydroxy-4-pyridinecarboxylic acid derivatives: synthesis and biological evaluation.
AID1759573Anti-ulcerative colitis activity in acetic acid-induced ulcerative colitis Wistar rat model assessed as body weight recovery measured as body weight gain at 400 mg/kg, po administrated for 14 days relative to control2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Design, synthesis and molecular modeling studies of novel mesalamine linked coumarin for treatment of inflammatory bowel disease.
AID1764369Antiinflammatory activity in DSS-induced ulcerative colitis mouse model assessed as rescue of colon length shortening at 200 mg/kg, po administered for 10 consecutive days2021Bioorganic & medicinal chemistry letters, 04-01, Volume: 37Synthesis of norisoboldine derivatives and bioactivity assay for inducing the generation of regulatory T cells.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1759564Anti-ulcerative colitis activity in acetic acid-induced Wistar rat ulcerative colitis model assessed as reduction in infiltration of inflammatory cells in colon at 400 mg/kg, po administrated for 14 days by microscopic analysis2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Design, synthesis and molecular modeling studies of novel mesalamine linked coumarin for treatment of inflammatory bowel disease.
AID417722Antiinflammatory activity against TNBS-induced Wistar rat colitis model assessed as decrease in severity of inflammation treated rectally 3 days after TNBS induction measured on day 72009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Colon-specific mutual amide prodrugs of 4-aminosalicylic acid for their mitigating effect on experimental colitis in rats.
AID1215378Drug uptake in human OATP1B1 expressed HEK293 cells at 20 uM relative to control cells in presence of 100 uM cyclosporine2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake.
AID293920Antiarthritic activity in Freund's adjuvant-induced arthritis Wistar rat model after 21 days2007European journal of medicinal chemistry, Jun, Volume: 42, Issue:6
Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrug of 5-aminosalicylic acid for colon-specific drug delivery in inflammatory bowel disease.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID622159Inhibition of xc-cystine-glutamate antiporter-mediated cystine uptake in human U87 cells using L-[14C]cystine as substrate after 15 mins by liquid scintillation counting2011Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20
Inhibition of xc⁻ transporter-mediated cystine uptake by sulfasalazine analogs.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1397964Inhibition of mouse recombinant glycolate oxidase expressed in Escherichia coli using glycolate as substrate by sulfonated DCIP dye-based assay2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
Salicylic Acid Derivatives Inhibit Oxalate Production in Mouse Hepatocytes with Primary Hyperoxaluria Type 1.
AID1909114Anti-ulcerative colitis activity against DSS-induced ulcerative colitis C57BL/6 mouse model assessed as reduction in DAI recovery score ratio at 50 mg/kg, IG via gavage administered for 7 days and measured everyday relative to control
AID1606532Anti-inflammatory activity against DSS-induced ulcerative colitis C57BL/6J mouse model assessed as re-epithelialization of colon at 3 and 30 mg/kg, po administered for 7 days and measured on day 7 by hoechst and eosin staining based microscopic analysis2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Small-Molecule Antagonist Targeting Exportin-1 via Rational Structure-Based Discovery.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID425628Antituberculosis activity against Mycobacterium paratuberculosis ATCC 19698 isolated from bovine assessed as effect on average time to detection of growth at >10'2 CFU of inoculum by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID1909041Anti-ulcerative colitis activity in IL-10-/- C57BL/6 mouse model of ulcerative colitis assessed as body weight recovery ratio at 50 mg/kg, IG via gavage for 8 weeks and measured everyday relative to control
AID1215380Drug uptake in human OATP1B3 expressed HEK293 cells at 20 uM relative to control cells in presence of 10 to 100 uM budesonide2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake.
AID704198Anticolitis activity in TNBS-induced C57Bl6 mouse experimental colitis model assessed as reduction colitis macroscopic scores at 150 mg/kg dosed as Pentasa formulation dosed 3 days before colitis induction2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
4-Oxo-1,4-dihydropyridines as selective CB₂ cannabinoid receptor ligands. Part 2: discovery of new agonists endowed with protective effect against experimental colitis.
AID1763259Inhibition of IL-6-induced cell adhesion in human U937 cells assessed as reduction in cell adhesion to HT-29 cells at 1000 uM relative to control2021Bioorganic & medicinal chemistry letters, 07-01, Volume: 43Synthesis and activity of N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)acetamide analogues as anticolitis agents via dual inhibition of TNF-α- and IL-6-induced cell adhesions.
AID639967Antiinflammatory activity against trinitrobenzenesulfonic acid-induced colitis in rat assessed as decrease in COX2 protein at 30 mM administered rectally QD for 6 days2012European journal of medicinal chemistry, Feb, Volume: 48Structure-activity relationship of salicylic acid derivatives on inhibition of TNF-α dependent NFκB activity: Implication on anti-inflammatory effect of N-(5-chlorosalicyloyl)phenethylamine against experimental colitis.
AID52790Inhibition of chymotrypsin at 250 uM2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID436411Aqueous solubility of the compound2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrugs of 5-aminosalicylic acid for colon-specific drug delivery in inflammatory bowel disease.
AID1215367Drug uptake in human SCLO1B1*15 mutant expressed HEK293 cells assessed as net uptake2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake.
AID1272114Antiulcerative colitis activity in TNBS-induced Sprague-Dawley rat colitis model assessed as effect on TNBS-induced inflammatory infiltrate at 115 mg/kg qd for 6 consecutive days by hematoxylin and eosin staining based light microscopic analysis2016European journal of medicinal chemistry, Jan-27, Volume: 108Synthesis, colon-targeted studies and pharmacological evaluation of an anti-ulcerative colitis drug 4-Aminosalicylic acid-β-O-glucoside.
AID1306047Antiinflammatory activity in DSS- induced C57BL/6 mouse colon colitis model assessed as degeneration/necrosis of crypt cells at 50 mg/kg, ig after 24 hrs by hematoxylin/eosin staining based assay2016Bioorganic & medicinal chemistry, 07-15, Volume: 24, Issue:14
Development of hydroxy-based sphingosine kinase inhibitors and anti-inflammation in dextran sodium sulfate induced colitis in mice.
AID1215351Inhibition of human OATP1B1 expressed HEK293 cells assessed as inhibition of [3H]sulfobromophthalein uptake by liquid scintillation counting2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake.
AID1215365Drug uptake in human SCLO1B1*1b mutant expressed HEK293 cells assessed as net uptake2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake.
AID320706Inhibition of PAD4 by ABPP-based assay2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Profiling Protein Arginine Deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors.
AID639969Antiinflammatory activity against trinitrobenzenesulfonic acid-induced colitis in rat assessed as decrease in myeloperoxidase activity at 30 mM administered rectally QD for 6 days2012European journal of medicinal chemistry, Feb, Volume: 48Structure-activity relationship of salicylic acid derivatives on inhibition of TNF-α dependent NFκB activity: Implication on anti-inflammatory effect of N-(5-chlorosalicyloyl)phenethylamine against experimental colitis.
AID1252320Antioxidant activity assessed as DPPH free radical scavenging activity at 0.01 to 1 mM after 30 mins2015Bioorganic & medicinal chemistry letters, Nov-01, Volume: 25, Issue:21
The antioxidant properties of salicylate derivatives: A possible new mechanism of anti-inflammatory activity.
AID1215376Drug uptake in human OATP2B1 expressed HEK293 cells at 20 uM relative to control cells in presence of 100 uM cyclosporine2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID445445Permeability at pH 6.5 by PAMPA method2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID1215371Drug uptake in human SCLO1B1*15 mutant expressed HEK293 cells assessed as net uptake measured per mg of protein2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake.
AID1606528Anti-inflammatory activity against DSS-induced ulcerative colitis C57BL/6J mouse model assessed as reduction in colon swelling at 3 and 30 mg/kg, po administered for 7 days and measured on day 7 by hoechst and eosin staining based microscopic analysis2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Small-Molecule Antagonist Targeting Exportin-1 via Rational Structure-Based Discovery.
AID293918Antiinflammatory activity in Wistar rat colon assessed as myeloperoxidase activity per 100 mg tissue2007European journal of medicinal chemistry, Jun, Volume: 42, Issue:6
Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrug of 5-aminosalicylic acid for colon-specific drug delivery in inflammatory bowel disease.
AID1499293Inhibition of TNF-alpha-induced adhesion of BCECF-labeled human U937 cells to human HT-29 cells at 10 uM preincubated for 1 hr followed by TNF-alpha challenge measured after 3 hrs by fluorescence microscopic method relative to control2017European journal of medicinal chemistry, Sep-08, Volume: 137Discovery and structure-activity relationship studies of 2-benzylidene-2,3-dihydro-1H-inden-1-one and benzofuran-3(2H)-one derivatives as a novel class of potential therapeutics for inflammatory bowel disease.
AID1215357Drug uptake in human OATP1B1 expressed HEK293 cells at 20 uM relative to control cells2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake.
AID1759580Anti-ulcerative colitis activity in acetic acid-induced ulcerative colitis Wistar rat model assessed as reduction in onset of diarrhea at 400 mg/kg, po administrated for 14 days and measured during initial 8 to 9 days of treatment2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Design, synthesis and molecular modeling studies of novel mesalamine linked coumarin for treatment of inflammatory bowel disease.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID190858Urinary recovery in colostomized rats at 2 hr intervals for 48 h1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Brush-border-enzyme-mediated intestine-specific drug delivery. Amino acid prodrugs of 5-aminosalicylic acid.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1864304Antiinflammatory activity in DSS-induced acute colitis C57BL/6 mouse model assessed as reduction in colon villi integrity in colon by measuring histopathological score at 100 mg/kg, po by H and E staining based analysis
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1293081Drug excretion in feces of human treated with Eudragit coated tablets1996Gut, Jul, Volume: 39, Issue:1
Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration.
AID624609Specific activity of expressed human recombinant UGT1A62000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID602690Reduction in TNF mRNA expression in C57Bl6 mouse intrarectally dosed TNBS-induced experimental colitis model at 150 mg/kg mixed in food and provided as ad libitum during course of experiment2011Bioorganic & medicinal chemistry, Jun-15, Volume: 19, Issue:12
New FAAH inhibitors based on 3-carboxamido-5-aryl-isoxazole scaffold that protect against experimental colitis.
AID1680654Inhibition of human CSE using L-Cys as the substrate by tandem well based HTS assay2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Discovery of a Bioactive Inhibitor with a New Scaffold for Cystathionine γ-Lyase.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1909033Antiinflammatory activity against DSS-induced C57BL/6 mouse model of acute ulcerative colitis assessed as inhibition ratio of TNF-alpha mRNA expression in colon tissue at 50 mg/kg, IG via gavage measured after 7 days by RT-qPCR analysis relative to contro
AID1909015Antiinflammatory activity against DSS-induced C57BL/6 mouse model of acute ulcerative colitis assessed as inhibition ratio of IL-6 protein expression at 50 mg/kg, IG via gavage measured after 7 days by ELISA relative to control
AID624612Specific activity of expressed human recombinant UGT1A92000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID716598Cytotoxicity against MDCK cells at 100 uM2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Enhanced anti-influenza agents conjugated with anti-inflammatory activity.
AID1215362Drug uptake in human OATP1B3 expressed HEK293 cells assessed as net uptake2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake.
AID602687Reduction in TNBS-induced colitis in intrarectally dosed C57Bl6 mouse experimental colitis model assessed as reduction in colitis macroscopic score at 150 mg/kg mixed in food and provided as ad libitum during course of experiment2011Bioorganic & medicinal chemistry, Jun-15, Volume: 19, Issue:12
New FAAH inhibitors based on 3-carboxamido-5-aryl-isoxazole scaffold that protect against experimental colitis.
AID1759569Anti-ulcerative colitis activity in acetic acid-induced ulcerative colitis Wistar rat model assessed as change in stool uniformity at 400 mg/kg, po administrated for 14 days2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Design, synthesis and molecular modeling studies of novel mesalamine linked coumarin for treatment of inflammatory bowel disease.
AID1864316Anti-inflammatory activity in TNBS induced IBD BALB/c mouse model assessed as reduction in weight by measuring disease activity index score at 100 mg/kg via oral gavage administered daily for 12 days measured daily
AID1499306Inhibition of LPS-induced TNF-alpha expression in human HT-29 cells at 10 uM preincubated for 1 hr followed by TNF-alpha challenge measured after 3 hrs by Western blot method2017European journal of medicinal chemistry, Sep-08, Volume: 137Discovery and structure-activity relationship studies of 2-benzylidene-2,3-dihydro-1H-inden-1-one and benzofuran-3(2H)-one derivatives as a novel class of potential therapeutics for inflammatory bowel disease.
AID80567Tested for weight loss in guinea pig at 60 umol concentration of compound1983Journal of medicinal chemistry, Sep, Volume: 26, Issue:9
A polymeric drug for treatment of inflammatory bowel disease.
AID1909069Antiinflammatory activity against IL-10-/- C57BL/6 mouse model of ulcerative colitis assessed as inhibition ratio of TNF-alpha mRNA expression in colon tissue at 50 mg/kg, IG via gavage and measured after 8 weeks by RT-qPCR analysis relative to control
AID731790Antiinflammatory activity in DSS-induced C57Bl/6 mouse colitis model assessed as inhibition MPO activity in colonic homogenate at 400 mg/kg/day administered intragastrically for 7 days2013European journal of medicinal chemistry, Apr, Volume: 62Peroxisome proliferator-activated receptor-γ mediates the anti-inflammatory effect of 3-hydroxy-4-pyridinecarboxylic acid derivatives: synthesis and biological evaluation.
AID1909049Anti-ulcerative colitis activity in IL-10-/- C57BL/6 mouse model of ulcerative colitis assessed as histopathological score recovery ratio at 50 mg/kg, IG via gavage for 8 weeks relative to control
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1321637Antiinflammatory activity in human HT-29 cells assessed as inhibition of TNF-alpha induced BCECF-AM labeled human U937 cell adhesion preincubated for 1 hr followed by stimulation with TNF-alpha for 3 hrs followed by further co-incubation with BCECF-AM lab2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
In vitro and in vivo inhibitory activity of 6-amino-2,4,5-trimethylpyridin-3-ols against inflammatory bowel disease.
AID1306034Antiinflammatory activity in DSS- induced C57BL/6 mouse colitis model assessed as change in body weight at 50 mg/kg, ig after 7 days2016Bioorganic & medicinal chemistry, 07-15, Volume: 24, Issue:14
Development of hydroxy-based sphingosine kinase inhibitors and anti-inflammation in dextran sodium sulfate induced colitis in mice.
AID1272106Antiulcerative colitis activity in TNBS-induced Sprague-Dawley rat colitis model assessed as decrease in severity of inflammation at 115 mg/kg qd for 6 consecutive days measured on 7th day2016European journal of medicinal chemistry, Jan-27, Volume: 108Synthesis, colon-targeted studies and pharmacological evaluation of an anti-ulcerative colitis drug 4-Aminosalicylic acid-β-O-glucoside.
AID1759574Anti-ulcerative colitis activity in acetic acid-induced ulcerative colitis Wistar rat model assessed as reduction in acetic acid-induced lipid peroxidation by measuring reduction in MDA level in colon at 400 mg/kg, po administrated for 14 days2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Design, synthesis and molecular modeling studies of novel mesalamine linked coumarin for treatment of inflammatory bowel disease.
AID1864310Antiinflammatory activity in DSS-induced acute colitis C57BL/6 mouse model assessed as reduction in lamina propria damage in colon by measuring histopathological score at 100 mg/kg, po by H and E staining based analysis
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID43581Inhibition of beta-lactamase at 100 uM2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID1306048Antiinflammatory activity in DSS- induced C57BL/6 mouse colon colitis model assessed as inhibition of IL6 expression at 50 mg/kg, ig after 24 hrs by hematoxylin staining based assay2016Bioorganic & medicinal chemistry, 07-15, Volume: 24, Issue:14
Development of hydroxy-based sphingosine kinase inhibitors and anti-inflammation in dextran sodium sulfate induced colitis in mice.
AID1909025Antiinflammatory activity against DSS-induced C57BL/6 mouse model of acute ulcerative colitis assessed as inhibition ratio of IL-6 mRNA expression in colon tissue at 50 mg/kg, IG via gavage measured after 7 days by RT-qPCR analysis relative to control
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1204228Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg indomethacin mol equivalent, ip administered 1 hr prior to carrageenan challenge measured at 4 hrs relative to control2015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
Synthesis and QSAR study of novel anti-inflammatory active mesalazine-metronidazole conjugates.
AID1306040Antiinflammatory activity in DSS- induced C57BL/6 mouse colitis model assessed as colon length at 50 mg/kg, ig after 10 days (Rvb = 45.68 +/- 1.34 mm)2016Bioorganic & medicinal chemistry, 07-15, Volume: 24, Issue:14
Development of hydroxy-based sphingosine kinase inhibitors and anti-inflammation in dextran sodium sulfate induced colitis in mice.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID425629Antituberculosis activity against Mycobacterium paratuberculosis ATCC 19698 isolated from bovine assessed as effect on average time to detection of growth at 10'5 CFU of inoculum by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID299085Decrease in inflammation in TNBS-induced Wistar rat colitis model after 24 to 48 hrs2007Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7
Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrug of 5-aminosalicylic acid with D-phenylalanine for colon specific drug delivery in inflammatory bowel disease.
AID1864308Antiinflammatory activity in DSS-induced acute colitis C57BL/6 mouse model assessed as reduction in number of goblet cells in colon by measuring histopathological score at 100 mg/kg, po by H and E staining based analysis
AID1204226Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg indomethacin mol equivalent, ip administered 1 hr prior to carrageenan challenge measured at 3 hrs relative to control2015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
Synthesis and QSAR study of novel anti-inflammatory active mesalazine-metronidazole conjugates.
AID77141Tested for cecal ulceration in diarrhea at 60 umol concentration of compound1983Journal of medicinal chemistry, Sep, Volume: 26, Issue:9
A polymeric drug for treatment of inflammatory bowel disease.
AID1764393Induction of Treg cell differentiation in DSS- induced ulcerative colitis mouse model assessed as number of Treg cells in spleens at 200 mg/kg, po administered for 10 consecutive days by flow cytometry analysis (Rvb= 6.49%)2021Bioorganic & medicinal chemistry letters, 04-01, Volume: 37Synthesis of norisoboldine derivatives and bioactivity assay for inducing the generation of regulatory T cells.
AID1759575Anti-ulcerative colitis activity in acetic acid-induced ulcerative colitis Wistar rat model assessed as reduction in acetic acid-induced oxidative stress by measuring increase in SOD level in colon at 400 mg/kg, po administrated for 14 days by UV spectrop2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Design, synthesis and molecular modeling studies of novel mesalamine linked coumarin for treatment of inflammatory bowel disease.
AID1594145Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding by measuring rhodanese enzyme activity 2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID417729Ulcerogenic effect in rat colon assessed as ulcer index at 1154.30 mg/kg by Rainsford's cold stress method2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Colon-specific mutual amide prodrugs of 4-aminosalicylic acid for their mitigating effect on experimental colitis in rats.
AID1909077Antiinflammatory activity against IL-10-/- C57BL/6 mouse model of ulcerative colitis assessed as inhibition ratio of IL-6 mRNA expression in colon tissue at 50 mg/kg, IG via gavage and measured after 8 weeks by RT-qPCR analysis relative to control
AID1272113Antiulcerative colitis activity in TNBS-induced Sprague-Dawley rat colitis model assessed as effect on TNBS-induced mucosal abscess at 115 mg/kg qd for 6 consecutive days by hematoxylin and eosin staining based light microscopic analysis2016European journal of medicinal chemistry, Jan-27, Volume: 108Synthesis, colon-targeted studies and pharmacological evaluation of an anti-ulcerative colitis drug 4-Aminosalicylic acid-β-O-glucoside.
AID1908994Anti-ulcerative colitis activity against DSS-induced ulcerative colitis C57BL/6 mouse model assessed as body weight recovery rate at 50 mg/kg, IG via gavage administered for 7 days and measured everyday relative to control
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1608178Selectivity index, ratio of IC50 for ovine COX1 to IC50 for recombinant human COX22019European journal of medicinal chemistry, Oct-15, Volume: 180Design of balanced COX inhibitors based on anti-inflammatory and/or COX-2 inhibitory ascidian metabolites.
AID602691Reduction in IL1-beta mRNA expression in C57Bl6 mouse intrarectally dosed TNBS-induced experimental colitis model at 150 mg/kg mixed in food and provided as ad libitum during course of experiment2011Bioorganic & medicinal chemistry, Jun-15, Volume: 19, Issue:12
New FAAH inhibitors based on 3-carboxamido-5-aryl-isoxazole scaffold that protect against experimental colitis.
AID1413395Inhibition of TNFalpha-mediated adhesion of BCECF fluorescence-labeled human U937 cells to human HT-29 cells at 1 uM pretreated for 1 hr followed by BCECF fluorescence-labeled human U937 cell/TNFalpha addition and measured after 3 hrs by fluorescence assa2018MedChemComm, Aug-01, Volume: 9, Issue:8
Synthesis and evaluation of 6-heteroarylamino-2,4,5-trimethylpyridin-3-ols as inhibitors of TNF-α-induced cell adhesion and inflammatory bowel disease.
AID445446Oral bioavailability in human2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1397963Inhibition of mouse recombinant glycolate oxidase expressed in Escherichia coli at 25 uM using glycolate as substrate after 1 min by sulfonated DCIP dye-based assay relative to control2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
Salicylic Acid Derivatives Inhibit Oxalate Production in Mouse Hepatocytes with Primary Hyperoxaluria Type 1.
AID1215358Drug uptake in human OATP2B1 expressed HEK293 cells assessed as net uptake measured per mg of protein2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake.
AID1413396Inhibition of TNFalpha-mediated adhesion of BCECF fluorescence-labeled human U937 cells to human HT-29 cells at 20 mM pretreated for 1 hr followed by BCECF fluorescence-labeled human U937 cell/TNFalpha addition and measured after 3 hrs by fluorescence ass2018MedChemComm, Aug-01, Volume: 9, Issue:8
Synthesis and evaluation of 6-heteroarylamino-2,4,5-trimethylpyridin-3-ols as inhibitors of TNF-α-induced cell adhesion and inflammatory bowel disease.
AID1346800Human Peroxisome proliferator-activated receptor-gamma (1C. Peroxisome proliferator-activated receptors)2005The Journal of experimental medicine, Apr-18, Volume: 201, Issue:8
Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,741)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990271 (7.24)18.7374
1990's737 (19.70)18.2507
2000's1009 (26.97)29.6817
2010's1339 (35.79)24.3611
2020's385 (10.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 95.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index95.27 (24.57)
Research Supply Index8.40 (2.92)
Research Growth Index4.93 (4.65)
Search Engine Demand Index176.59 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (95.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials540 (13.82%)5.53%
Reviews725 (18.56%)6.00%
Case Studies719 (18.41%)4.05%
Observational38 (0.97%)0.25%
Other1,884 (48.23%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (146)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
[NCT01120340]Phase 3105 participants (Actual)Interventional2005-10-31Completed
Comparative Efficacy and Safety Study in Patients With Active Ulcerative Colitis [NCT01257386]Phase 3251 participants (Actual)Interventional2010-11-30Completed
AN INVESTIGATOR-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ESTABLISH THERAPEUTIC EQUIVALENCE OF 1000 mg MESALAMINE RECTAL SUPPOSITORIES AND CANASA® RECTAL SUPPOSITORIES (1000 mg MESALAMINE, USP) IN THE TREATMENT OF MILD TO MODERATE ULC [NCT01172444]Phase 3158 participants (Actual)Interventional2010-06-30Terminated(stopped due to Enrollment difficulties)
Multi Center Ulcerative Colitis Pediatric Pentasa Intervention Trial (MUPPIT). A Randomized, Single-blinded, Controlled, Parallel, Induction Therapy With Once vs. Twice Daily Dosing of Pentasa in Pediatric UC. [NCT01201122]Phase 486 participants (Actual)Interventional2010-09-30Completed
Comparative Efficacy and Safety Study in Patients With Ulcerative Colitis in Remission Phase [NCT01257399]Phase 3251 participants (Actual)Interventional2010-11-30Completed
Clinical Study to Evaluate the Possible Efficacy of Nifuroxazide in Patient With Ulcerative Colitis [NCT05988528]Phase 2/Phase 350 participants (Anticipated)Interventional2023-08-20Recruiting
Randomized, Double-blind, Placebo-controlled Study to Evaluated the Efficacy of Combining Curcumin+5ASA Medication Versus 5ASA Medication Alone on Active Mild to Moderate Ulcerative Colitis Patients [NCT01320436]Phase 350 participants (Actual)Interventional2011-07-31Completed
The Role of Combined Application of Exclusive Enteral Nutrition in the Induction of Remission for Children With Newly Diagnosed Moderate to Severe Ulcerative Colitis [NCT04999241]Phase 440 participants (Anticipated)Interventional2024-03-01Not yet recruiting
[NCT02261636]150 participants (Actual)Observational2015-01-31Completed
A Phase 2a, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of IBD98-M Delayed-release Capsules to Induce Remission in Patients With Active, Mild to Moderate Ulcerative Colitis [NCT02493712]Phase 251 participants (Actual)Interventional2016-01-31Completed
Study of Pentasa® for Reducing Residual Systemic Immune Activation in Treated HIV Infection [NCT03399903]Phase 1/Phase 247 participants (Actual)Interventional2017-05-01Completed
Pharmacokinetics of IBD98-M 400mg-57.5/Day in Healthy Volunteers [NCT02196662]Phase 130 participants (Actual)Interventional2014-07-31Completed
A Phase III, Randomized Multi-centre, Double-blind, Parallel Group, Active Comparator Study to Compare the Efficacy and Safety of SPD476 (Mesalazine)2.4g/Day Once Daily With Asacol 1.6g/Day Twice Daily in the Maintenance of Remission in Patients With Ulce [NCT00151892]Phase 3829 participants (Actual)Interventional2005-04-08Completed
An Open Label, Single-site Pharmaco-Scintigraphic Study in Healthy Subjects With Radio-labelled TP05-tablets (Mesalazine) to Evaluate the Gastrointestinal Transit and Release Profile [NCT02306798]Phase 19 participants (Actual)Interventional2013-09-30Completed
Targeting Oxidative Stress in Chronic Beryllium Disease [NCT01088243]Phase 1/Phase 218 participants (Actual)Interventional2010-03-31Completed
A Phase 3, Multi-centre, Randomised, Double-blind, Active-controlled, Parallel-group Trial Investigating the Efficacy and Safety of FE 999315 Following 8 Weeks of Treatment for Mild to Moderate Active Ulcerative Colitis in Japanese Subjects [NCT03412682]Phase 3274 participants (Actual)Interventional2018-03-02Completed
An Open Label, Single-site Pharmaco-Scintigraphic Study in Healthy Subjects With Radio-labelled TP05-tablets (Mesalazine) to Evaluate the Gastrointestinal Transit and Release Profiles of Two Different Formulations. [NCT02306772]Phase 118 participants (Actual)Interventional2011-12-31Completed
Double-blind, Double-dummy, Randomised, Placebo-controlled, Multi-centre Phase III Study on the Efficacy and Tolerability of a 8-week Treatment With Budesonide vs. Mesalazine vs. Placebo in Patients With Lymphocytic Colitis [NCT01209208]Phase 357 participants (Actual)Interventional2010-05-31Completed
A Randomized, Open-label, Multiple Dose, Parallel Group Study to Evaluate 5 ASA and N Ac 5 ASA Pharmacokinetics Following Administration of Oral Doses of Asacol 2.4 g/Day and Lialda 2.4 g/Day for 7 Days in Healthy Volunteers [NCT00751699]Phase 137 participants (Actual)Interventional2007-03-31Completed
Therapeutic Effects of Mesalamine and Amitriptyline in IBS: a Randomized Clinical Trial [NCT02190526]Phase 40 participants (Actual)Interventional2014-09-30Withdrawn(stopped due to Study stopped due to lack of volunteer patients.)
A Phase I, Single- And Multiple-Dose, Relative Bioavailability and Pharmacokinetic Study of Encapsulated Mesalamine Granules Administered Orally to Healthy Volunteers [NCT00622375]Phase 124 participants (Actual)Interventional2008-02-29Completed
Mesalazine and Compound Glutamin Enema for the Treatment of Ulcerative Colitis Through Colonic Transendoscopic Enteral Tubing: A Multicenter, Randomized, Controlled Trail [NCT03917095]75 participants (Anticipated)Interventional2019-05-15Recruiting
Fecal Microbiota Therapy Vs 5-aminosalicylates for Induction of Remission in Newly Diagnosed Mild-moderately Active UC : a Pilot Study [NCT03716388]Phase 320 participants (Anticipated)Interventional2018-12-01Recruiting
A Phase II Double-blind, Randomized, Comparator-controlled Study of the Safety and Efficacy of Zoenasa™ Rectal Gel (Mesalamine Plus N-acetylcysteine) in Subjects With Left-sided Ulcerative Colitis [NCT01586533]Phase 2120 participants (Anticipated)Interventional2012-06-30Active, not recruiting
A Randomized Controlled Study of Qinghua Quyu Prescription Rectal Instillation for the Treatment of Ulcerative Colitis [NCT05780723]60 participants (Anticipated)Interventional2023-04-04Recruiting
Efficacy and Mode of Action of Mesalazine in the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D). [NCT01316718]Phase 4108 participants (Actual)Interventional2011-03-31Completed
Mesalamine to Reduce T Cell Activation in HIV Infection [NCT01090102]Phase 433 participants (Actual)Interventional2010-06-30Completed
A Randomized, Double-blind, Parallel-group Study to Assess the Safety and Efficacy of Asacol® (1.2 to 4.8g/Day) 400 mg Delayed-release Tablets Given Twice Daily for 26 Weeks to Children and Adolescents for the Maintenance of Remission of Ulcerative Coliti [NCT01004185]Phase 339 participants (Actual)Interventional2009-10-31Terminated(stopped due to Pediatric enrollment very slow.)
Adherence of a 1.600 mg Single Tablet 5-ASA Treatment of Ulcerative Colitis (EASI-trial) [NCT04133194]Phase 4200 participants (Anticipated)Interventional2019-11-28Recruiting
Prophylactic Oral Mesalamine for the Prevention of Immune-Related Colitis in Patients Treated With Ipilimumab/Nivolumab [NCT05663775]Phase 220 participants (Anticipated)Interventional2023-04-30Not yet recruiting
Combination Corticosteroids+5-aminosalicylic Acids Compared to Corticosteroids Alone in the Treatment of Moderate-severe Active Ulcerative Colitis: A Protocol of a Multi-center Prospective Randomized Investigator Blinded Trial. [NCT02665845]Phase 3160 participants (Actual)Interventional2016-06-13Completed
Effect of Mesalazine on Low Grade Mucosal Inflammation in Irritable Bowel Syndrome. A Pilot Double Blind Placebo Controlled Study. [NCT00774007]Phase 2/Phase 320 participants (Actual)Interventional2004-09-30Completed
Double-blind, Randomized, Placebo-controlled, Parallel Group, Multi-centre Phase III Clinical Study on the Efficacy and Tolerability of Mesalazine Granules vs. Placebo for the Prevention of Recurrence of Diverticulitis [NCT00695643]Phase 3345 participants (Actual)Interventional2008-01-31Terminated
Double-blind, Dose-response, Randomised, Placebo-controlled, Parallel Group, Multi-centre Phase III Clinical Study on the Efficacy and Tolerability of Mesalazine Granules vs. Placebo for the Prevention of Recurrence of Diverticulitis [NCT01038739]Phase 3330 participants (Actual)Interventional2010-01-31Terminated(stopped due to Stopped due to futility.)
A Randomized, Double-blind Study Investigating the Efficacy and Safety of Mesalazine With Hydrocortisone Sodium Succinate (100mg QD) Enema for 4-Week Treatment in Patients With Ulcerative Colitis (UC) [NCT03110198]Phase 4528 participants (Anticipated)Interventional2017-05-31Recruiting
Faecal Bacteriotherapy for Ulcerative Colitis [NCT03104036]Phase 261 participants (Actual)Interventional2017-06-19Completed
"Azione Chemiopreventiva Della Mesalazina Sul Cancro Del Colon-retto: Studio Pilota Per la Valutazione Degli Effetti Molecolari in Vivo Sulla Via di Segnalazione Proliferativa Della β-catenina (Official Title in Italian Language)" [NCT02077777]Phase 221 participants (Actual)Interventional2012-10-31Completed
A Randomized, Double-blind Study to Assess the Safety and Efficacy of Mesalamine Delayed-release Capsules in Children Aged 5 to 17 Years for the Maintenance of Remission of Ulcerative Colitis [NCT05316220]Phase 380 participants (Anticipated)Interventional2023-12-31Not yet recruiting
Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome - MesaCAPP [NCT03070574]Phase 28 participants (Actual)Interventional2017-11-24Terminated(stopped due to Due to poor patient recruitment and insufficient financing.)
Efficacy and Safety of Fecal Microbiota Transplantation as add-on Therapy in Patients With Mild-To-Moderate Ulcerative Colitis: A Randomized, Clinical Trial [NCT05538026]53 participants (Actual)Interventional2020-09-01Completed
Open-label, Monocentric Phase IIa Pilot Study Evaluating the Efficacy and Tolerability of a 4-week Treatment With Mesalazine Oral Suspension in Patients With Active Eosinophilic Esophagitis [NCT05488405]Phase 25 participants (Actual)Interventional2023-02-09Completed
Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome [NCT04920149]Phase 2260 participants (Anticipated)Interventional2022-03-21Recruiting
Multicentre, Controlled, Randomised, Investigator-Blinded, Comparative Study of Oral Mesalazine 4g Once Daily Versus Mesalazine 4g in Two Divided Doses in Patients With Active Ulcerative Colitis. [NCT00737789]Phase 3206 participants (Actual)Interventional2008-11-30Completed
A Randomized, Dose Ranging Trial of Mesalmine for the Treatment of Active Microscopic Colitis. [NCT00952952]Phase 2/Phase 370 participants (Actual)Interventional2007-02-28Completed
Double-blind, Double-dummy, Randomised, Multicentre, Comparative Study on the Efficacy and Safety of Azathioprine Versus Mesalazine for Prevention of Clinical Relapses in Crohn's Disease Patients With Postoperative Moderate or Severe Endoscopic Recurrence [NCT00946946]Phase 378 participants (Actual)Interventional2002-02-28Completed
Double-blind, Double-dummy, Randomised, Multicentre, 12-months, Comparative Study of the Efficacy and Tolerability of Once Daily 3.0 g Mesalazine Granules vs. Once Daily 1.5 g Mesalazine Granules vs. Three Times Daily 0.5 g Mesalazine Granules for Mainten [NCT00746447]Phase 3648 participants (Actual)Interventional2005-05-31Completed
A Double-Blind, Randomized, 6-Week, Parallel-Group Design Clinical Trial to Assess Safety and Efficacy of Asacol 4.8 g/Day (800 mg Tablet) Versus Asacol 2.4 g/Day (400 mg Tablet) for the Treatment of Moderately Active Ulcerative Colitis [NCT00073021]Phase 3386 participants (Actual)Interventional2000-09-30Completed
A Study to Evaluate the Relative Bioavailability of Two Mesalamine 4 gm/60 ml Rectal Enema Formulations [NCT00802451]48 participants (Actual)Interventional2003-02-28Completed
BE Study With Clinical Endpoints Comparing Mesalamine Delayed Release Tablets 400 mg to the Reference Listed Drug ASACOL® Delayed Release Tablets 400 mg in Patients With Mild to Moderately Active Ulcerative Colitis [NCT01045018]Phase 30 participants Interventional2008-01-31Completed
The Efficacy of Topically Applied Mesalazine Sustained-Release Tablets in Oral Lesions of Crohn's Disease [NCT02769494]Phase 30 participants (Actual)Interventional2016-03-31Withdrawn(stopped due to Lack of funds)
A Phase II, Randomized, Multi-centre, Double-blind, Parallel-group, Dose-ranging, Exploratory Study in Subjects With Mild to Moderate Ulcerative Colitis Treated With SPD476 (Mesalazine) Once Daily [NCT00545389]Phase 238 participants (Actual)Interventional2003-02-10Completed
Oral 5-aminosalicylic Acid Withdrawal in Long Standing Inactive Ulcerative Colitis: A Double-blind, Randomized, Placebo-controlled Trial [NCT02537210]177 participants (Actual)Interventional2015-09-30Completed
A Multi-center, Investigator-blinded, Randomized, 12-month, Parallel-group, Non-inferiority Study to Compare the Efficacy of 1.6 to 2.4 g Asacol® Therapy QD Versus Divided Dose (BID) in the Maintenance of Remission of Ulcerative Colitis [NCT00505778]Phase 31,027 participants (Actual)Interventional2007-07-31Completed
A Phase I Double-blind, Randomized, Comparator-controlled Study of the Safety and Tolerability of N-acetylcysteine Plus Mesalamine Enema in Subjects With Left-sided Ulcerative Colitis [NCT01020708]Phase 19 participants (Anticipated)Interventional2009-11-30Completed
PENTASA in Active Crohn's Disease: A 10-week, Double-blind, Multi-centre Trial Comparing PENTASA Sachet 6 g/Day (Mesalazine, Mesalamine) With Placebo. [NCT00862121]Phase 320 participants (Actual)Interventional2009-04-30Terminated(stopped due to Terminated due to poor recruitment)
The Efficacy and Tolerability of Bio-enhanced Curcumin (Diferuloylmethane) in the Induction of Remission in Patients With Mild to Moderate Ulcerative Colitis [NCT02683733]Phase 350 participants (Anticipated)Interventional2016-02-29Recruiting
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Use of Mesalamine Pellet Formulation 1.5G QD to Maintain Remission From Mild to Moderate Ulcerative Colitis [NCT00744016]Phase 3305 participants (Actual)Interventional2004-12-31Completed
A Randomized, Single-Blind Study to Assess Efficacy and Safety of Dosing Mesalazine 800 mg Tablets (Asacol®) at 2.4 g Once Daily Versus Divided Doses 3 Times Daily for 12 Months in Maintenance of Remission of Ulcerative Colitis. [NCT00708656]Phase 3213 participants (Actual)Interventional2006-10-31Completed
A Double-blind, Randomized, 6 Week, Parallel-group Design Clinical Trial in Patients With Mildly to Moderately Active Ulcerative Colitis to Assess the Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day [NCT00577473]Phase 3301 participants (Actual)Interventional2001-02-28Completed
A Multicentre, Randomised, Double-blind, Non-inferiority Trial Comparing the Efficacy and Safety of a New Modified Oral Extended Release Pentasa® (Mesalamine) 500 mg Tablet to the Currently Marketed Pentasa® (Mesalamine) 500 mg Tablet in Subjects With Act [NCT00603733]Phase 3288 participants (Actual)Interventional2007-10-31Completed
Study to Assess the Safety and Efficacy of Asacol® (1.2 to 4.8 g/Day) Administered as 400 mg Delayed-release Tablets Given Every 12 Hours for 6 Weeks to Children and Adolescents With Mildly-to-Moderately Active Ulcerative Colitis [NCT00713310]Phase 383 participants (Actual)Interventional2008-12-31Completed
Mechanistic Randomized Controlled Trial of Mesalazine in Symptomatic Diverticular Disease [NCT00663247]40 participants (Actual)Interventional2008-04-30Completed
A Multicentered Prospective Cohort Study of Chinese IBD Patients Concerning Cost-effectiveness Analysis, Therapeutic Effect Predictor Exploration and Gut Microbiota Analysis [NCT05386290]200 participants (Anticipated)Observational2020-07-09Enrolling by invitation
A Phase III, Randomised, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 Versus Placebo Over 104 Weeks in the Prevention of Recurrence of Diverticulitis. [NCT00545740]Phase 3590 participants (Actual)Interventional2007-11-28Completed
A Multicentre Randomized Open Study Comparing Azathioprine to Mesalazine for the Prevention of Postoperative Recurrence in the Crohn Disease [NCT00976690]Phase 383 participants (Actual)Interventional2002-10-31Completed
Role of Intestinal Protozoa and Helminths in the Course of Ulcerative Colitis [NCT03441893]Phase 1/Phase 2300 participants (Anticipated)Interventional2015-01-01Active, not recruiting
A Randomised Controlled Multicenter Trial Assessing the Efficacy and Safety of Mesalazine Therapy in Patients With Irritable Bowel Syndrome. [NCT00626288]Phase 3187 participants (Actual)Interventional2007-12-31Completed
Double-blind, Double-dummy, Randomised, Multi-centre, Comparative Phase III Clinical Study on the Efficacy and Tolerability of an 8 Week Oral Treatment With 9 mg Budesonide or 3 g Mesalazine in Patients With Active Ulcerative Colitis [NCT00747110]Phase 3343 participants (Actual)Interventional2007-10-31Completed
A Multicenter, Open-Label, Treatment Extension Trial to Evalaute the Long-Term Safety and Tolerability of Mesalamine Pellet Formulation [NCT00326209]Phase 3393 participants (Actual)Interventional2005-12-22Completed
First-line Treatment With Infliximab Versus Corticosteroids in Children With Newly Diagnosed Moderate to Severe Ulcerative Colitis [NCT04999228]Phase 440 participants (Anticipated)Interventional2021-11-01Recruiting
A Phase III, Randomized, Multi-center, Open-label, 12 to 14 Month Extension Study to Evaluate the Safety and Tolerability of SPD476 (Mesalazine) Given Once Daily vs. Twice Daily for the Maintenance of Ulcerative Colitis in Remission. [NCT00151944]Phase 3400 participants Interventional2003-11-26Completed
Evaluation of the Metabolome in Diverticular Disease and Effects of Probiotic Mixture VSL#3 vs Fibers, Rifaximin and Mesalazine on the Metabolome in Diverticular Disease of the Colon [NCT01831323]40 participants (Anticipated)Observational2012-12-31Recruiting
A Phase III, Randomised, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 Versus Placebo Over 104 Weeks in the Prevention of Recurrence of Diverticulitis. [NCT00545103]Phase 3592 participants (Actual)Interventional2007-12-06Completed
A Phase IV, Multi-center, Open-label Study to Assess Clinical Recurrence Related to Compliance With Treatment With MMX Mesalamine 2.4g/Day Given Once Daily for the Maintenance of Quiescent Ulcerative Colitis (UC) [NCT00446849]Phase 4290 participants (Actual)Interventional2007-05-01Completed
QUality of Life in pAtients With Mild to modeRate Active procTitis Treated by mesalaZine (Pentasa®) [NCT02368743]117 participants (Actual)Observational2015-12-31Completed
Double-blind, Double-dummy, Randomised, Multi-centre, Comparative Phase III Clinical Study on the Efficacy and Tolerability of an 8 Week Oral Treatment With Three Times Daily 1000 mg Mesalazine Versus Three Times Daily 2x500 mg Mesalazine in Patients With [NCT01745770]Phase 3306 participants (Actual)Interventional2013-01-31Completed
A Randomised, Double-blind, Double-dummy, Multicentre, Phase III, Non Inferiority Trial of an Oral Mesalazine Formulation in Patients With Active Mild to Moderate Ulcerative Colitis for the Induction of Remission. [NCT06176560]Phase 3376 participants (Anticipated)Interventional2024-03-31Not yet recruiting
Pentasa Once Daily in Ulcerative Colitis for Maintenance of Remission. A European Multi-centre Investigator Blinded Randomized Controlled Study of Pentasa Sachet Comparing One Gram Twice With Two Grams Once Daily [NCT00209300]Phase 3362 participants (Actual)Interventional2005-05-31Completed
The Effect on Mucosal Healing With Pentasa Sachet 4g in Mild to Moderate Active Small Bowel Crohn´s Disease, Evaluated by Video Capsule Endoscopy After 6 and 12 Weeks Treatment. A Pilot Study [NCT00245505]Phase 33 participants (Actual)Interventional2009-02-28Terminated(stopped due to Study terminated due to lack of eligible patients)
Double-blind, Double-dummy, Randomised, Multicentre, Comparative Study of the Efficacy and Tolerability of Once Daily 3.0 g Mesalazine Granules Versus Three Times Daily 1.0 g Mesalazine Granules in Patients With Active Ulcerative Colitis [NCT00449722]Phase 3380 participants Interventional2005-07-31Completed
Randomized, Double-blind, Multicentre Study to Compare the Efficacy and Safety of Budesonide Versus Mesalazine Suppository Versus a Combination Therapy of Budesonide/Mesalazine Suppositories in Patients With Acute Ulcerative Proctitis [NCT01966783]Phase 2320 participants (Anticipated)Interventional2013-09-30Completed
A Phase 4, Open-label, Multicenter, Prospective Study to Evaluate the Effect of Remission Status on the Ability to Maintain or Achieve Clinical and Endoscopic Remission During a 12-Month, Long-term Maintenance Phase With 2.4g/Day MMX Mesalamine/Mesalazine [NCT01124149]Phase 4759 participants (Actual)Interventional2010-06-29Completed
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Use of Mesalamine Pellet Formulation 1.5G QD to Maintain Remission From Mild to Moderate Ulcerative Colitis [NCT00767728]Phase 3256 participants (Actual)Interventional2004-12-31Completed
A Double-blind, Randomised, Placebo and Mesalazine Controlled Phase II Study to Explore the Safety and Activity of Dersalazine in Patients With Mild to Moderate Active Colitis [NCT00808977]Phase 280 participants (Anticipated)Interventional2008-12-31Completed
Efficacy of Mesalazine Combined With Biologics in the Treatment of Moderate to Severe Ulcerative Colitis: a Multicenter, Prospective, Randomized, Controlled Clinical Study [NCT05205603]Phase 4438 participants (Anticipated)Interventional2022-01-15Recruiting
A Phase II, Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week Study to Assess the Efficacy and Safety of Mesalamine Granules 750 mg and 1,500 mg Capsules Administered Once Daily in the Treatment of Irritable Bowel Syndrome With Diarrhea [NCT01177410]Phase 2148 participants (Actual)Interventional2010-07-31Completed
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis [NCT01016262]Phase 3119 participants (Actual)Interventional2009-11-30Terminated(stopped due to The decision was taken solely for business/administrative reasons, no safety considerations entered into this. Ongoing randomized patients to complete.)
Repurposing Atorvastatin in Patients With Ulcerative Colitis Treated With Mesalamine by Modulation of mTOR/NLRP3 Pathway. [NCT05567068]Phase 244 participants (Anticipated)Interventional2023-02-01Recruiting
Impact of Co-Receptor and HIV Viral Burden on Gut Mucosa [NCT00069498]Phase 114 participants Interventional1999-10-31Completed
Repurposing Fenofibrate in Modulating mTOR/NLRP3 Inflammasome in Patients With Ulcerative Colitis [NCT05781698]Phase 260 participants (Anticipated)Interventional2023-03-20Recruiting
Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease [NCT05986136]Phase 2/Phase 350 participants (Anticipated)Interventional2023-08-20Recruiting
Double-blind, Double-dummy, Randomised, Placebo-controlled, Multi-centre Phase III Clinical Study on the Efficacy and Tolerability of Budesonide Capsules vs. Mesalazine Granules vs. Placebo for Patients With Collagenous Colitis. [NCT00450086]Phase 392 participants (Actual)Interventional2007-03-31Completed
Once Daily Versus Conventional Dosing of Asacol in the Maintenance of Quiescent Ulcerative Colitis: A Randomized Pilot Trial [NCT00343850]Phase 330 participants (Actual)Interventional2006-09-30Completed
Randomized, Double-blind, Cross-over Study of the Efficacy of Mesalamine in Diarrhea-predominant Irritable Bowel Syndrome (dIBS) [NCT01327300]Phase 27 participants (Actual)Interventional2010-03-31Completed
An Observational Study of the Immunopathogenesis of and Response to Step-Up Inflammatory Bowel Disease Therapy for Hermansky-Pudlak Syndrome-Associated Colitis [NCT00514982]Phase 20 participants (Actual)Interventional2007-08-07Withdrawn
A Phase III, Randomized, Multi-Centre, Double-blind, Double Dummy, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Two Doses of SPD476 (Mesalazine) 2.4g and 4.8g Once Daily, With Reference to ASACOL 0.8g Three Times Daily, [NCT00548574]Phase 3343 participants (Actual)Interventional2003-12-04Completed
Efficacy of Optimized Thiopurine Therapy in Ulcerative Colitis (OPTIC) [NCT02910245]Phase 3136 participants (Anticipated)Interventional2016-11-30Recruiting
Clinical Study to Evaluate the Possible Efficacy of Fenofibrate in Patient With Ulcerative Colitis [NCT05753267]Phase 2/Phase 360 participants (Anticipated)Interventional2023-02-28Recruiting
Double-blind, Double-dummy, Randomized, Multicentre Study to Compare the Efficacy and Safety of Oral Budesonide (9 mg) and Oral Mesalazine (4.5 g) in Moderately Active Crohn's Disease Patients [NCT00300118]Phase 3311 participants (Actual)Interventional2004-09-30Completed
Phase 3, Multi-Center, Randomized, Double-Blind, Parallel-Arm, 52-Week Dose Comparison Study of the Efficacy and Safety of 25 mg QD and 50 mg QD of OPC-6335 Oral Tablets and 800 mg BID of Asacol® in the Maintenance of Ulcerative Colitis Remission [NCT00092508]Phase 31,725 participants (Anticipated)Interventional2004-05-31Completed
Administration of Hydroxychloroquine (Plaquenil) to African Americans and Hispanics for the Treatment of Mild to Severe Ulcerative Colitis [NCT05119140]Phase 1/Phase 220 participants (Anticipated)Interventional2022-06-10Recruiting
CLINICAL MANAGEMENT OF CHILDHOOD INTESTINAL LYMPHOID NODULAR HYPERPLASIA: A RANDOMIZED CONTROLLED CLINICAL TRIAL. [NCT01789294]Phase 4270 participants (Anticipated)Interventional2008-11-30Recruiting
Randomized, Double-blind, Double-dummy, Placebo-controlled, Phase III Clinical Trial on the Efficacy and Safety of a 48-weeks Treatment With Gastro-resistant Phosphatidylcholine (LT-02) Versus Placebo Versus Mesalamine for Maintenance of Remission in Pati [NCT02280629]Phase 3150 participants (Actual)Interventional2014-10-01Completed
A Phase 1, Multicenter, Open-label Study to Determine the Safety and Pharmacokinetics of MMX Mesalamine Following Administration in Children and Adolescents With Ulcerative Colitis [NCT01130844]Phase 152 participants (Actual)Interventional2010-10-08Completed
[NCT00167882]Phase 424 participants Interventional2005-07-31Completed
Prospective Experimental of Tripterygium Glycoside in the Treatment of Crohn's Disease for Induction Remission [NCT02044952]Phase 2/Phase 340 participants (Anticipated)Interventional2014-01-31Recruiting
A Phase III, Randomized, Multi-Centre, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) Versus SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute [NCT00503243]Phase 3280 participants (Actual)Interventional2003-09-30Completed
Mesalazine (PENTASA®) in Ulcerative Colitis: Correlation of the Information Level With Patient's Compliance in Everyday Practice [NCT01517607]506 participants (Actual)Observational2012-02-29Completed
Casein Glycomacropeptide in Active Distal Ulcerative Colitis (Pilot Study) [NCT01534312]24 participants (Actual)Interventional2012-01-31Completed
Mesalazine and/or Lactobacillus Casei in Maintaining Remission of Symptomatic Uncomplicated Diverticular Disease of the Colon: a Double-blind, Double-dummy, Placebo-controlled Study [NCT01534754]Phase 4250 participants (Actual)Interventional2009-01-31Completed
Open Label Safety and Efficacy Trial of Twice Daily Dosing of Asacol vs. Three Times Per Day Dosing for the Induction of Remission in Active Ulcerative Colitis [NCT00194818]Phase 47 participants (Actual)Interventional2003-06-30Completed
Test Treat Strategy to Prevent Ulcerative Colitis Relapse [NCT00652145]Phase 4119 participants (Actual)Interventional2008-09-30Completed
Efficacy and Safety of Fecal Microbiota Transplantation for Ulcerative Colitis [NCT03804931]Phase 2/Phase 3120 participants (Anticipated)Interventional2019-01-20Recruiting
Study to Determine the Pharmacokinetics of Mesalamine Following Administration of 30, 60, and 90 mg/kg/Day as 400 mg Delayed-release Tablets Given Every 12 Hours for 28 Days to Children/Adolescents With Active Ulcerative Colitis. [NCT00254618]Phase 134 participants (Actual)Interventional2005-10-31Terminated(stopped due to Slow enrollment.)
Double-blind, Randomised, Placebo-controlled, Parallel-group, Multi-centre Phase III Clinical Study on the Efficacy and Tolerability of Mesalazine Pellets vs. Placebo in Diverticular Disease [NCT01627262]Phase 2123 participants (Actual)Interventional2002-05-31Completed
A Phase 1, Open-label, Randomized, 3-period Crossover Taste Assessment Study to Characterize the Palatability of SHP429 When the Contents Are Sprinkled Onto Soft Foods or Emptied Into a Cup and Administered With Water in Healthy Adult Subjects [NCT02125292]Phase 118 participants (Actual)Interventional2014-06-02Completed
Mesalazine Treatment in IBS, a Double-blind Placebo-controlled Phase II Intervention Study in Adult Patients [NCT01699438]Phase 2211 participants (Actual)Interventional2012-04-30Completed
Randomised Placebo-controlled Trial of a Gut Immunomodulatory Agent (Mesalamine) to Tackle Environmental Enteropathy in Acutely Malnourished Children: A Pilot Study. [NCT01841099]Phase 1/Phase 244 participants (Actual)Interventional2013-06-30Completed
The Effect of Long-Acting Mesalamine on Post-Infective Irritable Bowel Syndrome- A Pilot Study [NCT01412372]Phase 361 participants (Actual)Interventional2010-06-30Completed
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of a 12 Week Treatment of Acute Diverticulitis With Asacol® 2.4 g/Day (400 mg Mesalamine Tablet), Followed by a 9 Month Treatment-free Observation Period [NCT00554099]Phase 2117 participants (Actual)Interventional2007-11-30Completed
Correlation of Mesalamine Pharmacokinetics With Local Availability [NCT01999400]30 participants (Actual)Interventional2012-04-30Completed
A Phase 1, Randomized, Open-label, Crossover, Drug Interaction Study Evaluating the Pharmacokinetic Profiles of Amoxicillin Administered Alone and in Combination With MMX® Mesalazine/Mesalamine in Healthy Adult Subjects [NCT01442688]Phase 162 participants (Actual)Interventional2011-10-07Completed
The Evaluation of the Efficacy of Asacol (Mesalazine) Suppository on the Treatment of Diarrhea-Induced Acute Fissure in Post-Chemotherapy Cancer Patients - A Randomized Controlled Trial [NCT05091775]Phase 1/Phase 2140 participants (Actual)Interventional2020-06-01Completed
Clinical Study Evaluating the Efficacy and Safety of Alpha-lipoic Acid in Patients With Ulcerative Colitis Treated With Mesalamine [NCT06067698]60 participants (Anticipated)Interventional2023-10-01Not yet recruiting
A Study to Evaluate the Relative Bioavailability of Two Mesalamine 4 gm/60 mL Rectal Enema Formulations [NCT00840203]Phase 172 participants (Actual)Interventional2003-05-31Completed
Chemopreventive Effects of Mesalazine in Patients at High Risk of Recurrent (Nonfamilial) Colorectal Adenomas [NCT01894685]Phase 274 participants (Actual)Interventional2012-07-31Completed
A Double-blind, Randomized, 6-week, Parallel-group Design Clinical Trial to Assess the Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day for the Treatment of Moderately Active Ulcerative Colitis. [NCT00350415]Phase 3772 participants (Actual)Interventional2006-06-30Completed
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Safety of Mesalamine 4 g Extended Release Granules (Sachet) for the Induction of Clinical and Endoscopic Remission in Active, Mild to Moderate Ulcerative Coli [NCT02522767]Phase 3228 participants (Actual)Interventional2015-10-31Completed
Multicenter Open-label Study Evaluating the Safety and Efficacy of Standardized Initial Therapy Using Either Mesalamine or Corticosteroids Then Mesalamine to Treat Children and Adolescents With Newly Diagnosed Ulcerative Colitis. [NCT01536535]Phase 4431 participants (Actual)Interventional2012-07-10Completed
A Retrospective Study to Assess 5-Aminosalicylic Acid Prescription Patterns and Treatment Outcomes in Patients With Ulcerative Colitis in Korea [NCT04499495]11,385 participants (Actual)Observational2021-10-25Completed
A Randomized, Double-blind, Placebo-controlled, Multi-centre, Superiority Study Investigating the Efficacy and Safety of PENTASA Enema Compared With Placebo Enema for 4-Week Treatment in Chinese Patients With Left-sided Active Ulcerative Colitis (UC) Foll [NCT02368717]Phase 3281 participants (Actual)Interventional2015-03-31Completed
Safety And Efficacy Study of Autologous Platelet-rich Plasma (PRP) and Thrombin Coagulum for the Topical Treatment of Rectal Mucosal Ulcers [NCT05912712]Phase 160 participants (Anticipated)Interventional2023-07-01Not yet recruiting
A Phase 1, Randomized, Open-label, Crossover, Drug Interaction Study Evaluating the Pharmacokinetic Profiles of Metronidazole Administered Alone and in Combination With MMX® Mesalazine/Mesalamine in Healthy Adult Subjects [NCT01418365]Phase 130 participants (Actual)Interventional2011-08-22Completed
A Multicentre, Double-blind, Randomised, Parallel-group, Phase III Study to Assess Efficacy and Safety of D9421-C 9 mg Versus Mesalazine 3 g in Patients With Active Crohn's Disease (CD) in Japan [NCT01514240]Phase 3123 participants (Actual)Interventional2012-02-29Completed
A Randomized Trial Comparing Once Daily Dosing vs. Multiple Doses a Day of Mesalamine in Pediatric Patients With Quiescent Ulcerative Colitis [NCT00349388]1 participants (Actual)Interventional2006-07-31Terminated(stopped due to none enrolled in second arm, therfore no analysis)
Conventional Step-Up Versus Infliximab Monotherapy in Patients With Active Moderate to Severe Ulcerative Colitis. A Randomized, Open Label, Prospective, Multicenter Study [NCT00984568]Phase 328 participants (Actual)Interventional2009-11-30Terminated(stopped due to Due to slow recruitment the study was stopped prematurely.)
A Phase 1, Randomized, Open-label, Crossover, Drug Interaction Study Evaluating the Pharmacokinetic Profiles of Sulfamethoxazole Administered Alone and in Combination With MMX® Mesalazine/Mesalamine in Healthy Adult Subjects [NCT01469637]Phase 144 participants (Actual)Interventional2011-11-07Completed
A Phase 1, Randomized, Open-label, Crossover, Drug Interaction Study Evaluating the Pharmacokinetic Profiles of Ciprofloxacin XR Administered Alone and in Combination With MMX® Mesalazine/Mesalamine in Healthy Adult Subjects [NCT01402947]Phase 130 participants (Actual)Interventional2011-07-25Completed
Full-replicate Study of APRISO 375 mg Extended-release Capsules Versus the Approved APRISO 375 mg Extended-release Capsules in Healthy Male and Female Subjects [NCT03327558]Phase 160 participants (Actual)Interventional2017-05-15Completed
A Phase 3, Multicenter, Randomized, Double-blind Study to Determine the Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis, in Both Acute and Maintenance Phases [NCT02093663]Phase 3107 participants (Actual)Interventional2014-12-12Completed
An Open Label, Single-site Pharmaco-Scintigraphic Study in Healthy Subjects and Patients With Active Ulcerative Colitis With Radio-labelled TP05-tablets to Evaluate the Gastrointestinal Transit and Release Profiles of Two Different Formulations (and Amend [NCT02306785]Phase 126 participants (Actual)Interventional2012-10-31Completed
Efficacy, Durability and Safety of Standardized Fecal Microbiota Transplantation for Severe Inflammatory Bowel Disease [NCT02335281]Phase 240 participants (Anticipated)Interventional2015-01-31Recruiting
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Safety of Mesalamine 2 g Extended Release Granules (Sachet) for Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis [NCT02522780]Phase 3276 participants (Actual)Interventional2016-02-01Completed
A Double-blind, Randomized, Placebo-controlled, Single-center, Dose-finding, Pilot Study Evaluating the Efficacy of VSL#3® in the Maintenance of Clinical and Endoscopic Remission of Mild-to-moderate UC [NCT03415711]14 participants (Actual)Interventional2017-04-28Terminated(stopped due to Administrative reasons)
Use of Certolizumab Following Ileocolectomy Lowers Endoscopic and Histological Recurrence Rates for Crohn's Disease at One Year Compared to Mesalamine [NCT01696942]Phase 410 participants (Actual)Interventional2013-02-28Terminated(stopped due to Lack of accrual)
A Randomised, Active-Controlled, Double-Blind and Open Label Extensions Study to Evaluate the Efficacy, Long-Term Safety and Tolerability of TP05 3.2g/Day for the Treatment of Active Ulcerative Colitis [NCT01903252]Phase 3817 participants (Actual)Interventional2013-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00073021 (12) [back to overview]Percentage of Treatment Success Patients at Week 6, ITT (Intent to Treat) Population
NCT00073021 (12) [back to overview]Percentage of Patients With Improvement in Physician Global Assessment (PGA)Score, ITT Population, Week 6
NCT00073021 (12) [back to overview]Percentage of Patients With Improvement in Rectal Bleeding, ITT Population, Week 6
NCT00073021 (12) [back to overview]Percentage of Treatment Success Patients at Week 3, ITT Population
NCT00073021 (12) [back to overview]Change From Baseline in Ulcerative Colitis Disease Activity Index (UCDAI) at Week 6, ITT Population
NCT00073021 (12) [back to overview]Mean Change From Baseline in Total Inflammatory Bowel Disease Questionnaire (IBDQ) at Week 3, All Randomized Patients
NCT00073021 (12) [back to overview]Percentage of Patients With Moderate, Left-Sided Disease at Baseline Classified as Treatment Success at Week 6, All Randomized Patients
NCT00073021 (12) [back to overview]Mean Change From Baseline in Total Inflammatory Bowel Disease Questionnaire (IBDQ) at Week 6, All Randomized Patients
NCT00073021 (12) [back to overview]Percentage of Participants Whose Rectal Bleeding & Sigmoidoscopy Score Both Improved From Baseline to Week 6, ITT Population
NCT00073021 (12) [back to overview]Percentage of Patients Whose Sigmoidoscopy Score Improved From Baseline to Week 6, ITT Population
NCT00073021 (12) [back to overview]Percentage of Patients With an Improvement in Stool Frequency, ITT Population, Week 6
NCT00073021 (12) [back to overview]Percentage of Patients With Improvement in Patient's Functional Assessment (PFA), ITT Population, Week 6
NCT00151892 (5) [back to overview]Withdrawal Due to Relapse of UC
NCT00151892 (5) [back to overview]Change From Baseline in Modified Ulcerative Colitis Disease Activity Index (UCDAI) Score at 6 Months
NCT00151892 (5) [back to overview]Endoscopic Remission of UC With No or Mild Symptoms at 6 Months
NCT00151892 (5) [back to overview]Endoscopic Remission of Ulcerative Colitis (UC) at 6 Months
NCT00151892 (5) [back to overview]Short Inflammatory Bowel Disease Questionnaire (SIBDQ) Total Score
NCT00326209 (4) [back to overview]Number of Participants With Potentially Clinically Significant (PCS) Hematology and Blood Chemistry Abnormalities
NCT00326209 (4) [back to overview]Number of Participants Who Prematurely Discontinued Treatment
NCT00326209 (4) [back to overview]Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
NCT00326209 (4) [back to overview]Number of Participants With Clinically Significant Change From Baseline in Vital Signs
NCT00349388 (1) [back to overview]Improved Medication Compliance.
NCT00446849 (6) [back to overview]Clinical Recurrence of Ulcerative Colitis (UC) During the Maintenance Phase at 6 Months
NCT00446849 (6) [back to overview]Clinical Recurrence of UC During the Maintenance Phase at 12 Months
NCT00446849 (6) [back to overview]Clinical Recurrence of UC During the Maintenance Phase Associated With Subject Compliance at 6 Months
NCT00446849 (6) [back to overview]Quiescent UC During the Maintenance Phase at 12 Months
NCT00446849 (6) [back to overview]Endoscopic Remission of UC During the Maintenance Phase at 12 Months
NCT00446849 (6) [back to overview]Clinical Recurrence of UC During the Maintenance Phase Associated With Subject Compliance at 12 Months
NCT00505778 (6) [back to overview]Number of Subjects Who Relapse/Flare Within 6 Months, ITT Population
NCT00505778 (6) [back to overview]Percentage of Participants Indicating Ulcerative Colitis in Remission (Patient Defined Remission Index), ITT Population, Month 6
NCT00505778 (6) [back to overview]Percentage of Patients Remaining in Remission at Month 12, ITT Population
NCT00505778 (6) [back to overview]Percentage of Patients Remaining in Remission at Month 3, ITT Population
NCT00505778 (6) [back to overview]Percentage of Patients Remaining in Remission at Month 6, ITT Population, Determined by the Simple Clinical Colitis Activity Index (SCCAI)
NCT00505778 (6) [back to overview]Total MARS (Medication Adherence Report Scale) Questionnaire Scores, ITT Population, Month 6
NCT00545103 (7) [back to overview]Number of CT Scans Performed Within 7 Days of Suspected Recurrence of Diverticulitis That Were Positive
NCT00545103 (7) [back to overview]Number of CT Scans Performed Within 7 Days of Suspected Recurrence of Diverticulitis That Were Negative
NCT00545103 (7) [back to overview]Number of CT Scans Performed More Than 7 Days From Suspected Recurrence of Diverticulitis That Were Positive
NCT00545103 (7) [back to overview]Percent of Subjects Who Are CT-Recurrence Free of Diverticulitis
NCT00545103 (7) [back to overview]Percent of Subjects Without Recurrence of Diverticulitis
NCT00545103 (7) [back to overview]Percent of Subjects Requiring Surgery for Diverticulitis
NCT00545103 (7) [back to overview]Number of CT Scans Performed More Than 7 Days From Suspected Recurrence of Diverticulitis That Were Negative
NCT00545740 (7) [back to overview]Number of CT Scans Performed Within 7 Days of Suspected Recurrence of Diverticulitis That Were Positive
NCT00545740 (7) [back to overview]Number of CT Scans Performed Within 7 Days of Suspected Recurrence of Diverticulitis That Were Negative
NCT00545740 (7) [back to overview]Number of CT Scans Performed More Than 7 Days From Suspected Recurrence of Diverticulitis That Were Positive
NCT00545740 (7) [back to overview]Number of CT Scans Performed More Than 7 Days From Suspected Recurrence of Diverticulitis That Were Negative
NCT00545740 (7) [back to overview]Percent of Subjects Without Recurrence of Diverticulitis
NCT00545740 (7) [back to overview]Percent of Subjects Who Were CT-Recurrence Free of Diverticulitis
NCT00545740 (7) [back to overview]Percent of Subjects Requiring Surgery for Diverticulitis
NCT00554099 (8) [back to overview]Change in GSS From Baseline to Week 52 - ITT Population
NCT00554099 (8) [back to overview]Percentage of Responders at Week 52 - ITT Population
NCT00554099 (8) [back to overview]Global Symptom Score (GSS) at Week 12, Primary Efficacy Population
NCT00554099 (8) [back to overview]Percentage of Responders at Week 12 - ITT Population
NCT00554099 (8) [back to overview]Recurrent Diverticulitis, Percentage, ITT Population, Week 12
NCT00554099 (8) [back to overview]Withdrawal Due to Surgery for Diverticulitis, Percentage, ITT Population, Week 12
NCT00554099 (8) [back to overview]Recurrent Diverticulitis, Percentage, ITT Population, Week 52
NCT00554099 (8) [back to overview]Change in GSS From Baseline to Week 12 - ITT Population
NCT00577473 (12) [back to overview]Rectal Bleeding Improvement at Week 6, All Randomized Patients (Percentage)
NCT00577473 (12) [back to overview]Rectal Bleeding Improvement at Week 3, All Randomized Patients (Percentage)
NCT00577473 (12) [back to overview]Physician's Global Assessment (PGA) Percentage of Patients Improved at Week 6, All Randomized Patients
NCT00577473 (12) [back to overview]Physician's Global Assessment (PGA) Percentage of Patients Improved at Week 3, All Randomized Patients
NCT00577473 (12) [back to overview]Percentage of Patients Classified as Treatment Success at Week 6, ITT Population
NCT00577473 (12) [back to overview]Improvement in Patient's Sigmoidoscopy Assessment Score at Week 6, All Randomized Patients (Percentage)
NCT00577473 (12) [back to overview]Percentage of Patients Classified as Treatment Success at Week 3, ITT Population
NCT00577473 (12) [back to overview]Improvement in Patient's Sigmoidoscopy Assessment Score at Week 3, All Randomized Patients (Percentage)
NCT00577473 (12) [back to overview]Improvement in Patient's Functional Assessment (PFA) at Week 6, All Randomized Patients (Percentage)
NCT00577473 (12) [back to overview]Improvement in Patient's Functional Assessment (PFA) at Week 3, All Randomized Patients (Percentage)
NCT00577473 (12) [back to overview]Stool Frequency Improvement at Week 6, All Randomized Patients (Percentage)
NCT00577473 (12) [back to overview]Stool Frequency Improvement at Week 3, All Randomized Patients (Percentage)
NCT00603733 (3) [back to overview]Active Phase: Proportion of Active Subjects Achieving Overall Improvement
NCT00603733 (3) [back to overview]Frequency of Adverse Events
NCT00603733 (3) [back to overview]Maintenance Phase: Proportion of Subjects Experiencing Relapse
NCT00652145 (3) [back to overview]Fecal Calprotectin <200 µg/g
NCT00652145 (3) [back to overview]Fecal Calprotectin Level <100 µg/g
NCT00652145 (3) [back to overview]Fecal Calprotectin Level <50µg/g
NCT00713310 (2) [back to overview]Treatment Success PUCAI Amended Endpoint (5 Point Scale Abdominal Pain), mITT
NCT00713310 (2) [back to overview]Treatment Success PUCAI (Pediatric Ulcerative Colitis Activity Index), mITT/Modified Intent to Treat Population
NCT00840203 (6) [back to overview]AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)
NCT00840203 (6) [back to overview]Cmax - Maximum Observed Concentration
NCT00840203 (6) [back to overview]Cmax - Maximum Observed Concentration
NCT00840203 (6) [back to overview]AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)
NCT00840203 (6) [back to overview]AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)
NCT00840203 (6) [back to overview]AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)
NCT00862121 (6) [back to overview]Percentage of Crohn's Disease Activity Index (CDAI) Responders at Week 10.
NCT00862121 (6) [back to overview]Relative Change From Baseline to Each Visit in Inflammatory Bowel Disease Questionnaire (IBDQ) Score
NCT00862121 (6) [back to overview]Relative Change From Baseline to Week 10 in Fecal Calprotectin
NCT00862121 (6) [back to overview]Relative Change From Baseline to Week 10 in Estimated Creatinine Clearance
NCT00862121 (6) [back to overview]Relative Change From Baseline to Each Visit in Work Productivity & Activity Impairment Questionnaire (WPAI_CD) Score Item 5 (Work Productivity)
NCT00862121 (6) [back to overview]Relative Change From Baseline to Each Visit in Serum C-reactive Protein (CRP)
NCT00984568 (2) [back to overview]Number of Participants Achieving Treatment Response
NCT00984568 (2) [back to overview]Number of Participants With Response at Week 4 and Steroid-Free Remission at Week 50
NCT01004185 (2) [back to overview]Treatment Success PUCAI (Pediatric Ulcerative Colitis Activity Index), mITT/Modified Intent to Treat Population
NCT01004185 (2) [back to overview]Treatment Success PUCAI Amended Endpoint (5 Point Scale Abdominal Pain), mITT
NCT01016262 (5) [back to overview]Percentage of Participants Who Were Responders at Week 3
NCT01016262 (5) [back to overview]Percentage of Participants Who Were Responders at Week 6
NCT01016262 (5) [back to overview]Time to Relief of Rectal Bleeding
NCT01016262 (5) [back to overview]Time to Relief of Tenesmus
NCT01016262 (5) [back to overview]Change From Baseline in Total Inflammatory Bowel Disease Questionnaire (IBDQ) Score at Week 6
NCT01088243 (4) [back to overview]Changes in Bronchoalveolar Lavage (BAL) Tumor Necrosis Factor Alpha (TNFa)
NCT01088243 (4) [back to overview]Lung Function
NCT01088243 (4) [back to overview]Change in Beryllium Lymphocyte Proliferation Responses (BeLPT) From Baseline to Week 6
NCT01088243 (4) [back to overview]Changes in Steady-state Glutathione (GSH) Levels From Baseline to Week 6
NCT01090102 (2) [back to overview]Log(10) Change in % Activated (CD38+HLA-DR+)CD8+ T Cells During the First 12 Weeks of Study
NCT01090102 (2) [back to overview]Log(10) Change in % Activated (CD38+HLA-DR+)CD8+ T Cells After Treatment Crossover
NCT01124149 (8) [back to overview]Percentage of Subjects in Complete Remission at Month 12 of Maintenance Phase
NCT01124149 (8) [back to overview]Percentage of Subjects in Partial Remission at Week 8 of Acute Phase
NCT01124149 (8) [back to overview]Percentage of Subjects in Clinical Remission at Month 12 of Maintenance Phase
NCT01124149 (8) [back to overview]Percentage of Subjects in Complete Remission at Week 8 of Acute Phase
NCT01124149 (8) [back to overview]Relapse in Ulcerative Colitis at Month 12 of Maintenance Phase
NCT01124149 (8) [back to overview]Improvement in Rectal Bleeding Score During the Acute Phase
NCT01124149 (8) [back to overview]Improvement in Stool Frequency Symptoms During the Acute Phase
NCT01124149 (8) [back to overview]Percentage of Subjects With Mucosal Healing at 12 Months of Maintenance Phase
NCT01130844 (11) [back to overview]CL of MMX Mesalamine Major Metabolite (Ac-5-ASA) at Steady State
NCT01130844 (11) [back to overview]Cmax of MMX Mesalamine Major Metabolite (Ac-5-ASA) at Steady State
NCT01130844 (11) [back to overview]Cumulative Amount of MMX Mesalamine (5-ASA) Recovered in Urine at Steady State
NCT01130844 (11) [back to overview]Cumulative Amount of MMX Mesalamine Major Metabolite (Ac-5-ASA) Recovered in Urine at Steady State
NCT01130844 (11) [back to overview]Maximum Plasma Concentration (Cmax) of MMX Mesalamine (5-ASA) at Steady State
NCT01130844 (11) [back to overview]Percentage of Dose Absorbed For MMX Mesalamine (5-ASA) in Urine at Steady State
NCT01130844 (11) [back to overview]Time to Maximum Plasma Concentration (Tmax) of MMX Mesalamine (5-ASA) at Steady State
NCT01130844 (11) [back to overview]Tmax of MMX Mesalamine Major Metabolite (Ac-5-ASA) at Steady State
NCT01130844 (11) [back to overview]Total Body Clearance (CL) of MMX Mesalamine (5-ASA) at Steady State
NCT01130844 (11) [back to overview]Area Under the Plasma Concentration Versus Time Curve (AUC) of MMX Mesalamine (5-ASA) at Steady State
NCT01130844 (11) [back to overview]AUC of MMX Mesalamine Major Metabolite (Ac-5-ASA) at Steady State
NCT01177410 (2) [back to overview]Proportion of Subjects Who Are Monthly Responders in Both Abdominal Pain and Stool Consistency for at Least 2 Months During the 3-month Treatment Period
NCT01177410 (2) [back to overview]The Number of Months That Subjects Are Monthly Responders in Both IBS-related Abdominal Pain AND Stool Consistency During the Entire Three Months.
NCT01327300 (6) [back to overview]Intestinal Permeability Testing
NCT01327300 (6) [back to overview]Changes in GIS Scores Between Baseline and After a 12 Week Intervention With Mesalamine or Placebo
NCT01327300 (6) [back to overview]Functional Bowel Disorder Severity Index (FBDSI)
NCT01327300 (6) [back to overview]IBS - Quality of Life (IBS-QOL)Score.
NCT01327300 (6) [back to overview]Hospital Anxiety and Depression Scale (HADS)
NCT01327300 (6) [back to overview]Number of Participants Who Had Evidence of Increased Levels of Pathologic Indicators of Colonic Mucosal Inflammation at 12 Weeks Compared to Baseline.
NCT01402947 (2) [back to overview]Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC 0→∞) of Ciprofloxacin XR
NCT01402947 (2) [back to overview]Maximum Plasma Concentration (Cmax) of Ciprofloxacin XR
NCT01412372 (6) [back to overview]Change in Average Bowel Consistency Score After an 8 Week Treatment Period.
NCT01412372 (6) [back to overview]Change in Average Overall Bowel Symptom Score (BSS) After an 8 Week Treatment Period
NCT01412372 (6) [back to overview]Change in Average Bloating Score After an 8 Week Treatment Period.
NCT01412372 (6) [back to overview]Change in Average Abdominal Pain Score After an 8 Week Treatment Period
NCT01412372 (6) [back to overview]Change in Average Bowel Frequency After 8-Week Treatment Period
NCT01412372 (6) [back to overview]Change in Average Overall IBS Specific Quality of Life Score After an 8 Week Treatment Period.
NCT01418365 (2) [back to overview]Area Under the Plasma Concentration Curve (AUC) at Steady State for Metronidazole
NCT01418365 (2) [back to overview]Maximum Plasma Concentration (Cmax) at Steady State for Metronidazole
NCT01442688 (2) [back to overview]Maximum Plasma Concentration (Cmax) for Amoxicillin
NCT01442688 (2) [back to overview]Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC 0→∞) for Amoxicillin
NCT01469637 (2) [back to overview]Maximum Plasma Concentration at Steady-State (Cmaxss) for Sulfamethoxazole
NCT01469637 (2) [back to overview]Area Under the Plasma Concentration Versus Time Curve Within a Dosing Interval at Steady-State (AUCss) for Sulfamethoxazole
NCT01514240 (35) [back to overview]Change in Observed CDAI Scores From Baseline to Weeks 4
NCT01514240 (35) [back to overview]Change in Observed CDAI Scores From Baseline to Weeks 8
NCT01514240 (35) [back to overview]Change in Total IBDQ Scores From Baseline to Weeks 10
NCT01514240 (35) [back to overview]Change in IBDQ Scores From Baseline to Weeks 8 - Systemic Symptom
NCT01514240 (35) [back to overview]Change in Observed CDAI Scores From Baseline to Weeks 2
NCT01514240 (35) [back to overview]Change in Total IBDQ Scores From Baseline to Weeks 4
NCT01514240 (35) [back to overview]Change in Total IBDQ Scores From Baseline to Weeks 8
NCT01514240 (35) [back to overview]Clinical Improvement Rates (Decrease in CDAI Score From Baseline of at Least 70 Points) at Weeks 2
NCT01514240 (35) [back to overview]Change in Total IBDQ Scores From Baseline to Weeks 2
NCT01514240 (35) [back to overview]Clinical Improvement Rates (Decrease in CDAI Score From Baseline of at Least 100 Points) at Weeks 2
NCT01514240 (35) [back to overview]Clinical Improvement Rates (Decrease in CDAI Score From Baseline of at Least 100 Points) at Weeks 4
NCT01514240 (35) [back to overview]Clinical Improvement Rates (Decrease in CDAI Score From Baseline of at Least 100 Points) at Weeks 8
NCT01514240 (35) [back to overview]Remission After 8-week of Treatment
NCT01514240 (35) [back to overview]Remission After 4-week of Treatment
NCT01514240 (35) [back to overview]Remission After 2-week of Treatment
NCT01514240 (35) [back to overview]Cumulative Remission Rate at Week 8
NCT01514240 (35) [back to overview]Cumulative Remission Rate at Week 4
NCT01514240 (35) [back to overview]Cumulative Remission Rate at Week 2
NCT01514240 (35) [back to overview]Clinical Improvement Rates (Decrease in CDAI Score From Baseline of at Least 70 Points) at Weeks 8
NCT01514240 (35) [back to overview]Clinical Improvement Rates (Decrease in CDAI Score From Baseline of at Least 70 Points) at Weeks 4
NCT01514240 (35) [back to overview]Change in IBDQ Scores From Baseline to Weeks 10 - Bowel Function
NCT01514240 (35) [back to overview]Change in IBDQ Scores From Baseline to Weeks 10 - Emotional Function
NCT01514240 (35) [back to overview]Change in IBDQ Scores From Baseline to Weeks 10 - Social Function
NCT01514240 (35) [back to overview]Change in IBDQ Scores From Baseline to Weeks 10 - Systemic Symptom
NCT01514240 (35) [back to overview]Change in IBDQ Scores From Baseline to Weeks 2 - Bowel Function
NCT01514240 (35) [back to overview]Change in IBDQ Scores From Baseline to Weeks 2 - Emotional Function
NCT01514240 (35) [back to overview]Change in IBDQ Scores From Baseline to Weeks 2 - Social Function
NCT01514240 (35) [back to overview]Change in IBDQ Scores From Baseline to Weeks 2 - Systemic Symptom
NCT01514240 (35) [back to overview]Change in IBDQ Scores From Baseline to Weeks 4 - Bowel Function
NCT01514240 (35) [back to overview]Change in IBDQ Scores From Baseline to Weeks 4 - Emotional Function
NCT01514240 (35) [back to overview]Change in IBDQ Scores From Baseline to Weeks 4 - Social Function
NCT01514240 (35) [back to overview]Change in IBDQ Scores From Baseline to Weeks 4 - Systemic Symptom
NCT01514240 (35) [back to overview]Change in IBDQ Scores From Baseline to Weeks 8 - Bowel Function
NCT01514240 (35) [back to overview]Change in IBDQ Scores From Baseline to Weeks 8 - Emotional Function
NCT01514240 (35) [back to overview]Change in IBDQ Scores From Baseline to Weeks 8 - Social Function
NCT01536535 (3) [back to overview]Number of Participants Receiving a Colectomy
NCT01536535 (3) [back to overview]Number of Participants Who Needed Additional Therapy or Colectomy
NCT01536535 (3) [back to overview]Number of Participants With Corticosteroid Free Remission (SFR)
NCT01696942 (2) [back to overview]Number of Participants With Endoscopic Recurrence of Crohn's Disease
NCT01696942 (2) [back to overview]Clinical Recurrence Rates of Crohn's Disease
NCT01903252 (33) [back to overview]Period 2: UC-Related Complications
NCT01903252 (33) [back to overview]Period 2: Urgency
NCT01903252 (33) [back to overview]Period 3: Clinical and Endoscopic Remission
NCT01903252 (33) [back to overview]Period 3: Clinical and Endoscopic Response
NCT01903252 (33) [back to overview]Period 3: Clinical Remission
NCT01903252 (33) [back to overview]Period 3: Clinical Response
NCT01903252 (33) [back to overview]Period 3: Endoscopic Remission
NCT01903252 (33) [back to overview]Period 3: Endoscopic Response
NCT01903252 (33) [back to overview]Period 3: No Urgency
NCT01903252 (33) [back to overview]Period 3: Rectal Bleeding Sub Score of 0
NCT01903252 (33) [back to overview]Period 3: Stool Frequency Sub-score 0
NCT01903252 (33) [back to overview]Period 3: UC-Related Complications
NCT01903252 (33) [back to overview]Period 1: Endoscopic Response
NCT01903252 (33) [back to overview]Period 1: Change in Endoscopic Score From Baseline
NCT01903252 (33) [back to overview]Period 1: Change in Mayo Score From Baseline
NCT01903252 (33) [back to overview]Period 1: Change in Partial Mayo Score From Baseline
NCT01903252 (33) [back to overview]Period 1: Change in Physician Global Assessment Score From Baseline
NCT01903252 (33) [back to overview]Period 1: Change in Rectal Bleeding Score From Baseline
NCT01903252 (33) [back to overview]Period 1: Change in Stool Frequency Score
NCT01903252 (33) [back to overview]Period 1: Clinical and Endoscopic Remission
NCT01903252 (33) [back to overview]Period 1: Clinical and Endoscopic Response
NCT01903252 (33) [back to overview]Period 1: Clinical Remission
NCT01903252 (33) [back to overview]Period 1: Clinical Remission
NCT01903252 (33) [back to overview]Period 1: Clinical Remission at Both Week 8 and 12
NCT01903252 (33) [back to overview]Period 1: Clinical Response
NCT01903252 (33) [back to overview]Period 1: Clinical Response at Both Week 8 and Week 12
NCT01903252 (33) [back to overview]Period 1: Endoscopic Remission
NCT01903252 (33) [back to overview]Period 1: Rectal Bleeding Score of 0
NCT01903252 (33) [back to overview]Period 1: Rectal Bleeding Sub-score of 0
NCT01903252 (33) [back to overview]Period 2: Clinical Remission
NCT01903252 (33) [back to overview]Period 2: Clinical Response, Open-Label Extended Induction
NCT01903252 (33) [back to overview]Period 2: Rectal Bleeding Sub-score of 0
NCT01903252 (33) [back to overview]Period 2: Stool Frequency 0
NCT01999400 (4) [back to overview]The AUC of Metabolite (N-acetyl-mesalamine) in Plasma
NCT01999400 (4) [back to overview]The AUC of Mesalamine in Distal Jejunum
NCT01999400 (4) [back to overview]The AUC of Mesalamine in Plasma
NCT01999400 (4) [back to overview]The AUC of Metabolite (N-acetyl-mesalamine) in Distal Jejunum
NCT02093663 (10) [back to overview]Number of Participants With Clinical and Endoscopic Response During Double Blind Acute Phase at Week 8 Using Central Reading
NCT02093663 (10) [back to overview]Number of Participants With Clinical and Endoscopic Response During Double Blind Acute Phase at Week 8 Using Local Reading
NCT02093663 (10) [back to overview]Number of Participants With Clinical and Endoscopic Response During Double-Blind Maintenance Phase at Week 26 Using Central Reading
NCT02093663 (10) [back to overview]Number of Participants With Clinical and Endoscopic Response During Double-Blind Maintenance Phase at Week 26 Using Local Reading
NCT02093663 (10) [back to overview]Number of Participants With Clinical Response During Double-Blind Acute Phase at Week 8
NCT02093663 (10) [back to overview]Number of Participants With Clinical Response During Double-blind Maintenance Phase at Week 26
NCT02093663 (10) [back to overview]Number of Participants With Improvement in Pediatric Ulcerative Colitis Activity Index (PUCAI) Score During Double-blind Acute Phase at Week 8
NCT02093663 (10) [back to overview]Number of Participants With Remission at Pediatric Ulcerative Colitis Activity Index (PUCAI) Score During Double-Blind Maintenance Phase at Week 26
NCT02093663 (10) [back to overview]Change From Baseline in Daily Ulcerative Colitis Scale (DUCS) Score During Double-Blind Acute Phase
NCT02093663 (10) [back to overview]Change From Baseline in Daily Ulcerative Colitis Scale (DUCS) Score During Double-Blind Maintenance Phase
NCT02125292 (8) [back to overview]Number of Participants Who Detected an Aftertaste of Mesalamine
NCT02125292 (8) [back to overview]Number of Participants Willing to Take Mesalamine Via Treatment Method on a Regular Basis
NCT02125292 (8) [back to overview]Number of Participants With Positive Responses to Palatability Assessment of The Aftertaste of Mesalamine
NCT02125292 (8) [back to overview]Number of Participants With Potentially Clinically Important Laboratory Results
NCT02125292 (8) [back to overview]Number of Participants Who Experienced an Adverse Event
NCT02125292 (8) [back to overview]Number of Participants With Potentially Clinically Important Electrocardiogram (ECG) Results
NCT02125292 (8) [back to overview]Number of Participants With Positive Responses to Palatability Assessment of The Taste of Mesalamine
NCT02125292 (8) [back to overview]Number of Participants With Potentially Clinically Important Vital Signs
NCT02493712 (2) [back to overview]Improvement Rate
NCT02493712 (2) [back to overview]Remission Rate
NCT02522767 (15) [back to overview]Proportion of Subject With Abnormal Laboratory Values (Hematology)
NCT02522767 (15) [back to overview]The Change From Baseline in Rectal Bleeding Score at Weeks 2, 4, and 8
NCT02522767 (15) [back to overview]Number of Participants Experiencing Adverse Events
NCT02522767 (15) [back to overview]Time to Normal Stool Pattern
NCT02522767 (15) [back to overview]Time to Cessation of Rectal Bleeding
NCT02522767 (15) [back to overview]The Proportion of Subjects With Endoscopic Improvement
NCT02522767 (15) [back to overview]Proportion of Subjects With Remission
NCT02522767 (15) [back to overview]The Proportion of Subjects in Clinical Remission at Weeks 2, 4, and 8
NCT02522767 (15) [back to overview]The Change From Baseline in Fecal Calprotectin Levels at Week 8
NCT02522767 (15) [back to overview]Proportion of Subjects With Remission in the Primary Endpoint and the Physician's Global Assessment (PGA) Score of ≤1 (Modified Mayo Score)
NCT02522767 (15) [back to overview]The Change From Baseline in Serum C-reactive Protein (CRP) Levels at Weeks 2, 4, and 8
NCT02522767 (15) [back to overview]The Change From Baseline in Health Related Quality of Life (QoL) Scores
NCT02522767 (15) [back to overview]Severity of Adverse Events
NCT02522767 (15) [back to overview]Proportion of Subjects With Abnormal Laboratory Values (Serum Chemistry)
NCT02522767 (15) [back to overview]Proportion of Subjects With Abnormal Laboratory Values (Coagulation)
NCT02522780 (12) [back to overview]Proportion of Subjects With Markedly Abnormal Laboratory Values: Hematology
NCT02522780 (12) [back to overview]Proportion of Subjects With Markedly Abnormal Laboratory Values: Coagulation
NCT02522780 (12) [back to overview]Proportion of Subjects in Clinical Remission at Month 2, 4, and 6
NCT02522780 (12) [back to overview]Severity of Adverse Events
NCT02522780 (12) [back to overview]Proportion of Subjects With an Increase From Baseline in the Clinical and Endoscopic Response Score by 2 or More Points in at Least 1 Component or by 1 or More Points in at Least 2 Components at Month 6
NCT02522780 (12) [back to overview]Proportion of Subjects With Remission at Month 6
NCT02522780 (12) [back to overview]Time to Relapse
NCT02522780 (12) [back to overview]Change From Baseline in Fecal Calprotectin Levels at Month 2, 4, and 6
NCT02522780 (12) [back to overview]Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Scores at Months 2, 4, and 6
NCT02522780 (12) [back to overview]Change From Baseline in Serum C-reactive Protein (CRP) Levels at Month 2, 4, and 6
NCT02522780 (12) [back to overview]Number of Subjects With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT02522780 (12) [back to overview]Proportion of Subjects With Markedly Abnormal Laboratory Values: Serum Chemistry

Percentage of Treatment Success Patients at Week 6, ITT (Intent to Treat) Population

Treatment success defined as complete response (PGA score 0 and complete resolution of stool frequency, rectal bleeding, PFA (patient's functional assessment), normal sigmoidoscopy) or partial response (improvement from baseline PGA and improvement in 1 clinical assessment [stool frequency, rectal bleeding, PFA, sigmoidoscopy] and no worsening in any other clinical assessments) (NCT00073021)
Timeframe: 6 Weeks

InterventionPercentage of Participants (Number)
Asacol 2.4 g/Day59.2
Asacol 4.8 g/Day71.8

[back to top]

Percentage of Patients With Improvement in Physician Global Assessment (PGA)Score, ITT Population, Week 6

PGA -Physician's Global Assessment - 0=quiescent disease (all parameters 0), 1=mild disease (parameters mostly 1's) 2=moderate (parameters mostly 2's), 3=severe (parameters mostly 3's) [parameters: combination of stool frequency, rectal bleeding, PFA & sigmoidoscopy findings] If scoring equal default to physician judgement. (NCT00073021)
Timeframe: 6 Weeks

InterventionPercentage of Participants (Number)
Asacol 2.4 g/Day73.5
Asacol 4.8 g/Day83.2

[back to top]

Percentage of Patients With Improvement in Rectal Bleeding, ITT Population, Week 6

Rectal Bleeding (0=no blood seen, 1=streaks of blood with stool less than half of the time, 2=obvious blood with stool most of the time, 3=blood alone passed) (NCT00073021)
Timeframe: 6 Weeks

InterventionPercentage of Participants (Number)
Asacol 2.4 g/Day77.5
Asacol 4.8 g/Day78.5

[back to top]

Percentage of Treatment Success Patients at Week 3, ITT Population

Treatment success defined as complete response (PGA score 0 and complete resolution of stool frequency, rectal bleeding, PFA (patient's functional assessment), normal sigmoidoscopy) or partial response (improvement from baseline PGA and improvement in 1 clinical assessment [stool frequency, rectal bleeding, PFA, sigmoidoscopy] and no worsening in any other clinical assessments) (NCT00073021)
Timeframe: 3 Weeks

InterventionPercentage of Participants (Number)
Asacol 2.4 g/Day51.5
Asacol 4.8 g/Day61.3

[back to top]

Change From Baseline in Ulcerative Colitis Disease Activity Index (UCDAI) at Week 6, ITT Population

UCDAI - sum of clinical assessment scores (stool frequency score [0=normal, 1=1-2 stools > normal/day, 2=3-4 stools > normal/day, 3=5 or more stools > normal/day], rectal bleeding score [0=no blood seen, 1=streaks of blood with stool less than half of the time, 2=obvious blood with stool most of the time, 3=blood alone passed and PGA score [0=quiescent disease, 1=mild, 2=moderate, 3=severe]) and sigmoidoscopy score [0=normal, 1=mild, 2=moderate, 3=severe] (NCT00073021)
Timeframe: 6 weeks

InterventionScores on a Scale (Mean)
Asacol 2.4 g/Day-3.2
Asacol 4.8 g/Day-3.7

[back to top]

Mean Change From Baseline in Total Inflammatory Bowel Disease Questionnaire (IBDQ) at Week 3, All Randomized Patients

IBDQ-32 questions divided into 4 categories: bowel, systemic, emotional and social. Each question graded with the following responses: 1-more than ever before, 2-extremely frequently, 3-very frequently, 4-moderate increase in frequency, 5-some increase in frequency, 6-slight increase in frequency or 7-not at all/normal; 1/worst thru 7/best. Scoring 32 - 224 - higher score better. (NCT00073021)
Timeframe: 3 Weeks

InterventionScores on a Scale (Mean)
Asacol 2.4 g/Day30.4
Asacol 4.8 g/Day29.8

[back to top]

Percentage of Patients With Moderate, Left-Sided Disease at Baseline Classified as Treatment Success at Week 6, All Randomized Patients

Treatment success defined as complete response (PGA score 0 and complete resolution of stool frequency, rectal bleeding, PFA (patient's functional assessment), normal sigmoidoscopy) or partial response (improvement from baseline PGA and improvement in 1 clinical assessment [stool frequency, rectal bleeding, PFA, sigmoidoscopy] and no worsening in any other clinical assessments) (NCT00073021)
Timeframe: 6 Weeks

InterventionPercentage of Participants (Number)
Asacol 2.4 g/Day60.0
Asacol 4.8 g/Day71.1

[back to top]

Mean Change From Baseline in Total Inflammatory Bowel Disease Questionnaire (IBDQ) at Week 6, All Randomized Patients

IBDQ-32 questions divided into 4 categories: bowel, systemic, emotional and social. Each question graded with the following responses: 1-more than ever before, 2-extremely frequently, 3-very frequently, 4-moderate increase in frequency, 5-some increase in frequency, 6-slight increase in frequency or 7-not at all/normal; 1/worst thru 7/best. Scoring 32-224 - higher score better. (NCT00073021)
Timeframe: 6 Weeks

InterventionScores on a Scale (Mean)
Asacol 2.4 g/Day43.1
Asacol 4.8 g/Day40.4

[back to top]

Percentage of Participants Whose Rectal Bleeding & Sigmoidoscopy Score Both Improved From Baseline to Week 6, ITT Population

Rectal Bleeding - 0=no blood seen, 1=streaks of blood w/stool less than half of the time, 2=obvious blood w/stool most of the time, 3=blood alone passed Sigmoidoscopy Assessment Score - 0=normal (intact vascular pattern, no friability or granularity), 1=mild (erythema, diminished or absent vascular markings; mild granularity; friability), 2=moderate (marked erythema, granularity; absent vascular markings; bleeds with minimal trauma; no ulcerations) 3=severe (spontaneous bleeding, ulcerations) (NCT00073021)
Timeframe: 6 Weeks

InterventionPercentage of Participants (Number)
Asacol 2.4 g/Day59.8
Asacol 4.8 g/Day63.6

[back to top]

Percentage of Patients Whose Sigmoidoscopy Score Improved From Baseline to Week 6, ITT Population

Sigmoidoscopy Assessment Score (0=normal intact vascular pattern, no friability or granularity, 1=mild erythema; diminished or absent vascular markings; mild granularity; friability, 2=moderate marked erythema, granularity; absent vascular markings; bleeds with minimal trauma; no ulcerations, 3=severe spontaneous bleeding, ulcerations) (NCT00073021)
Timeframe: 6 Weeks

InterventionPercentage of Participants (Number)
Asacol 2.4 g/Day69.0
Asacol 4.8 g/Day75.2

[back to top]

Percentage of Patients With an Improvement in Stool Frequency, ITT Population, Week 6

0=Normal stool frequency per day, 1=1-2 stools greater than normal per day, 2=3-4 stools greater than normal per day, 3=5 or more stools greater than normal per day (NCT00073021)
Timeframe: 6 Weeks

InterventionPercentage of Participants (Number)
Asacol 2.4 g/Day71.3
Asacol 4.8 g/Day74.0

[back to top]

Percentage of Patients With Improvement in Patient's Functional Assessment (PFA), ITT Population, Week 6

PFA - 0=generally well, 1=fair, 2=poor, 3=terrible (NCT00073021)
Timeframe: 6 Weeks

InterventionPercentage of Participants (Number)
Asacol 2.4 g/Day70.5
Asacol 4.8 g/Day69.6

[back to top]

Withdrawal Due to Relapse of UC

Relapse is defined as withdrawal from the study due to lack of efficacy. (NCT00151892)
Timeframe: Over 6 Months

Interventionpercent of participants (Number)
SPD47612.8
Asacol14.6

[back to top]

Change From Baseline in Modified Ulcerative Colitis Disease Activity Index (UCDAI) Score at 6 Months

The modified UCDAI score is the sum of the scores of 4 parameters (stool frequency, rectal bleeding, endoscopy score, and physician global assessment), each scoring between 0 and 3, making 12 the worst score. (NCT00151892)
Timeframe: Baseline and 6 months

InterventionUnits on a scale (Mean)
SPD4760.061
Asacol0.059

[back to top]

Endoscopic Remission of UC With No or Mild Symptoms at 6 Months

Endoscopic remission with no or mild symptoms is defined as an endoscopy score of less than or equal to 1 and a combined symptom score (stool frequency plus rectal bleeding) of less than or equal to 1. Endoscopy score (mucosal appearance) ranges from 0-3 (0 = normal, 1 = mild , 2 = moderate, 3 = severe). Rectal bleeding is assessed on a scale from 0-3 (0 = no rectal bleeding, 1 = streaks of blood, 2 = obvious blood, 3 = mostly blood). Stool frequency is assessed on a scale of 0-2 (0 = 0-1 more than normal per day, 1 = 2-3 more than normal per day, 2 = 4 or more than normal per day). (NCT00151892)
Timeframe: 6 Months

Interventionpercent of participants (Number)
SPD47679.0
Asacol75.6

[back to top]

Endoscopic Remission of Ulcerative Colitis (UC) at 6 Months

Endoscopic remission is defined as an endoscopy score of less than or equal to 1. Endoscopy score (mucosal appearance) ranges from 0-3 (0 = normal [intact vascular pattern; no friability or granulation], 1 = mild [erythema; decreased vascular pattern; minimal granularity], 2 = moderate [marked erythema; granularity; friability; absent vascular pattern; bleeding with minimal trauma; no ulcerations], 3 = severe [ulceration; spontaneous bleeding]. (NCT00151892)
Timeframe: 6 Months

Interventionpercent of participants (Number)
SPD47683.7
Asacol81.5

[back to top]

Short Inflammatory Bowel Disease Questionnaire (SIBDQ) Total Score

Quality of life (QoL) was assessed using the SIBDQ. SIBDQ total score is calculated from the sum of 10 questions. Each question is scored on a scale from 1 (poor QoL) to 7 (good QoL) with total scores ranging from 10 to 70. Higher scores indicate better QoL. (NCT00151892)
Timeframe: 6 Months

InterventionUnits on a scale (Mean)
SPD47659.523
Asacol59.664

[back to top]

Number of Participants With Potentially Clinically Significant (PCS) Hematology and Blood Chemistry Abnormalities

Criteria for potentially clinically significant abnormal hematology and blood chemistry values included: hemoglobin (grams/deciliter [g/dL]): <10 and ≥3 decrease, or >20; hematocrit (%): <30 and ≥10 decrease, or >60; platelets (*10^9 cells/liter): <100 or >700 (normal: 150-400); white blood cells (*10^9 cells/liter): <2.3 or >16.2 (normal: 3.5-11.1); alanine aminotransferase (units/liter [U/L]): ≥3 * upper limit of normal (ULN) (normal range 0-47 U/L); aspartate aminotransferase (U/L): ≥3 * ULN (normal range 0-37 U/L); total bilirubin (micromoles/liter [µmol/L]): >2 times; and calcium creatinine clearance (milliliters/minute [mL/min]): ≤50. (NCT00326209)
Timeframe: Baseline up to follow-up (24.5 months)

InterventionParticipants (Count of Participants)
Hemoglobin (g/dL)Hematocrit (%)Platelets (*10^9 cells/L)White blood cells (*10^9 cells/L)Alanine aminotransferase (U/L)Aspartate aminotransferase (U/L)Total bilirubin (µmol/L)Calcium creatinine clearance (mL/min)
Encapsulated Mesalamine Granules (eMG)875133362

[back to top]

Number of Participants Who Prematurely Discontinued Treatment

Number of participants who prematurely discontinued treatment due to any reason were reported. (NCT00326209)
Timeframe: Baseline up to Month 24

InterventionParticipants (Count of Participants)
Encapsulated Mesalamine Granules (eMG)282

[back to top]

Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A TEAE was defined as any event with a start date occurring on or after treatment Day 1 or, if pre-existing, worsening after treatment Day 1. Serious AEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section. (NCT00326209)
Timeframe: Baseline (Day 1) up to follow-up (24.5 months)

InterventionParticipants (Count of Participants)
Encapsulated Mesalamine Granules (eMG)280

[back to top]

Number of Participants With Clinically Significant Change From Baseline in Vital Signs

Vital signs included systolic and diastolic blood pressure, pulse rate, body temperature, or body weight. (NCT00326209)
Timeframe: Baseline, up to follow-up visit (Month 24.5)

InterventionParticipants (Count of Participants)
Encapsulated Mesalamine Granules (eMG)0

[back to top]

Improved Medication Compliance.

Not applicable : unable to measure secondary outcome because no one was enrolled in once a day dose arm. Therefore, no comparisons can be made to see if once a day dosing would have higher compliance than taking medication BID or TID (NCT00349388)
Timeframe: overall study

InterventionParticipants (Count of Participants)
Asacol Once a Day Dosing0
Asacol BID/TID Dosing1

[back to top]

Clinical Recurrence of Ulcerative Colitis (UC) During the Maintenance Phase at 6 Months

Clinical recurrence is defined as 4 or more bowel movements per day above the subject's normal frequency and associated with any of the following: urgency, abdominal pain, or rectal bleeding. (NCT00446849)
Timeframe: 6 months

Interventionparticipants (Number)
YesNoMissing
MMX Mesalamine (Maintenance Phase)4615011

[back to top]

Clinical Recurrence of UC During the Maintenance Phase at 12 Months

Clinical recurrence is defined as 4 or more bowel movements per day above the subject's normal frequency and associated with any of the following: urgency, abdominal pain, or rectal bleeding. (NCT00446849)
Timeframe: 12 Months

Interventionparticipants (Number)
YesNoMissing
MMX Mesalamine (Maintenance Phase)6912513

[back to top]

Clinical Recurrence of UC During the Maintenance Phase Associated With Subject Compliance at 6 Months

Clinical recurrence is defined as 4 or more bowel movements per day above the subject's normal frequency and associated with any of the following: urgency, abdominal pain, or rectal bleeding. Compliance is a subject's adherence to a recommended course of treatment and for this study is calculated: [(Sum of days' supplies dispensed) divided by (Sum of days in all refill intervals)] x 100. (NCT00446849)
Timeframe: 6 Months

InterventionPercent of participants (Number)
< 80% Compliant (n = 36)80-120% Compliant (n = 158)> 120% Compliant (n = 2)
MMX Mesalamine (Maintenance Phase)36.120.90

[back to top]

Quiescent UC During the Maintenance Phase at 12 Months

Quiescent UC is defined as scores of 0 for both rectal bleeding and bowel movements. Rectal bleeding is assessed on a scale from 0-3 (0 = no rectal bleeding, 1 = streaks of blood, 2 = obvious blood, 3 = mostly blood). Bowel movements are assessed on a scale of 0-2 (0 = 0-1 more than normal per day, 1 = 2-3 more than normal per day, 2 = 4 or more than normal per day). (NCT00446849)
Timeframe: 12 Months

InterventionParticipants (Number)
MMX Mesalamine (Maintenance Phase)101

[back to top]

Endoscopic Remission of UC During the Maintenance Phase at 12 Months

Endoscopic remission is defined as an endoscopy score of less than or equal to 1. Endoscopy score (mucosal appearance) ranges from 0-3 (0 = normal [intact vascular pattern; no friability or granulation], 1 = mild [erythema; decreased vascular pattern; minimal granularity], 2 = moderate [marked erythema; granularity; friability; absent vascular pattern; bleeding with minimal trauma; no ulcerations], 3 = severe [ulceration; spontaneous bleeding]. (NCT00446849)
Timeframe: 12 Months

InterventionParticipants (Number)
MMX Mesalamine (Maintenance Phase)124

[back to top]

Clinical Recurrence of UC During the Maintenance Phase Associated With Subject Compliance at 12 Months

Clinical recurrence is defined as 4 or more bowel movements per day above the subject's normal frequency and associated with any of the following: urgency, abdominal pain, or rectal bleeding. Compliance is a subject's adherence to a recommended course of treatment and for this study is calculated: (Sum of days' supplies dispensed) divided by (Sum of days in all refill intervals) x 100. (NCT00446849)
Timeframe: 12 months

InterventionPercent of participants (Number)
< 80% Compliant (n = 40)80-120% Compliant (n = 154)
MMX Mesalamine (Maintenance Phase)52.531.2

[back to top]

Number of Subjects Who Relapse/Flare Within 6 Months, ITT Population

Relapse/flare is defined as SCCAI >= 5. Simple Clinical Colitis Activity Index: minimum score 0, maximum score 19, reflects disease activity over the 24 hours prior to completion. Composite Score: bowel frequency (day, 0-3) (night, 0-2), defecation urgency (0-3), blood in stool (0-3), general well being (0-4), extracolonic features (arthritis, pyoderma gangrenosum, erythema nodosum, uveitis - 1 per manifestation). (NCT00505778)
Timeframe: 6 months

InterventionParticipants (Number)
Mesalamine Once-Daily45
Mesalamine Twice-Daily39

[back to top]

Percentage of Participants Indicating Ulcerative Colitis in Remission (Patient Defined Remission Index), ITT Population, Month 6

Is your ulcerative colitis in remission (not active)? Y/N (NCT00505778)
Timeframe: 6 months

InterventionPercentage of Participants (Number)
Mesalamine Once-Daily83.1
Mesalamine Twice-Daily86.6

[back to top]

Percentage of Patients Remaining in Remission at Month 12, ITT Population

Remission defined as SCCAI score < 5. Simple Clinical Colitis Activity Index: minimum score 0, maximum score 19, reflects disease activity over the 24 hours prior to completion. Composite Score: bowel frequency (day, 0-3) (night, 0-2), defecation urgency (0-3), blood in stool (0-3), general well being (0-4), extracolonic features (arthritis, pyoderma gangrenosum, erythema nodosum, uveitis - 1 per manifestation). (NCT00505778)
Timeframe: 12 months

InterventionPercentage of Participants (Number)
Mesalamine Once-Daily85.4
Mesalamine Twice-Daily85.4

[back to top]

Percentage of Patients Remaining in Remission at Month 3, ITT Population

Remission defined as SCCAI < 5. Simple Clinical Colitis Activity Index: minimum score 0, maximum score 19, reflects disease activity over the 24 hours prior to completion. Composite Score: bowel frequency (day, 0-3) (night, 0-2), defecation urgency (0-3), blood in stool (0-3), general well being (0-4), extracolonic features (arthritis, pyoderma gangrenosum, erythema nodosum, uveitis - 1 per manifestation). (NCT00505778)
Timeframe: 3 months

InterventionPercentage of Participants (Number)
Mesalamine Once-Daily94.8
Mesalamine Twice-Daily95.6

[back to top]

Percentage of Patients Remaining in Remission at Month 6, ITT Population, Determined by the Simple Clinical Colitis Activity Index (SCCAI)

Remission defined as SCCAI <5. Simple Clinical Colitis Activity Index: minimum score 0, maximum score 19, reflects disease activity over the 24 hours prior to completion. Composite Score: bowel frequency (day, 0-3) (night, 0-2), defecation urgency (0-3), blood in stool (0-3), general well being (0-4), extracolonic features (arthritis, pyoderma gangrenosum, erythema nodosum, uveitis - 1 per manifestation). (NCT00505778)
Timeframe: 6 months

InterventionPercentage of Participants (Number)
Mesalamine Once-Daily90.5
Mesalamine Twice-Daily91.8

[back to top]

Total MARS (Medication Adherence Report Scale) Questionnaire Scores, ITT Population, Month 6

MARS: Composite score for the following statements: I change how many times per day I take my medicine, I forget to use it, I stop taking it for a while, I only use it when I am having active symptoms, I decide to miss out on a dose, I take less than instructed, I take more than instructed, I avoid using it if I can, I use it regularly every day (reverse scored): 5-never, 4-rarely, 3-sometimes, 2-often, 1-very often. Minimum score 9, maximum score 45. (NCT00505778)
Timeframe: 6 months

InterventionMARS Score (Mean)
Mesalamine Once-Daily42.3
Mesalamine Twice-Daily41.8

[back to top]

Number of CT Scans Performed Within 7 Days of Suspected Recurrence of Diverticulitis That Were Positive

A positive CT scan was defined as a CT scan that showed bowel wall thickening (>5 mm) and/or fat stranding as read by the central reader. (NCT00545103)
Timeframe: up to 104 Weeks

,,,
InterventionNumber of CT Scans (Number)
PositivePresence of abdominal pain15% increase in WBC from baselineAbdominal pain + 15% increase in WBC
Placebo30291111
SPD476 (1.2 g)49482323
SPD476 (2.4 g)45392422
SPD476 (4.8 g)35341818

[back to top]

Number of CT Scans Performed Within 7 Days of Suspected Recurrence of Diverticulitis That Were Negative

A negative CT scan was defined as a CT scan that did not show bowel wall thickening (>5 mm) and/or fat stranding as read by the central reader. (NCT00545103)
Timeframe: up to 104 weeks

,,,
InterventionNumber of CT Scans (Number)
NegativePresence of abdominal pain15% increase in WBC from BaselineAbdominal pain + 15% increase in WBC
Placebo151243
SPD476 (1.2 g)9811
SPD476 (2.4 g)8622
SPD476 (4.8 g)221744

[back to top]

Number of CT Scans Performed More Than 7 Days From Suspected Recurrence of Diverticulitis That Were Positive

A positive CT scan was defined as a CT scan that showed bowel wall thickening (>5 mm) and/or fat stranding as read by the central reader. (NCT00545103)
Timeframe: up to 104 weeks

,,,
InterventionNumber of CT Scans (Number)
PositivePresence of abdominal pain15% increase in WBC from baselineAbdominal pain + 15% increase in WBC
Placebo1100
SPD476 (1.2 g)0000
SPD476 (2.4 g)0000
SPD476 (4.8 g)1000

[back to top]

Percent of Subjects Who Are CT-Recurrence Free of Diverticulitis

CT-recurrence of diverticulitis is defined as: a positive spiral CT scan for diverticulitis showing, at a minimum, fat stranding with or without bowel wall thickening >5 mm or surgical intervention for diverticular disease. Withdrawals considered as CT-recurrences. (NCT00545103)
Timeframe: up to 104 weeks

Interventionpercentage of subjects (Number)
SPD476 (1.2 g)62.8
SPD476 (2.4 g)59.2
SPD476 (4.8 g)69.1
Placebo66.9

[back to top]

Percent of Subjects Without Recurrence of Diverticulitis

Recurrence of diverticulitis is defined as the presence of each and all of the following 3 items: 1) abdominal pain, 2) a 15% increase in white blood cell count from baseline, 3) bowel wall thickening (>5 mm) and/or fat stranding as evidenced by spiral computerized axial tomography (CT) scan; OR surgical intervention for diverticular disease. Withdrawals are considered as recurrences. (NCT00545103)
Timeframe: up to 104 Weeks

Interventionpercentage of subjects (Number)
SPD476 (1.2 g)62.8
SPD476 (2.4 g)59.2
SPD476 (4.8 g)69.1
Placebo67.6

[back to top]

Percent of Subjects Requiring Surgery for Diverticulitis

(NCT00545103)
Timeframe: up to 104 Weeks

Interventionpercentage of subjects (Number)
SPD476 (1.2 g)4.7
SPD476 (2.4 g)2.7
SPD476 (4.8 g)2.0
Placebo1.4

[back to top]

Number of CT Scans Performed More Than 7 Days From Suspected Recurrence of Diverticulitis That Were Negative

A negative CT scan was defined as a CT scan that did not show bowel wall thickening (>5 mm) and/or fat stranding as read by the central reader. (NCT00545103)
Timeframe: up to 104 weeks

,,,
InterventionNumber of CT Scans (Number)
NegativePresence of abdominal pain15% increase in WBC from baselineAbdominal pain + 15% increase in WBC
Placebo0000
SPD476 (1.2 g)1100
SPD476 (2.4 g)0000
SPD476 (4.8 g)0000

[back to top]

Number of CT Scans Performed Within 7 Days of Suspected Recurrence of Diverticulitis That Were Positive

A positive CT scan was defined as a CT scan that showed bowel wall thickening (>5 mm) and/or fat stranding as read by the central reader. (NCT00545740)
Timeframe: Up to 104 weeks

,,,
InterventionNumber of CT scans (Number)
PositivePresence of abdominal pain15% increase in WBC from baselinePresence in abdominal pain + 15% increase in WBC
Placebo38372423
SPD476 (1.2 g)37301717
SPD476 (2.4 g)39392424
SPD476 (4.8 g)55542828

[back to top]

Number of CT Scans Performed Within 7 Days of Suspected Recurrence of Diverticulitis That Were Negative

A negative CT scan was defined as a CT scan that did not show bowel wall thickening (>5 mm) and/or fat stranding as read by the central reader. (NCT00545740)
Timeframe: Up to 104 weeks

,,,
InterventionNumber of CT scans (Number)
NegativePresence of abdominal pain15% increase in WBC from baselinePresence in abdominal pain + 15% increase in WBC
Placebo10711
SPD476 (1.2 g)191955
SPD476 (2.4 g)10822
SPD476 (4.8 g)5522

[back to top]

Number of CT Scans Performed More Than 7 Days From Suspected Recurrence of Diverticulitis That Were Positive

A positive CT scan was defined as a CT scan that showed bowel wall thickening (>5 mm) and/or fat stranding as read by the central reader. (NCT00545740)
Timeframe: Up to 104 weeks

,,,
InterventionNumber of CT scans (Number)
PositivePresence of abdominal pain15% increase in WBC from baselinePresence of abdominal pain + 15% increase in WBC
Placebo1100
SPD476 (1.2 g)0000
SPD476 (2.4 g)0000
SPD476 (4.8 g)1100

[back to top]

Number of CT Scans Performed More Than 7 Days From Suspected Recurrence of Diverticulitis That Were Negative

A negative CT scan was defined as a CT scan that did not show bowel wall thickening (>5 mm) and/or fat stranding as read by the central reader. (NCT00545740)
Timeframe: Up to 104 weeks

,,,
InterventionNumber of CT scans (Number)
NegativePresence of abdominal pain15% increase in WBC from baselinePresence of abdominal pain + 15% increase in WBC
Placebo3311
SPD476 (1.2 g)0000
SPD476 (2.4 g)3210
SPD476 (4.8 g)2200

[back to top]

Percent of Subjects Without Recurrence of Diverticulitis

Recurrence of diverticulitis is defined as the presence of each and all of the following 3 items: 1) abdominal pain, 2) a 15% increase in white blood cell count from baseline, 3) bowel wall thickening (>5 mm) and/or fat stranding as evidenced by spiral computerized axial tomography (CT) scan; OR surgical intervention for diverticular disease. Withdrawals are considered as recurrences. (NCT00545740)
Timeframe: Up to 104 weeks

Interventionpercentage of subjects (Number)
SPD476 (1.2 g)62.2
SPD476 (2.4 g)62.9
SPD476 (4.8 g)52.7
Placebo64.6

[back to top]

Percent of Subjects Who Were CT-Recurrence Free of Diverticulitis

CT-recurrence of diverticulitis is defined as: a positive spiral CT scan for diverticulitis showing, at a minimum, fat stranding with or without bowel wall thickening >5 mm or surgical intervention for diverticular disease. Withdrawals considered as CT-recurrences. (NCT00545740)
Timeframe: Up to 104 weeks

Interventionpercentage of subjects (Number)
SPD476 (1.2 g)61.5
SPD476 (2.4 g)62.2
SPD476 (4.8 g)52.7
Placebo63.9

[back to top]

Percent of Subjects Requiring Surgery for Diverticulitis

(NCT00545740)
Timeframe: Up to 104 weeks

Interventionpercentage of subjects (Number)
SPD476 (1.2 g)2.8
SPD476 (2.4 g)2.8
SPD476 (4.8 g)3.3
Placebo2.0

[back to top]

Change in GSS From Baseline to Week 52 - ITT Population

GSS - Abdominal Pain & Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse). (NCT00554099)
Timeframe: Baseline to Week 52

InterventionScores on a Scale (Mean)
Placebo-16.82
Mesalamine-17.30
Mesalamine & Probiotic-16.00

[back to top]

Percentage of Responders at Week 52 - ITT Population

Responder - patient whose GSS scores for all symptoms were either 0 or 1 GSS - Abdominal Pain & Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse). (NCT00554099)
Timeframe: 52 Weeks

InterventionPercentage of Participants (Number)
Placebo50.0
Mesalamine66.7
Mesalamine & Probiotic29.2

[back to top]

Global Symptom Score (GSS) at Week 12, Primary Efficacy Population

GSS - Abdominal Pain & Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse). (NCT00554099)
Timeframe: 12 Weeks

InterventionScores on a Scale (Mean)
Placebo7.3
Mesalamine4.4
Mesalamine & Probiotic5.9

[back to top]

Percentage of Responders at Week 12 - ITT Population

Responder - patient whose GSS scores for all symptoms were either 0 or 1 GSS - Abdominal Pain & Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse). (NCT00554099)
Timeframe: 12 Weeks

InterventionPercentage of Participants (Number)
Placebo41.4
Mesalamine62.5
Mesalamine & Probiotic48.1

[back to top]

Recurrent Diverticulitis, Percentage, ITT Population, Week 12

At least one report of recurrent diverticulitis since the last visit (prior to the Week 12 visit). (NCT00554099)
Timeframe: 12 Weeks

InterventionPercentage of Participants (Number)
Placebo20.0
Mesalamine12.5
Mesalamine & Probiotic11.8

[back to top]

Withdrawal Due to Surgery for Diverticulitis, Percentage, ITT Population, Week 12

(NCT00554099)
Timeframe: 12 Weeks

InterventionPercentage of Participants (Number)
Placebo2.4
Mesalamine5.0
Mesalamine & Probiotic0.0

[back to top]

Recurrent Diverticulitis, Percentage, ITT Population, Week 52

At least one report of recurrent diverticulitis since the last visit (prior to the Week 52 visit). (NCT00554099)
Timeframe: 52 Weeks

InterventionPercentage of Participants (Number)
Placebo31.0
Mesalamine28.1
Mesalamine & Probiotic37.0

[back to top]

Change in GSS From Baseline to Week 12 - ITT Population

GSS - Abdominal Pain & Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse). (NCT00554099)
Timeframe: Baseline to Week 12

InterventionScores on a Scale (Mean)
Placebo-16.14
Mesalamine-17.63
Mesalamine & Probiotic-16.11

[back to top]

Rectal Bleeding Improvement at Week 6, All Randomized Patients (Percentage)

0-no blood seen, 1- streaks of blood with stool less than half of the time, 2- obvious blood with stool most of the time, 3- blood alone passed. Scoring Scale: 0-good thru 3-worse. (NCT00577473)
Timeframe: Week 6

InterventionPercentage of Participants (Number)
Asacol 2.4 g/Day60.2
Asacol 4.8 g/Day71.5

[back to top]

Rectal Bleeding Improvement at Week 3, All Randomized Patients (Percentage)

0: no blood seen, 1: streaks of blood with stool less than half of the time, 2: obvious blood with stool most of the time, 3: blood alone passed, Scoring Scale: 0-good thru 3-worse. (NCT00577473)
Timeframe: Week 3

InterventionPercentage of Participants (Number)
Asacol 2.4 g/Day48.1
Asacol 4.8 g/Day59.1

[back to top]

Physician's Global Assessment (PGA) Percentage of Patients Improved at Week 6, All Randomized Patients

PGA - 0-quiescent disease activity (all 0's) , 1-mild (mostly 1's), 2-moderate (mostly 2's), 3-severe (mostly 3's) based upon on scoring for stool frequency, rectal bleeding, PFR (patient's functional assessment - 0-well, 1-fair, 2-poor, 3-terrible), sigmoidoscopy findings. Improvement defined as complete response (remission, score = 0) or partial response (improvement on treatment). Scoring Scale: 0-good thru 3-worse. (NCT00577473)
Timeframe: Week 6

InterventionPercentage of Participants (Number)
Asacol 2.4 g/Day61.4
Asacol 4.8 g/Day64.8

[back to top]

Physician's Global Assessment (PGA) Percentage of Patients Improved at Week 3, All Randomized Patients

PGA - 0-quiescent disease activity (all 0's) , 1-mild (mostly 1's), 2-moderate (mostly 2's), 3-severe (mostly 3's) based upon on scoring for stool frequency, rectal bleeding, PFR (patient's functional assessment - 0-well, 1-fair, 2-poor, 3-terrible), sigmoidoscopy findings. Improvement defined as either complete response (remission, score = 0) or partial response (improvement on treatment). Scoring Scale: 0-good thru 3-worse. (NCT00577473)
Timeframe: Week 3

InterventionPercentage of Participants (Number)
Asacol 2.4 g/Day49.3
Asacol 4.8 g/Day44.8

[back to top]

Percentage of Patients Classified as Treatment Success at Week 6, ITT Population

Treatment Success - complete or partial response; Complete = complete resolution of clinical assessments (stool frequency, rectal bleeding, PFA [patient's functional assessment], sigmoidoscopy) and PGA (physician global assessment) = 0, Partial = improvement from baseline PGA score and improvement in at least 1 of the clinical assessments [decrease of at least 1 on scale] and no worsening [no score increases] of remaining clinical assessments. Each clinical assessment graded using scale 0/normal, better thru 3/severe, worse. (NCT00577473)
Timeframe: 6 weeks

InterventionPercentage of Participants (Number)
Asacol 2.4 g/Day51.3
Asacol 4.8 g/Day55.9

[back to top]

Improvement in Patient's Sigmoidoscopy Assessment Score at Week 6, All Randomized Patients (Percentage)

0-normal (intact vascular pattern, no friability or granularity), 1-mild (erythema; diminished or absent vascular markings; mild granularity; friability), 2-moderate (marked erythema, granularity; absent vascular markings; bleeds with minimal trauma; no ulcerations), 3-severe (spontaneous bleeding, ulcerations). Scoring Scale: 0-good thru 3-worse. (NCT00577473)
Timeframe: Week 6

InterventionPercentage of Participants (Number)
Asacol 2.4 g/Day66.7
Asacol 4.8 g/Day73.2

[back to top]

Percentage of Patients Classified as Treatment Success at Week 3, ITT Population

Treatment Success - complete or partial response; Complete = complete resolution of clinical assessments (stool frequency, rectal bleeding, PFA [patient's functional assessment], sigmoidoscopy) and PGA (physician global assessment) = 0, Partial = improvement from baseline PGA score and improvement in at least 1 of the clinical assessments [decrease of at least 1 on scale] and no worsening [no score increases] of remaining clinical assessments. Each clinical assessment graded using scale 0/normal, better thru 3/severe, worse. (NCT00577473)
Timeframe: 3 weeks

InterventionPercentage of Participants (Number)
Asacol 2.4 g/Day42.0
Asacol 4.8 g/Day38.7

[back to top]

Improvement in Patient's Sigmoidoscopy Assessment Score at Week 3, All Randomized Patients (Percentage)

0-normal (intact vascular pattern, no friability or granularity), 1-mild (erythema; diminished or absent vascular markings; mild granularity; friability), 2-moderate (marked erythema, granularity; absent vascular markings; bleeds with minimal trauma; no ulcerations), 3-severe (spontaneous bleeding, ulcerations). Scoring Scale: 0-good thru 3-worse. (NCT00577473)
Timeframe: Week 3

InterventionPercentage of Participants (Number)
Asacol 2.4 g/Day51.5
Asacol 4.8 g/Day52.0

[back to top]

Improvement in Patient's Functional Assessment (PFA) at Week 6, All Randomized Patients (Percentage)

0-generally well, 1-fair, 2-poor, 3-terrible (NCT00577473)
Timeframe: Week 6

InterventionPercentage of Participants (Number)
Asacol 2.4 g/Day54.1
Asacol 4.8 g/Day60.7

[back to top]

Improvement in Patient's Functional Assessment (PFA) at Week 3, All Randomized Patients (Percentage)

0-generally well, 1-fair, 2-poor, 3-terrible (NCT00577473)
Timeframe: Week 3

InterventionPercentage of Participants (Number)
Asacol 2.4 g/Day42.2
Asacol 4.8 g/Day49.6

[back to top]

Stool Frequency Improvement at Week 6, All Randomized Patients (Percentage)

0: normal stool frequency per day, 1: 1-2 stools greater than normal per day, 2: 3-4 stools greater than normal per day, 3: 5 or more stools greater than normal per day, Scoring Scale: 0-good thru 3-worse. (NCT00577473)
Timeframe: Week 6

InterventionPercentage of Participants (Number)
Asacol 2.4 g/Day63.2
Asacol 4.8 g/Day66.7

[back to top]

Stool Frequency Improvement at Week 3, All Randomized Patients (Percentage)

0: normal stool frequency per day, 1: 1-2 stools greater than normal per day, 2: 3-4 stools greater than normal per day, 3: 5 or more stools greater than normal per day, Scoring Scale: 0-good thru 3-worse. (NCT00577473)
Timeframe: Week 3

InterventionPercentage of Participants (Number)
Asacol 2.4 g/Day46.7
Asacol 4.8 g/Day54.3

[back to top]

Active Phase: Proportion of Active Subjects Achieving Overall Improvement

"Overall improvement is defined as either a complete remission or a clinical response to therapy as measured by the Ulcerative Colitis Disease Activity Index (UCDAI).~Complete remission is defined as: i) a score of 0 or 1 for stool frequency; ii) a score of 0 for rectal bleeding; iii) a score of 0 for endoscopy findings and iv) a Physician's Global Assessment (PGA) score of 0 or 1.~A clinical response to therapy in the active disease phase is defined as i) improvement in the baseline PGA score; ii) improvement in endoscopy findings and in at least one other clinical assessment (stool frequency, rectal bleeding); iii) no worsening in any other clinical assessment; iv) a decrease of 2 or more points on the UCDAI score." (NCT00603733)
Timeframe: From baseline to week 8

Interventionpercentage of participants (Number)
Pentasa® Modified Extended Release64.1
Pentasa®69.2

[back to top]

Frequency of Adverse Events

Safety dataset represents all patients in all study phases exposed to study drug at anytime during study. Safety dataset was a combination of the active, run-in and maintenance phases and therefore it is not possible to report the adverse events per phase. (NCT00603733)
Timeframe: From baseline to week 24

Interventionpercentage of patients with TEAEs (Number)
Pentasa® Modified Extended Release52.4
Pentasa®45.1

[back to top]

Maintenance Phase: Proportion of Subjects Experiencing Relapse

Relapse is defined as a UCDAI score of at least 3 and a score of at least 1 for endoscopy (NCT00603733)
Timeframe: Up to week 24

Intervention% of subjects with relapse (90% CI) (Number)
Pentasa® Modified Extended Release24.6
Pentasa®11.8

[back to top]

Fecal Calprotectin <200 µg/g

(NCT00652145)
Timeframe: at 6 weeks after randomization

Interventionparticipants (Number)
Increase Dose of Mesalamine10
Maintain Baseline Mesalamine Dose2

[back to top]

Fecal Calprotectin Level <100 µg/g

(NCT00652145)
Timeframe: at 6 weeks after randomization

Interventionparticipants (Number)
Increase Dose of Mesalamine10
Maintain Baseline Mesalamine Dose3

[back to top]

Fecal Calprotectin Level <50µg/g

(NCT00652145)
Timeframe: 6 weeks after randomization

Interventionparticipants (Number)
Increase Mesalamine Dose by 2.4g/Day7
Maintain Mesalmine Dose1

[back to top]

Treatment Success PUCAI Amended Endpoint (5 Point Scale Abdominal Pain), mITT

PUCAI 0-85, abdominal pain amended (no pain/0, very mild/2.5, mild/5, moderate/7.5, severe/10), rectal bleeding (none/0, small <50% stool/10, small with most stools/20, large >50% stool/30), stool consistency (formed/0, partially/5, unformed/10), # per 24 hrs (0-2/0, 3-5/5, 6-8/10, >8/15), nocturnal bowel movements (no/0, yes/10), activity level (no limitation/0, occasional limitation/5, severely restricted/10) Remission <10, Mild 10-34, Moderate 35-64, Severe 65-85, Success score<10 at Wk 6 (complete) or reduction of >=20 points baseline to Wk 6 with Wk 6 score>=10 (partial) (NCT00713310)
Timeframe: Baseline and Week 6

Intervention% participants with treatment success (Number)
Low Dose56.1
High Dose57.5

[back to top]

Treatment Success PUCAI (Pediatric Ulcerative Colitis Activity Index), mITT/Modified Intent to Treat Population

PUCAI 0-85, abdominal pain (no pain/0, pain ignored/5, pain not ignored/10), rectal bleeding (none/0, small <50% stool/10, small with most stools/20, large >50% stool/30), stool consistency (formed/0, partially/5, unformed/10), # per 24 hrs (0-2/0, 3-5/5, 6-8/10, >8/15), nocturnal bowel movements (no/0, yes/10), activity level (no limitation/0, occasional limitation/5, severely restricted/10) Remission <10, Mild 10-34, Moderate 35-64, Severe 65-85, Success score<10 at Wk 6 (complete) or reduction of >=20 points baseline to Wk 6 with Wk 6 score>=10 (partial) (NCT00713310)
Timeframe: Baseline and 6 weeks

Intervention% participants with treatment success (Number)
Low Dose56.1
High Dose55.0

[back to top]

AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)

AUC0-t results for N-Acetylmesalamine metabolite (NCT00840203)
Timeframe: Blood samples collected over 48 hour period

Interventionng*h/mL (Mean)
Mesalamine40873.915
Rowasa®42644.677

[back to top]

Cmax - Maximum Observed Concentration

Bioequivalence based on Cmax (NCT00840203)
Timeframe: Blood samples collected over 48 hour period

Interventionng/mL (Mean)
Mesalamine1451.739
Rowasa®1500.290

[back to top]

Cmax - Maximum Observed Concentration

Cmax results for N-Acetylmesalamine metabolite (NCT00840203)
Timeframe: Blood samples collected over 48 hour period

Interventionng/mL (Mean)
Mesalamine2274.652
Rowasa®2284.884

[back to top]

AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)

Bioequivalence based on AUC0-t (NCT00840203)
Timeframe: Blood samples collected over 48 hour period

Interventionng*h/mL (Mean)
Mesalamine21543.597
Rowasa®22911.830

[back to top]

AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)

Bioequivalence based on AUC0-inf (NCT00840203)
Timeframe: Blood samples collected over 48 hour period

Interventionng*h/mL (Mean)
Mesalamine24458.932
Rowasa®26862.895

[back to top]

AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)

AUC0-inf results for N-Acetylmesalamine metabolite (NCT00840203)
Timeframe: Blood samples collected over 48 hour period

Interventionng*h/mL (Mean)
Mesalamine46564.373
Rowasa®49692.278

[back to top]

Percentage of Crohn's Disease Activity Index (CDAI) Responders at Week 10.

The Crohn's Disease Activity Index (CDAI) is a composite score to quantify symptoms of Crohn's disease. It has a range of 0-600; higher scores are worse. A responder is defined as a participant who achieved a reduction in the CDAI score to <150 or a decrease in CDAI score of at least 70. (NCT00862121)
Timeframe: At Week 10, end of treatment

Interventionpercentage of participants (Number)
Mesalazine43
Placebo55

[back to top]

Relative Change From Baseline to Each Visit in Inflammatory Bowel Disease Questionnaire (IBDQ) Score

The IBDQ is a measure of the impact of inflammatory bowel disease (IBD) on health-related quality-of-life (HRQL; mood, social activities, daily life, and IBD-related health worries). Higher scores are better; Total IBDQ score can range from 32 (very poor HRQL) to 224 (perfect HRQL). (NCT00862121)
Timeframe: Within the 10 week treatment period

,
InterventionIBDQ score (Mean)
BaselineWeek 10
Mesalazine138.57164
Placebo130.27121.88

[back to top]

Relative Change From Baseline to Week 10 in Fecal Calprotectin

Fecal calprotectin is an inflammatory marker for the gastrointestinal tract. Higher values indicate more serious inflammation. (NCT00862121)
Timeframe: At Week 10, end of treatment

,
Interventionmicrogram/gram faeces (Mean)
BaselineWeek 10
Mesalazine244.5181.57
Placebo3621180.17

[back to top]

Relative Change From Baseline to Week 10 in Estimated Creatinine Clearance

A lower creatinine clearance indicates worsening of renal function. Creatinine clearance was estimated from serum creatinine levels, using the Cockcroft-Gault formula. (NCT00862121)
Timeframe: At Week 10, end of treatment

,
InterventionmL/min (Mean)
BaselineWeek 10
Mesalazine122.63124
Placebo102.55105.11

[back to top]

Relative Change From Baseline to Each Visit in Work Productivity & Activity Impairment Questionnaire (WPAI_CD) Score Item 5 (Work Productivity)

The WPAI_CD Item 5 measures the impact of Crohn's disease on work productivity (while working). The score is recorded by the patient on a visual analog scale, from 0 to 10. Lower scores are better, while higher scores indicate greater negative effect on work productivity. (NCT00862121)
Timeframe: Within the 10 week treatment period

,
InterventionWPAI_CD Item 5 score (Mean)
BaselineWeek 10
Mesalazine4.171.83
Placebo54.4

[back to top]

Relative Change From Baseline to Each Visit in Serum C-reactive Protein (CRP)

Serum CRP is a laboratory measure of acute inflammation. Higher values are worse. (NCT00862121)
Timeframe: Within the 10 week treatment period

,
Interventionmg/L (Mean)
BaselineWeek 10
Mesalazine8.237.76
Placebo10.259.48

[back to top]

Number of Participants Achieving Treatment Response

"Response was defined as a minimum decrease from baseline in total Mayo score of 3 points and 30% up to and including 4 weeks after the start of treatment. The Mayo score consists of the following 4 subscores: stool frequency; rectal bleeding; endoscopy results; physician's global assessment. Each subscore~is rated on a scale from 0 (best) to 3 (worst). The total Mayo score is calculated as the sum of the 4 subscores and ranges from 0 (best) to 12 (worst)." (NCT00984568)
Timeframe: Up to Week 4

InterventionParticipants (Number)
Top-Hold10
Step-Up10

[back to top]

Number of Participants With Response at Week 4 and Steroid-Free Remission at Week 50

Response at Week 4 was defined as a minimum decrease from baseline in Mayo score of 3 points and 30%. Steroid-free remission at Week 50 was defined as a total Mayo score (including endoscopic assessment) of 2 points or lower and no individual subscore exceeding 1. The Mayo score consists of the following 4 subscores: stool frequency; rectal bleeding; endoscopy results; physician's global assessment. Each subscore is rated on a scale from 0 (best) to 3 (worst). The total Mayo score is calculated as the sum of the 4 subscores and ranges from 0 (best) to 12 (worst). (NCT00984568)
Timeframe: Week 50

InterventionParticipants (Number)
Top-Hold5
Step-Up5

[back to top]

Treatment Success PUCAI (Pediatric Ulcerative Colitis Activity Index), mITT/Modified Intent to Treat Population

PUCAI Score (0-85, sum of scores for each): abdominal pain (0/5/10 - no pain/ignored/not ignored), rectal bleeding (0/10/20/30 - none, small amount <50% of stools, small amount most stools, large amount >50%), stool consistency (0/5/10 - formed, partially formed, completely formed), # stools/24 hrs. (0/5/10/15 - 0-2/3-5/6-8/>8), nocturnal bowel/any diarrhea causing wakening (0/10 - no/yes), activity level (0/5/10 - no limitation/occ limitation, severe restrictions). Remission <10, Mild 10-34, Moderate 35-64, Severe 65-85. Remission defined as Treatment Success. (NCT01004185)
Timeframe: Week 26

Interventionpercentage of participants (Number)
High Dose53.3
Low Dose60

[back to top]

Treatment Success PUCAI Amended Endpoint (5 Point Scale Abdominal Pain), mITT

PUCAI Score (0-85, sum of scores for each) abdominal pain (0/2.5/5/7.5/10 - no pain/very mild/mild/moderate/severe), rectal bleeding (0/10/20/30 - none, small amount <50% of stools, small amount most stools, large amount >50%), stool consistency (0/5/10 - formed, partially formed, completely formed), # stools/24 hrs. (0/5/10/15 - 0-2/3-5/6-8/>8), nocturnal bowel/any diarrhea causing wakening (0/10 - no/yes), activity level (0/5/10 - no limitation/occ limitation, severe restrictions). Remission <10, Mild 10-34, Moderate 35-64, Severe 65-85. Remission is Treatment Success. (NCT01004185)
Timeframe: Week 26

Interventionpercentage of participants (Number)
High Dose60
Low Dose60

[back to top]

Percentage of Participants Who Were Responders at Week 3

Participants considered as responders if they had total Mayo DAI score less than 3 points and no individual sub-scores greater than or equal to 2. Mayo DAI is a semi-quantitative scale which consists of 4 sub-scales: stool frequency, rectal bleeding, findings of flexible proctosigmoidoscopy or colonoscopy and physician global assessment, each sub-scale ranged from 0 to 3 (0=normal, 3=severe). The total Mayo DAI score ranges from 0 (normal or inactive disease) to 12 (severe disease). (NCT01016262)
Timeframe: Week 3

Interventionpercentage of participants (Number)
MAX-002 (Double-blind Phase)36.6
Canasa® (Double-blind Phase)38.5
Placebo (Double-blind Phase)12.8

[back to top]

Percentage of Participants Who Were Responders at Week 6

Participants were considered as responders if they had total Mayo Disease Activity Index (DAI) score less than 3 points and no individual sub-scores greater than or equal to 2. Mayo DAI is a semi-quantitative scale which consists of 4 sub-scales: stool frequency, rectal bleeding, findings of flexible proctosigmoidoscopy or colonoscopy and physician global assessment, each sub-scale ranged from 0 to 3 (0=normal, 3=severe). The total Mayo DAI score ranges from 0 (normal or inactive disease) to 12 (severe disease). (NCT01016262)
Timeframe: Week 6

Interventionpercentage of participants (Number)
MAX-002 (Double-blind Phase)56.1
Canasa® (Double-blind Phase)46.2
Placebo (Double-blind Phase)23.1

[back to top]

Time to Relief of Rectal Bleeding

Time to relief of rectal bleeding was defined as number of days from randomization (Day 1) up to the first date of 3 consecutive days without observation of rectal bleeding during the double-blind phase. (NCT01016262)
Timeframe: Day 1 up to Week 6

Interventiondays (Median)
MAX-002 (Double-blind Phase)6
Canasa® (Double-blind Phase)5
Placebo (Double-blind Phase)21

[back to top]

Time to Relief of Tenesmus

Time to relief of tenesmus (feeling of constantly needing to pass stools, even if the bowels are already empty) was defined as the number of days from randomization (Day 1) up to the first date of 3 consecutive days without observation of tenesmus during the double-blind phase. (NCT01016262)
Timeframe: Day 1 up to Week 6

Interventiondays (Median)
MAX-002 (Double-blind Phase)3
Canasa® (Double-blind Phase)2
Placebo (Double-blind Phase)1

[back to top]

Change From Baseline in Total Inflammatory Bowel Disease Questionnaire (IBDQ) Score at Week 6

The IBDQ is used to measure disease specific quality of life. The IBDQ consists of a self-administered 32-item questionnaire that evaluates quality of life across 4 domains of wellness: bowel symptoms (10 questions), systemic symptoms (5 questions), social symptoms (5 questions) and emotional function (12 questions). The response to each question is graded on 7-point likert scale, ranging from 1 (worst aspect) to 7 (best aspect). The total IBDQ is computed as the sum of the responses to the individual IBDQ questions. The total score ranges from 32 to 224 with higher scores indicating a better quality of life. (NCT01016262)
Timeframe: Baseline, Week 6

,,
Interventionunits on a scale (Mean)
Baseline (n= 41, 39, 39)Change at Week 6 (n= 41, 39, 31)
Canasa® (Double-blind Phase)153.1942.42
MAX-002 (Double-blind Phase)153.4530.59
Placebo (Double-blind Phase)149.1824.48

[back to top]

Changes in Bronchoalveolar Lavage (BAL) Tumor Necrosis Factor Alpha (TNFa)

Secondary outcomes include changes in bronchoalveolar lavage (BAL) tumor necrosis factor alpha (TNFa) (NCT01088243)
Timeframe: baseline and week 6

Interventionpg/ml (Mean)
Mesalamine62
Placebo-1750

[back to top]

Lung Function

Secondary outcomes include changes in lung function, which will be assessed with Forced expiratory volume in 1 second percent predicted (FEV1), Forced vital capacity percent predicted (FVC) and Diffusing capacity percent predicted (DLCO). (NCT01088243)
Timeframe: baseline and week 6

,
Interventionpercentage of predicted value (Mean)
FEV1 % predFVC % predDLCO % pred
Mesalamine2.21.62.4
Placebo-0.91-0.08-0.16

[back to top]

Change in Beryllium Lymphocyte Proliferation Responses (BeLPT) From Baseline to Week 6

"Primary endpoints are beryllium proliferation responses (BeLPT) in PBMCs (peripheral blood mononuclear cells) and BAL (bronchoalveolar lavage) cells. The BeLPT is a blood test that measures the immune response to beryllium exposure. If immune cells multiply in response to beryllium, this is considered an abnormal test results. If immune cells do not multiple, this is considered a normal test results. Results are reported as stimulation index, which is a ratio of the number of cells grown with beryllium compared to the number of cells grown without beryllium. A value of 2.5 or less is considered normal, and a value greater than 2.5 is abnormal." (NCT01088243)
Timeframe: baseline and week 6

,
InterventionStimulation index (Mean)
BALPBMC
Mesalamine48.6122.07
Placebo9.333.8

[back to top]

Changes in Steady-state Glutathione (GSH) Levels From Baseline to Week 6

Secondary outcomes include changes in steady-state GSH levels in beryllium specific CD4+ T cell in bronchoalveolar lavage fluid (BALF) (NCT01088243)
Timeframe: baseline and week 6

Interventionmmol/mg (Mean)
Mesalamine4.93
Placebo10.38

[back to top]

Log(10) Change in % Activated (CD38+HLA-DR+)CD8+ T Cells During the First 12 Weeks of Study

(NCT01090102)
Timeframe: Week 0, Week 12

InterventionLog10(percentage of T cells) (Mean)
Mesalamine Then Placebo0.03
Placebo Then Mesalamine-0.01

[back to top]

Log(10) Change in % Activated (CD38+HLA-DR+)CD8+ T Cells After Treatment Crossover

Log(10) change in the percentage of activated T cells during the second 12 weeks of the study (NCT01090102)
Timeframe: Week 12, Week 24

InterventionLog10(percentage of T cells) (Mean)
Mesalamine Then Placebo0.003
Placebo Then Mesalamine-0.03

[back to top]

Percentage of Subjects in Complete Remission at Month 12 of Maintenance Phase

Complete remission was defined as a modified Ulcerative Colitis Disease Activity Index (UC-DAI) <=1 with a score of 0 for rectal bleeding and stool frequency and at least a 1-point reduction in endoscopy score from baseline. The modified UC-DAI score is the sum of the scores of 4 parameters (stool frequency, rectal bleeding, endoscopy score, and physician global assessment), each scoring between 0 and 3, making 12 the worst score. Endoscopy score (mucosal appearance) ranges from 0-3 (0 = normal, 1 = mild , 2 = moderate, 3 = severe). Rectal bleeding is assessed on a scale from 0-3 (0 = no rectal bleeding, 1 = streaks of blood, 2 = obvious blood, 3 = mostly blood). Stool frequency is assessed on a scale of 0-2 (0 = 0-1 more than normal per day, 1 = 2-3 more than normal per day, 2 = 4 or more than normal per day). (NCT01124149)
Timeframe: 12 months

Interventionpercentage of subjects (Number)
MMX Mesalamine/ Mesalazine (Complete Remission Acute Phase)47.8
MMX Mesalamine/ Mesalazine (Partial Remission Acute Phase)26.0

[back to top]

Percentage of Subjects in Partial Remission at Week 8 of Acute Phase

Partial remission was defined as a modified UC-DAI <=3 with a combined stool frequency and rectal bleeding score of <=1 and not in complete remission. The modified UC-DAI score is the sum of the scores of 4 parameters (stool frequency, rectal bleeding, endoscopy score, and physician global assessment), each scoring between 0 and 3, making 12 the worst score. Endoscopy score (mucosal appearance) ranges from 0-3 (0 = normal, 1 = mild , 2 = moderate, 3 = severe). Rectal bleeding is assessed on a scale from 0-3 (0 = no rectal bleeding, 1 = streaks of blood, 2 = obvious blood, 3 = mostly blood). Stool frequency is assessed on a scale of 0-2 (0 = 0-1 more than normal per day, 1 = 2-3 more than normal per day, 2 = 4 or more than normal per day). (NCT01124149)
Timeframe: 8 weeks

Interventionpercentage of subjects (Number)
MMX Mesalamine/ Mesalazine39.3

[back to top]

Percentage of Subjects in Clinical Remission at Month 12 of Maintenance Phase

Clinical remission was defined as a score of 0 for rectal bleeding and stool frequency. Rectal bleeding is assessed on a scale from 0-3 (0 = no rectal bleeding, 1 = streaks of blood, 2 = obvious blood, 3 = mostly blood). Stool frequency is assessed on a scale of 0-2 (0 = 0-1 more than normal per day, 1 = 2-3 more than normal per day, 2 = 4 or more than normal per day). (NCT01124149)
Timeframe: 12 months

Interventionpercentage of subjects (Number)
MMX Mesalamine/ Mesalazine (Complete Remission Acute Phase)58.8
MMX Mesalamine/ Mesalazine (Partial Remission Acute Phase)40.4

[back to top]

Percentage of Subjects in Complete Remission at Week 8 of Acute Phase

Complete (clinical and endoscopic) remission was defined as a modified UC-DAI <=1 with a score of 0 for rectal bleeding and stool frequency and at least a 1-point reduction in endoscopy score from baseline. The modified UC-DAI score is the sum of the scores of 4 parameters (stool frequency, rectal bleeding, endoscopy score, and physician global assessment), each scoring between 0 and 3, making 12 the worst score. Endoscopy score (mucosal appearance) ranges from 0-3 (0 = normal, 1 = mild , 2 = moderate, 3 = severe). Rectal bleeding is assessed on a scale from 0-3 (0 = no rectal bleeding, 1 = streaks of blood, 2 = obvious blood, 3 = mostly blood). Stool frequency is assessed on a scale of 0-2 (0 = 0-1 more than normal per day, 1 = 2-3 more than normal per day, 2 = 4 or more than normal per day). (NCT01124149)
Timeframe: 8 Weeks

Interventionpercentage of subjects (Number)
MMX Mesalamine/ Mesalazine25.9

[back to top]

Relapse in Ulcerative Colitis at Month 12 of Maintenance Phase

Relapse was defined in the Maintenance Phase as the need for alternative treatment for UC (including surgery); subjects were classified as having a relapse if they had withdrawn from the study due to a lack of efficacy. (NCT01124149)
Timeframe: 12 months

Interventionpercentage of subjects (Number)
MMX Mesalamine/ Mesalazine (Complete Remission Acute Phase)6.0
MMX Mesalamine/ Mesalazine (Partial Remission Acute Phase)10.5

[back to top]

Improvement in Rectal Bleeding Score During the Acute Phase

Improvement was defined as at least a 1-point reduction in the rectal bleeding score from baseline at each assessment point. Rectal bleeding is assessed on a scale from 0-3 (0 = no rectal bleeding, 1 = streaks of blood, 2 = obvious blood, 3 = mostly blood). (NCT01124149)
Timeframe: 3 and 8 weeks

Interventionpercentage of subjects (Number)
Week 3Week 8
MMX Mesalamine/ Mesalazine42.459.8

[back to top]

Improvement in Stool Frequency Symptoms During the Acute Phase

Improvement was defined as at least a 1-point reduction in the stool frequency score from baseline at each assessment point. Stool frequency is assessed on a scale of 0-2 (0 = 0-1 more than normal per day, 1 = 2-3 more than normal per day, 2 = 4 or more than normal per day). (NCT01124149)
Timeframe: 3 and 8 weeks

Interventionpercentage of subjects (Number)
3 Weeks8 Weeks
MMX Mesalamine/ Mesalazine38.558.9

[back to top]

Percentage of Subjects With Mucosal Healing at 12 Months of Maintenance Phase

Subjects with mucosal healing were defined as subjects who had an endoscopy score <=1. Endoscopy score (mucosal appearance) ranges from 0-3 (0 = normal, 1 = mild , 2 = moderate, 3 = severe). (NCT01124149)
Timeframe: 12 months

Interventionpercentage of subjects (Number)
MMX Mesalamine/ Mesalazine (Complete Remission Acute Phase)76.4
MMX Mesalamine/ Mesalazine (Partial Remission Acute Phase)63.5

[back to top]

CL of MMX Mesalamine Major Metabolite (Ac-5-ASA) at Steady State

(NCT01130844)
Timeframe: Over a 24-hour period starting on day 7

InterventionL/h (Mean)
MMX Mesalamine Metabolite (30mg/kg)16.2
MMX Mesalamine Metabolite (60 mg/kg)12.2
MMX Mesalamine Metabolite (100 mg/kg)10.0

[back to top]

Cmax of MMX Mesalamine Major Metabolite (Ac-5-ASA) at Steady State

(NCT01130844)
Timeframe: Over a 24-hour period starting on day 7

Interventionug/L (Mean)
MMX Mesalamine Metabolite (30mg/kg)2396
MMX Mesalamine Metabolite (60 mg/kg)4113
MMX Mesalamine Metabolite (100 mg/kg)4968

[back to top]

Cumulative Amount of MMX Mesalamine (5-ASA) Recovered in Urine at Steady State

(NCT01130844)
Timeframe: Over a 24-hour period starting on day 7

Interventionmg (Mean)
MMX Mesalamine (30mg/kg)162
MMX Mesalamine (60 mg/kg)298
MMX Mesalamine (100 mg/kg)235

[back to top]

Cumulative Amount of MMX Mesalamine Major Metabolite (Ac-5-ASA) Recovered in Urine at Steady State

(NCT01130844)
Timeframe: Over a 24-hour period starting on day 7

Interventionmg (Mean)
MMX Mesalamine Metabolite (30mg/kg)532
MMX Mesalamine Metabolite (60 mg/kg)708
MMX Mesalamine Metabolite (100 mg/kg)593

[back to top]

Maximum Plasma Concentration (Cmax) of MMX Mesalamine (5-ASA) at Steady State

Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated. (NCT01130844)
Timeframe: Over a 24-hour period starting on day 7

Interventionug/L (Mean)
MMX Mesalamine (30mg/kg)1884
MMX Mesalamine (60 mg/kg)3825
MMX Mesalamine (100 mg/kg)4314

[back to top]

Percentage of Dose Absorbed For MMX Mesalamine (5-ASA) in Urine at Steady State

The percentage of the dose absorbed was calculated as: 100 x (Xu0-24h 5-ASA + [0.7847* Xu0-24h Ac-5-ASA])/dose, where 0.7847 is the ratio of the molecular weight of 5-ASA (153.14) to the molecular weight of Ac-5-ASA (195.15). Xu0-24h is equal to the cumulative amount recovered in urine in the time interval of 0 to 24 hours. (NCT01130844)
Timeframe: Over a 24-hour period starting on day 7

Interventionpercentage of dose absorbed (Mean)
MMX Mesalamine (30mg/kg)29.4
MMX Mesalamine (60 mg/kg)27.0
MMX Mesalamine (100 mg/kg)22.1

[back to top]

Time to Maximum Plasma Concentration (Tmax) of MMX Mesalamine (5-ASA) at Steady State

Tmax is the time after administration of a drug when the maximum plasma concentration in the body is reached. (NCT01130844)
Timeframe: Over a 24-hour period starting on day 7

Interventionhours (Median)
MMX Mesalamine (30mg/kg)6.00
MMX Mesalamine (60 mg/kg)8.98
MMX Mesalamine (100 mg/kg)1.98

[back to top]

Tmax of MMX Mesalamine Major Metabolite (Ac-5-ASA) at Steady State

(NCT01130844)
Timeframe: Over a 24-hour period starting on day 7

Interventionhours (Median)
MMX Mesalamine Metabolite (30mg/kg)9.00
MMX Mesalamine Metabolite (60 mg/kg)7.48
MMX Mesalamine Metabolite (100 mg/kg)1.98

[back to top]

Total Body Clearance (CL) of MMX Mesalamine (5-ASA) at Steady State

Clearance of a substance from the blood by the kidneys. (NCT01130844)
Timeframe: Over a 24-hour period starting on day 7

InterventionL/h (Mean)
MMX Mesalamine (30mg/kg)6.48
MMX Mesalamine (60 mg/kg)5.94
MMX Mesalamine (100 mg/kg)4.95

[back to top]

Area Under the Plasma Concentration Versus Time Curve (AUC) of MMX Mesalamine (5-ASA) at Steady State

AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body. (NCT01130844)
Timeframe: 2, 4, 6, 9, 12, 16, and 24 hours post-dose on day 7

Interventionug*h/L (Mean)
MMX Mesalamine (30mg/kg)21411
MMX Mesalamine (60 mg/kg)46173
MMX Mesalamine (100 mg/kg)49213

[back to top]

AUC of MMX Mesalamine Major Metabolite (Ac-5-ASA) at Steady State

(NCT01130844)
Timeframe: 2, 4, 6, 9, 12, 16, and 24 hours post-dose on day 7

Interventionug*h/L (Mean)
MMX Mesalamine Metabolite (30mg/kg)30942
MMX Mesalamine Metabolite (60 mg/kg)58119
MMX Mesalamine Metabolite (100 mg/kg)63067

[back to top]

Proportion of Subjects Who Are Monthly Responders in Both Abdominal Pain and Stool Consistency for at Least 2 Months During the 3-month Treatment Period

A weekly responder in abdominal pain is defined as a ≥30% improvement from baseline in the weekly average abdominal pain score on a 10-point scale (0=no pain - 10= worst possible pain). A weekly responder in stool consistency is defined as ≥50% reduction in the number of days in a week with stool consistency of Type 6 or 7 compared with baseline using the Bristol Stool Scale. Monthly responders are subjects who are weekly responders in both abdominal pain and stool consistency for at least two out of four weeks. (NCT01177410)
Timeframe: 3 months

Interventionparticipants (Number)
Mesalamine Granules 1500 mg24
Mesalamine Granules 750 mg15
Placebo14

[back to top] [back to top]

Intestinal Permeability Testing

"Ability of test substances to permeate the intestinal mucosa. The Lactulose/Mannitol test (Genova Diagnostics®, Ashville, NC) directly measures the ability of mannitol and lactulose to permeate the intestinal mucosa. Patient ingests 5 grams of lactulose and 2 grams of mannitol dissolved in a 100 ml of water. Urine is then collected for 24 hours and the ratio of the urinary excretion of lactulose to mannitol is measured. This testing is performed only after completion of each treatment period , after 12 weeks of mesalamine and after 12 weeks of placebo.~Normal ratio of lactulose/mannitol is any value <0.7. An abnormal ratio is defined as >0.7 ratio. The lactulose is measured in the urine as g/kg and the urinary excretion of mannitol is also measures as g/kg." (NCT01327300)
Timeframe: At the completion of each 12-week treatment period, all of which are during the time period from 03/25/2010 to 02/01/2012 (up to 2 years)

Interventionratio (Mean)
Mesalamine0.07
Placebo0.04

[back to top]

Changes in GIS Scores Between Baseline and After a 12 Week Intervention With Mesalamine or Placebo

Patients rated the severity of their GI symptoms. The GIS scale goes from 1 to 7 with 1 being the worse and 7 as the best score showing improvement in symptoms. The GIS was performed at week one and at week 12 during each of the interventions. The comparisons below list the mean difference for each intervention from baseline (BL) with standard deviations then we list the p-value for the differences of baseline to intervention are reported using the Mann-Whitney test with a two-tailed p value provided. (NCT01327300)
Timeframe: Baseline and at 12 weeks post-intervention

Interventionunits on a scale (Mean)
Mesalamine2.72
Placebo2.22

[back to top]

Functional Bowel Disorder Severity Index (FBDSI)

Subjects rate pain on a standardized scale. This is a standardized test used to evaluate patients with IBS. Baseline values are compared to 12 weeks after mesalamine and 12 weeks after placebo treatments. The FBDSI is score is interpreted as such: Severity of IBS is rated as none (0 points), mild (1-36 points), moderate as 37-110 points and severe as >110 points. Therefore patients can have a score higher than 110. (NCT01327300)
Timeframe: An FBDSI score is administered at the beginning of each 12-week treatment period (baseline) and at the end of each 12-week treatment period.

Interventionunits on a scale (Mean)
Mesalamine-14.5
Placebo17

[back to top]

IBS - Quality of Life (IBS-QOL)Score.

A questionnaire is given to each patient and was completed at baseline then after 12 weeks of intervention with mesalamine and then placebo in the cross-over study. The IBS-QOL comprises 34 items with 5-point response scales (0 to 4) that cover eight dimensions of HRQL: dysphoria (8 items), interference with activity (7 items), body image (4 items), health worry (3 items),food avoidance (3 items), social reaction (4 items), sexual concerns (2 items) and relationships (3 items). Higher values indicate better HRQL after converting the raw score on the IBS-QOL into 0 to 100 points. (NCT01327300)
Timeframe: at the time of recruitment and after completion of each 12-week treatment period, all of which are during the time period from 03/25/2010 to 02/01/2012 (up to 2 years)

Interventionunits on a scale (Mean)
Mesalamine11
Placebo-12.2

[back to top]

Hospital Anxiety and Depression Scale (HADS)

"A questionnaire is given to each patient with scoring done on a Likert scale ranking from 0-42 which combines anxiety and depression scales. Each of these are scored from 0-21 depending on anxiety versus the depression parameters. Comparison of change in HADs after 12 weeks of intervention with either mesalamine or placebo is provided here with only the total value provided-range is from 0-42.~Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 3 with zero being none at all or occasional and 3 as most of the time. The scale used is a Likert scale and therefore the data returned from the HADS is ordinal.~The best score for the HADS therefore is a 0 with the worst score a 42 for combined anxiety and depression scores.~For the subscales of depression and anxiety, the best score is a 0 and the worst is a 21. This data is not provided here.~Data below includes the change from baseline in the HADS scores." (NCT01327300)
Timeframe: at the time of recruitment and after completion of each 12-week treatment period, all of which are during the time period from 03/25/2010 to 02/01/2012 (up to 2 years)

,
Interventionunits on a scale (Mean)
HADS score- change from baseline c/w 12 weeksHADS Score-end of 12 weeks
Mesalamine1.214
Placebo-2.413

[back to top]

Number of Participants Who Had Evidence of Increased Levels of Pathologic Indicators of Colonic Mucosal Inflammation at 12 Weeks Compared to Baseline.

"Colonoscopy/flexible sigmoidoscopy will be performed and mucosal biopsies will be obtained. Each biopsy was stained for activated t lymphocytes, mast cells and eosinophils .~CD117 staining was done for Mast cells. H and E staining was used to identify lymphocytes and eosinophils. Each path specimen was then noted to have increased versus normal number of these inflammatory cells." (NCT01327300)
Timeframe: For 2 times: First time: at the time of patient recruitment in the study Second time: after the completion of first 12-week treatment period, all of which are during the time period from 02/25/2010 to 02/01/2012 (up to 2 years)

,
Interventionparticipants (Number)
Increased Mast cells-CD 117 Positive stainingIncreased eosinophil countsIncreased Activated T lymphocytes-CD3
Mesalamine232
Placebo233

[back to top]

Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC 0→∞) of Ciprofloxacin XR

AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body. (NCT01402947)
Timeframe: Assessed over a 24-hour period starting post-dose on day 4

Interventionng*h/ml (Mean)
MMX Placebo + Ciprofloxacin7805
MMX Mesalazine/Mesalamine + Ciprofloxacin7934

[back to top]

Maximum Plasma Concentration (Cmax) of Ciprofloxacin XR

Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated. (NCT01402947)
Timeframe: Assessed over a 24-hour period starting post-dose on day 4

Interventionng/ml (Mean)
MMX Placebo + Ciprofloxacin1455
MMX Mesalazine/Mesalamine + Ciprofloxacin1433

[back to top]

Change in Average Bowel Consistency Score After an 8 Week Treatment Period.

Measured using the Bristol Stool form scale 1-7, with 1 being the most formed and 7 the least formed. (NCT01412372)
Timeframe: Baseline and 8 weeks

Interventionscore on a scale (Mean)
Placebo-0.5
Mesalamine-0.8

[back to top]

Change in Average Overall Bowel Symptom Score (BSS) After an 8 Week Treatment Period

BSS score measured from sum of BSS items of abdominal pain severity, bloating severity, diarrhea severity, constipation severity, and how satisfied are you with bowel habits, and measured on a scale of 0% to 100%, 0 being not severe and 100 being very severe. (NCT01412372)
Timeframe: Baseline and 8 weeks

Interventionscore on a scale (Mean)
Placebo-4
Mesalamine-13

[back to top]

Change in Average Bloating Score After an 8 Week Treatment Period.

Measured on a scale of 0% to 100%, 0 being not severe and 100 being very severe. (NCT01412372)
Timeframe: Baseline and 8 weeks

Interventionscore on a scale (Mean)
Placebo-4
Mesalamine-8

[back to top]

Change in Average Abdominal Pain Score After an 8 Week Treatment Period

Measured on a scale of 0% to 100%, 0 being not severe and 100 being very severe. (NCT01412372)
Timeframe: Baseline and 8 weeks

Interventionscore on a scale (Mean)
Placebo-5
Mesalamine-9

[back to top]

Change in Average Bowel Frequency After 8-Week Treatment Period

Measured by the participant reported average number of daily bowel movements. (NCT01412372)
Timeframe: Baseline and 8 weeks

InterventionBowel movements per day (Mean)
Placebo0.0
Mesalamine-0.9

[back to top]

Change in Average Overall IBS Specific Quality of Life Score After an 8 Week Treatment Period.

As measured by the IBS specific Quality of Life questionnaire which consists of 34 items scored on a scale of 0% to 100%, 0 being not at all and 100 being extremely. (NCT01412372)
Timeframe: Baseline and 8 weeks

Interventionscore on a scale (Mean)
Placebo4
Mesalamine8

[back to top]

Area Under the Plasma Concentration Curve (AUC) at Steady State for Metronidazole

AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body. (NCT01418365)
Timeframe: Assessed over a 24-hour period starting post-dose on day 4

Interventionng*h/ml (Mean)
Metronidazole + MMX Placebo217686
Metronidazole + MMX Mesalazine/Mesalamine215809

[back to top]

Maximum Plasma Concentration (Cmax) at Steady State for Metronidazole

Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated. (NCT01418365)
Timeframe: Assessed over a 24-hour period starting post-dose on day 4

Interventionng/ml (Mean)
Metronidazole + MMX Placebo28193
Metronidazole + MMX Mesalazine/Mesalamine28057

[back to top]

Maximum Plasma Concentration (Cmax) for Amoxicillin

Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated. (NCT01442688)
Timeframe: Assessed over a 24-hour period starting post-dose on day 4

Interventionug/ml (Mean)
Amoxicillin + MMX Placebo10.3
Amoxicillin + MMX Mesalazine/Mesalamine10.2

[back to top]

Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC 0→∞) for Amoxicillin

AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body. (NCT01442688)
Timeframe: Assessed over a 24-hour period starting post-dose on day 4

Interventionh*ug/ml (Mean)
Amoxicillin + MMX Placebo27.8
Amoxicillin + MMX Mesalazine/Mesalamine28.3

[back to top]

Maximum Plasma Concentration at Steady-State (Cmaxss) for Sulfamethoxazole

Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated. (NCT01469637)
Timeframe: Assessed over a 24-hour period starting post-dose on day 4

Interventionug/ml (Mean)
Sulfamethoxazole + MMX Placebo89.1
Sulfamethoxazole + MMX Mesalazine/Mesalamine100

[back to top]

Area Under the Plasma Concentration Versus Time Curve Within a Dosing Interval at Steady-State (AUCss) for Sulfamethoxazole

AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure of how much and how long a drug stays in a body. (NCT01469637)
Timeframe: Assessed over a 24-hour period starting post-dose on day 4

Interventionh*ug/ml (Mean)
Sulfamethoxazole + MMX Placebo786
Sulfamethoxazole + MMX Mesalazine/Mesalamine909

[back to top]

Change in Observed CDAI Scores From Baseline to Weeks 4

"Crohn's Disease Activity Index (CDAI) score is calculated based on the data collected in the diary card. The total CDAI score ranges from 0 to approximately 600, a higher scores indicating more severe disease. The target population of total CDAI score 180 to 400 is defined mild to modarate active Crohn's disease. Total CDAI score 150 less or equal is evaluated as a remission.~Patients are asked to fill the following items in the diary card (from the morning in preceding day to the morning in current day). (1) Number of liquid or very soft stools (2) Abdominal pain rating (none, mild, moderate, severe) (3) General well-being (generally well, slightly under par, poor, very poor, terrible) (4) Body temperature (if a patient feels fever) (5) Intake of loperamide or other opiates for diarrhoea. The data for the calculation of CDAI score in diary card is then transcribed by the investigator(s) into the eCRFs at each clinical visit." (NCT01514240)
Timeframe: 4 Week

InterventionScores on a scale (Least Squares Mean)
D9421-C 9mg + Mesalazine Placebo-58.7
Mesalazine 3g + D9421-C Placebo-28.7

[back to top]

Change in Observed CDAI Scores From Baseline to Weeks 8

"Crohn's Disease Activity Index (CDAI) score is calculated based on the data collected in the diary card. The total CDAI score ranges from 0 to approximately 600, a higher scores indicating more severe disease. The target population of total CDAI score 180 to 400 is defined mild to modarate active Crohn's disease. Total CDAI score 150 less or equal is evaluated as a remission.~Patients are asked to fill the following items in the diary card (from the morning in preceding day to the morning in current day). (1) Number of liquid or very soft stools (2) Abdominal pain rating (none, mild, moderate, severe) (3) General well-being (generally well, slightly under par, poor, very poor, terrible) (4) Body temperature (if a patient feels fever) (5) Intake of loperamide or other opiates for diarrhoea. The data for the calculation of CDAI score in diary card is then transcribed by the investigator(s) into the eCRFs at each clinical visit." (NCT01514240)
Timeframe: 8 Week

InterventionScores on a scale (Least Squares Mean)
D9421-C 9mg + Mesalazine Placebo-67.0
Mesalazine 3g + D9421-C Placebo-45.7

[back to top]

Change in Total IBDQ Scores From Baseline to Weeks 10

The Inflammatory Bowel Disease Questionnaire (IBDQ) is a standard measure of HRQL in Crohn's disease patients (Guyatt G et al 1989). The validated Japanese version of the IBDQ was used in this study (Hashimoto H et al 2003). The IBDQ contains 32 questions; each with seven possible answers ranging from 1 to 7, where 7 is the most favourable. Ten questions are related to bowel symptoms, five to systemic symptoms, twelve to emotional function, and five to social function. The corresponding answers will be added to form four subscores and a total score: bowel function score (10 - 70), systemic symptom score (5 - 35), emotional function score (12 - 84), social function score (5 - 35) and the total score (32 - 224), with higher scores indicating more favorable outcome. (NCT01514240)
Timeframe: 10 Week

InterventionScores on a scale (Least Squares Mean)
D9421-C 9mg + Mesalazine Placebo21.1
Mesalazine 3g + D9421-C Placebo7.1

[back to top]

Change in IBDQ Scores From Baseline to Weeks 8 - Systemic Symptom

The Inflammatory Bowel Disease Questionnaire (IBDQ) is a standard measure of HRQL in Crohn's disease patients (Guyatt G et al 1989). The validated Japanese version of the IBDQ was used in this study (Hashimoto H et al 2003). The IBDQ contains 32 questions; each with seven possible answers ranging from 1 to 7, where 7 is the most favourable. Ten questions are related to bowel symptoms, five to systemic symptoms, twelve to emotional function, and five to social function. The corresponding answers will be added to form four subscores and a total score: bowel function score (10 - 70), systemic symptom score (5 - 35), emotional function score (12 - 84), social function score (5 - 35) and the total score (32 - 224), with higher scores indicating more favorable outcome. (NCT01514240)
Timeframe: 8 Week

InterventionScores on a scale (Least Squares Mean)
D9421-C 9mg + Mesalazine Placebo3.5
Mesalazine 3g + D9421-C Placebo1.2

[back to top]

Change in Observed CDAI Scores From Baseline to Weeks 2

"Crohn's Disease Activity Index (CDAI) score is calculated based on the data collected in the diary card. The total CDAI score ranges from 0 to approximately 600, a higher scores indicating more severe disease. The target population of total CDAI score 180 to 400 is defined mild to modarate active Crohn's disease. Total CDAI score 150 less or equal is evaluated as a remission.~Patients are asked to fill the following items in the diary card (from the morning in preceding day to the morning in current day). (1) Number of liquid or very soft stools (2) Abdominal pain rating (none, mild, moderate, severe) (3) General well-being (generally well, slightly under par, poor, very poor, terrible) (4) Body temperature (if a patient feels fever) (5) Intake of loperamide or other opiates for diarrhoea. The data for the calculation of CDAI score in diary card is then transcribed by the investigator(s) into the eCRFs at each clinical visit." (NCT01514240)
Timeframe: 2 Week

InterventionScores on a scale (Least Squares Mean)
D9421-C 9mg + Mesalazine Placebo-38.5
Mesalazine 3g + D9421-C Placebo-15.7

[back to top]

Change in Total IBDQ Scores From Baseline to Weeks 4

The Inflammatory Bowel Disease Questionnaire (IBDQ) is a standard measure of HRQL in Crohn's disease patients (Guyatt G et al 1989). The validated Japanese version of the IBDQ was used in this study (Hashimoto H et al 2003). The IBDQ contains 32 questions; each with seven possible answers ranging from 1 to 7, where 7 is the most favourable. Ten questions are related to bowel symptoms, five to systemic symptoms, twelve to emotional function, and five to social function. The corresponding answers will be added to form four subscores and a total score: bowel function score (10 - 70), systemic symptom score (5 - 35), emotional function score (12 - 84), social function score (5 - 35) and the total score (32 - 224), with higher scores indicating more favorable outcome. (NCT01514240)
Timeframe: 4 Week

InterventionScores on a scale (Least Squares Mean)
D9421-C 9mg + Mesalazine Placebo19.4
Mesalazine 3g + D9421-C Placebo6.8

[back to top]

Change in Total IBDQ Scores From Baseline to Weeks 8

The Inflammatory Bowel Disease Questionnaire (IBDQ) is a standard measure of HRQL in Crohn's disease patients (Guyatt G et al 1989). The validated Japanese version of the IBDQ was used in this study (Hashimoto H et al 2003). The IBDQ contains 32 questions; each with seven possible answers ranging from 1 to 7, where 7 is the most favourable. Ten questions are related to bowel symptoms, five to systemic symptoms, twelve to emotional function, and five to social function. The corresponding answers will be added to form four subscores and a total score: bowel function score (10 - 70), systemic symptom score (5 - 35), emotional function score (12 - 84), social function score (5 - 35) and the total score (32 - 224), with higher scores indicating more favorable outcome. (NCT01514240)
Timeframe: 8 Week

InterventionScores on a scale (Least Squares Mean)
D9421-C 9mg + Mesalazine Placebo18.3
Mesalazine 3g + D9421-C Placebo5.8

[back to top]

Clinical Improvement Rates (Decrease in CDAI Score From Baseline of at Least 70 Points) at Weeks 2

Clinical improvement is defined as CDAI score of <=150 or a decrease in CDAI score from baseline of at least 70 points. (NCT01514240)
Timeframe: 2 Week

InterventionParticipants (Number)
D9421-C 9mg + Mesalazine Placebo19
Mesalazine 3g + D9421-C Placebo11

[back to top]

Change in Total IBDQ Scores From Baseline to Weeks 2

The Inflammatory Bowel Disease Questionnaire (IBDQ) is a standard measure of HRQL in Crohn's disease patients (Guyatt G et al 1989). The validated Japanese version of the IBDQ was used in this study (Hashimoto H et al 2003). The IBDQ contains 32 questions; each with seven possible answers ranging from 1 to 7, where 7 is the most favourable. Ten questions are related to bowel symptoms, five to systemic symptoms, twelve to emotional function, and five to social function. The corresponding answers will be added to form four subscores and a total score: bowel function score (10 - 70), systemic symptom score (5 - 35), emotional function score (12 - 84), social function score (5 - 35) and the total score (32 - 224), with higher scores indicating more favorable outcome. (NCT01514240)
Timeframe: 2 Week

InterventionScores on a scale (Least Squares Mean)
D9421-C 9mg + Mesalazine Placebo16.2
Mesalazine 3g + D9421-C Placebo5.7

[back to top]

Clinical Improvement Rates (Decrease in CDAI Score From Baseline of at Least 100 Points) at Weeks 2

Clinical improvement is defined as CDAI score of <=150 or a decrease in CDAI score from baseline of at least 100 points. (NCT01514240)
Timeframe: 2 Week

InterventionParticipants (Number)
D9421-C 9mg + Mesalazine Placebo14
Mesalazine 3g + D9421-C Placebo10

[back to top]

Clinical Improvement Rates (Decrease in CDAI Score From Baseline of at Least 100 Points) at Weeks 4

Clinical improvement is defined as CDAI score of <=150 or a decrease in CDAI score from baseline of at least 100 points. (NCT01514240)
Timeframe: 4 Week

InterventionParticipants (Number)
D9421-C 9mg + Mesalazine Placebo19
Mesalazine 3g + D9421-C Placebo11

[back to top]

Clinical Improvement Rates (Decrease in CDAI Score From Baseline of at Least 100 Points) at Weeks 8

Clinical improvement is defined as CDAI score of <=150 or a decrease in CDAI score from baseline of at least 100 points. (NCT01514240)
Timeframe: 8 Week

InterventionParticipants (Number)
D9421-C 9mg + Mesalazine Placebo24
Mesalazine 3g + D9421-C Placebo17

[back to top]

Remission After 8-week of Treatment

"For the primary efficacy variable Remission after 8 weeks of treatment, Crohn's Disease Activity Index CDAI scores was used to determine the patient's response. Remission for this study is defined as a CDAI score of ≤150. A patient who drops out without any remission before week 8 was considered as a nonresponder (no remission) for this analysis. A patient who drops out before Week 8, but was in remission at the time of dropout, was considered in remission after dropout in this analysis." (NCT01514240)
Timeframe: 8 Week

InterventionParticipants (Number)
D9421-C 9mg + Mesalazine Placebo17
Mesalazine 3g + D9421-C Placebo14

[back to top]

Remission After 4-week of Treatment

"For the secondary efficacy variable Remission after 4 weeks of treatment, Crohn's Disease Activity Index CDAI scores was used to determine the patient's response. Remission for this study is defined as a CDAI score of ≤150." (NCT01514240)
Timeframe: 4 Week

InterventionParticipants (Number)
D9421-C 9mg + Mesalazine Placebo12
Mesalazine 3g + D9421-C Placebo7

[back to top]

Remission After 2-week of Treatment

"For the secondary efficacy variable Remission after 2 weeks of treatment, Crohn's Disease Activity Index CDAI scores was used to determine the patient's response. Remission for this study is defined as a CDAI score of ≤150." (NCT01514240)
Timeframe: 2 Week

InterventionParticipants (Number)
D9421-C 9mg + Mesalazine Placebo7
Mesalazine 3g + D9421-C Placebo6

[back to top]

Cumulative Remission Rate at Week 8

Remission rate is defined as CDAI score of less than or equal to 150. Cumulative remission rate at Week 8 is obtained by Kaplan-Meier (KM) estimates. (NCT01514240)
Timeframe: 8 Week

InterventionPercentage of participants (Number)
D9421-C 9mg + Mesalazine Placebo37.5
Mesalazine 3g + D9421-C Placebo30.4

[back to top]

Cumulative Remission Rate at Week 4

Remission rate is defined as CDAI score of less than or equal to 150. Cumulative remission rate at Week 4 is obtained by Kaplan-Meier (KM) estimates. (NCT01514240)
Timeframe: 4 Week

InterventionPercentage of participants (Number)
D9421-C 9mg + Mesalazine Placebo25.0
Mesalazine 3g + D9421-C Placebo17.9

[back to top]

Cumulative Remission Rate at Week 2

Remission rate is defined as CDAI score of less than or equal to 150. Cumulative remission rate at Week 2 is obtained by Kaplan-Meier (KM) estimates. (NCT01514240)
Timeframe: 2 Week

InterventionPercentage of participants (Number)
D9421-C 9mg + Mesalazine Placebo12.5
Mesalazine 3g + D9421-C Placebo10.7

[back to top]

Clinical Improvement Rates (Decrease in CDAI Score From Baseline of at Least 70 Points) at Weeks 8

Clinical improvement is defined as CDAI score of <=150 or a decrease in CDAI score from baseline of at least 70 points. (NCT01514240)
Timeframe: 8 Week

InterventionParticipants (Number)
D9421-C 9mg + Mesalazine Placebo27
Mesalazine 3g + D9421-C Placebo18

[back to top]

Clinical Improvement Rates (Decrease in CDAI Score From Baseline of at Least 70 Points) at Weeks 4

Clinical improvement is defined as CDAI score of <=150 or a decrease in CDAI score from baseline of at least 70 points. (NCT01514240)
Timeframe: 4 Week

InterventionParticipants (Number)
D9421-C 9mg + Mesalazine Placebo22
Mesalazine 3g + D9421-C Placebo13

[back to top]

Change in IBDQ Scores From Baseline to Weeks 10 - Bowel Function

The Inflammatory Bowel Disease Questionnaire (IBDQ) is a standard measure of HRQL in Crohn's disease patients (Guyatt G et al 1989). The validated Japanese version of the IBDQ was used in this study (Hashimoto H et al 2003). The IBDQ contains 32 questions; each with seven possible answers ranging from 1 to 7, where 7 is the most favourable. Ten questions are related to bowel symptoms, five to systemic symptoms, twelve to emotional function, and five to social function. The corresponding answers will be added to form four subscores and a total score: bowel function score (10 - 70), systemic symptom score (5 - 35), emotional function score (12 - 84), social function score (5 - 35) and the total score (32 - 224), with higher scores indicating more favorable outcome. (NCT01514240)
Timeframe: 10 Week

InterventionScores on a scale (Least Squares Mean)
D9421-C 9mg + Mesalazine Placebo6.9
Mesalazine 3g + D9421-C Placebo3.6

[back to top]

Change in IBDQ Scores From Baseline to Weeks 10 - Emotional Function

The Inflammatory Bowel Disease Questionnaire (IBDQ) is a standard measure of HRQL in Crohn's disease patients (Guyatt G et al 1989). The validated Japanese version of the IBDQ was used in this study (Hashimoto H et al 2003). The IBDQ contains 32 questions; each with seven possible answers ranging from 1 to 7, where 7 is the most favourable. Ten questions are related to bowel symptoms, five to systemic symptoms, twelve to emotional function, and five to social function. The corresponding answers will be added to form four subscores and a total score: bowel function score (10 - 70), systemic symptom score (5 - 35), emotional function score (12 - 84), social function score (5 - 35) and the total score (32 - 224), with higher scores indicating more favorable outcome. (NCT01514240)
Timeframe: 10 Week

InterventionScores on a scale (Least Squares Mean)
D9421-C 9mg + Mesalazine Placebo8.0
Mesalazine 3g + D9421-C Placebo1.3

[back to top]

Change in IBDQ Scores From Baseline to Weeks 10 - Social Function

The Inflammatory Bowel Disease Questionnaire (IBDQ) is a standard measure of HRQL in Crohn's disease patients (Guyatt G et al 1989). The validated Japanese version of the IBDQ was used in this study (Hashimoto H et al 2003). The IBDQ contains 32 questions; each with seven possible answers ranging from 1 to 7, where 7 is the most favourable. Ten questions are related to bowel symptoms, five to systemic symptoms, twelve to emotional function, and five to social function. The corresponding answers will be added to form four subscores and a total score: bowel function score (10 - 70), systemic symptom score (5 - 35), emotional function score (12 - 84), social function score (5 - 35) and the total score (32 - 224), with higher scores indicating more favorable outcome. (NCT01514240)
Timeframe: 10 Week

InterventionScores on a scale (Least Squares Mean)
D9421-C 9mg + Mesalazine Placebo2.4
Mesalazine 3g + D9421-C Placebo1.2

[back to top]

Change in IBDQ Scores From Baseline to Weeks 10 - Systemic Symptom

The Inflammatory Bowel Disease Questionnaire (IBDQ) is a standard measure of HRQL in Crohn's disease patients (Guyatt G et al 1989). The validated Japanese version of the IBDQ was used in this study (Hashimoto H et al 2003). The IBDQ contains 32 questions; each with seven possible answers ranging from 1 to 7, where 7 is the most favourable. Ten questions are related to bowel symptoms, five to systemic symptoms, twelve to emotional function, and five to social function. The corresponding answers will be added to form four subscores and a total score: bowel function score (10 - 70), systemic symptom score (5 - 35), emotional function score (12 - 84), social function score (5 - 35) and the total score (32 - 224), with higher scores indicating more favorable outcome. (NCT01514240)
Timeframe: 10 Week

InterventionScores on a scale (Least Squares Mean)
D9421-C 9mg + Mesalazine Placebo3.8
Mesalazine 3g + D9421-C Placebo1.2

[back to top]

Change in IBDQ Scores From Baseline to Weeks 2 - Bowel Function

The Inflammatory Bowel Disease Questionnaire (IBDQ) is a standard measure of HRQL in Crohn's disease patients (Guyatt G et al 1989). The validated Japanese version of the IBDQ was used in this study (Hashimoto H et al 2003). The IBDQ contains 32 questions; each with seven possible answers ranging from 1 to 7, where 7 is the most favourable. Ten questions are related to bowel symptoms, five to systemic symptoms, twelve to emotional function, and five to social function. The corresponding answers will be added to form four subscores and a total score: bowel function score (10 - 70), systemic symptom score (5 - 35), emotional function score (12 - 84), social function score (5 - 35) and the total score (32 - 224), with higher scores indicating more favorable outcome. (NCT01514240)
Timeframe: 2 Week

InterventionScores on a scale (Least Squares Mean)
D9421-C 9mg + Mesalazine Placebo6.1
Mesalazine 3g + D9421-C Placebo2.7

[back to top]

Change in IBDQ Scores From Baseline to Weeks 2 - Emotional Function

The Inflammatory Bowel Disease Questionnaire (IBDQ) is a standard measure of HRQL in Crohn's disease patients (Guyatt G et al 1989). The validated Japanese version of the IBDQ was used in this study (Hashimoto H et al 2003). The IBDQ contains 32 questions; each with seven possible answers ranging from 1 to 7, where 7 is the most favourable. Ten questions are related to bowel symptoms, five to systemic symptoms, twelve to emotional function, and five to social function. The corresponding answers will be added to form four subscores and a total score: bowel function score (10 - 70), systemic symptom score (5 - 35), emotional function score (12 - 84), social function score (5 - 35) and the total score (32 - 224), with higher scores indicating more favorable outcome. (NCT01514240)
Timeframe: 2 Week

InterventionScores on a scale (Least Squares Mean)
D9421-C 9mg + Mesalazine Placebo5.1
Mesalazine 3g + D9421-C Placebo1.3

[back to top]

Change in IBDQ Scores From Baseline to Weeks 2 - Social Function

The Inflammatory Bowel Disease Questionnaire (IBDQ) is a standard measure of HRQL in Crohn's disease patients (Guyatt G et al 1989). The validated Japanese version of the IBDQ was used in this study (Hashimoto H et al 2003). The IBDQ contains 32 questions; each with seven possible answers ranging from 1 to 7, where 7 is the most favourable. Ten questions are related to bowel symptoms, five to systemic symptoms, twelve to emotional function, and five to social function. The corresponding answers will be added to form four subscores and a total score: bowel function score (10 - 70), systemic symptom score (5 - 35), emotional function score (12 - 84), social function score (5 - 35) and the total score (32 - 224), with higher scores indicating more favorable outcome. (NCT01514240)
Timeframe: 2 Week

InterventionScores on a scale (Least Squares Mean)
D9421-C 9mg + Mesalazine Placebo1.9
Mesalazine 3g + D9421-C Placebo0.6

[back to top]

Change in IBDQ Scores From Baseline to Weeks 2 - Systemic Symptom

The Inflammatory Bowel Disease Questionnaire (IBDQ) is a standard measure of HRQL in Crohn's disease patients (Guyatt G et al 1989). The validated Japanese version of the IBDQ was used in this study (Hashimoto H et al 2003). The IBDQ contains 32 questions; each with seven possible answers ranging from 1 to 7, where 7 is the most favourable. Ten questions are related to bowel symptoms, five to systemic symptoms, twelve to emotional function, and five to social function. The corresponding answers will be added to form four subscores and a total score: bowel function score (10 - 70), systemic symptom score (5 - 35), emotional function score (12 - 84), social function score (5 - 35) and the total score (32 - 224), with higher scores indicating more favorable outcome. (NCT01514240)
Timeframe: 2 Week

InterventionScores on a scale (Least Squares Mean)
D9421-C 9mg + Mesalazine Placebo3.0
Mesalazine 3g + D9421-C Placebo1.0

[back to top]

Change in IBDQ Scores From Baseline to Weeks 4 - Bowel Function

The Inflammatory Bowel Disease Questionnaire (IBDQ) is a standard measure of HRQL in Crohn's disease patients (Guyatt G et al 1989). The validated Japanese version of the IBDQ was used in this study (Hashimoto H et al 2003). The IBDQ contains 32 questions; each with seven possible answers ranging from 1 to 7, where 7 is the most favourable. Ten questions are related to bowel symptoms, five to systemic symptoms, twelve to emotional function, and five to social function. The corresponding answers will be added to form four subscores and a total score: bowel function score (10 - 70), systemic symptom score (5 - 35), emotional function score (12 - 84), social function score (5 - 35) and the total score (32 - 224), with higher scores indicating more favorable outcome. (NCT01514240)
Timeframe: 4 Week

InterventionScores on a scale (Least Squares Mean)
D9421-C 9mg + Mesalazine Placebo6.6
Mesalazine 3g + D9421-C Placebo2.8

[back to top]

Change in IBDQ Scores From Baseline to Weeks 4 - Emotional Function

The Inflammatory Bowel Disease Questionnaire (IBDQ) is a standard measure of HRQL in Crohn's disease patients (Guyatt G et al 1989). The validated Japanese version of the IBDQ was used in this study (Hashimoto H et al 2003). The IBDQ contains 32 questions; each with seven possible answers ranging from 1 to 7, where 7 is the most favourable. Ten questions are related to bowel symptoms, five to systemic symptoms, twelve to emotional function, and five to social function. The corresponding answers will be added to form four subscores and a total score: bowel function score (10 - 70), systemic symptom score (5 - 35), emotional function score (12 - 84), social function score (5 - 35) and the total score (32 - 224), with higher scores indicating more favorable outcome. (NCT01514240)
Timeframe: 4 Week

InterventionScores on a scale (Least Squares Mean)
D9421-C 9mg + Mesalazine Placebo7.0
Mesalazine 3g + D9421-C Placebo2.1

[back to top]

Change in IBDQ Scores From Baseline to Weeks 4 - Social Function

The Inflammatory Bowel Disease Questionnaire (IBDQ) is a standard measure of HRQL in Crohn's disease patients (Guyatt G et al 1989). The validated Japanese version of the IBDQ was used in this study (Hashimoto H et al 2003). The IBDQ contains 32 questions; each with seven possible answers ranging from 1 to 7, where 7 is the most favourable. Ten questions are related to bowel symptoms, five to systemic symptoms, twelve to emotional function, and five to social function. The corresponding answers will be added to form four subscores and a total score: bowel function score (10 - 70), systemic symptom score (5 - 35), emotional function score (12 - 84), social function score (5 - 35) and the total score (32 - 224), with higher scores indicating more favorable outcome. (NCT01514240)
Timeframe: 4 Week

InterventionScores on a scale (Least Squares Mean)
D9421-C 9mg + Mesalazine Placebo2.5
Mesalazine 3g + D9421-C Placebo0.7

[back to top]

Change in IBDQ Scores From Baseline to Weeks 4 - Systemic Symptom

The Inflammatory Bowel Disease Questionnaire (IBDQ) is a standard measure of HRQL in Crohn's disease patients (Guyatt G et al 1989). The validated Japanese version of the IBDQ was used in this study (Hashimoto H et al 2003). The IBDQ contains 32 questions; each with seven possible answers ranging from 1 to 7, where 7 is the most favourable. Ten questions are related to bowel symptoms, five to systemic symptoms, twelve to emotional function, and five to social function. The corresponding answers will be added to form four subscores and a total score: bowel function score (10 - 70), systemic symptom score (5 - 35), emotional function score (12 - 84), social function score (5 - 35) and the total score (32 - 224), with higher scores indicating more favorable outcome. (NCT01514240)
Timeframe: 4 Week

InterventionScores on a scale (Least Squares Mean)
D9421-C 9mg + Mesalazine Placebo3.3
Mesalazine 3g + D9421-C Placebo1.3

[back to top]

Change in IBDQ Scores From Baseline to Weeks 8 - Bowel Function

The Inflammatory Bowel Disease Questionnaire (IBDQ) is a standard measure of HRQL in Crohn's disease patients (Guyatt G et al 1989). The validated Japanese version of the IBDQ was used in this study (Hashimoto H et al 2003). The IBDQ contains 32 questions; each with seven possible answers ranging from 1 to 7, where 7 is the most favourable. Ten questions are related to bowel symptoms, five to systemic symptoms, twelve to emotional function, and five to social function. The corresponding answers will be added to form four subscores and a total score: bowel function score (10 - 70), systemic symptom score (5 - 35), emotional function score (12 - 84), social function score (5 - 35) and the total score (32 - 224), with higher scores indicating more favorable outcome. (NCT01514240)
Timeframe: 8 Week

InterventionScores on a scale (Least Squares Mean)
D9421-C 9mg + Mesalazine Placebo6.5
Mesalazine 3g + D9421-C Placebo2.4

[back to top]

Change in IBDQ Scores From Baseline to Weeks 8 - Emotional Function

The Inflammatory Bowel Disease Questionnaire (IBDQ) is a standard measure of HRQL in Crohn's disease patients (Guyatt G et al 1989). The validated Japanese version of the IBDQ was used in this study (Hashimoto H et al 2003). The IBDQ contains 32 questions; each with seven possible answers ranging from 1 to 7, where 7 is the most favourable. Ten questions are related to bowel symptoms, five to systemic symptoms, twelve to emotional function, and five to social function. The corresponding answers will be added to form four subscores and a total score: bowel function score (10 - 70), systemic symptom score (5 - 35), emotional function score (12 - 84), social function score (5 - 35) and the total score (32 - 224), with higher scores indicating more favorable outcome. (NCT01514240)
Timeframe: 8 Week

InterventionScores on a scale (Least Squares Mean)
D9421-C 9mg + Mesalazine Placebo5.9
Mesalazine 3g + D9421-C Placebo1.6

[back to top]

Change in IBDQ Scores From Baseline to Weeks 8 - Social Function

The Inflammatory Bowel Disease Questionnaire (IBDQ) is a standard measure of HRQL in Crohn's disease patients (Guyatt G et al 1989). The validated Japanese version of the IBDQ was used in this study (Hashimoto H et al 2003). The IBDQ contains 32 questions; each with seven possible answers ranging from 1 to 7, where 7 is the most favourable. Ten questions are related to bowel symptoms, five to systemic symptoms, twelve to emotional function, and five to social function. The corresponding answers will be added to form four subscores and a total score: bowel function score (10 - 70), systemic symptom score (5 - 35), emotional function score (12 - 84), social function score (5 - 35) and the total score (32 - 224), with higher scores indicating more favorable outcome. (NCT01514240)
Timeframe: 8 Week

InterventionScores on a scale (Least Squares Mean)
D9421-C 9mg + Mesalazine Placebo2.3
Mesalazine 3g + D9421-C Placebo0.7

[back to top]

Number of Participants Receiving a Colectomy

Number of participants who received a colectomy within 52 weeks (NCT01536535)
Timeframe: Within 52 weeks

InterventionParticipants (Count of Participants)
Mild UC Disease2
Moderate to Severe UC23

[back to top]

Number of Participants Who Needed Additional Therapy or Colectomy

Number of participants who needed additional therapy or colectomy. Additional therapy included Anti-Tumour Necrosis Factor alpha (TNFα), Calcineurin inhibitor, Immunomodulator (NCT01536535)
Timeframe: Within 52 weeks

InterventionParticipants (Count of Participants)
Mild UC Disease46
Moderate to Severe UC151

[back to top]

Number of Participants With Corticosteroid Free Remission (SFR)

"Week 52 CS-free remission: Number of participants with a PUCAI < 10 and no corticosteroids (CS) for 28 days without additional therapy or colectomy. Participants in both groups received corticosteroids, biologics, or colectomies, if symptomatic.~The Pediatric Ulcerative Colitis Activity Index (PUCAI) is a non-invasive disease activity index. The index measures include abdominal pain, rectal bleeding, stool consistency, number of stools per 24 hours, nocturnal stools, and activity level. A total score less than 10 indicates remission, Mild disease activity is 10-30, Moderate 35-60, Severe disease activity 65-85." (NCT01536535)
Timeframe: 52 weeks

InterventionParticipants (Count of Participants)
Mild UC80
Moderate to Severe UC70

[back to top]

Number of Participants With Endoscopic Recurrence of Crohn's Disease

To compare the endoscopic recurrence rates at one year following surgery between patients treated with certolizumab and mesalamine. (NCT01696942)
Timeframe: One year following enrollment

InterventionParticipants (Count of Participants)
Cimzia Treatment Arm0
Mesalamine Treatment Arm0

[back to top]

Clinical Recurrence Rates of Crohn's Disease

To evaluate the difference in clinical recurrence rates between certolizumab and mesalamine after 4 weeks, 3 months, 6 months, 9 months, and 12 months of use following ileocolectomy for Crohn's disease using the Crohn's Disease Activity Index (CDAI). CDAI scores of 150 or greater are considered a recurrence. (NCT01696942)
Timeframe: 4 weeks, 3 months, 6 months, 9 months, and 12 months

,
InterventionParticipants (Count of Participants)
4 week CDAI recurrence3 month CDAI reccurence6 month CDAI recurrence9 month CDAI recurrence12 month CDAI recurrence
Cimzia Treatment Arm32120
Mesalamine Treatment Arm11200

[back to top] [back to top]

Period 2: Urgency

Percentage of patients achieving an Urgency Score of 0. A score of 0 indicates no urgency reported in any of the three days prior to the visit at week 16. A score of 1 indicates urgency reported in any of the three days prior to the visits. (NCT01903252)
Timeframe: Week 16

InterventionParticipants (Count of Participants)
Extended Induction109

[back to top]

Period 3: Clinical and Endoscopic Remission

Mayo Score of <= 2 points with no individual sub-score > 1 (NCT01903252)
Timeframe: Week 38

Interventionpercentage of participants (Number)
1.6g/Day Maintenance Open-Label65.8
3.2/Day Maintenance Open-Label39.4
4.8g/Day Maintenance Open-Label29.6

[back to top]

Period 3: Clinical and Endoscopic Response

Both has to be achieved, Clinical and Endoscopic Response which is defined by a decrease from baseline in the Mayo score of ≥ 3 points and > 30% of the baseline score, with an accompanying decrease in the rectal bleeding sub-score of ≥ 1 point or an absolute rectal bleeding sub-score of 0 or 1. (NCT01903252)
Timeframe: Week 38

Interventionpercentage of participants (Number)
1.6g/Day Maintenance Open-Label89.6
3.2/Day Maintenance Open-Label78.1
4.8g/Day Maintenance Open-Label69.3

[back to top]

Period 3: Clinical Remission

Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS) (NCT01903252)
Timeframe: Week 38

Interventionpercentage of participant (Number)
1.6g/Day Maintenance Open-Label70.3
3.2/Day Maintenance Open-Label33.9
4.8g/Day Maintenance Open-Label30.7

[back to top]

Period 3: Clinical Response

A decrease in the PMCS of ≥ 2 points and ≥ 30% from baseline, with a decrease in the rectal bleeding sub-score of ≥ 1 point or absolute rectal bleeding sub-score of 1 or 0. (NCT01903252)
Timeframe: Week 38

Interventionpercentage of participants (Number)
1.6g/Day Maintenance Open-Label94.1
3.2/Day Maintenance Open-Label83.9
4.8g/Day Maintenance Open-Label78.4

[back to top]

Period 3: Endoscopic Remission

Percentage of each dose group achieving an endoscopy sub score of 0 (NCT01903252)
Timeframe: Week 38

Interventionpercentage of participants (Number)
1.6g/Day Maintenance Open-Label37.6
3.2/Day Maintenance Open-Label32.4
4.8g/Day Maintenance Open-Label13.6

[back to top]

Period 3: Endoscopic Response

Endoscopic response was define as a reduction in the Mayo endoscopic sub score of at least one. (NCT01903252)
Timeframe: Week 38

Interventionpercentage of participants (Number)
1.6g/Day Maintenance Open-Label73.8
3.2/Day Maintenance Open-Label58.8
4.8g/Day Maintenance Open-Label53.3

[back to top]

Period 3: No Urgency

No urgency is a score of 0 and indicates that patients did not report urgency during any of the three days prior to the visit at week 38. A score of 1 indicates that urgency was reported during any of these three days. (NCT01903252)
Timeframe: Week 38

InterventionParticipants (Count of Participants)
1.6g/Day Maintenance Open-Label161
3.2/Day Maintenance Open-Label173
4.8g/Day Maintenance Open-Label109

[back to top]

Period 3: Rectal Bleeding Sub Score of 0

Percentage of each dose group achieving the endpoint rectal bleeding subscore 0 (NCT01903252)
Timeframe: Week 38

Interventionpercentage of participants (Number)
1.6g/Day Maintenance Open-Label88.1
3.2/Day Maintenance Open-Label76.3
4.8g/Day Maintenance Open-Label74.9

[back to top]

Period 3: Stool Frequency Sub-score 0

Patients achieving a Stool Frequency sub-score of 0 (NCT01903252)
Timeframe: Week 38

InterventionParticipants (Count of Participants)
1.6g/Day Maintenance Open-Label148
3.2/Day Maintenance Open-Label101
4.8g/Day Maintenance Open-Label66

[back to top] [back to top]

Period 1: Endoscopic Response

Endoscopic response was define as a reduction in the Mayo endoscopic sub score of at least one. (NCT01903252)
Timeframe: Week 8

InterventionParticipants (Count of Participants)
TP05 (Mesalazine)185
Asacol (Mesalazine, Tillotts Pharma AG)196

[back to top]

Period 1: Change in Endoscopic Score From Baseline

Between-Group Difference of Endoscopic Score, Change from Baseline. The changes from baseline to week 8 values in sigmoidoscopic (mucosal) appearance scores will be compared between the two treatment groups. A value of 0 in the endoscopic score means normal or inactive disease and a value of 3 means severe disease. Change from Baseline is calculated Baseline-score minus week 8-score. A large difference between baseline to week 8 indicates treatment success. (NCT01903252)
Timeframe: Baseline and Week 8

Interventionunits on a scale (Mean)
TP05 (Mesalazine)0.5
Asacol (Mesalazine)0.6

[back to top]

Period 1: Change in Mayo Score From Baseline

"Between-Group Difference of Mayo Score, Change from Baseline The changes from baseline to week 8 values in Mayo scores are compared between the two treatment groups.~The Mayo scoring system is a well-established tool for assessing UC disease activity. The Mayo score is the sum of 4 component sub-scores, each scored on a scale ranging from 0 representing no pathology to 3 for severe disease. The 4 component sub-scores consist of, 1) stool frequency, 2) rectal bleeding, 3) flexible sigmoidoscopy scores, and 4) physician's global assessment. A Mayo score of 0 indicates no pathology and a score of 12, severe disease. Change from Baseline is calculated Baseline-score minus week 8-score. A larger change in Mayo score from baseline when patients experienced acute disease, indicates improvement and treatment success." (NCT01903252)
Timeframe: Baseline and Week 8

Interventionunits on a scale (Mean)
TP05 (Mesalazine)3.1
Asacol (Mesalazine)3.2

[back to top]

Period 1: Change in Partial Mayo Score From Baseline

Between-Group Difference of Partial Mayo Score, Change from Baseline to Week 8 The Partial Mayo Score is the sum of the component sub-scores, 1) stool frequency, 2) rectal bleeding and 3) physician's global assessment. A partial Mayo Score of 0 indicates no disease and a maximum score of 9 indicates severe symptoms. Change from Baseline is calculated Baseline-score minus week 8-score. A larger change in Partial Mayo Score from Baseline where patients experienced acute disease, indicates improvement and treatment success. (NCT01903252)
Timeframe: Baseline and Week 8

Interventionunits on a scale (Mean)
TP05 (Mesalazine)2.5
Asacol (Mesalazine)2.5

[back to top]

Period 1: Change in Physician Global Assessment Score From Baseline

"Between-Group Difference of Physician Global Assessment Score, Change from Baseline.~The changes from baseline to week 8 values in the Physician Global Assessment score will be compared between the two treatment groups. A value of 0 means no pathology and a value of 3 means severe disease. Change from Baseline is calculated Baseline-score minus week 8-score. A large difference between baseline to week 8 indicates treatment success." (NCT01903252)
Timeframe: Baseline and Week 8

Interventionunits on a scale (Mean)
TP05 (Mesalazine)0.6
Asacol (Mesalazine)0.7

[back to top]

Period 1: Change in Rectal Bleeding Score From Baseline

Between-Group Difference of Rectal Bleeding Score, Change from Baseline The changes from baseline to week 8 values in rectal bleeding scores will be compared between the two treatment groups. A value of 0 indicates no rectal bleeding, a value of 3 indicates only blood is passing. Change from Baseline is calculated Baseline-score minus week 8-score. A large difference at week 8 compared to baseline is indicative of treatment success. (NCT01903252)
Timeframe: Baseline and Week 8

Interventionunits on a scale (Mean)
TP05 (Mesalazine)0.9
Asacol (Mesalazine)1.0

[back to top]

Period 1: Change in Stool Frequency Score

Between-Group Difference of Stool Frequency Score, Change from Baseline The changes from baseline to week 8 values in stool frequency will be compared between the two treatment groups. Values for stool frequency range between 0 and 3. A value of 0 indicates normal stool frequency, a value of 3 indicates 5 or more stools than normal. Change from Baseline is calculated Baseline-score minus week 8-score. A large difference between week 8 values and baselines indicates treatment success. (NCT01903252)
Timeframe: Baseline and Week 8

Interventionunits on a scale (Mean)
TP05 (Mesalazine)0.9
Asacol (Mesalazine)0.9

[back to top]

Period 1: Clinical and Endoscopic Remission

Mayo Score of <= 2 points with no individual sub-score > 1 (NCT01903252)
Timeframe: Week 8

InterventionParticipants (Count of Participants)
TP05 (Mesalazine)87
Asacol (Mesalazine, Tillotts Pharma AG)95

[back to top]

Period 1: Clinical and Endoscopic Response

Clinical and Endoscopic Response was defined as a decrease in the Mayo score of ≥3 points from baseline and a reduction of ≥ 30% from baseline with either an accompanying decrease in the rectal bleeding sub-score of at least 1 point or an absolute rectal bleeding sub-score of 0 or 1 at the Week 8 visit. If a subject withdrew from the study prior to Week 8 or their response status was not evaluable due to incomplete and/or invalid data, the subject was considered a non-responder. (NCT01903252)
Timeframe: Week 8

InterventionParticipants (Count of Participants)
TP05 (Mesalazine)221
Asacol (Mesalazine)236

[back to top]

Period 1: Clinical Remission

Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS) (NCT01903252)
Timeframe: Week 12

InterventionParticipants (Count of Participants)
TP05 (Mesalazine)93
Asacol (Mesalazine, Tillotts Pharma AG)113

[back to top]

Period 1: Clinical Remission

Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS) (NCT01903252)
Timeframe: Week 8

InterventionParticipants (Count of Participants)
TP05 (Mesalazine)92
Asacol (Mesalazine, Tillotts Pharma AG)110

[back to top]

Period 1: Clinical Remission at Both Week 8 and 12

Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS) (NCT01903252)
Timeframe: Week 8 and week 12

InterventionParticipants (Count of Participants)
TP05 (Mesalazine)66
Asacol (Mesalazine, Tillotts Pharma AG)80

[back to top]

Period 1: Clinical Response

A decrease in the PMCS of ≥ 2 points and ≥ 30% from baseline, with a decrease in the rectal bleeding sub-score of ≥ 1 point or absolute rectal bleeding sub-score of 1 or 0. (NCT01903252)
Timeframe: Week 12

InterventionParticipants (Count of Participants)
TP05 (Mesalazine)223
Asacol (Mesalazine, Tillotts Pharma AG)233

[back to top]

Period 1: Clinical Response at Both Week 8 and Week 12

A decrease in the Partial Mayo Score of ≥ 2 points and ≥ 30% from baseline, with a decrease in the rectal bleeding sub-score of ≥ 1 point or absolute rectal bleeding sub-score of 1 or 0. (NCT01903252)
Timeframe: Week 8 and Week 12

InterventionParticipants (Count of Participants)
TP05 (Mesalazine)216
Asacol (Mesalazine, Tillotts Pharma AG)230

[back to top]

Period 1: Endoscopic Remission

Endoscopic remission was defined as a Mayo endoscopy subscore of 0 (NCT01903252)
Timeframe: Week 8

InterventionParticipants (Count of Participants)
TP05 (Mesalazine)36
Asacol (Mesalazine, Tillotts Pharma AG)44

[back to top]

Period 1: Rectal Bleeding Score of 0

Rectal bleeding sub-score of 0 was defined as a sub score on the rectal bleeding component of the Mayo score (NCT01903252)
Timeframe: Week 12

InterventionParticipants (Count of Participants)
TP05 (Mesalazine)193
Asacol (Mesalazine, Tillotts Pharma AG)205

[back to top]

Period 1: Rectal Bleeding Sub-score of 0

Rectal bleeding sub-score of 0 was defined as a sub score on the rectal bleeding component of the Mayo score (NCT01903252)
Timeframe: Week 8

InterventionParticipants (Count of Participants)
TP05 (Mesalazine)212
Asacol (Mesalazine, Tillotts Pharma AG)226

[back to top]

Period 2: Clinical Remission

Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS) (NCT01903252)
Timeframe: Week 16

InterventionParticipants (Count of Participants)
Extended Induction53

[back to top]

Period 2: Clinical Response, Open-Label Extended Induction

A decrease in the PMCS of ≥ 2 points and ≥ 30% from baseline, with a decrease in the rectal bleeding sub-score of ≥ 1 point or absolute rectal bleeding sub-score of 1 or 0. (NCT01903252)
Timeframe: Week 16

InterventionParticipants (Count of Participants)
Extended Induction183

[back to top]

Period 2: Rectal Bleeding Sub-score of 0

Percentage of patients achieving the endpoint rectal bleeding sub-score of 0 (NCT01903252)
Timeframe: Week 16

InterventionParticipants (Count of Participants)
Extended Induction146

[back to top]

Period 2: Stool Frequency 0

Percentage of patients achieving the endpoint stool frequency sub-score of 0 (NCT01903252)
Timeframe: Week 16

InterventionParticipants (Count of Participants)
Extended Induction64

[back to top]

The AUC of Metabolite (N-acetyl-mesalamine) in Plasma

The AUC is the area under the concentration-time curve from time 0 to last time point. The data are organized by the different drug formulations of mesalamine, which include Pentasa (0 to 72 hours), Apriso (0 to 72 hours), Lialda (0 to 96 hours), and Delzicol (0 to 24 hours). The AUC is measured in units of nanomoles of N-acetyl-mesalamine per liter of plasma (nM) multiplied by time in hours (nM*h). The AUC results are reported over the time-period because this provides a more meaningful comparison of potential differences in the bioequivalence of formulations. (NCT01999400)
Timeframe: 0 hours pre-dose and up to 96 hours post-dose

InterventionnM*h (Mean)
Pentasa162
Apriso189
Lialda124
Delzicol20.4

[back to top]

The AUC of Mesalamine in Distal Jejunum

The AUC is the area under the concentration-time curve from time 0 to 7 hours. The data are organized by the different drug formulations of mesalamine, which include Pentasa, Apriso, and Lialda. The AUC is measured in units of micromoles of mesalamine per liter of plasma (µM) multiplied by time in hours (µM*h).The AUC results are reported over the time-period because this provides a more meaningful comparison of potential differences in the bioequivalence of formulations. The solution formulation (Delzicol) was not administered in this portion of the study. Therefore no results pertaining to the solution formulation are included in this outcome measure. (NCT01999400)
Timeframe: 0 hours pre-dose and up to 7 hours post-dose

InterventionuM*h (Mean)
Pentasa8456
Apriso4923
Lialda2.9

[back to top]

The AUC of Mesalamine in Plasma

The AUC is the area under the concentration-time curve from time 0 to last time point. The data are organized by the different drug formulations of mesalamine, which include Pentasa (0 to 72 hours), Apriso (0 to 72 hours), Lialda (0 to 96 hours), and Delzicol (0 to 24 hours). The AUC is measured in units of nanomoles of mesalamine per liter of plasma (nM) multiplied by time in hours (nM*h). The AUC results are reported over the time-period because this provides a more meaningful comparison of potential differences in the bioequivalence of formulations. (NCT01999400)
Timeframe: 0 hours pre-dose and up to 96 hours post-dose

InterventionnM*h (Mean)
Pentasa40.8
Apriso57.6
Lialda36.8
Delzicol7.9

[back to top]

The AUC of Metabolite (N-acetyl-mesalamine) in Distal Jejunum

The AUC is the area under the concentration-time curve from time 0 to 7 hours. The data are organized by the different drug formulations of mesalamine, which include Pentasa, Apriso, and Lialda. The AUC is measured in units of micromoles of mesalamine per liter of plasma (µM) multiplied by time in hours (µM*h).The AUC results are reported over the time-period because this provides a more meaningful comparison of potential differences in the bioequivalence of formulations. The solution formulation (Delzicol) was not administered in this portion of the study. Therefore no results pertaining to the solution formulation are included in this outcome measure. (NCT01999400)
Timeframe: 0 hours pre-dose and up to 7 hours post-dose

InterventionuM*h (Mean)
Pentasa5048
Apriso1225
Lialda3.4

[back to top]

Number of Participants With Clinical and Endoscopic Response During Double Blind Acute Phase at Week 8 Using Central Reading

Clinical and endoscopic response was defined as UC-DAI <=2 with rectal bleeding = 0 and stool frequency <=1, and PGA = 0, and with mucosal healing (endoscopy score <=1) at least a 1 point reduction in endoscopy score from baseline based on central reading. Participants with missing data at week 8 were assumed not to had a clinical response. Participants who completed week 8 but did not have central reading endoscopies at both baseline and week 8 were excluded. Number of participants with clinical and endoscopic response were reported. (NCT02093663)
Timeframe: Week 8

InterventionParticipants (Count of Participants)
Double-Blind Acute (DBA) Phase: Low Dose1
Double-Blind Acute (DBA) Phase: High Dose3

[back to top]

Number of Participants With Clinical and Endoscopic Response During Double Blind Acute Phase at Week 8 Using Local Reading

Clinical and endoscopic response was defined as UC-DAI < or =2 with rectal bleeding = 0 and stool frequency < or =1, and PGA = 0, and with mucosal healing (endoscopy score < or =1) at least a 1 point reduction in endoscopy score from baseline based on local reading. Participants with missing data at week 8 were assumed not to had a clinical response. Participants who completed week 8 but did not have local reading endoscopies at both baseline and week 8 were excluded. Number of participants with clinical and endoscopic response were reported. (NCT02093663)
Timeframe: Week 8

InterventionParticipants (Count of Participants)
Double-Blind Acute (DBA) Phase: Low Dose1
Double-Blind Acute (DBA) Phase: High Dose4

[back to top]

Number of Participants With Clinical and Endoscopic Response During Double-Blind Maintenance Phase at Week 26 Using Central Reading

Clinical and endoscopic response was defined as UC-DAI < or =2 with rectal bleeding=0, stool frequency < or =1, PGA=0, and with mucosal healing (endoscopy score < or =1) based on central reading at Week 26. Number of participants with clinical and endoscopic response during double-blind maintenance phase at Week 26 using central reading were reported. (NCT02093663)
Timeframe: Week 26

InterventionParticipants (Count of Participants)
Double-Blind Maintenance (DBM) Phase: Low Dose13
Double-Blind Maintenance (DBM) Phase: High Dose11

[back to top]

Number of Participants With Clinical and Endoscopic Response During Double-Blind Maintenance Phase at Week 26 Using Local Reading

Clinical and endoscopic response was defined as UC-DAI < or = 2 with rectal bleeding=0, stool frequency < or = 1, PGA=0, and with mucosal healing (endoscopy score < or = 1) based on local reading. Number of participants who had maintained clinical and endoscopic response during double-blind maintenance phase at week 26 using local reading were reported. (NCT02093663)
Timeframe: Week 26

InterventionParticipants (Count of Participants)
Double-Blind Maintenance (DBM) Phase: Low Dose18
Double-Blind Maintenance (DBM) Phase: High Dose12

[back to top]

Number of Participants With Clinical Response During Double-Blind Acute Phase at Week 8

Clinical response was defined as partial ulcerative colitis disease activity index (UC-DAI) score < or =1 with rectal bleeding = 0, stool frequency < or =1, and physician's global assessment (PGA = 0). Number of participants with clinical response were reported. (NCT02093663)
Timeframe: Week 8

InterventionParticipants (Count of Participants)
Double-Blind Acute (DBA) Phase: Low Dose10
Double-Blind Acute (DBA) Phase: High Dose17

[back to top]

Number of Participants With Clinical Response During Double-blind Maintenance Phase at Week 26

Clinical response was defined as partial UC-DAI <=1 with (rectal bleeding = 0, stool frequency < or =1, and PGA = 0). Number of participants who had maintained clinical response were reported. (NCT02093663)
Timeframe: Week 26

InterventionParticipants (Count of Participants)
Double-Blind Maintenance (DBM) Phase: Low Dose23
Double-Blind Maintenance (DBM) Phase: High Dose24

[back to top]

Number of Participants With Improvement in Pediatric Ulcerative Colitis Activity Index (PUCAI) Score During Double-blind Acute Phase at Week 8

PUCAI was a physician-administered measure that focuses on 6 key signs and symptoms of UC and activity limitations producing a total score ranging from 0-85 with higher scores being worse. Recommended cut-off scores to differentiate disease activity are < 10 (remission); 11-30 (mild); 31-64 (moderate) and > 65 (severe). Participants with an improvement (change of greater than or equal to [> or =] 20 points) in PUCAI score. Number of participants with improvement in PUCAI score during Double-blind Acute Phase at Week 8 were reported. (NCT02093663)
Timeframe: Week 8

InterventionParticipants (Count of Participants)
Double-Blind Acute (DBA) Phase: Low Dose10
Double-Blind Acute (DBA) Phase: High Dose16

[back to top]

Number of Participants With Remission at Pediatric Ulcerative Colitis Activity Index (PUCAI) Score During Double-Blind Maintenance Phase at Week 26

PUCAI was a physician-administered measure that focuses on 6 key signs and symptoms of UC and activity limitations producing a total score ranging from 0-85 with higher scores being worse. Recommended cut-off scores to differentiate disease activity are < 10 (remission); 11-30 (mild); 31-64 (moderate) and > 65 (severe). Number of participants with remission at PUCAI score during double-blind maintenance phase at week 26 were reported. (NCT02093663)
Timeframe: Week 26

InterventionParticipants (Count of Participants)
Double-Blind Maintenance (DBM) Phase: Low Dose29
Double-Blind Maintenance (DBM) Phase: High Dose27

[back to top]

Change From Baseline in Daily Ulcerative Colitis Scale (DUCS) Score During Double-Blind Acute Phase

DUCS score was to measure 7 specific signs or symptom and one impact (abdominal pain, nocturnal stool, daytime stool, blood in stool, diarrhea, urgency, tiredness) of UC with each item score ranged from 0 (worst) to 10 (best) with the overall score ranged from 0 (worst) to 70 (best) based on the responses. Change in the DUCS score from baseline to Week 8 during DBA phase were reported. (NCT02093663)
Timeframe: Baseline to Week 8

,
InterventionScore on the scale (Mean)
BaselineWeek 2Week 4Week 8
Double-Blind Acute (DBA) Phase: High Dose31.6-13.2-16.7-23.1
Double-Blind Acute (DBA) Phase: Low Dose32.2-14.1-15.6-18.2

[back to top]

Change From Baseline in Daily Ulcerative Colitis Scale (DUCS) Score During Double-Blind Maintenance Phase

DUCS score was to measure 7 specific signs or symptom and one impact (abdominal pain, nocturnal stool, daytime stool, blood in stool, diarrhea, urgency, tiredness) of UC with each score range from 0 (worst) to 10 (best) with the overall score ranging from 0 (worst) to 70 (best) based on the responses. Change from Baseline in DUCS score during double-blind maintenance phase at week 13 and Week 26 wwere reported. (NCT02093663)
Timeframe: Baseline, Week 13, and Week 26

,
InterventionScore on the scale (Mean)
BaselineWeek 13Week 26
Double-Blind Maintenance (DBM) Phase: High Dose4.6-0.14.4
Double-Blind Maintenance (DBM) Phase: Low Dose5.81.71.3

[back to top]

Number of Participants Who Detected an Aftertaste of Mesalamine

"An aftertaste assessment was completed 5 minutes after administration of investigational product to assess whether the participants detected an aftertaste. The participants answered Yes or No to the following question: Was there an aftertaste? The number of participants who answered Yes is reported." (NCT02125292)
Timeframe: 5 minutes post-dose

Interventionparticipants (Number)
Mesalamine (Vanilla Yogurt)0
Mesalamine (Applesauce)4
Mesalamine (Dosing Cup)1

[back to top]

Number of Participants Willing to Take Mesalamine Via Treatment Method on a Regular Basis

"The participants were asked to answer Yes or No to the following question: Would you be willing to take medicine this way on a regular basis if necessary? The number of participants who answered Yes is reported." (NCT02125292)
Timeframe: Immediately post-dose

Interventionparticipants (Number)
Mesalamine (Vanilla Yogurt)18
Mesalamine (Applesauce)17
Mesalamine (Dosing Cup)18

[back to top]

Number of Participants With Positive Responses to Palatability Assessment of The Aftertaste of Mesalamine

"An aftertaste assessment was completed 5 minutes after administration of investigational product to assess the subject's rating of aftertaste and means of administration. The assessment consisted of a 5-point rating scale. The participants were asked to choose one of the following responses to the statement The aftertaste (if present) was acceptable: strongly agree, agree, neutral, disagree, or strongly disagree. The number of participants who chose either of the top two responses (strongly agree, agree) is reported." (NCT02125292)
Timeframe: 5 minutes post-dose

Interventionparticipants (Number)
Mesalamine (Vanilla Yogurt)0
Mesalamine (Applesauce)3
Mesalamine (Dosing Cup)1

[back to top]

Number of Participants With Potentially Clinically Important Laboratory Results

Clinical laboratory assessments included hematology, chemistry and urinalysis parameters, all measured 6 hours post-dose. All clinical laboratory assays were performed according to the laboratory's normal procedures. Reference ranges were supplied by the laboratory and were used to assess the clinical laboratory data for clinical significance and out-of-range pathological changes. The investigator assessed out-of-range clinical laboratory values for clinical significance and indicated whether or not the values were clinically significant. (NCT02125292)
Timeframe: 1 day

Interventionparticipants (Number)
HematologyBiochemistryUrinalysis
All Participants003

[back to top]

Number of Participants Who Experienced an Adverse Event

Participants were monitored for treatment-emergent adverse events through the follow-up assessment, which occurred 2 days +/- 1 day post-dose. (NCT02125292)
Timeframe: 4 days

Interventionparticipants (Number)
Serious Adverse EventNon-serious Adverse Event
All Participants02

[back to top]

Number of Participants With Potentially Clinically Important Electrocardiogram (ECG) Results

Subjects underwent a standard 12-lead ECG 6 hours post-dose. The investigator assessed if the ECG tracing was normal or abnormal; if abnormal, the investigator made a determination of whether or not the abnormality was clinically significant. (NCT02125292)
Timeframe: 1 day

Interventionparticipants (Number)
All Participants0

[back to top]

Number of Participants With Positive Responses to Palatability Assessment of The Taste of Mesalamine

"A taste assessment was completed immediately after investigational product was administered to assess the subject's taste/liking of the formulation. The assessment consisted of a 5-point rating scale. Participants were asked to choose one of the following responses to the statement The taste was acceptable: strongly agree, agree, neutral, disagree, or strongly disagree. The number of participants who chose either of the top two responses (strongly agree, agree) is reported." (NCT02125292)
Timeframe: Immediately post-dose

Interventionparticipants (Number)
Mesalamine (Vanilla Yogurt)17
Mesalamine (Applesauce)16
Mesalamine (Dosing Cup)13

[back to top]

Number of Participants With Potentially Clinically Important Vital Signs

Vital sign assessments included systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate and body temperature measurements, all measured 6 hours post-dose. Study personnel used both absolute values and change from baseline values to determine if the vital sign was potentially clinically important. Criteria for the potential clinical importance of both absolute and change from baseline values were pre-specified. A participant's vital sign had to meet both the absolute and change from baseline criteria to be considered as potentially clinically important. (NCT02125292)
Timeframe: 1 day

Interventionparticipants (Number)
All Participants0

[back to top]

Improvement Rate

"Clinical improvement over a 6-weeks treatment period was defined as a ≥ 3 point reduction from Baseline in the modified UCDAI (Ulcerative Colitis Disease Activity Index ) score.~Modified UCDAI scoring system is sum of following 4 subscores (parameters). Higher score means worst disease condition.~Rectal bleeding: score 1 (Streaks of blood), score 2 (obvious blood), score 3 (Mostly Blood) Stool frequency: score 1 (1-2/day> normal), score 2 (3-4/day >normal), score 3 (>4/day> normal) Mucosal appearance: score 1 (Erythema, decrased vascular pattern, Minimal granularity), score 2 (Marked erythema, Friability, Granularity, Absent vascular pattern, Bleeding minimal trauma, No ulcerations), score 3 (Ulceration Spontaneous bleeding) Physician's Global Assessment: score 1 (mild), score 2 (Moderate), score 3 (Severe)" (NCT02493712)
Timeframe: 6 weeks

InterventionParticipants (Count of Participants)
High Dose Group5
Low Dose Group3
Placebo3

[back to top]

Remission Rate

"Percentage of patients in remission over a 6-week treatment period. Remission is defined as a modified UCDAI (Ulcerative Colitis Disease Activity Index) score of ≤1, with a score of 0 for rectal bleeding and stool frequency, no mucosal friability, and sigmoidoscopy score not exceeding 1).~Modified UCDAI scoring system is sum of following 4 subscores (parameters). Higher score means worst disease condition.~Rectal bleeding: score 1 (Streaks of blood), score 2 (obvious blood), score 3 (Mostly Blood) Stool frequency: score 1 (1-2/day> normal), score 2 (3-4/day >normal), score 3 (>4/day> normal) Mucosal appearance: score 1 (Erythema, decreased vascular pattern, Minimal granularity), score 2 (Marked erythema, Friability, Granularity, Absent vascular pattern, Bleeding minimal trauma, No ulcerations), score 3 (Ulceration Spontaneous bleeding) Physician's Global Assessment: score 1 (mild), score 2 (Moderate), score 3 (Severe)" (NCT02493712)
Timeframe: 6 weeks

InterventionParticipants (Count of Participants)
High Dose Group2
Low Dose Group1
Placebo2

[back to top]

Proportion of Subject With Abnormal Laboratory Values (Hematology)

"Proportion of subjects with markedly abnormal changes from baseline in hematology values are presented.~>= greater than equal to; <= less than equal to." (NCT02522767)
Timeframe: Up to Week 16

,,
InterventionParticipants (Count of Participants)
Eosinophils/Leukocytes (%), Normal>=10 to AbnormalErythrocytes (10^6/uL), Low<=3.5 to AbnormalErythrocytes (10^6/uL), Normal<=3.5 to AbnormalHematocrit (%), Low<=0.32 to AbnormalHematocrit (%), Normal<=0.32 to AbnormalHematocrit (%), Normal>=0.56 to AbnormalHemoglobin (g/dL), Low<=115 to AbnormalHemoglobin (g/dL), Normal<=115 to AbnormalLeukocytes (10^3/uL), Normal <=2.8 to AbnormalLeukocytes (10^3/uL), Normal >=16.0 to AbnormalLeukocytes (10^3/uL), High >=16.0 to AbnormalLymphocytes/Leukocytes (%), Low<=10 to AbnormalLymphocytes/Leukocytes (%), Normal<=10 to AbnormalLymphocytes/Leukocytes (%), High>=80 to AbnormalNeutrophils/Leukocyte (%), Normal<=15 to AbnormalNeutrophils/Leukocyte (%), Normal>=90 to AbnormalNeutrophils/Leukocyte (%), High >=90 to AbnormalPlatelets (10^3/uL), High>=700 to Abnormal
Mesalamine02140021121000412002
Mesalamine (Open-Label)44254037292211612212
Placebo24013123150213200110

[back to top]

The Change From Baseline in Rectal Bleeding Score at Weeks 2, 4, and 8

Defined as change from baseline in rectal bleeding score at Week 2, 4, and 8 based on subject daily diary. Rectal Bleeding Score is graded 0-3, where 0 is best. (NCT02522767)
Timeframe: From baseline to Week 2, 4, and 8

,
Interventionscores on a scale (Mean)
Week 2Week 4Week 8
Mesalamine-0.39-0.56-0.64
Placebo-0.23-0.34-0.35

[back to top]

Number of Participants Experiencing Adverse Events

"An adverse event (AE) is defined as any untoward medical occurrence in a subject taking part in a clinical trial.~A 'treatment-emergent AE (TEAE)' is defined as an AE which occurs in the time interval from initial dosing (investigational medicinal product [IMP] intake) to the end of treatment visit.~Proportion of subjects with any TEAE (serious or non-serious) are presented." (NCT02522767)
Timeframe: Up to Week 16

,,
InterventionParticipants (Count of Participants)
Any TEAESerious AE
Mesalamine281
Mesalamine (Open-Label)312
Placebo370

[back to top]

Time to Normal Stool Pattern

Defined as time in days from randomization to the first day of 3 consecutive days with a stool frequency score of 0, based on subject daily diary. (NCT02522767)
Timeframe: Up to Week 8

Interventiondays (Median)
Mesalamine55.0
PlaceboNA

[back to top]

Time to Cessation of Rectal Bleeding

"Defined as time in days from randomization to the first day of 3 consecutive days with a rectal bleeding score of 0, based on subject's daily diary.~The statistical test was to be conducted only if the primary analysis was significant." (NCT02522767)
Timeframe: Up to Week 8

Interventiondays (Median)
Mesalamine18.0
Placebo43.0

[back to top]

The Proportion of Subjects With Endoscopic Improvement

Defined as an Endoscopic Response Score of 0 or 1, with at least a 1 point reduction from baseline in the endoscopic score at Week 8. (NCT02522767)
Timeframe: At Week 8

InterventionParticipants (Count of Participants)
Mesalamine34
Placebo22

[back to top]

Proportion of Subjects With Remission

"The proportion of subjects with remission was defined by the Clinical and Endoscopic Response Score: 0 for rectal bleeding; 0 or 1 with at least 1 point decrease from baseline for stool frequency; 0 or 1 for endoscopic score.~The Clinical and Endoscopic Response Score ranged between 0-9, higher scores indicating greater disease severity. This score had two components: Clinical Response which assessed subject's symptoms and ranged between 0-6, and Endoscopic Response which assessed objective evidence of inflammation and ranged between 0-3.~Further, the Clinical Response component included two subscales: stool frequency and rectal bleeding (each ranged between 0-3 each) obtained from subjects' daily records. The Endoscopic Response component had one subscale: flexible sigmoidoscopy/colonoscopy (ranging between 0-3)." (NCT02522767)
Timeframe: At Week 8

InterventionParticipants (Count of Participants)
Mesalamine19
Placebo13

[back to top]

The Proportion of Subjects in Clinical Remission at Weeks 2, 4, and 8

Defined as a score of 0 for rectal bleeding and 0 or 1 with at least 1 point decrease from baseline for stool frequency in the Clinical Response Score subset. (NCT02522767)
Timeframe: At Week 2, 4, and 8

,
InterventionParticipants (Count of Participants)
Week 2Week 4Week 8
Mesalamine192940
Placebo172628

[back to top]

The Change From Baseline in Fecal Calprotectin Levels at Week 8

The adjusted mean change from baseline in fecal calprotectin levels at Week 8 are presented. (NCT02522767)
Timeframe: From baseline to Week 8

Interventionug/g (Mean)
Mesalamine-144.93
Placebo-119.56

[back to top]

Proportion of Subjects With Remission in the Primary Endpoint and the Physician's Global Assessment (PGA) Score of ≤1 (Modified Mayo Score)

"The Modified Mayo score was calculated as the sum of the Clinical and Endoscopic Response Score (Range: 0-9, and the standard PGA score (range: 0-3; normal [score=0], mild disease [score=1], moderate disease [score=2], severe disease [score=3]).~The statistical test was to be conducted only if the primary analysis was significant." (NCT02522767)
Timeframe: At Week 8

InterventionParticipants (Count of Participants)
Mesalamine19
Placebo11

[back to top]

The Change From Baseline in Serum C-reactive Protein (CRP) Levels at Weeks 2, 4, and 8

The adjusted mean changes in serum CRP levels from baseline and their difference between treatment groups are presented for each time point. (NCT02522767)
Timeframe: From baseline to Week 2, 4, and 8

,
Interventionmg/L (Mean)
Week 2Week 4Week 8
Mesalamine0.60-0.86-2.01
Placebo0.25-1.05-0.73

[back to top] [back to top]

Severity of Adverse Events

The proportion of subjects with intensity of AEs (classified as mild, moderate or severe) are presented. (NCT02522767)
Timeframe: Up to Week 16

,,
InterventionParticipants (Count of Participants)
MildModerateSevere
Mesalamine2365
Mesalamine (Open-Label)21111
Placebo27153

[back to top]

Proportion of Subjects With Abnormal Laboratory Values (Serum Chemistry)

"Proportion of subjects with markedly abnormal changes in serum chemistry laboratory values are presented.~ALT= Alanine aminotransferase; AST= Aspartate aminotransferase; BUN= Blood urea nitrogen; GGT= Gamma glutamyl transferase." (NCT02522767)
Timeframe: Up to Week 16

,,
InterventionParticipants (Count of Participants)
ALT (U/L), Normal >3xULN to AbnormalAST (U/L), Normal >3xULN to AbnormalAST (U/L), High >3xULN to AbnormalBilirubin (mg/dL), Normal >=1.5xULN to AbnormalBilirubin (mg/dL), High >=1.5xULN to AbnormalBUN (mg/dL), Normal >=10.7 to AbnormalCalcium (mg/dL), Normal <=1.8 to AbnormalChloride (mmol/L), Normal >=115 to AbnormalChloride (mmol/L), High >=115 to AbnormalGGT (U/L), High >3xULN to AbnormalGlucose (mg/dL), Normal >=10 to AbnormalGlucose (mg/dL), High >=10 to AbnormalPotassium (mmol/L), Normal <=3.0 to AbnormalPotassium (mmol/L), Normal >=5.8 to AbnormalPotassium (mmol/L), High >=5.8 to AbnormalSodium (mmol/L), Low<=130 to Abnormal
Mesalamine1101201112101100
Mesalamine (Open-Label)2211411114111310
Placebo0000110002120001

[back to top]

Proportion of Subjects With Abnormal Laboratory Values (Coagulation)

"Proportion of subjects with markedly abnormal changes from baseline values in coagulation laboratory values are presented.~INR= International normalized ratio." (NCT02522767)
Timeframe: Up to Week 16

,,
InterventionParticipants (Count of Participants)
Prothrombin INR, Normal <0.8 to AbnormalProthrombin INR, Normal >1.1 to AbnormalProthrombin INR, High >1.1 to Abnormal
Mesalamine0144
Mesalamine (Open-Label)12822
Placebo01410

[back to top]

Proportion of Subjects With Markedly Abnormal Laboratory Values: Hematology

Proportion of subjects with markedly abnormal changes from baseline in hematology values are presented. Criteria for markedly abnormal laboratory (Hematology): Basophils/Leukocytes: >=5%, Eosinophils/Leukocytes: >=10%, Erythrocytes: <=3.5*10^6/μL, Hematocrit: <=0.32%; >=0.56%, Hemoglobin: <=11.5 g/dL, Leukocytes: <=2.8*10^3/μL; >=16.0*10^3/μL, Lymphocytes/Leukocytes: <=10%; >=80%, Monocytes/Leukocytes: >=20%, Neutrophils/Leukocytes: <=15%; >=90%, Platelets: <=75*10^3/μL; >=700*10^3/μL. Data is presented cumulative for all pathways. (NCT02522780)
Timeframe: Baseline, Month 6

,
InterventionParticipants (Count of Participants)
Basophils/Leukocytes: >=5%Eosinophils/Leukocytes: >=10%Erythrocytes: <=3.5*10^6/μLHematocrit: <=0.32%Hematocrit: >=0.56%Hemoglobin: <=11.5 g/dLLeukocytes: <=2.8*10^3/μLLeukocytes: >=16.0*10^3/μLLymphocytes/Leukocytes: <=10%Lymphocytes/Leukocytes: >=80%Monocytes/Leukocytes: >=20%Neutrophils/Leukocytes: <=15%Neutrophils/Leukocytes: >=90%Platelets: <=75*10^3/μLPlatelets: >=700*10^3/μL
Mesalamine0321829423000001
Placebo17101223404010000

[back to top]

Proportion of Subjects With Markedly Abnormal Laboratory Values: Coagulation

Proportion of subjects with markedly abnormal changes from baseline in coagulation values are presented. Criteria for markedly abnormal laboratory (coagulation): Activated Partial Thromboplastin Time (aPTT): >70 seconds (sec), Prothrombin International Normalized Ratio (INR): <0.8; >1.1. Data is presented cumulative for all pathways. (NCT02522780)
Timeframe: Baseline, Month 6

,
InterventionParticipants (Count of Participants)
aPTT: >70 secProthrombin INR: <0.8Prothrombin INR: >1.1
Mesalamine0046
Placebo0254

[back to top]

Proportion of Subjects in Clinical Remission at Month 2, 4, and 6

The proportion of subjects in clinical remission was defined as a score of 0 for rectal bleeding and 0 or 1 for stool frequency based on clinical response score component of the Clinical and Endoscopic Response Score. Clinical response score component had two subscales to assess subject's symptoms: rectal bleeding ranging from 0 (no blood seen) to 3 (blood alone passes) and stool frequency ranging from 0 (normal number of stools) to 3 (>=5 stools more than normal). The scores of clinical response component ranged from 0 (normal) to 6 (severe disease), higher scores indicating greater disease severity. Data is presented cumulative for all pathways. (NCT02522780)
Timeframe: Month 2, 4, and 6

,
InterventionParticipants (Count of Participants)
Month 2Month 4Month 6
Mesalamine12211396
Placebo11611389

[back to top]

Severity of Adverse Events

The number of subjects with intensity of AEs (classified as mild, moderate or severe) were presented. Data is presented cumulative for all pathways. (NCT02522780)
Timeframe: Up to Month 6

,
InterventionParticipants (Count of Participants)
MildModerateSevere
Mesalamine32182
Placebo32223

[back to top]

Proportion of Subjects With an Increase From Baseline in the Clinical and Endoscopic Response Score by 2 or More Points in at Least 1 Component or by 1 or More Points in at Least 2 Components at Month 6

The proportion of subjects with an increase from baseline in the Clinical and Endoscopic Response Score by 2 or more points in at least 1 component, or by 1 or more points in at least 2 components were reported. The Clinical and Endoscopic Response Score ranged between 0 (normal) to 9 (severe disease), higher scores indicating greater disease severity. The score included clinical response component to assess subject's symptoms and endoscopic response component to assess objective evidence of inflammation. Clinical Response component had two subscales: stool frequency ranging from 0 (normal number of stools) to 3 (>=5 stools more than normal) and rectal bleeding ranging from 0 (no blood seen) to 3 (blood alone passes). The Endoscopic Response component had one subscale: flexible sigmoidoscopy/colonoscopy ranging from 0 (normal) to 3 (severe disease). Data is presented cumulative for all pathways. (NCT02522780)
Timeframe: Month 6

InterventionParticipants (Count of Participants)
Mesalamine14
Placebo30

[back to top]

Proportion of Subjects With Remission at Month 6

The proportion of subjects with remission was defined by Clinical and Endoscopic Response Score: 0 for rectal bleeding; 0 or 1 for stool frequency; 0 or 1 for endoscopic score. The Clinical and Endoscopic Response Score ranged between 0 (normal) to 9 (severe disease), higher scores indicating greater disease severity. The score included clinical response component to assess subject's symptoms and endoscopic response component to assess objective evidence of inflammation. Clinical response component had two subscales: stool frequency ranging from 0 (normal number of stools) to 3 (>=5 stools more than normal) and rectal bleeding ranging from 0 (no blood seen) to 3 (blood alone passes). The Endoscopic response component had one subscale: flexible sigmoidoscopy/colonoscopy ranging from 0 (normal) to 3 (severe disease). Data is presented cumulative for all pathways. (NCT02522780)
Timeframe: Month 6

InterventionParticipants (Count of Participants)
Mesalamine82
Placebo.67

[back to top]

Time to Relapse

Time to relapse was defined as the number of days from randomization to the day of withdrawal due to escalation of therapy. Data is presented cumulative for all pathways. (NCT02522780)
Timeframe: Time from randomization to the day of withdrawal due to escalation of therapy (up to 6 months)

Interventiondays (Median)
MesalamineNA
PlaceboNA

[back to top]

Change From Baseline in Fecal Calprotectin Levels at Month 2, 4, and 6

The adjusted mean change from baseline in fecal calprotectin levels at Month 2, 4, and 6 were reported. Data is presented cumulative for all pathways. (NCT02522780)
Timeframe: Baseline, Month 2, 4, and 6

,
Interventionmcg/g (Mean)
Month 2Month 4Month 6
Mesalamine-94.8-41.7-43.5
Placebo12.853.636.4

[back to top]

Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Scores at Months 2, 4, and 6

The IBDQ is an instrument used to assess quality of life in adult subjects with ulcerative colitis. It includes 32 questions on 4 domains of Health-Related Quality-of-Life (HRQOL): Bowel Systems (10 items), Emotional Function (12 items), Social Function (5 items), and Systemic Function (5 items). Subjects were asked to recall symptoms and quality of life from the last 2 weeks and rate each item on a 7-point Likert scale (1=worst to 7=best). The total IBDQ was computed as the sum of the responses to the individual IBDQ questions. The total score can range between 32 to 224 with higher scores indicating a better HRQOL. The adjusted mean change from baseline at Month 2, 4, and 6 for the IBDQ total scores were reported. Data is presented cumulative for all pathways. (NCT02522780)
Timeframe: Baseline, Month 2, 4, and 6

,
Interventionpoints on a score (Mean)
Month 2Month 4Month 6
Mesalamine-1.3-0.6-0.5
Placebo-0.4-0.3-1.2

[back to top]

Change From Baseline in Serum C-reactive Protein (CRP) Levels at Month 2, 4, and 6

The adjusted mean change from baseline in serum CRP levels at Month 2, 4, and 6 were reported. Data is presented cumulative for all pathways. (NCT02522780)
Timeframe: Baseline, Month 2, 4, and 6

,
Interventionmg/L (Mean)
Month 2Month 4Month 6
Mesalamine0.81.00.8
Placebo2.20.92.5

[back to top]

Number of Subjects With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is defined as any untoward medical occurrence in a subject participating in a clinical trial. Any AEs includes serious as well as non-serious AEs. An SAE is defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in a congenital anomaly/birth defect, or was an important medical event. Any AE which occurred in the time interval from initial dosing (investigational medicinal product [IMP] intake) to the end of treatment visit (Month 6) was considered treatment-emergent. Data is presented cumulative for all pathways. (NCT02522780)
Timeframe: Up to Month 6

,
InterventionParticipants (Count of Participants)
Any Treatment-Emergent AEsTreatment-Emergent SAEs
Mesalamine422
Placebo493

[back to top]

Proportion of Subjects With Markedly Abnormal Laboratory Values: Serum Chemistry

Proportion of subjects with markedly abnormal changes from baseline in serum chemistry values are presented. Criteria for markedly abnormal laboratory (serum chemistry): Alanine Aminotransferase (ALT): >3*upper limit of normal (ULN), Alkaline Phosphatase (ALP): >3*ULN and 25% increase (inc) from baseline (BL), Aspartate Aminotransferase (AST): >3* ULN, Bilirubin: >=1.5* ULN, Blood Urea Nitrogen: >=10.7 mg/dL, Calcium: <=1.8 mg/dL; >=3.9 mg/dL, Chloride: <=90 mmol/L; >=115 mmol/L, Creatinine: >=177 mg/dL, Gamma Glutamyl Transferase: >3*ULN, Glomerular Filtration Rate (GFR): <30 mL/min, Glucose: <=2.8 mg/dL; >=10 mg/dL, Potassium: <=3.0 mmol/L; >=5.8 mmol/L, Sodium: <=130 mmol/L; >=155 mmol/L. Data is presented cumulative for all pathways. (NCT02522780)
Timeframe: Baseline, Month 6

,
InterventionParticipants (Count of Participants)
ALT: >3*ULNALP: >3*ULN & 25% inc from BLAST: >3*ULNBilirubin: >=1.5*ULNBlood Urea Nitrogen: >=10.7 mg/dLCalcium: <=1.8 mg/dLCalcium: >=3.9 mg/dLChloride: <=90 mmol/LChloride: >=115 mmol/LCreatinine: >=177 mg/dLGamma Glutamyl Transferase: >3*ULNGFR: <30 mL/minGlucose: <=2.8 mg/dLGlucose: >=10 mg/dLPotassium: <=3.0 mmol/LPotassium: >=5.8 mmol/LSodium: <=130 mmol/LSodium: >=155 mmol/L
Mesalamine1028809000600110000
Placebo102511012000400140200

[back to top]